Breast Cancer—Local/Regional/Adjuvant

Abstract e12500: Difference in clinicopathological characteristics between pure and mixed invasive micropapillary breast carcinomas from eastern China.
First Author: Rong Wang, PhD/MD

Abstract e12501: Genomic testing, biomarkers and treatment patterns in early breast cancer (eBC).
First Author: Alex Rider

Abstract e12502: Analysis of the prognostic factors of triple-negative breast cancer and the clinical efficacy of postoperative radiotherapy in early cases.
First Author: XT Cheng

Abstract e12503: Paclitaxel-induced peripheral neuropathy in early-stage breast cancer patients.
First Author: Jacqueline Liu, PharmD

Abstract e12504: Treatment patterns and the use of Ki67 testing in HR+, HER2- early breast cancer.
First Author: Jacqueline Brown

Abstract e12505: Adjuvant chemotherapy with or without an anthracycline in older adults with node-negative triple-negative breast cancer (TNBC): A SEER Medicare study.
First Author: Anna R Schreiber, MD

Abstract e12506: Baseline skeletal muscle density and adverse outcomes during chemotherapy for early breast cancer.
First Author: Gabriel Aleixo, MD

Abstract e12507: Characterization of patients enrolled in the abemaciclib adjuvant monarchE study: Early breast cancer (EBC) high-risk of recurrence based on clinicopathological features and/or cellular proliferation by standardized Ki-67 expression.
First Author: Nadia Harbeck, MD

Abstract e12508: Breast cancer recurrence rate in patients treated for early breast cancer.
First Author: Cecilia Munguti, MBChB

Abstract e12509: Recurrence risk stratification by Dutch clinical risk criteria for early-stage luminal breast cancer patients in Taiwan: A population-based analysis.
First Author: Lei Lei, MD
Abstract e12510: Endocrine therapy adherence of premenopausal Mexican breast cancer patients.
First Author: Cynthia Villarreal-Garza, MD, DSc

Abstract e12511: Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients.
First Author: Wen Xia, PhD

First Author: Jan Sieluk, PharmD, PhD

Abstract e12513: RelB silencing to reverse tamoxifen resistance by regulating GPx4 and ferroptosis in breast cancer.
First Author: Zhi Xu, PhD

First Author: Yadav Pandey, MD

First Author: Xiaoyu Chong, Bachelor's Degree

First Author: Veli Bakalov

Abstract e12517: Factors associated with the use of adjuvant neratinib in stage I-III HER2-positive breast cancer.
First Author: Ericson Stoen, MD

Abstract e12518: Practice-changing use of 21-gene oncotype DX breast recurrence score assay in a public hospital in Brazil: Results of 155 cases.
First Author: Andre Mattar, MD, PhD

Abstract e12519: The adjuvant radiotherapy benefits on pure mucinous breast carcinoma patients in different age stages: A SEER-based study.
First Author: Xiaoqing Wei

Abstract e12520: Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
First Author: Christoph Suppan, MD
Abstract e12521: Genomic testing in early breast cancer (EBC) for low middle income countries (LMIC): Is it worth the cost?  
First Author: Gunjan Shrivastav, MD

Abstract e12522: Impact of Ki67 and Oncotype DX on intra- and inter-observer adjuvant treatment agreement and confidence.  
First Author: Luca Licata, MD

Abstract e12523: Chemotherapy-induced neutropenia among breast cancer patients presenting to a tertiary hospital in Nigeria.  
First Author: Omolola Salako, MBBS

Abstract e12524: High-risk of recurrence for nodal micrometastasis with breast pathologic complete response (ypT0/Tis ypN1mi) after neoadjuvant chemotherapy.  
First Author: Esmeralda Garcia Torralba, MD

Abstract e12525: How much is too much? Multidisciplinary management of elderly early-stage breast cancer (BC) patients.  
First Author: Elizabeth R. Berger, MD, MS

Abstract e12526: Incidence of diabetes and prediabetes unmasked by dexamethasone in women undergoing (neo) adjuvant taxane therapy.  
First Author: Dana Mahinbakht

Abstract e12527: Is the toxicity of breast radiotherapy higher in patients with collagen vascular disease? A systematic review of the literature.  
First Author: Wei Liu, MD

First Author: Yinduo Zeng, MD, PhD

Abstract e12529: Development of cardiac events in postmenopausal breast cancer patients treated with Aromatase inhibitor (AI) and Selective estrogen receptor modulator (SERM).  
First Author: Priyanka Parajuli

Abstract e12530: Nine weeks versus six months of adjuvant trastuzumab in HER2-positive breast cancer: 3-year disease-free survival results.  
First Author: Maher Saifo, MD

Abstract e12531: Neoadjuvant chemotherapy versus adjuvant chemotherapy in breast cancer patients: Analysis of breast conserving rate and de-escalation of axillary surgery in 5,141 Korean women.  
First Author: Young Joo Lee, MD
Abstract e12532: Usage and factors associated with adjuvant bisphosphonate therapy among postmenopausal women diagnosed with early-stage breast cancer.
First Author: Veera Durga Sravanthi Panuganty, MD, FRCPC

Abstract e12533: Analysis of the fatigue benefit, functionality, and body composition of a program of therapeutic exercise and healthy lifestyle habits in patients breast cancer operated.
First Author: Sofía Ruíz, MD

Abstract e12534: Omitting chemotherapy in more patients with early breast cancer in the post-TAILORx era.
First Author: Christos Markopoulos, MD, PhD

Abstract e12535: Comparison of pathological features of estrogen receptor-positive/HER2-negative early breast cancer in the intermediate-risk group of the 21 gene recurrence score (Oncotype Dx) divided into low and high-risk groups by the 95 gene classifier (Curebest 95GC Breast).
First Author: Yoshihiko Kamada, MD, PhD

Abstract e12536: Molecular profiling and quantitative image analysis reveal spatial intratumor heterogeneity in TNBC.
First Author: Karuna Mittal

Abstract e12537: Prevalence of trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients treated in a real life setting during a 10 year period.
First Author: Natalia Camejo, MD

Abstract e12538: Independent prognostic factors for survival and recurrence outcomes by treatment modality in breast cancer.
First Author: Sherry X. Yang, MD, PhD

Abstract e12539: Practice-changing use of the 21-gene oncotype DX breast recurrence score test in Latin American hospitals.
First Author: Henry Leonidas Gomez

Abstract e12540: Effects of cardioprotective medications on breast cancer survival: A retrospective study from an academic center from Southern Illinois.
First Author: Manjari Rani Regmi, MD

Abstract e12541: Effect of farrerol on the proliferation of estrogen receptor-positive breast cancer by downregulating oncogenic genes with estrogen receptor response elements.
First Author: Xiao-Qing Lu
Abstract e12542: Assessment of the sexual health of breast cancer survivors and their interest in discussing their difficulties with their doctors during follow-up.
First Author: Natalia Camejo, MD

Abstract e12543: Correlation between five-year overall survival by PREDICT and 21 gene recurrence score (RS) in a Mexican private institution.
First Author: Geovani Amador García, MD

Abstract e12544: Real-world data on adjuvant bisphosphonate use in a breast cancer center in Mexico.
First Author: Omar Peña-Curiel, MD

Abstract e12545: Prognosis, biological characteristics and importance of treatment's delay of breast cancer diagnosed during pregnancy.
First Author: Wendy Munoz-Montano

First Author: Fang Chen

Abstract e12547: Radiation therapy following breast conserving surgery (BCS) in women with early-stage breast cancer and low oncotype scores.
First Author: Nicholas Damico, MD

Abstract e12548: Single center retrospective study on cardiac safety of anti-HER2 agents and anthracyclines.
First Author: Odalys Estefania Lara Garcia, MD

First Author: Priyanka Parajuli

Abstract e12550: Hormones as indicator of relapse-free period in breast cancer (BC).
First Author: Natalia Yu. Samaneva

Abstract e12551: Assessment of the risk of tumor progression in different subtypes of breast cancer.
First Author: Liubov Yu Vladimirova, MD, PhD

Abstract e12552: Adipophilin expression as an independent marker for poor prognosis of patients with triple-negative breast cancer.
First Author: Katsuhiro Yoshikawa, MD
Abstract e12553: Prognostic value of circulating nucleosomes in primary breast cancer. 
First Author: Michal Mego, MD, PhD

Abstract e12554: ER-/PgR+ breast cancer is a separate entity characterized by distinct phenotype: Comprehensive reevaluation of cases from Polish and Hungarian centers. 
First Author: Elzbieta Senkus-Konefka, MD, PhD

Abstract e12555: Biological analysis of HER2 equivocal (2+) cases in primary breast cancer. 
First Author: Reiki Nishimura, MD, PhD

Abstract e12556: The association between breast density and HER2-positive breast cancer: a population-based case-control study. 
First Author: Vivian Tan, BSc

Abstract e12557: Significance of PDL1 positive in TNBC. 
First Author: Seiichi Imanishi, MD, PhD

First Author: Elena P. Ulianova

Abstract e12559: Immunological changes with perception of cold in breast cancer (BC) patients. 
First Author: Shipra Gandhi, MD

Abstract e12560: The clinical impact of the inflammatory biomarker on survival of breast cancer patients. 
First Author: Yuka Inoue, MD. PhD.

Abstract e12561: Prognostic factors impacting survival in early HER2-positive breast cancer (BC): Results from a 1,142 patients database study. 
First Author: Roberto Hegg

Abstract e12562: Loss of Her-2 expression after neo-adjuvant therapy with dual anti-Her-2 agents (Pertuzumab/Herceptin) with chemotherapy in locally advanced Her-2 positive breast cancer. 
First Author: Niraj K. Gupta, MBBS

Abstract e12563: Immunogenicity and transcriptomic biology in Nottingham histologic grade 3 breast cancer. 
First Author: Hideo Takahashi, MD

Abstract e12564: WNT/β–catenin pathway activation correlates with the increase of tumor-associated macrophages in triple negative breast cancer (TNBC). 
First Author: Eleonora Timperi, PhD
Abstract e12565: Relationship of the breast ductal carcinoma in situ (DCIS) immune microenvironment with clinicopathological features: An institutional experience.
First Author: Lauren Eisenbud, MD

Abstract e12566: The clinical impact of the expression of the cancer stem cell marker CD44v9 in early triple negative breast cancer (TNBC).
First Author: Eriko Tokunaga, MD, PhD

Abstract e12567: Breast cancer: The Indian scenario.
First Author: Ajay Gogia, MD, MBBS

Abstract e12568: Correlation of hormonal receptor level and survival outcome in HER2-positive nonmetastatic breast cancer.
First Author: Mengdi Chen

Abstract e12569: Real-world clinical analysis and overall survival-related biomarker of breast cancer (BC) patients under 35 years old.
First Author: Jinpu Yu

Abstract e12570: Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.
First Author: Fabio Conforti, MD

Abstract e12571: Prognostic value of tumor: Infiltrating lymphocytes and androgen receptors correlation in triple negative breast cancer.
First Author: Ana Tecic Vuger, MD

Abstract e12572: Genomic profiling of triple negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy.
First Author: Foluso Olabisi Ademuyiwa, MD, MPH

Abstract e12573: 4D radiomic biomarker of functional tumor heterogeneity to predict breast cancer recurrence in pretreatment dynamic FDG-PET.
First Author: Rhea Chitalia, BSE

Abstract e12574: Clinical relevance of miR-143 expression in ER-positive breast cancer patients.
First Author: Yoshihisa Tokumaru, MD

Abstract e12575: Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer.
First Author: Ji Ma

Abstract e12576: Increased favorability of small breast cancers.
First Author: Shigeto Maeda, MD, PhD
Abstract e12577: A nomogram based on genetic and clinicopathologic features to predict the nonsentinel lymph node metastases in Chinese women breast cancer patients.
First Author: Liling Zhu

Abstract e12578: Change of circulating tumor DNA (ctDNA) during neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients.
First Author: Ji-Yeon Kim, MD

Abstract e12579: Survival outcomes of metaplastic breast carcinoma: An Indian tertiary care center data.
First Author: Lalnun Puii

Abstract e12580: Differential intrinsic chemo- and radiosensitivity between triple-negative breast cancer subtypes.
First Author: Toshima Z Parris, PhD

Abstract e12581: Immunological predictive and prognostic factors in patients with stage II-III triple negative breast cancer.
First Author: Olga Gordeeva

Abstract e12582: Presence of human papillomavirus DNA in breast cancer patients: SERUM and tissue analysis.
First Author: Sara Ravaioli, PhD

Abstract e12583: Functional hotness score based on three genes predicts long-term survival of triple-negative breast cancer independent from tumor mutational burden.
First Author: Eriko Katsuta, MD PhD

Abstract e12584: Association of Th2 high tumors with aggressive features of breast cancer.
First Author: Yoshihisa Tokumaru, MD

Abstract e12585: Developing a breast cancer tissue biobank in low and middle income countries (LMICs): A research program-based approach for improving molecular profiling.
First Author: Avinash Sharma, MD

Abstract e12586: Breast cancer pathology patterns in Armenia.
First Author: Davit Zohrabyan

Abstract e12587: Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.
First Author: Shlomit Shachar, MD
Abstract e12588: Phenotype variants of invasive breast cancer differ in associations between the primary tumor size and its Ki-67 value.
First Author: Sven Kurbel, MD, PhD

Abstract e12589: Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).
First Author: Katherine Sanchez, MD

Abstract e12590: A systems medicine-based approach for finding metabolic targets applied to primary basal-like breast cancer.
First Author: Daniel Cook, PhD.

Abstract e12591: The association between race and intrinsic subtype on hormone receptor-positive breast cancer among young black women.
First Author: Sonya Reid, MD

Abstract e12592: 4-gene score to predict response to neoadjuvant chemotherapy, metastasis, and survival.
First Author: Masanori Oshi, MD

Abstract e12593: E2F cell cycle pathway score as a predictive biomarker of ER+/HER2- breast cancer response to neoadjuvant chemotherapy.
First Author: Masanori Oshi, MD

Abstract e12594: Breast cancer in women aged 80 years and older: Clinical characteristics and treatment patterns according to biologic subtype.
First Author: Stephanie M Wong, MD, MPH

Abstract e12595: Impact of preoperative magnetic resonance imaging (MRI) on conservative surgery (CSur) among curable breast cancer (BC) patients treated in a specialized center in Latin America.
First Author: Julianne Maria da Silva Lima, MD

Abstract e12596: Five day accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) in stage 0-II breast cancer: A report of 135 cases with up to two-year follow-up.
First Author: Rufus J. Mark, MD

Abstract e12597: Radiation therapy to improve survival in early-stage HER2-positive breast cancer with high-level of tumor infiltrating lymphocytes.
First Author: Jason A Mouabbi, MD
Abstract e12598: Tolerance of concurrent CDK inhibitor and radiation therapy in metastatic breast cancer patients.
First Author: Arnaud Beddok

Abstract e12599: Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy.
First Author: Mizuho Tazo

Abstract e12600: Long-term outcomes of preoperative radiotherapy in locally advanced breast cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) database.
First Author: Zhe Pan

Abstract e12601: Does localization technique matter for nonpalpable tumors?
First Author: Anees B. Chagpar, MD, MPH, MBA, MSc, MA, FACS, FRCS

Abstract e12602: Association between obesity and the clinical stage of newly diagnosed breast cancer: Experience with 2212 patients.
First Author: Bader I Alshamsan, MBBS

Abstract e12603: Validation of the Van Nuys Prognostic Index in 737 patients with ductal carcinoma in situ (DCIS) treated at Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
First Author: Michal Kunkiel, MD

Abstract e12604: Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
First Author: Ruby Guo, AB

Abstract e12605: The impact of endogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).
First Author: Orly Yariv

Abstract e12606: The impact of exogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).
First Author: Orly Yariv

First Author: Eileen Rakovitch, MD, MSc, FRCPC

Abstract e12608: Predictors of post-mastectomy radiation (PMRT) in node-negative breast cancer patients.
First Author: Laura Sheriff
Abstract e12609: Axillary management after neoadjuvant chemotherapy in breast cancer: A survey by Brazilian Society of Mastology.
First Author: Antonio Luiz Frasson

Abstract e12610: Magseed localisation for loco-regional breast and lymph node recurrences: Placement prior to chemotherapy to allow focused removal of the initially diseased tissue.
First Author: Carol Benn

Abstract e12611: Secondary cancer after breast conserving therapy as a negative predictor of overall survival: Preparing wisely.
First Author: Kenshiro Shiraishi, MD

Abstract e12612: Patients over 65 with early breast cancer and preference for intraoperative radiation despite no survival benefit.
First Author: Annie Tang

Abstract e12613: Advantages of intraoperative digital specimen radiography (IDSR) in breast surgery.
First Author: Lyudmila Zhukova, MD, PhD

Abstract e12614: Giant tumors of the breast in adolescents and types of reconstruction during thelarche.
First Author: Peter Kern, MD PhD

Abstract e12615: Are there inequities in reconstruction after mastectomy in breast cancer patients related to race or insurance status?
First Author: Paul J. Chuba, MD, PhD

Abstract e12616: Radiation and cardiotoxicity: A retrospective analysis of a midwest population.
First Author: Nitin Tandan

Abstract e12617: Abrrant expression of a subset of epithelial–mesenchymal transition genes in triple-negative breast cancer before and after EC-T neoadjuvant chemotherapy.
First Author: Liyuan Wei, MD

Abstract e12618: Gene expression profiling involved in response to neoadjuvant therapy in breast cancer.
First Author: Salvador Bofill, Ph.D, MD

Abstract e12619: Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy for breast cancer: Results from a prospective institutional database.
First Author: Megan Tesch
Abstract e12620: Prognostic and predictive value of neutrophil/lymphocyte ratio in patients with triple-negative and HER2-positive breast cancer undergoing neoadjuvant systemic therapy.
First Author: Agnieszka I. Jagiello-Gruszfeld, MD, PhD

Abstract e12621: Characterization of weakly hormone receptor (HR)-positive, HER-negative breast cancer (BC) and current treatment strategies.
First Author: Johanna Poterala, MD

First Author: Amit Kulkarni, MD

Abstract e12623: Identification of CCN1 transferred by extracellular vesicles derived from breast cancer cells responsible for doxorubicin-resistance.
First Author: Sujin Yang, Dr.

Abstract e12624: Treatment patterns and clinical outcomes of patients with early triple negative breast cancer at a tertiary medical center.
First Author: Julia C. Tchou, MD, PhD

Abstract e12625: Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted?
First Author: Elena Parvez

Abstract e12626: Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in young women with breast cancer: Prognosis and axillary node surgery.
First Author: Sung-chan Gwark, M.D., Ph.D.

Abstract e12627: Clinical value of kinase Aurora-A serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy: Pilot study.
First Author: Beata Kotowicz, PhD

Abstract e12628: The effect of carboplatin dosing on pCR rate in ER+/HER2+ patients receiving neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP).
First Author: Sacha Jon Howell, MD

Abstract e12629: Tumor-infiltrating lymphocytes in breast cancer: Association of high levels of CD3, CD8 cells, and Immunoscore with pathologic CR in patients receiving neoadjuvant chemotherapy.
First Author: Bernardo Leon Rapoport, MD

Abstract e12630: 21-gene recurrence score assay as a predictor of pathological response in neoadjuvant chemotherapy administration for ER-positive/HER2-negative early-stage breast
cancer.
First Author: Serafin Morales Murillo

Abstract e12631: The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research.
First Author: Ayane Yamaguchi, MD

Abstract e12632: Pathological complete response rates in HER2 amplified breast cancers based on levels of HER2 amplification.
First Author: Ina Patel, DO

Abstract e12633: Caveolin-1 expression to predict efficacy of nab-paclitaxel and cyclophosphamide followed by fluorouracil, epirubicin, and cyclophosphamide in neoadjuvant chemotherapy for operable breast cancer in the phase II clinical trial.
First Author: Yuri Kimura

Abstract e12634: Comparing efficacy and toxicity profile of weekly paclitaxel to dose-dense paclitaxel (every two weeks) in treatment of breast cancer: A meta-analysis and systematic review.
First Author: Usman Khan, MD

First Author: Hirotaka Miyashita

First Author: Evelyne Guay, BSc

First Author: Nicholas Zdenkowski, BMed, FRACP, PhD

Abstract e12638: Prognostic biomarker candidates of neoadjuvant chemotherapy for luminal B-positive locally advanced breast cancer.
First Author: Zhaoyun Liu, MD

Abstract e12639: Analysis of factors associated with pathological complete response (pCR) in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy.
First Author: Neda Stjepanovic, MD
Abstract e12640: Neoadjuvant systemic therapy utilization and outcomes in breast cancer (BC).
First Author: Marya Hussain

Abstract e12641: Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
First Author: Silvia Antolin, MD PhD

Abstract e12642: Translesion synthesis genes POLI and REV1 in breast tumors and response to neoadjuvant chemotherapy.
First Author: Patricia Thompson, PhD

Abstract e12643: Biodynamic response prediction in breast cancer patients receiving neoadjuvant chemotherapy.
First Author: Travis Morgan, MBA

Abstract e12644: Comprehensive analysis of long noncoding RNA expression in circulation of breast cancer patients on neoadjuvant therapy.
First Author: Boris Krastev

Abstract e12645: Variability in metabolic cross-feeding behaviors in breast cancer and response to neoadjuvant chemotherapy.
First Author: Joseph R Peterson, Ph.D.

Abstract e12646: Anti-PD-1 responsive circulating immune cells as biomarkers of response to neoadjuvant chemotherapy in HER2+ breast cancer (BC).
First Author: Nicola Gaynor

Abstract e12647: A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.
First Author: Peter A. Fasching, MD

Abstract e12648: Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.
First Author: Nicholas J. Robert, MD

Abstract e12649: Discordance between molecular subtyping from pre- and post-neoadjuvant chemotherapy (NACT) biopsy specimens in a Brazilian breast cancer cohort.
First Author: Monique Celeste Tavares, MD, PhD
Abstract e12650: SimBioSys TumorScope: Spatio-temporal modeling of the tumor microenvironment to predict chemotherapeutic response.
First Author: John A Cole Jr., Ph.D.

Abstract e12651: Perfusion kinetics from clinical DCE mris increase the accuracy of predictions of tumor response to chemotherapy.
First Author: John A Cole Jr., Ph.D.

Abstract e12652: Metabolic profile in Mexican young women breast cancer (YWBC) to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC).
First Author: Marlid Cruz-Ramos, MD, DSc

Abstract e12653: Incidence of brain metastases in patients receiving neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in HER2-positive early breast cancer (BC).
First Author: Emanuela Ferraro, MD

Abstract e12654: Impact of malnutrition and anemia at diagnosis in both: Pathological response and tumor-infiltrating-lymphocytes post neoadjuvant chemotherapy.
First Author: Katia MERCEDES Roque, MD

Abstract e12655: Pathological outcomes of HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab or dual anti-HER2 therapy and carboplatin with docetaxel: A Maria Sklodowska-Curie National Research Institute of Oncology experience.
First Author: Agnieszka I. Jagiello-Gruszfeld, MD, PhD

Abstract e12656: Spatiotemporal modeling with SimBioSys TumorScope to predict chemotherapeutic response in breast tumor microenvironments.
First Author: Chaitanya K Mamillapalli, MD

Abstract e12657: Need for systematic de-escalation of care in HER2+ breast cancer patients.
First Author: Tushar Pandey

Abstract e12658: Neoadjuvant chemotherapy in locally advanced breast cancer: Clinicopathological characteristics and correlation with pathological complete response.
First Author: Priyanshu Choudhary

**Breast Cancer—Metastatic**

Abstract e13000: Test measuring signaling activity in live patient tumor cells to identify PI3KCA WT patients who may benefit from PI3K inhibitors.
First Author: Lance G. Laing, PhD
First Author: Junqing Chen

First Author: Krithika Krishnarao

Abstract e13003: Acquired immune deficiency of cancer: Evaluation of NK cell number as a predictor of overall survival in breast cancer.
First Author: R. Michael Williams, MD, PhD

Abstract e13004: Comparisons of survival time in BRCA-positive patients with metastatic breast cancer using electronic health records (EHRs).
First Author: Yookyung Christy Choi, PharmD

Abstract e13005: Real-world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients.
First Author: Dirk Hempel, MD

Abstract e13006: STAT6 expression and trastuzumab resistance in HER2+ breast cancer.
First Author: Melody A. Cobleigh, MD

First Author: Yongheng Liu, Ph.D.

Abstract e13008: Assisting decision making on the use of carboplatin for metastatic breast cancer.
First Author: Juan Luis Gomez Marti

Abstract e13009: A site-specific approach to improved antibody-drug conjugates.
First Author: James Italia

Abstract e13010: Extrapolation of indications and drug interchangeability as barriers to use trastuzumab-dkst biosimilar in Brazil.
First Author: Heloisa Magda Resende

Abstract e13011: Cardiotoxicity manifestations in metastatic breast cancer patients treated with trastuzumab as first line.
First Author: Shira Sherman
Abstract e13012: Targeted therapies: How can CT imaging improve evaluations and help understand mechanism of drug action?
First Author: Hubert Beaumont, PhD

Abstract e13013: Barriers to accessibility of targeted therapy for breast cancer: A qualitative study in Yerevan, Armenia.
First Author: Darshan Shingala

Abstract e13014: New potential therapeutic-sequence strategies of TDM1 in the revolutionary era of metastatic HER2-positive breast cancer treatment: a monocentric retrospective experience.
First Author: Maria Vita Sanò

First Author: Serdar Karakaya

Abstract e13016: Impact of neratinib on outcomes in HER2+ metastatic breast cancer patients with or without central nervous system disease at baseline: Findings from the NALA trial.
First Author: Cristina Saura, MD, PhD

Abstract e13017: Real-world incidence and management of durable complete response in de novo metastatic HER2-positive breast cancer.
First Author: Claire Elizabeth Powers Smith, M.D.

Abstract e13018: Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
First Author: Jin Sun Lee, MD

Abstract e13019: Real-world study of the treatments following trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multicentral cohort study (WJOG12519B).
First Author: Sasagu Kurozumi, PhD, MD

First Author: Norikazu Masuda, MD, PhD

First Author: Josee-Lyne Ethier, MD, MS, FRCPC

Abstract e13022: Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials.
First Author: Zefei Jiang, MD
Abstract e13023: A national real-world prospective study to assess the effectiveness of adjuvant trastuzumab-dkst in HER2 breast cancer.
First Author: Leandro Ladislau Alves, PhD

Abstract e13024: Safety of a trastuzumab biosimilar, used under routine clinical practice conditions in adult HER2+ breast cancer patients in Morocco.
First Author: Hassan Errihani, MD

Abstract e13025: Distribution of oncotype recurrence scores in invasive lobular carcinomas.
First Author: Kelly Suchman

First Author: Ana Acuna Villaorduna, MD

Abstract e13027: Patient-reported pain and pain medication impact in patients with HR+ Her2-neg advanced breast cancer: A U.S. FDA pooled analysis.
First Author: Bellinda King-Kallimanis, PhD

Abstract e13028: A retrospective analysis of CDK4/6 inhibitors among adult female patients with metastatic breast cancer.
First Author: Silvia Comis, MD

Abstract e13029: CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
First Author: Maysa M. Abu-Khalaf, MD

Abstract e13030: Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
First Author: Anja Kovac, MD

Abstract e13031: Metastasis by semi-quantitative oestrogen receptor expression in stage I-III early diagnosed triple positive breast cancer patients.
First Author: Jasmine Van de Kerkhof

Abstract e13032: The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer.
First Author: Emma Zattarin, MD

Abstract e13033: CDK4/6 inhibitors beyond second line, is it worthy? A real-world data experience.
First Author: Alejandro Falcón
Abstract e13034: Metastatic-free intervals and risk of breast cancer-specific mortality among patients with hormone receptor-positive breast cancer: a population-based analysis from the Surveillance, Epidemiology, and End Results registries.  
First Author: Gregory Sampang Calip, PharmD, MPH, PhD

Abstract e13035: CDK4/6 inhibitors and hormone therapy in hormone receptor-positive advanced breast cancer: Real-world data and intrinsic subtypes defined by PAM50.  
First Author: Tamara Diaz Redondo, MD

Abstract e13036: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2.  
First Author: Karen A. Gelmon, MD

Abstract e13037: Integrative assessment of the effect of renal function on ribociclib treatment and dose recommendation in advanced breast cancer patients.  
First Author: Yan Ji, MD

Abstract e13038: Cardiac complications of CDK4/6 inhibitors for breast cancer.  
First Author: Samip R. Master, MD, MBBS

Abstract e13039: Real-world hematologic toxicities in patients > 70 versus < 69 with ER positive metastatic breast cancer on CDK 4/6 inhibitors: Single-institution retrospective study.  
First Author: Coral Olazagasti

Abstract e13040: Prediction of early progression (EP) to CDKIs first line treatment in ER+/HER2-metastatic breast cancer (MBC) using machine learning.  
First Author: Jose Manuel Jerez, PhD

Abstract e13041: Radiomics risk score (RRS) on CT to predict survival and response to CDK 4/6 inhibitors in hormone receptor (HR) positive metastatic breast cancer (MBC).  
First Author: Siddharth Kunte, MBBS

Abstract e13042: Association of tumor infiltrating lymphocytes (TILs) density and PD-L1 expression with pembrolizumab (P) plus gemcitabine (Gem) efficacy in patients with HER2-negative advanced breast cancer (ABC) from the GEICAM/2015-04 (PANGEA-Breast) study.  
First Author: Luis De La Cruz Merino Sr., PhD

Abstract e13043: Absolute lymphocyte count to predict progression-free survival in patients with metastatic breast cancer treated with palbociclib.  
First Author: Takayuki Kobayashi, PhD, MD
Abstract e13044: Keeping oncologists current with CDK4/6 inhibitors in HR+ breast cancer: The impact of online education.
First Author: Kinjal Parikh, PharmD, BCOP

Abstract e13045: Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2- advanced breast cancer.
First Author: Jesús Fuentes Antrás

Abstract e13046: Real-world treatment patterns among metastatic breast cancer patients by BRCA status and phenotype.
First Author: Wendy Sebby, MPH

First Author: Funda Meric-Bernstam, MD

Abstract e13048: Real-world incidence, duration, and severity of treatment-emergent (TE) neutropenia among patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB) or palbociclib (PAL).
First Author: Lee S. Schwartzberg, MD, FACP

Abstract e13049: SERENA-2: A randomized, open-label, parallel-group, multicenter phase II study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer.
First Author: Mafalda Oliveira, MD, PhD

Abstract e13050: Exploratory analysis of Treat ER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer.
First Author: Catherine Doyle, FRCPC, MD

Abstract e13051: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
First Author: Min Hwan Kim, MD PhD

Abstract e13052: Comparison of treatment-related adverse events (TRAE) of different CDK4/6 inhibitors (CDK4/6i) in metastatic breast cancer (MBC): A network meta-analysis.
First Author: Alexandra Desnoyers, MD

Abstract e13053: Real-world clinical outcomes in patients receiving cyclin-dependent kinase 4/6 inhibitors (iCDK 4/6) for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer in Mexico.
First Author: Benigno Rodriguez, MD
Abstract e13054: Real-world survival data of palbociclib in advanced and metastatic breast cancer: A multicenter experience in Lebanon.
First Author: Lewis Nasr

Abstract e13055: Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.
First Author: Gul Basaran, MD

Abstract e13056: A single institution retrospective study of the effect of starting doses in patients with ER-positive metastatic breast cancer on CDK 4/6 inhibitors.
First Author: Wingsze Liu

Abstract e13057: Palbociclib in hormone positive metastatic breast cancer: A real world multicenter Indian experience.
First Author: Amit Rauthan, MD

Abstract e13058: Prescribing preferences for hormone sensitive (HR+) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era.
First Author: Bruce A. Feinberg, DO

Abstract e13059: EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): A retrospective observational study.
First Author: Sanjeev Balu, PhD, MBA, B.Pharmacy

Abstract e13060: Overall survival (OS) in post-menopausal women with HR+/HER2− advanced breast cancer (ABC) receiving a CDK4 & 6 inhibitor (CDK4&6i) + fulvestrant (FUL) after progressing on/after prior endocrine therapy (ET): A network meta-analysis (NMA).
First Author: Alison Davie

Abstract e13061: Resensitization of palbociclib-resistant MCF-7 cells by inhibiting TGF-β-induced epithelial-mesenchymal transition.
First Author: Minsun Chang, PhD

Abstract e13062: A prospective, open-label, multicenter, phase IV clinical study on the safety and efficacy of lobaplatin in the treatment of metastatic breast cancer.
First Author: Binghe Xu, MD, PhD

Abstract e13063: A novel proteomic mass spectrometry-based approach to reveal functionally heterogeneous tumor clones in breast cancer metastases and identify clone-specific drug targets.
First Author: Nawale Hajjaji, MD, PhD
Abstract e13064: Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China.
First Author: Shaoyan Lin

Abstract e13065: Yttrium-90 radioembolization for breast cancer with liver metastases: A focus on mortality, adverse reactions, and radiological response.
First Author: Patrick Heckman, DO

Abstract e13066: Metaplastic breast cancer: A retrospective analysis over 14 years.
First Author: Pooja Gogia Bhasin, MD

Abstract e13067: Ixabepilone efficacy and tolerability in metastatic breast cancer (MBC) patients in a real-world setting.
First Author: Tara Hyder

Abstract e13068: Effect of ARID1a oncogenic loss of function mutations on overall survival in metastatic breast cancer patients.
First Author: Veronica Mariotti, MD

Abstract e13069: Treatment (tx) trends among patients (pts) with HER2- advanced breast cancer (ABC) and BRCA1/2 mutation(s) (BRCA1/2mut): Results from a real-world multi-country study.
First Author: Alexander Niyazov, PharmD, MPH

Abstract e13070: Bone scintigraphy and PET-CT: A necessary alliance for bone metastasis detection in breast cancer?
First Author: Joana Cristo Santos

Abstract e13071: Real-world data on biweekly docetaxel-gemcitabine (DG) as salvage treatment for advanced breast cancer (ABC).
First Author: Carolina Ortiz, MD

Abstract e13072: Multicenter Italian bone metastasis database: First prospective data on breast cancer patients.
First Author: Alberto Bongiovanni

Abstract e13073: Asymptomatic versus symptomatic metastatic breast cancer: Potential effects on prognosis and quality adjusted life years (QALYs).
First Author: Kosho Yamanouchi, MD, PhD

Abstract e13074: BRCA1/2 mutation testing trends among patients (pts) with HER2- advanced breast cancer (ABC): Results from a real-world multi-country study.
First Author: Reshma L. Mahtani, DO
First Author: Sofía Ruiz, MD

Abstract e13076: Treatment patterns and clinical outcomes among patients (pts) with HER2+ advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study.
First Author: Elias Obeid, MD, MPH

Abstract e13077: Treatment patterns and clinical outcomes among patients (pts) with HER2−advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study.
First Author: Elias Obeid, MD, MPH

Abstract e13078: Development of an artificial intelligence model to dynamically predict metastatic recurrence of early-stage breast cancer patients.
First Author: Vivek Prabhakar Vaidya

Abstract e13079: A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).
First Author: Ozge Gumusay, MD

Abstract e13080: Macrocytosis as a predictor of response to capecitabine in solid cancers: A meta-analysis.
First Author: Fahad Almugbel

Abstract e13081: Prognosis of breast cancer patients with initial bone metastasis: A population-based study.
First Author: Deyue LIU

First Author: Ayako Ueno

Abstract e13083: Assessment for markers of poor prognosis in a real-world evidence study of treatment patterns in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea and Taiwan.
First Author: Diego Novick, MD, PhD

First Author: Shlomit S. Shachar, MD
Abstract e13085: Gemcitabine with carboplatin in metastatic breast cancer: Characterizing outcomes in a modern, real-world population.
First Author: Jordyn Paige Higgins, PharmD

Abstract e13086: The role of circCNIH4 in the adipocyte's effects on metastasis of breast cancer cells.
First Author: Xiu Chen

Abstract e13087: Expression of CD44 and CD133 markers in regional metastases from breast cancer.
First Author: Aleksandr B. Sagakyants

Abstract e13088: BRCA1/2 and CHEK2 mutation prevalence in patients with breast and/or ovarian cancer in the South of Russia.
First Author: Natalia A. Petrusenko

Abstract e13089: Enzymatic tissue disintegration leads to the loss of immunophenotype of breast cancer stem cells.
First Author: Aleksandr B. Sagakyants

Abstract e13090: Apatinib to prolong overall survival from recurrence to death in metastatic breast cancer: A single-center experience from east China.
First Author: Lei Shi

Abstract e13091: Depressive factors associated with breast cancer.
First Author: Alexandre Alberto Mendes Tostes, MD, MSc

Abstract e13092: Feasibility of real-time serial comprehensive tumor analytics: Pilot study of olaparib and durvalumab in metastatic triple negative breast cancer (mTNBC).
First Author: Allen Li, MD, MS

Abstract e13093: Del-1 and MFG-E8 expression to differentially modulate prognosis of patients with triple-negative breast cancer.
First Author: Soo Jung Lee, MD. Ph.D.

Abstract e13094: Very long term follow-up of high dose chemotherapy followed by autologous stem cell transplantation in high risk locally advanced triple negative breast cancer.
First Author: Bayan A Al-Share, MD

Abstract e13095: Physician treatment preferences for metastatic triple negative breast cancer (mTNBC) in an era of immunotherapy.
First Author: Ajeet Gajra, FACP, MBBS, MD
Abstract e13096: Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).
First Author: Elias Eteshola, PhD (c)

Abstract e13097: Economic evaluation of SP142 IHC assay versus 22C3 IHC assay in patients with unresectable locally advanced or metastatic triple-negative breast cancer in the Brazilian private healthcare system.
First Author: Rodrigo Shimabukuro Ho

Abstract e13098: Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
First Author: Miriam Nuncia Cantarero

Abstract e13099: Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer.
First Author: Ji Ma

Abstract e13100: Role of E2F3 and shugoshin I in epithelial-to-mesenchymal transition and cell invasion in breast cancer.
First Author: Shirley Jusino, PhD (c)

Abstract e13101: Pilot trial of priming with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency (DDRD) followed by cisplatin (cis) and nab-paclitaxel (nab pac) in chemotherapy-pretreated metastatic triple negative breast cancer (metTNBC) pts.
First Author: Joyce O'Shaughnessy, MD

Abstract e13102: Evaluating progression-free survival in black and white women with triple-negative breast cancer in pooled clinical trials from a synthetic control database (SCD) and real-world electronic medical records (EMR).
First Author: Mark Layton Watson, MD, PhD

Abstract e13103: 12-month uptake of PD-L1 testing and atezolizumab (atezo) + nab-paclitaxel (nab-pac) treatment in metastatic triple-negative breast cancer (mTNBC) following accelerated FDA-approval in the United States.
First Author: Leisha A. Emens, MD, PhD

Abstract e13104: PD-L1 IHC 22C3 pharmdx demonstrates precision and reproducibility in detecting PD-L1 expression in triple negative breast cancer.
First Author: Karina Kulangara, PhD

Abstract e13105: Key pathways analysis of triple negative breast cancer in Asian vs non-Asian population using bioinformatics tools.
First Author: Rassanee Bissanum
Abstract e13106: Dual TGF-β and AURKA targeting enhances chemosensitivity in triple-negative breast cancer.
First Author: Fahad Ahmed Faruqi, MD, MPH

Abstract e13107: Outcomes of transarterial chemoembolization (TACE) of the liver in patients with metastatic triple-negative breast cancer (TNBC).
First Author: Anna E. Storozhakova

Abstract e13108: A retrospective single-center study investigating the clinical significance of grade in triple-negative breast cancer.
First Author: Caroline M. Hamm, MD

Abstract e13109: Deoptimized influenza virus for treatment of TNBC and induction of anticancer immunity in the EMT6 mouse model.
First Author: Marcin Stawowczyk, PhD

Abstract e13110: Triple-negative and non–triple-negative breast cancer in a south Indian cohort.
First Author: Narayanankutty Edavalath Warrier, MD

**Cancer Prevention, Risk Reduction, and Genetics**

Abstract e13500: Genomic origin and immune-related status of pulmonary sarcomatoid carcinoma.
First Author: Xuewen Liu

Abstract e13501: SASS6 to promote proliferation of esophageal squamous carcinoma cells by inhibiting the p53 signaling pathway.
First Author: Yuanmei Chen

Abstract e13502: Next generation sequencing reveals the phylogenetic relationship of multi-organ metastatic colon cancer and molecular determinants of metastasis.
First Author: Dandan Hu, MD

Abstract e13503: Genomic landscape of FGF/FGFR pathway alternations across 12,372 pan-cancer patients.
First Author: Yongmei Yin, MD

First Author: Dmitry Yu. Gvaldin
Abstract e13505: Staging the cancer ecosystem: Survival data from a registry study of patients with active cancer.
First Author: James R. Cunningham, MD

Abstract e13506: Genomic characterization of preclinical models derived from primary and metastatic sites from rapid autopsy patients in PDMR.
First Author: Li Chen, Ph.D.

First Author: Talal Ahmed, PhD

Abstract e13508: Comprehensive profiling of MDM2/TP53 genomic aberration in Chinese patients with diverse malignancies.
First Author: Dongkai Zhou

First Author: Joseba Rebollo

Abstract e13510: NGS-based molecular profiling (a multi-center collaborative, observation study in Japan) highlights pathogenic variants of DNA-repair genes in advanced or recurrent endometrial cancer.
First Author: Hiroyuki Fujiwara, MD, PhD

Abstract e13511: Precision medicine, genetics and genomics in a community cancer clinic.
First Author: Sourat Darabi, PhD, MS

First Author: Rui Fu

Abstract e13513: Identification of paclitaxel resistance through a new statistical approach based on a random forest of perfect trees classification.
First Author: Jean-Michel Nguyen, MD, PhD

Abstract e13514: Genomic alterations and clinical correlations of Chinese patients with hepatoid adenocarcinoma of the stomach/alpha-fetoprotein gastric cancer.
First Author: Tianshu Liu, MD

Abstract e13515: Association between MUC5B mutation and prognosis across solid tumors.
First Author: Qun Zhao
Abstract e13516: Differential expression of micro-RNA in tumor and non-tumor tissues of patients with colorectal cancer.
First Author: Inna A. Novikova

Abstract e13517: Druggable fusion gene landscape in solid tumors.
First Author: Gareth Haydn Williams, BSc MBChB PhD FRCPath FLSW

Abstract e13518: Features of iso-miR expression in colon tumor tissue.
First Author: Natalya N. Timoshkina

Abstract e13519: Novel mutations of SYK gene in solid tumors.
First Author: Jian Shi

Abstract e13520: Genomic landscape and clinicopathological characteristics of lung cancer in young Chinese patients.
First Author: Jiexia Zhang, MD

Abstract e13521: Immunofocus-PD-L1 high throughput quantitative next generation sequencing assay.
First Author: Gareth Haydn Williams, BSc MBChB PhD FRCPath FLSW

Abstract e13522: Identification of kinase domain duplications across diverse cancer types in Chinese population by comprehensive genomic profiling (CGP).
First Author: Baohua Wang, MD

Abstract e13523: Incidence of mutated DNA damage response pathway and clinically actionable alterations in Chinese patients with unknown primary tumor revealed by comprehensive genomic profiling.
First Author: Shibao Wang, MD

Abstract e13524: Clinicopathological features of patients with ovarian and breast cancer with BRCA mutation.
First Author: Metin Ozkan

Abstract e13525: YsRNA aberrant expression in colorectal cancer patients.
First Author: Inna A. Novikova

First Author: Gillian Hooker, PhD, ScM, LCGC

Abstract e13527: Characteristics of EGFR uncommon mutations in Chinese cancer patients.
First Author: Minghui Wang, M.D.
Abstract e13528: Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
First Author: Jie Wang, MD, PhD

Abstract e13529: Distinct genomic and immune microenvironment between thymomas and thymic carcinomas.
First Author: Kaicheng Wang

Abstract e13530: Genomic characterization of sub-centimeter pulmonary nodules.
First Author: Muyun Peng, MD

Abstract e13531: The effect of transcriptional activity of genes regulating DNA repair and apoptosis on the effectiveness of radiation therapy in rectal cancer patients.
First Author: Natalia G Kosheleva

Abstract e13532: A new PMS2 gene variant of unknown significance: How pathogenic is it?
First Author: Clarissa Gondim Picanço-Albuquerque, PhD

Abstract e13533: Expression profile and co-expression analysis of ADH1A in human solid tumors.
First Author: Wenqi Huang

Abstract e13534: Enrichment of circulating tumor DNA from cell-free DNA of hematopoietic origin.
First Author: Jason Terrell, MD

Abstract e13535: Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).
First Author: Daniel Louis Hertz, PhD, PharmD

Abstract e13536: Characteristics of breast cancer in Slovenian patients with germline CHEK2 c.444+1G>A mutation.
First Author: Nikola Besic

Abstract e13537: Association of tumor mutations with arterial thromboembolism risk in patients with solid cancer.
First Author: Ka-wai Ho

Abstract e13538: The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB).
First Author: Sanjeevani Arora, PhD
Abstract e13539: The prevalence of targetable genomic alterations is substantially high in rare tumors.
First Author: Shuhang Wang, MD

Abstract e13540: Family cancer patterns and variation by race and ethnicity among individuals with pathogenic variants in multi-gene cancer predisposition panels at a large urban comprehensive cancer center.
First Author: Sushma Tatineni, MD

Abstract e13541: Communication of genetic testing results and cascade testing among Mexican carriers of cancer-associated variants and their families.
First Author: Yanin Chavarri Guerra, MD

First Author: Yuan Qiu

First Author: Kwang-Huei Lin

Abstract e13544: HBV-human DNA integration in non-hepatic tumors.
First Author: Lei Liu, MD

Abstract e13545: SLC3A2 mutation as a genetic biomarker for dMMR in colorectal cancer.
First Author: Jian Xiao, PhD

Abstract e13546: The prognostic value of HRD mutations in liver cancer.
First Author: Jinzhang Chen, MD

Abstract e13547: Comprehensive analysis of advanced-stage solid tumors from TCGA reveal widespread variation of genomics evidence levels across cancer types.
First Author: Dilhan Weeraratne, PhD

Abstract e13548: Next generation sequencing analysis of key genes in breast cancer patients from Kazakh population.
First Author: Aliya Abdrakhmanova

Abstract e13549: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for advanced breast cancer patients with high risk for Hereditary Breast and Ovarian Cancer Syndrome (HBOC).
First Author: Rosane Oliveira Sant'Ana, MD, PhD
Abstract e13550: A discrete choice experiment (DCE) study evaluating preferences of Asian adults for inherited cancer risk testing.
First Author: Ru Jin Tay

Abstract e13551: Landscape of mutational signatures in 10,000 solid tumors from the Chinese population.
First Author: Aaron Chevalier

Abstract e13552: Exploring African American males' attitudes towards genetic testing for prostate cancer risk.
First Author: Amy Leader, DrPH, MPH

Abstract e13553: Prevalence of BRCA1 and BRCA 2 and other mutations in Chilean population.
First Author: Carolina Selman

First Author: Jianing Yu

Abstract e13555: MLsurvival: an automated machine learning tool for survival analysis of cancer patients.
First Author: Wei Zhou

Abstract e13556: Treating obesity as primary prevention of cancer.
First Author: Chowdhury Ferdous

First Author: You-cai Zhu

Abstract e13558: Outcome of mammography examination among asymptomatic women.
First Author: Hadijat Oluseyi Kolade-Yunusa

Abstract e13559: Dietary consumption of tea and the risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
First Author: Robert J. Thomas, MD

Abstract e13560: Dietary intake of broccoli and the risk of cancer in the prostate, lung, colorectal, and ovarian cancer (PCLO) screening trial.
First Author: Robert J. Thomas, MD

Abstract e13561: Early cancer detection using multi-omic approach including epigenetic signal from ultra-small fragments.
First Author: Johnny Wu
Abstract e13562: Association of chronic hepatitis C virus infection with an increased risk of lung cancer: A systematic review and meta-analysis.
First Author: Ben Ponvilawan, MD

Abstract e13563: “Smoke and screens”: How streaming spreads the habit of smoking.
First Author: Maximiliano Brandon, MD

Abstract e13564: Importance of public awareness of the association of tobacco products to bladder cancer.
First Author: N Mullai, MD

First Author: Coral Olazagasti

Abstract e13566: The role of HPV vaccination as a cancer prevention agent.
First Author: N Mullai, MD

Abstract e13567: Breast cancer in younger patients in Southeast of Brazil: 10-year analysis.
First Author: Sabina B. Aleixo, MD

Abstract e13568: Proteomic screening of saturated fatty acid-induced hepatocytes-derived exosomes.
First Author: Yi-Ting Liu

Abstract e13569: The study on the effect of depression on breast cancer incidence through IDO/kynurenine pathway.
First Author: Yanmei Zhang Jr., Master

Abstract e13570: ‘Detect Early Be Safe–Care for Mother (DEBS-CaM)’ project: School-based interventions to improve awareness and screening for breast cancer among the young mothers of Kerala.
First Author: Narayananankutty Warrier, MD, DM, FRCP

Abstract e13571: Lung cancer incidence in never smokers in the Southeast of Brazil: 10 years analysis.
First Author: Jose Zago Pulido, MD

Abstract e13572: Assessing risk-based LDCT screening strategies versus the current USPSTF lung cancer screening recommendations at an institutional setting.
First Author: Carol Velez Martinez, MD
Abstract e13573: Mammographic screening and socio-epidemiological profile of Amerindian riverside women in the Amazon forest.
First Author: Juliana Ramos Chaves, MD

Abstract e13574: Highlights of BRCA genetic testing in prostate cancer from a real-world patient cohort in Australia.
First Author: Inga Tinton

Abstract e13575: Subsequent pregnancy and long-term safety from breast cancer patients.
First Author: Yunyeong Kim

Abstract e13576: Molecular testing patterns and implications for treatment at a cancer center.
First Author: Clarissa Lam

Abstract e13577: Rate of breast cancer screening and genetic testing in high-risk patients under age 40.
First Author: Christine Velazquez, MD

Abstract e13578: The relationship between leptin, leptin receptor, and FGFR1 in primary human breast tumors.
First Author: Wyatt Shoemaker, BA

Abstract e13579: Highly accurate NGS-based multi-gene testing in the diagnosis of thyroid nodules with indeterminate cytology.
First Author: Yuntao Song

Abstract e13580: Overview of obesity and breast cancer in Brazil: 24 year of follow up.
First Author: Andrea Z Pereira, MD, PhD

Abstract e13581: Breast cancer incidence and behavior in younger patients: A study from the surveillance, epidemiology, and end results (SEER) database.
First Author: Zuha Nasim

Abstract e13582: A nomogram to predict the probability of breast intraductal tumors in patients with nipple discharge: A report based on our 13-year clinical experience.
First Author: Siyuan Jiang

Abstract e13583: Cancer incidence in Behçet's Disease.
First Author: Deniz Can Guven

Abstract e13584: Is there an association between air pollution levels and lung cancer incidence?
First Author: Seema Patel
Abstract e13585: Statin use is associated with a lower risk of diffuse large B-cell lymphoma: A systematic review and meta-analysis.
First Author: Ben Ponvilawan, MD

Abstract e13586: Proximity to oil refineries and risk of cancer: A population-based analysis.
First Author: Stephen B. Williams, MD, MS

Abstract e13587: A retrospective chart review evaluating the relationship between cancer diagnosis and drinking water source on the Lower Eastern Shore of Maryland.
First Author: Angela Marie DeRidder, MD, MPH

Abstract e13588: Impact of the molecular pathology of breast cancer on mortality rates and overall survival in a Haitian cancer clinic.
First Author: Joseph Bernard Jr., MD

Abstract e13589: Epidemiological profile of cancers among adolescent and young adult patients of a Haitian cancer program.
First Author: Joseph Bernard Jr., MD

Abstract e13590: Association of tumor mutational burden with age in solid tumors.
First Author: Zhuang Yu

Abstract e13591: Relationship between nutritional status and length of hospital stay in oncological surgery.
First Author: Carl Meissner

Abstract e13592: Epidemiology and mortality of metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States.
First Author: Katrine Wallace

Abstract e13593: Can body size explain the excess cancer risk in men?
First Author: Cecilia Radkiewicz, MD, PhD

Abstract e13594: The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility.
First Author: Lele Song, M.D., Ph.D.

Abstract e13595: Impact of socioeconomic status on the incidence and mortality of multiple myeloma in the United States.
First Author: Ibrahim Omore

First Author: Sharareh Seifi, MD
Abstract e13597: Former smokers as the most frequent smoking status in patients with lung cancer in Brazil.
First Author: Guilherme Jorge Costa Sr., Doctorate

Abstract e13598: Marital status and survival analysis of patients with pure mucinous breast carcinoma: A SEER population-based retrospective study.
First Author: Fan Tang

Abstract e13599: Hormone-replacement therapy may be associated with increased incidence of luminal breast cancer: Results from a large-scale health maintenance organization (HMO) analysis.
First Author: Nava Siegelmann-Danieli, MD

Abstract e13600: Epidemiology of adenoid cystic carcinoma in the United States.
First Author: Tirza Areli Calderón Boyle, PhD, MPH

Abstract e13601: Differential effect of obesity on comorbidity risk in younger and older women with early breast cancer.
First Author: Michael Lorentsen, MD

Abstract e13602: Prevalence of pathogenic non-BRCA1/2 gene variants in patients with suspected hereditary breast and ovarian cancer at a referral hospital in northeastern Brazil.
First Author: Rosane Oliveira Sant'Ana, MD, PhD

Abstract e13603: Prevalence of germline mutations in BRCA1/2 in patients from northeastern Brazil.
First Author: Clarissa Gondim Picanço-Albuquerque, PhD

Abstract e13604: Serum phospholipids fatty acids and breast cancer risk by pathological subtype: EpiGEICAM study.
First Author: Marina Pollan, PhD

First Author: Ryan M. O'Keefe, BA

Abstract e13606: Anaerobes in prostate cancer: New approaches to treatment and prevention.
First Author: Tim RTD Oliver, MD

Abstract e13607: Pharmacogenetics findings in Brazilian cancer patients.
First Author: Luis Eduardo Werneck De Carvalho, MD, PhD
Abstract e13608: Role of CD8+ T-cell infiltration in breast tumors of Black women compared to White women.
First Author: Yara Abdou, MD

Abstract e13609: CA 15-3 elevation in U.S. women without breast cancer.
First Author: Xiao Hu, MD, MPH

Abstract e13610: All-cause and cancer mortality in a private health plan in Brazil: Ten years retrospective analysis.
First Author: Joao Paulo Reis Neto

Abstract e13611: Meta-analysis and single-center experience on the comprehensive genomic characterization and landscape of BRCA1 and BRCA2 in Turkey.
First Author: Atil Bisgin, MD, PhD

Abstract e13612: Is the incidence of breast cancer increasing? Using the NCDB and autoregressive integrated moving average models (ARIMA) to forecast breast cancer to 2030.
First Author: Leah Elson, MS

Abstract e13613: Epidemiology and outcome of patients with colorectal cancer and inflammatory bowel disease: A retrospective analysis of a patient cohort reporting to a large cancer center.
First Author: Susen Burock, MD

Abstract e13614: Disparities in cancer premature mortality in Brazil: Predictions up to 2030 and sustainable development goals.
First Author: Marianna De Camargo Cancela, DDS, MSc, PhD

Abstract e13615: Mortgage discrimination and breast cancer survival among older women in the United States.
First Author: Kirsten M. M. Beyer

Abstract e13616: Lung cancer chemotherapy and radiotherapy toxicity in patients with HIV.
First Author: Tinaye Mutetwa, MSc

Abstract e13617: Quantification of inequities in breast cancer incidence in New Mexico through Bayesian disease mapping.
First Author: David Zahrieh

Abstract e13618: Lipid levels and survival after obesity-related cancer in the Women’s Health Initiative CVD biomarker cohort.
First Author: Gayane Hovsepian, BS
Abstract e13619: Male breast cancer: Epidemiological evaluation and clinical outcomes.
First Author: Edla Renata Cavalcante

Abstract e13620: Breast cancer, cardiac events, and survival: Do outcomes differ in urban and rural populations? A retrospective analysis of a midwest population.
First Author: Nitin Tandan

First Author: Yvonne Sada, MD, MPH

Abstract e13622: Cardiac events and breast cancer survival analysis in caucasians and minorities: A retrospective study in central Illinois.
First Author: Asad Cheema, MD

Abstract e13623: Clinical, sociodemographic, and pathological characteristics of breast cancer in the United States: A cross-sectional analysis from the National Cancer Database (NCDB).
First Author: Zeina A. Nahleh, MD

Abstract e13624: Comorbidities and survival in breast cancer: A retrospective cohort study from an academic institution in southern Illinois.
First Author: Ruby Maini, MD

Abstract e13625: Impact of tuberculosis on mortality and healthcare resource utilization in cancer patients: A nationwide inpatient sample analysis.
First Author: Ishaan Vohra, MBBS

Abstract e13626: Tobacco still haunting Kentuckians: Adolescent and young adult (AYA) cancer trend from the Kentucky SEER database.
First Author: Aasems Jacob, MD

Abstract e13627: Cancer site distribution in district hospital in central India.
First Author: Dinesh Pendharkar, MD, PhD

Abstract e13628: Identifying the most vulnerable areas for the occurrence of new cases and deaths related to cervical cancer in the city of Recife, Brazil: See to act.
First Author: Jurema Telles O Lima, MD, PhD

Abstract e13629: The spectrum of cancer in adolescents and young adults (AYAs): An observational study in a single institution from 2015-2019.
First Author: Wei Lin Goh
Abstract e13630: Hematological malignancies in the adolescent and young adult (AYA) population in Singapore.
First Author: Eileen Yi Ling Poon, MD

Abstract e13631: Breast cancer frequency and survival by molecular subtype in central Illinois.
First Author: Hamsa Sahib

Abstract e13632: Reproductive risk factor patterns in the Caribbean affecting breast cancer age of onset.
First Author: Alex Sanchez-Covarrubias, MD

Abstract e13633: Comparing breast cancer characteristics and outcomes between black U.S.-born patients and black immigrant patients from individual Caribbean islands.
First Author: Danielle Cerbon, MD

Abstract e13634: Epidemiology, prevalence, and prognosis of multiple malignancies of a subpopulation of a large German cancer center.
First Author: Gina Rüter, MD

Abstract e13635: Survival and cardiac outcomes in elderly individuals with breast cancer: A retrospective study from an academic center.
First Author: Ruby Maini, MD

First Author: Jordan Alana Ciuro

Abstract e13637: Mutation spectrum of EGFR in 21,324 patients with non-small cell lung cancer successfully tested by multiple platforms in a CAP-accredited laboratory.
First Author: Linlin Mao

First Author: Xiaoxiang Guan, MD

First Author: Pooja Parekh, BA

Abstract e13640: Germline DNA repair gene mutations in Taiwan prostate cancer patients.
First Author: Wilson Huang
Abstract e13641: The genes CNV features in the tumor cells in patients with ovarian serous adenocarcinoma.
First Author: Marieta R. Tsandekova

Abstract e13642: The actionable genomic mutational landscape in solid tumours.
First Author: Marco Loddo, BSc PhD

Abstract e13643: Genetic predisposition to childhood cancer: A retrospective cohort analysis in a multidisciplinary genetic cancer counseling Unit.
First Author: Nuria Rodriguez Salas, PhD

Abstract e13644: Validation of the fully automated idylla system for microsatellite instability detection in Chinese colorectal cancer patients.
First Author: Qian Wang, M.D.

First Author: Jorge Ramón, MD

Abstract e13646: Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.
First Author: Umut Disel, MD

Abstract e13647: Development of novel detection system using artificial intelligence for genetic alterations with low allele frequencies in next generation sequencing analysis: Result from LC-SCRUM-Japan.
First Author: Hibiki Udagawa, MD, PhD

Abstract e13648: Analysis of gene copy number in esophageal patient-derived tumor xenografts.
First Author: Ekaterina A. Lukbanova

First Author: Tatiana P. Protasova

Abstract e13650: Time to receive genomic test results and first-line (1L) therapy choice for patients (pts) with EGFR-mutated advanced non-small cell lung cancer (aNSCLC).
First Author: Xiaoliang Wang

Abstract e13651: Analysis of germline mutations in Chinese colorectal cancer patients with next-generation sequencing.
First Author: Jing Gao
Abstract e13652: Economic burden of not testing for FLT3 to treat acute myeloid leukemia.
First Author: Raymond Henderson

Abstract e13653: Cancer risks associated with the HOXB13 c.251G>A variant in men and women referred for hereditary cancer genetic testing.
First Author: Melanie Jones, PhD

Abstract e13654: Genomic characterizations of KIT and PDGFRA in Chinese pan-cancer patients.
First Author: Xianze Xiong

Abstract e13655: The alteration of TERT in 10,000 Chinese patients with solid tumors.
First Author: Jie Lin, BA, MD

Abstract e13656: Association of rs7372209 single nucleotide polymorphism in gene for miRNA-26a-1 with tumor localization and disease outcome in patients with colorectal cancer from Bulgaria.
First Author: Galya Mihaylova

First Author: Ruifang Mao

Abstract e13658: An ultra-sensitive multiplexed enrichment of rare DNA variants via toehold exchange principle.
First Author: Yue Pu, Ph.D.

Abstract e13659: Accurate prediction of somatic variants using deep learning model.
First Author: Peng Zhang

Abstract e13660: Landscape of germline mutations in 1144 patients (Pts) with gastrointestinal (GI) cancers.
First Author: Mohamed E. Salem, MD

First Author: Xiang Wang, Ph.D.

Abstract e13662: Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies.
First Author: Ziyang Li, Dr.

Abstract e13663: The prevalence of CDK12 alterations in Chinese cancer patients and the association with tumor mutation burden (TMB) and survival.
First Author: Ke Li
Abstract e13664: Genomic comparisons between different radiological features in ground glass nodules under 20 mm in diameter.
First Author: Muyun Peng, MD

Abstract e13665: Clinical characters of somatic DNA damage repair (DDR) gene mutations in Chinese NSCLC patients.
First Author: Ke Ma, M.D

Abstract e13666: Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.
First Author: Xiaonan Zhao, Ph.D

Abstract e13667: Biomarker testing patterns and trends among patients with metastatic lung cancer.
First Author: Suwei Wang, PhD

Abstract e13668: A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices.
First Author: Hinco J. Gierman, MSc, PhD

Abstract e13669: Development CRISPR-Cas12-based rapid EGFR mutation detection kit.
First Author: Kei Kunimasa, MD, PhD

Abstract e13670: PALB2 mutations in Brazilian patients from North-Northeast regions.
First Author: Thamara Ferreira, MD

Abstract e13671: Application of MammaPrint test on Chinese patient with breast cancer.
First Author: Chen Tian

Abstract e13672: Super-MSI: CfDNA-based pan-cancer microsatellite instability detection.
First Author: Xiaomeng Sun, PhD

Abstract e13673: Ki-67 versus MammaPrint/BluePrint for assessing luminal type breast cancer.
First Author: Chen Tian

Abstract e13674: The prognostic role of somatic BRCA mutations in ovarian cancer: Preliminary results from an observational multicenter cohort study.
First Author: Claudia Piombino

Abstract e13675: Application of next generation sequencing (NGS) in gastrointestinal stromal tumor (GIST).
First Author: Bin Li
Abstract e13676: Clinical use of RNA sequencing and oncobox analytics to predict personalized targeted therapeutic efficacy.
First Author: Elena Poddubskaya, MD

Abstract e13677: Prevalence of BRCA1/2 pathogenic variants in triple negative breast cancer patients stratified according to age at diagnosis.
First Author: Ana Blatnik, MD

Abstract e13678: Tumor sequencing aids to identify individuals with hereditary cancer.
First Author: Teresa Imizcoz-Fabra

Abstract e13679: Germline genetic mutational landscape and characteristics of men with prostate cancer (PCa): A single institution experience.
First Author: Sunil Adige

Abstract e13680: Genetic testing experiences and emotional reactions among individuals with variant of uncertain significance results from cancer multiplex genetic testing.
First Author: Jada G. Hamilton, Ph.D., M.P.H.

Abstract e13681: Performance of cell-free tumor DNA testing for 101 clinical laboratories on College of American Pathologists proficiency tests.
First Author: Christina M Lockwood

Abstract e13682: Characteristics of probands with mutations predisposing to gynecologic cancers enrolled in a facilitated cascade testing protocol.
First Author: Kristina Hwang

Abstract e13683: The positive correlation between tumor mutation burden and the purity of tumor samples in non–small cell lung cancer and colorectal cancer.
First Author: Jian Tong, MD

First Author: Fei Ma, M.D.

Abstract e13685: Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene blood-based comprehensive genomic profiling assay.
First Author: Ryan Woodhouse

Abstract e13686: Determination of incidence of germline pathogenic mutations in the UAE and development of a telegenetics program in the Asia-pacific/Middle East region.
First Author: Shaheenah S. Dawood, FACP, FRCP

Abstract e13687: A DNA-mutational panel for liquid biopsy-based pan-cancer early detection.
First Author: Zhao Yi
Abstract e13688: Circulating exosome DANCR correlated to the recurrence of hepatitis C virus-related hepatocellular carcinoma.
First Author: Shu-Chi Wang

First Author: Zorica Tomasevic, MD

Abstract e13690: Characteristics and survival of secondary male breast cancer: SEER database analysis.
First Author: John Khoury, MD

Care Delivery and Regulatory Policy

Abstract e14000: A tailored predication model to improve outcomes and mortality in geriatric indigenous women with breast cancer of western Australia.
First Author: Azim Khan, MBBS, AMC

Abstract e14001: The multi-disciplinary meeting as a tool to identify patients for clinical trials and translational research.
First Author: H Winter

Abstract e14002: Direct access to genetic services: An exploratory analysis of email contacts received under a multidisciplinary breast/ovarian program.
First Author: Irina Coelho

Abstract e14003: The optimal living and wellness program: Piloting a novel survivorship care model.
First Author: Stacie Corcoran, MS

Abstract e14004: Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients.
First Author: Kevin Nathaniel Johns, MD

Abstract e14005: Role of technology in a prospective surveillance and early intervention model for preventing lymphedema: The RE-AIM framework.
First Author: Deonni Stolldorf, PhD RN

Abstract e14006: Advancing precision medicine in clinical oncology: Whole exome paired tumor-normal DNA and RNA sequencing at a single-institution cancer center.
First Author: Kevin McDonnell, MD, PhD
Abstract e14007: Utilizing an advanced practice provider (APP) led acute care clinic to improve access to high quality, patient centered, cost effective cancer care.
First Author: Megan Spradlin, MPAS, PA-C

Abstract e14008: Effect of access to care on outcomes of rural and elderly patients with primary central nervous system lymphoma.
First Author: Scott C. Howard, MD

First Author: Carol Benn

Abstract e14010: An optimal care coordination model for Medicaid patients with lung cancer: Lessons learned from the beta testing phase of a multisite initiative in the United States.
First Author: Matthew Smeltzer, PhD, MS

Abstract e14011: Utilization of imaging and outcomes of care among metastatic colorectal cancer (mCRC) patients (pts) receiving bevacizumab containing regimens.
First Author: Afsaneh Barzi, MD, PhD

Abstract e14012: Systematic analysis of chemotherapy agents for home-based administration.
First Author: XiangyunGe Ye

Abstract e14013: Rural challenges in a decade of crowdfunding for cancer care.
First Author: Ahmed Khalil

Abstract e14014: Toxicity of HDMTX administration at TJUH: A retrospective review to guide establishment of an outpatient treatment program.
First Author: Kelsey Sokol, MD

Abstract e14015: Access to breast/ovarian genetic testing: 20 years of a multidisciplinary program.
First Author: Fatima H Vaz, MD, MSc

Abstract e14016: Lessons learned from clinical trial queries on small biopsy collections from an academic cancer center.
First Author: Jamie Voyten

Abstract e14017: Provider perspectives of video visits in oncology.
First Author: Nathan Handley, MD, MBA

Abstract e14018: Descriptive evaluation of frequent patient referrals to our cardio-oncology clinic: The Mayo experience.
First Author: Anza Zahid, M.B.B.S
Abstract e14019: Provider and patient insights into the cancer care journey.
First Author: Sarah McLarty, PharmD

Abstract e14020: Patterns in detection of recurrence among patients treated for breast cancer.
First Author: Lena Saltbæk, MD

Abstract e14021: The pink vans: Bringing cancer screening closer to home.
First Author: Frederic Ivan Leong Ting, MD, RN

First Author: Chongrui Xu, MD, PhD

Abstract e14023: Single-institutional analysis of clinicopathologic features and overall survival (OS) in melanoma patients (pts).
First Author: Ding Wang, MD, PhD

Abstract e14024: Clinical trials navigator: Patient-centered access to clinical trials.
First Author: Caroline M. Hamm, MD

Abstract e14025: First validation of the supportive care score (SCC) scale: Alert scale for referral of solid cancer patients to supportive oncology team.
First Author: Mathilde Chastenet Jr.

Abstract e14026: Patient-reported outcomes integrated within electronic medical record in patients with head and neck cancer.
First Author: Stephanie Ossowski, MD, MPH

Abstract e14027: Improving provider practice patterns in ordering FDG PET/CT for breast cancer patients at a safety-net hospital.
First Author: Daria Abolghasemi, DO

Abstract e14028: Primary care provider involvement in thyroid cancer survivorship care.
First Author: Archana Radhakrishnan, MD, MHS

Abstract e14029: The impact of integrating an oncology nurse practitioner into an acute care hospital emergency department: An Australian tertiary cancer centre experience.
First Author: Gillian Blanchard

Abstract e14030: Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic.
First Author: Amin Virani
Abstract e14031: Development and validation of a new clinical prediction model of catheter-related thrombosis in cancer patients.
First Author: Binliang Liu

Abstract e14032: Associations between patient-reported outcomes and physiatry assessments in an integrative model of a survivorship clinic.
First Author: Hira Latif, MD

Abstract e14033: Interdisciplinary risk assessment and delay of chemotherapy.
First Author: Juliana Souza, MD, MD

Abstract e14034: Optimizing the febrile neutropenia care process in cancer patients in a third level spanish hospital.
First Author: Maria Pilar Solis-Hernandez, MD

Abstract e14035: Quality care in survivorship: Lessons learned from the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI).
First Author: Charles L. Shapiro, MD, FASCO

Abstract e14036: Perceptions of cancer care coordination in patient-family caregiver dyads.
First Author: Izumi Okado, PhD

Abstract e14037: Early nutrition intervention in cancer patients: A systematic review and meta-analysis.
First Author: Bhavina D O Batubhai, MD

Abstract e14038: Predictors of electronic patient-reported outcomes use in the survivorship setting.
First Author: Bridgette Thom, PhD

Abstract e14039: 4R Care Delivery Program results: impact of implementation metrics on patient self-management and 4R usefulness.
First Author: Julia Rachel Trosman, PhD, MBA

Abstract e14040: National evidence-based oncology navigation metrics: Multisite exploratory study to demonstrate value and sustainability of navigation programs.
First Author: Tricia Strusowski

First Author: Leong Melissa
Abstract e14042: Optimizing infusion wait time: Redesigning medication order verification/approval at a comprehensive cancer center.
First Author: Neda Hashemi-Sadraei, MD

Abstract e14043: Prospective evaluation of patients for stereotactic radiosurgery/radiotherapy (SRS/SRT) by an experienced SRS/SRT radiation oncologist at a hospital-based cancer center lacking SRS/SRT capability.
First Author: Don Stacy II, MD

Abstract e14044: Utilization of online crowdfunding for alternative cancer treatments at home and abroad.
First Author: Joshua David Gruhl, MD

Abstract e14045: Lenalidomide use in multiple myeloma.
First Author: Denise Meade, MBA

First Author: Denise Meade, MBA

Abstract e14047: Oncology volume assessment program: Novel approach to determine patient volumes at Vanderbilt-Ingram Cancer Center (VICC) and Vanderbilt University Medical Center (VUMC).
First Author: Leeland Ekstrom, PhD

Abstract e14048: Clinical evaluation and performance of QIAGEN Clinical Insight Interpret (QCI-I) as a reporting tool for a comprehensive cancer panel (TSO 500).
First Author: Nikhil Shri Sahajpal, PhD

First Author: Alind Gupta

Abstract e14050: Patient trial matching using pseudo-siamese network.
First Author: Cao Xiao

Abstract e14051: Clinical utility of comprehensive genomic pathway and integrated network analyses in personalized oncology.
First Author: Nikhil Shri Sahajpal, PhD

Abstract e14052: Computational pathological identification of prostate cancer following neoadjuvant treatment.
First Author: Belma Dogdas, PhD
Abstract e14053: Prospectively assessing risk of acute care utilization for patients with an active cancer diagnosis.
First Author: Valerie Pracilio Csik, MPH

Abstract e14054: Phenotyping clinical trial treatment regimens in cancer: An integrative ontology, artificial intelligence and knowledge engineering approach.
First Author: Yun Mai, Ph.D

Abstract e14055: Prediction of pathologic complete remission (pCR) to neoadjuvant chemotherapy (NAC) using machine learning models in patients with breast cancer (BC).
First Author: Ji-Yeon Kim, MD

Abstract e14056: Development of an algorithm using natural language processing to identify metastatic breast cancer patients from clinical notes.
First Author: Krishna Kumar Swaminathan

Abstract e14057: Deep learning to develop transcriptomic model for survival prediction in TCGA patients with hepatocellular carcinoma.
First Author: Hao Yu

Abstract e14058: Electronic patient-reported outcomes (ePROs) and machine learning (ML) in predicting the presence and onset of immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) therapies.
First Author: Sanna Iivanainen, MD, Ph.D

Abstract e14059: Impact of augmented intelligence (AI) on identification and management of depression in oncology.
First Author: John Frownfelter

Abstract e14060: mCODER: a web-application for clinical data capture based on the ASCO mCODE standard.
First Author: Nadia Znassi, PhD

Abstract e14061: Non-user physician perspectives about an oncology clinical decision-support system: A qualitative study.
First Author: Hermano Alexandre Lima Rocha, MD, MPH, PhD

First Author: Meng Ma, Ph.D

Abstract e14063: A mixed methods study for the evaluation of a digital health solution for cancer multidisciplinary team meetings using simulation-based research methods.
First Author: Clarissa Gardner, BSc
Abstract e14064: Machine learning for prospective identification of immunotherapy related adverse events (irAEs).
First Author: Daniel Margalski

Abstract e14065: Prioritizing targeted therapies in an evidence-based manner, integrating biological context and functional precision medicine.
First Author: Simina Boca

Abstract e14066: Realtime autOmetically updated data warehOuse in healTh care (ROOT-S).
First Author: Hyun Ae Jung, MD

First Author: Emma C. Scott, PhD

First Author: Daniel Gustavo Pellacani Petrini, M.Sc.

Abstract e14069: Machine learning analysis on American Gut Project microbiome data to identify subjects with cancer both with and without chemotherapy exposure.
First Author: Oguz Akbilgic, Associate Professor

Abstract e14070: A review of gynecological cancers studies of concordance with individual clinicians or multidisciplinary tumor boards for an artificial intelligence-based clinical decision-support system.
First Author: Yull Edwin Arriaga, MD

Abstract e14071: Machine learning models to predict the response to anti-cancer therapy in metastatic melanoma patients.
First Author: Romain Goussault

Abstract e14072: Evaluation of a regularly updated knowledge base for curation of somatic mutations detected in whole exomes of melanoma and lung, colorectal, and breast cancers.
First Author: Stephanie J. Yaung, PhD

Abstract e14073: Enhanced co-expression extrapolation (COXEN) gene selection method for building anticancer drug response prediction models.
First Author: Yitan Zhu

First Author: Jian Li, PhD
Abstract e14075: Using oral morphine-equivalent values to track the analgesic effect of treatments in clinical trials.
First Author: Stephen A Raymond, PhD

Abstract e14076: Independent validation of paige prostate: Assessing clinical benefit of an artificial intelligence tool within a digital diagnostic pathology laboratory workflow.
First Author: Christopher Kanan, PhD

First Author: Paul Henry Frankel, PhD

Abstract e14078: The association of adaptive early phase study design and late phase study results in oncology using clinicaltrials.gov data.
First Author: Donna Elise Levy

Abstract e14079: Representing cancer clinical trial criteria and attributes using ontologies: An NLP-assisted approach.
First Author: Kyeryoung Lee, Ph.D

Abstract e14080: Survival among breast cancer patients with a history of previous cancer.
First Author: Sandi Pruitt, PhD

Abstract e14081: A novel approach to quantitatively synthesize subgroup findings from multiple trials.
First Author: Devon J Boyne, MSc

Abstract e14082: The role of baseline lesion selection on reader performance in oncologic clinical trials.
First Author: Anu Bansal

Abstract e14083: The joint i3+3 (Ji3+3) design for phase I / II adoptive cell therapy clinical trials.
First Author: Yuan Ji, PhD

Abstract e14084: Patient engagement in clinical trial design and implementation: A pragmatic approach to valued insights.
First Author: Dawn Aubel, Ed.D, MPH

Abstract e14085: Recruiting patients with advanced cancer to participate in a non-opioid intervention for chronic pain management.
First Author: Preethi Selvan, MPH

Abstract e14086: Leveraging clinical pathways to identify patient-reported clinical trial enrollment barriers.
First Author: Mishellene McKinney
Abstract e14087: The landscape of gastrointestinal oncologic phase III clinical trials in the last two decades.
First Author: Joseph Abi Jaoude, MD

Abstract e14088: Professional medical writing assistance in oncology clinical trials.
First Author: Joseph Abi Jaoude, MD

Abstract e14089: Clinical trial feasibility assessment and start-up tool (CTFAST).
First Author: Amanda Tice, RN

Abstract e14090: Beyond classical surrogate endpoints in trials of PD1/PD-L1 immune checkpoint inhibitors (ICI) plus chemotherapy (CT).
First Author: Guillermo Villacampa

Abstract e14091: A retrospective review of early-phase designs and endpoints used in clinical development of small molecule or tyrosine kinase inhibitors (TKIs) for cancer treatment.
First Author: Brian S. Henick, MD

Abstract e14092: Transforming the site feasibility assessment process for oncology clinical trials.
First Author: Dax Kurbegov, MD

First Author: Kai Hsin Liao, PhD

Abstract e14094: Comparison of the predictive power of survival of the Royal Marsden Score (RMS), the Gustave Rousy Immunescore (GRIM score), the MDACC score (MDAS) and the LIPI score in phase I trials patients.
First Author: Eduardo Castanon Alvarez, MD

Abstract e14095: Harnessing tumor immunity with chemotherapy: Mathematical modeling for decision-making in combinatorial regimen with immune-oncology drugs.
First Author: Vesna Cuplov, Ph.D.

Abstract e14096: HIV status and history of prior malignancy in immunotherapy trials.
First Author: John Xie, MD

Abstract e14097: A simulation study of loss to follow up: The impact on time to event and prevention.
First Author: Donna Elise Levy
Abstract e14098: Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.
First Author: Wanyuan Cui, MBBS, FRACP

Abstract e14099: The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials.
First Author: Igal Kushnir, MD

Abstract e14100: Impact of organ function based standard exclusion criteria in diffuse large b-cell lymphoma (DLBCL) patients: Who gets left behind?
First Author: Arushi Khurana, MBBS

Abstract e14101: Use of Twitter among cancer clinicians and researchers and the associations with scientific impact of its users and followers.
First Author: Winson Y. Cheung, MD, MPH

Abstract e14102: An innovative approach to manage cancer patient information for care coordination and monitoring using a digital health platform for a nonprofit tertiary cancer care institute in India.
First Author: Sharon Hensley Alford, PhD

Abstract e14103: Pilot study for the use of wearable devices for patients undergoing oral chemotherapy.
First Author: Monaliben Patel, MD

Abstract e14104: Continuous monitoring of mobility performance trajectory in patients receiving chemotherapy.
First Author: Sudha Yarlagadda, MD

Abstract e14105: Using a bi-directional digital health platform for cancer care coordination and monitoring to enhance the cancer care continuum between patients, clinicians and caregivers.
First Author: Sharon Hensley Alford, PhD

Abstract e14106: Initial Experience with Cancer Guidelines Navigator, a tool to standardize and improve the quality of cancer care in Sub-Saharan Africa, at Ocean Road Cancer Institute in Tanzania.
First Author: Fernando Jose Suarez Saiz, MD

Abstract e14107: Interventional multicenter study to assess the feasibility of an e-health system (ZEMY) designed to manage symptoms and treatment-related toxicities in patients with breast cancer.
First Author: Luis Teixeira, M.D., Ph.D.
Abstract e14108: Optimizing cancer care using digital technologies requires coordinated multi-stakeholder effort.
First Author: Sendhilnathan Ramalingam, MD

Abstract e14109: Adherence to remote versus clinic-based collection of patient-reported outcomes in patients with advanced lung cancer.
First Author: Peter Edward Gabriel, MD, MS, BA

Abstract e14110: Augmentation of a minimal multidisciplinary tumor board with clinical decision support to triage breast cancer patients in the United Kingdom.
First Author: Hartmut Kristeleit, MD

Abstract e14111: Pan-Canadian evidence based, consensus driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
First Author: Kiran Virik, MD, FRACP, FRCPC

Abstract e14112: Evaluation of cancer patients comfort with and interest in interacting with various social robot configurations in a clinical environment.
First Author: Julio Hajdenberg, MD, FACP

Abstract e14113: Social media and gynecologic cancers: The impact of Twitter #GYNCSM.
First Author: Christina Lizaso, MNO

Abstract e14114: Associations between concordance with oncology clinical decision support and clinical outcomes in lung cancer patients.
First Author: Suthida Suwanvecho, MD

Abstract e14115: Mobile health applications in oncology.
First Author: Vivek Upadhyay

Abstract e14116: Oncology early development technology to facilitate early analysis of safety and efficacy data.
First Author: Mireya Vaca, MS

Abstract e14117: Use of artificial intelligence to improve access to initial leukemia diagnosis in low- and middle-income countries.
First Author: Tania Raquel Cerrato, MD

First Author: Nathaniel Hendrix
Abstract e14119: Preferences and motivational factors for the use of digital technology in real world oncology studies.
First Author: Nadeeka Dias, PhD

Abstract e14120: Design of eSyM: An ePRO-based symptom management tool fully integrated in the electronic health record (Epic) to foster patient/clinician engagement, sustainability, and clinical impact.
First Author: Michael J. Hassett, MD, MPH, FASCO

Abstract e14121: Sickness absence and disability pension among Swedish women before breast cancer relapse.
First Author: Hedayati Elham, MD PhD

Abstract e14122: The use of patient health information outside the circle of care: Consent preferences of patients from a large academic cancer centre.
First Author: Fei Fei Liu, FASTRO, FRCPC, MD

Abstract e14123: The changing atlas of clinical research in cancer: Measuring accessibility to clinical trials.
First Author: Luca Mazzarella, MD, PhD

Abstract e14124: The validity of VALID act: Cost modeling cancer diagnostics regulation by the FDA.
First Author: Richard Huang, MD

Abstract e14125: FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.
First Author: Dianne Spillman, BS

Abstract e14126: Responding to narrowing discrimination protections: Can hospital policies protect transgender and gender diverse patients with cancer?
First Author: Ash Alpert

Abstract e14127: QT assessments in oncology drug development and related labels.
First Author: Nan Zheng, PhD

Abstract e14128: Regulatory decision patterns for oncological products: Comparison between FDA, EMA, and Swissmedic over a decade.
First Author: Ulrich Peter Rohr, MD

Abstract e14129: Medicaid expansion and trends in cancer stage at diagnosis.
First Author: John Withington, FRCS(Urol) MD(Res)
First Author: Bhakti Arondekar, PhD

First Author: Christopher G. C. A. Jackson, FRACP

Abstract e14132: Using multiple perspectives analysis to propose state cancer control policy in Abia State, Nigeria.
First Author: Kelechi Ngozi Eguzo, MD, MPH

Abstract e14133: Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
First Author: Regina Li

Abstract e14134: How to better anticipate innovative anticancer drugs and their potential challenges: A European survey from the iPAAC WP9.
First Author: Hélène Denis, PharmD

First Author: Nikolaos Tsoukalas, MD, MS, PhD

First Author: Loretta A. Williams, PhD, APRN, AOCN

Abstract e14137: Clinical practice guideline for persons at risk of and with cancer-related lymphedema.
First Author: Pamela Ginex, EdD

First Author: HOda Jradi

Abstract e14139: Optimization of screening tools in patients eligible to receive immune-checkpoint inhibitors.
First Author: Lorena Ostios-Garcia, MD

First Author: Pamela Ginex, EdD
Abstract e14141: How the NIH Genetic Testing Registry and Medical Genetics Summaries can help oncologists adopt pharmacogenetics guidelines.
First Author: Adriana Jose Malheiro, MS, CGC

Abstract e14142: Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital.
First Author: Reid Christian Bowers, PA-C

First Author: Marika Cinausero, MD

Abstract e14144: Complementary and alternative medicine use among cancer patients at a private hospital in Brazil.
First Author: Eliza Dalsasso Ricardo

First Author: Sara Ashraf, MD

Abstract e14146: To scan or not to scan: An evaluation of preoperative MRI use in primary breast cancer assessments.
First Author: Tesia McKenzie, MD

Abstract e14147: Safe handling system construction for hazardous drugs (HDs) through the HD exposure surveillance by National Hospital Organization Network in Japan.
First Author: Kenjiro Aogi, MD

First Author: Silvio Ken Garattini, MD

Abstract e14149: A template for generic assessment of tumor response: "myRECIST".
First Author: Stephen Raskin, MD

First Author: Bohdan Baralo, MD

Abstract e14151: The impact of patients’ and physicians’ characteristics on surgery decision for head and neck cancer: Results of a national survey.
First Author: Agnès Dupret-Bories Sr., MD, PhD

Abstract e14152: Overcoming clinical trial accrual barriers at UPMC: A successful experience.
First Author: Vincent Edgar Reyes, MD
Abstract e14153: Using a tele-oncology service provides a direct benefit to patients and caregivers in rural communities in the Intermountain West.
First Author: Derrick S. Haslem, MD

Abstract e14154: The impact of telemedicine on patient-reported outcomes in urologic oncology.
First Author: Adam John Gadzinski, MD, MS

Abstract e14155: Substantial ninety-nine percent reduction of turnaround time for QTc diagnostics using smartphone-based tele-cardiology.
First Author: Lena-Sophie Sophie Fink, B. Sc.

Central Nervous System Tumors

Abstract e14500: Association of leukocyte count (neutrophilia and lymphopenia) with poor prognosis in patients with high-grade gliomas in a Guatemalan cohort.
First Author: Rixci Ramirez, PhD, MD

Abstract e14501: Combination chemotherapy versus temozolomide (TMZ) for patients with MGMT methylated (m-MGMT) glioblastoma (GBM): Results of cellworks omics biosimulation—myCare-015.
First Author: Michael Castro, MD

Abstract e14502: The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement.
First Author: Veena M. Singh, MD

Abstract e14503: Upfront or delayed radiation with next generation tyrosine kinase inhibitor therapy in driver mutation positive NACLC brain metastasis.
First Author: Mike Yang

First Author: Cecilia Jiang

Abstract e14505: CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI).
First Author: David Benjamin Shultz, MD, PhD

First Author: Jarushka Naidoo, MBBS
First Author: Zheng-Yun James Zhan

Abstract e14508: Leptomeningeal metastasis from non-small cell lung cancer- outcomes from a tertiary care center.
First Author: Dilip Harindran Vallathol, MBBS, MD, DM

Abstract e14509: DCE-MRI Evaluation of 10 patients with brain metastases treated with RRx-001, a Myc inhibitor and a CD47 and PD-L1 downregulator, in a phase I/II trial called BRAINSTORM.
First Author: Michelle Miran Kim, MD

Abstract e14510: Prospective investigation of patent foramen ovale as a mechanism for brain metastasis in patients without prior lung involvement.
First Author: Rebecca Levin-Epstein, MD

First Author: Takehiro Tozuka

Abstract e14512: Invasive histopathological growth pattern is a poor prognostic indicator in patients with surgically resected brain metastases.
First Author: Matthew Dankner

Abstract e14513: Treatment outcomes in melanoma with brain metastases in the era of immunotherapy: An analysis of the National Cancer Database.
First Author: Justin Moyers, MD

Abstract e14514: Does extent of resection of glioblastoma multiforme affect survival?
First Author: Emad Eldin Nabil

Abstract e14515: In Vivo-like model of glial tumors: Creation of primary cell lines.
First Author: Sofia V. Timofeeva

Abstract e14516: Stereotactic radiosurgery for residual lesions of pineal nongerminomatous germ cell tumors after conventional radiotherapy: A retrospective study.
First Author: Mingyao Lai

Abstract e14517: Controlled IL-12 in combination with cemiplimab-rwlc in adult subjects with recurrent glioblastoma.
First Author: Rimas Vincas Lukas, MD
Abstract e14518: Therapeutic effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with concomitant temozolomide alone in children with DIPG: A single-center experience with 82 cases.
First Author: Mingyao Lai

First Author: Naila Agayar Mammadova

Abstract e14520: Quantitative imaging biomarkers of CNS lymphoma and its correlation with genotypic markers.
First Author: Aleksandr Filippov

Abstract e14521: Assessment of patient-reported outcomes in patients treated with radiation therapy to brain malignant tumors.
First Author: Li Yang

First Author: Karim Keshwani

Abstract e14523: Major histocompatibility complex class 1 (MHC1) loss among patients with glioblastoma (GBM).
First Author: Michael Castro, MD

Abstract e14524: Predictive evaluation of quantitative spatial profiling of the tumor microenvironment by multiplex immunofluorescence in recurrent glioblastoma treated with PD-1 inhibitors.
First Author: David Cieremans, BA

Abstract e14525: Effect of temozolomide chronotherapy in patients with high-grade glioma.
First Author: Himachandana Atluri, MD

Abstract e14526: Survival characteristics of patients with first progression of glioblastoma at Cleveland Clinic Foundation.
First Author: Yasmeen Rauf

First Author: Alice Nayane Rosa Morais, MD

Abstract e14528: Combined structural and perfusion MRI enhanced by machine learning may outperform standalone modalities and radiological expertise in high-grade glioma
surveillance: A proof-of-concept study.
First Author: Diana Roettger, PhD

First Author: Hanna Moisander-Joyce, MD

Abstract e14530: Venous thromboembolic events in glioblastoma patients: common complication but not a major reason for death.
First Author: Dorothee Gramatzki, MD

Abstract e14531: Ten-year experience of the Vall d’Hebron Institute of Oncology early drug development unit (VHIO-UITM) treating patients (pts) with primary CNS tumors (pCNS).
First Author: Maria Vieito, MD

Abstract e14532: Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.
First Author: Dong Won Baek, M.D.

Abstract e14533: Effect of cumulative dexamethasone dose during concomitant chemoradiation on lymphopenia in patients with newly diagnosed glioblastoma.
First Author: Stephen Ahn, M.D.

Abstract e14534: Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma.
First Author: Shihong Wu

Abstract e14535: Updated safety/feasibility study of concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma.
First Author: Rachel Grossman, MD

Abstract e14536: EF-19, a post-approval registry study of tumor treating fields (TTFields) in recurrent glioblastoma (rGBM).
First Author: Jay-Jiguang Zhu, MD, PhD

Abstract e14537: Survival in low-grade gliomas in patients (pts) over 50 years (>50y) at diagnosis: Is biology or suboptimal treatment driving poor outcomes?
First Author: Maria Vieito, MD

Abstract e14538: Genomic profiling identified novel prognostic biomarker in Chinese glioma patients.
First Author: Hainan Li
Abstract e14539: NF1 may serve as a novel genetic biomarker of response to treatment and prognosis in glioblastoma (GBM).
First Author: Bin Huang

Abstract e14540: Craniospinal irradiation in patients diagnosed with glioblastoma with primitive neuronal component prevents distant intracranial and leptomeningeal recurrences.
First Author: Boryana M Eastman, MD, PhD

Abstract e14541: Safety and efficacy of bevacizumab biosimilar in glioma.
First Author: Gunjesh Kumar Singh

Abstract e14542: Refusal trends of recommended treatments for glioblastomas.
First Author: Sonikpreet Aulakh, MBBS, MD

Abstract e14543: Post-operative disposition and readmission rates in repeat resections for glioblastoma.
First Author: Alex Guzner

Abstract e14544: A retrospective analysis of cost and survival outcomes based on consolidation regimens in primary central nervous system lymphoma.
First Author: Savannah Gelhard

Abstract e14545: Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM).
First Author: Anna K. Nowak, PhD, MBBS, FRACP

Abstract e14546: Clinical features and outcomes of neuroblastomas in adults.
First Author: Dawood Findakly, MD

Abstract e14547: Identification of genetic alterations in childhood and adolescence glioblastoma (GBM) using next generation sequencing strategy.
First Author: Debora Cabral de Carvalho Corrêa, BMSc

Abstract e14548: Nanoliposomal irinotecan and metronomic temozolomide for patients with recurrent glioblastoma: BrUOG329, A phase IB/IIA Brown University Oncology Research Group (BrUOG) trial.
First Author: Heinrich Elinzano, MD

Abstract e14549: Differential expression of KDM1A and SMAD7 genes in gliomas depending on the tumor grade.
First Author: Anton A. Pushkin
Abstract e14550: Role of miR-122-5P, miR-107, miR-22-3P, and miR-330-3P microRNAs in regulation of HIF1A expression in high-grade gliomas.
First Author: Anton A. Pushkin

Abstract e14551: The correlation between molecular characteristics and treatment outcomes in patients (pts) with grade 2-3 (G2-3) gliomas.
First Author: Jaleh Fallah, MD

Abstract e14552: Epidermal growth factor receptor expression as a molecular determinant of glioblastoma response to the dopamine receptor D2 antagonist, ONC201.
First Author: Yuyu He

Abstract e14553: Never too young: Retrospective study on age and racial disparity in the outcome of primary CNS Lymphoma in south Texas.
First Author: Snegha Ananth, MD

Abstract e14554: Tolerability of radiation with concurrent temozolomide and effect on survival in chemo-refractory CNS lymphoma.
First Author: Anna Mary Brown Laucis, MD, MPhil

Developmental Therapeutics—Immunotherapy

Abstract e15000: Risk of bleeding and significant thrombocytopenia in cancer patients treated with immune checkpoint inhibitors.
First Author: Tariq Zuheir Kewan, MD

Abstract e15001: Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors.
First Author: Barbara Hickingbottom, MD

Abstract e15002: Correlation of clinical activity of NEO201 mAb with the expression of NK activation markers and levels of soluble factors.
First Author: M. Pia Morelli, MD, MD, PhD, PhD

Abstract e15003: AFM24 as a novel, highly potent, bispecific EGFR/CD16A innate cell engager designed for the treatment of EGFR-positive malignancies.
First Author: Uwe Reusch

Abstract e15004: Characterization of BDG8: An antibody-human IL-2 complex that selectively activates the effector arm of the immune system.
First Author: Timothy Wyant, PhD
Abstract e15005: To target and to block: A dual functional SIRPα antibody fusion for the treatment of solid tumors.
First Author: Anna Reischer, MD

Abstract e15006: A novel CSF-1R neutralizing antibody, DCB-AB21, as a potential therapeutics for tumors.
First Author: Chen-Hsuan HO, PhD

Abstract e15007: Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323).
First Author: Bruce Keyt, PhD

Abstract e15008: Phase I trial characterizing the pharmacokinetic profile and NK and CD8+ t cell expansion with n-803, a chimeric IL-15 superagonist, in healthy volunteers.
First Author: John M. Wrangle, MD, MPH

Abstract e15009: Phase I study of CDX-1140 alone and in combination with CDX-301 in patients with advanced cancers.
First Author: Rachel E. Sanborn, MD

Abstract e15010: Fc-optimized anti-CD40 agonist antibody for the treatment of bladder cancer.
First Author: Jeffrey L Wong, MD, PhD

Abstract e15011: MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients.
First Author: Xichun Hu, MD

Abstract e15012: Prospective analysis of antinuclear antibodies prevalence in a pan-tumor sample.
First Author: Silvia Roa, MD

Abstract e15013: A pilot trial of multiple-TSA-specific adoptive immune cell (MAIC) as adjuvant therapy in gastrointestinal cancer.
First Author: Wei Shi

Abstract e15014: Profiling antigen specificity concurrently with protein and mRNA quantification using high throughput single-cell multiomics reveal surprising similarities between bystander and tumor specific CD8+ tumor-infiltrating lymphocytes (TILs) in renal cell carcinoma (RCC).
First Author: Aaron Tyznik

Abstract e15015: Immunotherapy combining NK and T cell activation with IL-15 super agonist (N-803), off-the-shelf high-affinity CD16 NK (haNK) or PDL1 targeted haNK and checkpoint
inhibitor in relapsed/refractory advanced pancreatic cancer.
First Author: Tara Elisabeth Seery, MD

Abstract e15016: Effect of activating chimeric receptor on IL-15 armored NK cell on providing in vitro and in vivo antigen specific tumor response.
First Author: Louis F. Chai, MD

First Author: Isabella Pascheto, B.Sc.

Abstract e15018: Impact of CD38 knockout in NK cells on daratumumab-mediated cytotoxicity and cellular metabolism.
First Author: Yuya Nagai, MD, PhD

Abstract e15019: Genetic modification ofiovance TIL through talen-mediated knockout of PD-1 as a strategy to overcome resistance to the PD-1 axis.
First Author: Krit Ritthipichai

Abstract e15020: Impact of type of salvage therapy (ST) and response to bridging therapy (BT) on CAR-T therapy outcomes for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
First Author: Arushi Khurana, MBBS

Abstract e15021: TCR-engineered T-cell therapy through personalized identification of CDR3 clonotypes.
First Author: Zishan Zhou

Abstract e15022: Analysis of the efficacy ofCIK therapy in adjuvant treatment of colorectal cancer.
First Author: Rui Guo

Abstract e15023: Platelets impact the responsiveness of immune checkpoint blockade therapy in solid tumors.
First Author: Brian P Riesenberg, Ph.D

Abstract e15024: Phase I study of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) in refractory metastatic solid tumors.
First Author: Sant P. Chawla, MD

Abstract e15025: Protein mislocalization as a novel target for CAR-T cell therapy.
First Author: Alessandro Di Tullio
Abstract e15026: Results from Melanoma Antigen Redirected Vaccine Stimulated Autologous Lymphocytes (MARVSmALo): A pilot study.
First Author: Joy M. Fulbright, MD

Abstract e15027: CoupledCAR technology for treating thyroid cancer.
First Author: Lei Xiao, PhD

Abstract e15028: Dominant negative PD1 armored CART cells to induce remission in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.
First Author: Chengfei Pu

Abstract e15029: Fine-tuned scFv-expressing CAR-T cells showed marked antitumor reactivity in vivo.
First Author: Toshiki Ochi, MD, PhD

Abstract e15030: Initial safety with a novel next-generation ADP-A2M4CD8 SPEAR T-cell construct incorporating a CD8α co-receptor.
First Author: Marcus O. Butler, MD

Abstract e15031: MDK-701 as a potent and selective peptide-based agonist of the human IL-7 receptor.
First Author: William J Dower, PhD

Abstract e15032: Phase I clinical trial of NY-ESO-1-specific TCR-engineered T cell transfer combined with novel T cell stimulator CHP:NE1 without pre-conditioning chemotherapy for NY-ESO-1 expressing soft tissue sarcoma.
First Author: Mikiya Ishihara, MD, PhD

Abstract e15033: Targeting non-engrafting IL-2 activated intentionally mismatched donor lymphocytes with monoclonal or bispecific antibodies for treatment of otherwise incurable cancer.
First Author: Shimon Slavin, MD

Abstract e15034: Hypomagnesemia is associated with decreased clinical response and survival in CAR-T therapy for lymphoma.
First Author: Sangeetha Gandhi

Abstract e15035: Novel CoupledCAR technology for treating colorectal cancer.
First Author: Lei Xiao, PhD

Abstract e15036: Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon.
First Author: Arjun Khunger, MD
First Author: Adam A Dempsey, Ph.D.

Abstract e15038: hPG80 (Progastrin), a novel blood-based biomarker for detection of neuroendocrine neoplasms.
First Author: Aman Chauhan, MBBS

Abstract e15039: The landscape of gene fusions and the correlation with immunotherapy biomarkers in Chinese patients with advanced solid tumor.
First Author: Wenshuai Liu, MD

Abstract e15040: Circulating extracellular vesicles as biomarkers for immune-checkpoint inhibitors in advanced NSCLC.
First Author: Diego Signorelli, MD PhD

Abstract e15041: Dynamic change in blood derived variant allele frequency as a predictive marker for response from checkpoint inhibitor-based therapies among metastatic solid tumors.
First Author: Shumei Kato, MD

First Author: Jose Garcia Sanchez, MD

Abstract e15043: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients.
First Author: Jayant Khandare, PhD

Abstract e15044: Peripheral cytokine as a pan-cancer predictor for immunotherapy with anti-PD-1/PD-L1 antibody.
First Author: Shoujian Ji

Abstract e15045: Clinical and laboratory features of cancer patients with hyperprogressive disease after treatment with immune checkpoint inhibitors.
First Author: Ruqin Chen, MD, MS

Abstract e15046: Predicting the efficacy of nivolumab combined with radiation therapy by longitudinal liquid biopsy with artificial intelligence for patients with metastatic breast cancer (translational research of the KBCRN-B-002 trial).
First Author: Kosuke Kawaguchi, MD, PhD

Abstract e15047: Leukocytes with bound platelets as a predictive biomarker for immune-related adverse events (irAEs) in advanced non-small cell lung cancer (NSCLC) patients (pts)
receiving anti-PD-(L)1 agents.
First Author: Mariona Riudavets, MD

Abstract e15048: Serum parameters as prognostic biomarkers to predict efficacy of anti PD-1/PD-L1 therapy in patients with solid tumors: A retrospective data analysis.
First Author: Christoph Minichsdorfer, MD

First Author: Paul R. Walker, MD, FACP

Abstract e15050: Utilizing serum proteome to understand response and resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer.
First Author: Andrew A. Davis, MD

Abstract e15051: Association of dynamic changes of methylated SFRP2 in ctDNA with prognosis in advanced gastric cancer.
First Author: Yan Haijiao

Abstract e15052: DNA damage and repair gene panel as a biomarker of immune checkpoint inhibitor response.
First Author: Ming Huang Chen, PhD

First Author: Maarten J. IJzerman, BSc, MSc, PhD

Abstract e15054: Dysregulation of immune checkpoint proteins in newly diagnosed early breast cancer patients.
First Author: Ronald Anderson, PhD

First Author: Richie Uba, PharmD

Abstract e15056: Monitoring early clearance of circulating tumor DNA as an effective tool to predict clinical benefits of immune checkpoint inhibitors in lung cancer patients: the preliminary results from clinical trial NCT04203095.
First Author: Di Zheng

Abstract e15057: Correlation between JAK1/2 expression and immune-related genes and JAK2 gene variants: A pan-cancer analysis.
First Author: Lichao Xu, Ph.D.
First Author: Nune Karapetyan, MD, MPH

First Author: Yina Wang, M.D.

Abstract e15060: Treatment-related adverse events of combination immune checkpoint inhibitors: Systematic review and meta-analysis.
First Author: Robin Park

Abstract e15061: Characterization of the immune tumor microenvironment of HER2-positive breast cancer following treatment with entinostat and immune checkpoint inhibition.
First Author: Evanthia T. Roussos Torres, MD

Abstract e15062: Assessing long-term survival improvement of immune-checkpoint inhibitors (ICI) anticancer agents approved by the Food and Drug Administration: A meta-analysis of randomized controlled trials (RCTs).
First Author: Louis Everest, BSc (c)

Abstract e15063: Real-world usage and outcomes for patients treated with immune checkpoint inhibitors across multiple treatment indications in the Veterans Affairs system.
First Author: Jennifer La, PhD

Abstract e15064: The effect of concomitant cannabinoids during immune checkpoint inhibitor treatment of advanced stage malignancy.
First Author: Adam Biedny, DO

Abstract e15065: Impact of systemic corticosteroids on survival outcomes in patients with immune-checkpoint inhibitor enterocolitis.
First Author: Leah L. Thompson

Abstract e15066: Association of body mass index (BMI) with clinical efficacy of immune checkpoint inhibitors (ICI) in advanced cancer patients: A retrospective analysis.
First Author: Raphael Brandao Moreira, MD

Abstract e15067: Changing paradigm in oncology clinical trials: Cox-TEL—Adjustment made ready for early crossover and tail tale.
First Author: Emily Pei-Ying Lin, MD, PhD

First Author: Vaibhav G. Patel, MD
Abstract e15069: Analysis of the management of immunotherapy-derived toxicity in the Stockholm region.
First Author: Lisa Elena Esther Villabona, MD, PhD

Abstract e15070: Immune checkpoint inhibitor resistance and its association with drug clearance in animal models of cancer cachexia.
First Author: Alyssa Marie M. Castillo

Abstract e15071: A prospective cohort study of HLA-B44 supertype as predictor of response to novel immune checkpoint combinations.
First Author: Tatiana Hernandez-Guerrero, MD

Abstract e15072: PSGL-1 as a novel macrophage checkpoint that can modulate tumor inflammation in tumors with less T cell infiltration.
First Author: Ani Nguyen, PhD

Abstract e15073: Efficacy of immunotherapy combination regimens in patients with “cold” tumors enrolled in early clinical trials.
First Author: Omar Saavedra, MD

Abstract e15074: A multidisciplinary immune-related toxicity (IR-Tox) program for immune-related adverse events: A two-year experience.
First Author: Aanika Balaji, BS

Abstract e15075: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: A machine learning approach.
First Author: Brian Dreyfus, MPH

Abstract e15076: Multidisciplinary team management for high grade immune-related adverse events (irAEs): A single center experience.
First Author: PRABHSIMRANJOT SINGH, MD

Abstract e15077: Transcriptomic features of immune-related adverse events to anti-PD-1 therapy in combination with chemotherapy in non-squamous non-small cell lung cancer (nsq NSCLC).
First Author: Li Zhang, MD

Abstract e15078: Computed tomography defined skeletal muscle as a biomarker for predicting overall survival in metastatic patients treated with immune checkpoint blockade therapies.
First Author: Sami Antoun, MD

Abstract e15079: Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH).
First Author: Michel Obeid, MD, PhD
Abstract e15080: Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A systematic review and meta-analysis.
First Author: Filippo G. Dall’Olio

First Author: Min Yuan

Abstract e15082: Molecular alterations with hyperprogression in lung cancer patients treated with immune checkpoint inhibitors in a large health system.
First Author: Eyob ale Tadesse, MD

Abstract e15083: Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.
First Author: Chao Ren

Abstract e15084: Nephrotoxicity due to immune checkpoint inhibitors in rural oncology.
First Author: Chady Abboud Leon, MD

Abstract e15085: A phase I, open-label study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3 in patients with relapsed or refractory diffuse large B-cell lymphoma.
First Author: Adam Steven Asch, MD

Abstract e15086: Immunohistochemistry analyses of LAG-3 expression across different tumor types and co-expression with PD-1.
First Author: Francine Chen, MD

Abstract e15087: Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer.
First Author: Hirotaka Miyashita

Abstract e15088: Body composition and risk of immune-related adverse events during anti-PD(L)1.
First Author: Karijn Suijkerbuijk, MD, PhD

First Author: Felipe Soto

Abstract e15090: PSGL-1 is a novel macrophage checkpoint in immuno-oncology.
First Author: Dominika Nowakowska, PhD
Abstract e15091: Markers of immune checkpoint inhibitor efficacy in the AACR Project GENIE database.
First Author: Yuanchu J Yang

Abstract e15092: Molecular profiling of long-term responders to immunotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Joan Frigola

Abstract e15093: Macrophage determines immnophenotype and predicts anti-PD-L1 response of urothelial cancer: Results from phase II clinical trial.
First Author: Dongqiang Zeng, PhD, VMD

Abstract e15094: Correlation of HLA-B*35 and DRB1*11 alleles with a high risk of interstitial aseptic pneumonitis in cancer patients receiving PD-1/PDL1 immune-checkpoint blockade.
First Author: Pierpaolo Correale, MD/PhD

Abstract e15095: Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.
First Author: Eleonora Ghisoni, MD

Abstract e15096: Neurotoxicity associated with immune checkpoint inhibitors: Systematic review and meta-analysis.
First Author: Muhammad Zain Farooq, MD, MBBS

Abstract e15097: Smoking status and immunotherapy outcomes in smoking-associated cancers.
First Author: Tomi Jun, MD

Abstract e15098: Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients.
First Author: Balaji Agoram, PhD

Abstract e15099: Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis.
First Author: Yamin Jie, M.D. Ph.D.

Abstract e15100: Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data.
First Author: Prantesh Jain, MD

Abstract e15101: A rational approach to nivolumab dosing using cost analysis.
First Author: Alex Renner, MD
Abstract e15102: Is chronic refractory colitis from immune checkpoint inhibitor associated with good cancer outcome?
First Author: Weijie Ma, MD

Abstract e15103: Thyroid dysfunction and immune checkpoint inhibitor outcomes.
First Author: Mitchell S. von Itzstein, MD

Abstract e15104: Survival follow-up of patients (pts) enrolled on early-phase clinical trials.
First Author: Deirdre Kelly, MBChB

Abstract e15105: Retrospective analysis of the activity and safety of non-steroidal anti-inflammatory drugs (NSAIDs) on immune checkpoint inhibitors (CPI) among patients (pts) with renal cell carcinoma (RCC) and urothelial carcinoma (UC).
First Author: Nieves M. Chanza, MD

Abstract e15106: Oral adverse events in cancer patients treated with immune checkpoint inhibitors.
First Author: Yuanming Xu, DDS

Abstract e15107: Amplified immune activation and antitumor responses with an effector function enhanced TIGIT antibody, SGN-TGT.
First Author: Alyson Smith, Ph.D.

Abstract e15108: Impact of body mass index on survival rates in patients receiving immune checkpoint inhibitors.
First Author: Diana Maslov, MD, MS

First Author: Teja Ganta, MD

Abstract e15110: The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients.
First Author: Si-Qi Tang

Abstract e15111: IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study.
First Author: BIN LIAN, MD, BS

First Author: Jian Zeng
Abstract e15113: Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.
First Author: Biagio Ricciuti, MD

Abstract e15114: Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials.
First Author: Jennifer Leigh McQuade, MD

Abstract e15115: Identifying intermediate surrogate endpoints for OS in immune checkpoint inhibitor trials: A prediction model using objective response rate as a predictor of survival at 12 months.
First Author: Won-Hee Yoon, MBBS

First Author: Anjali Rao, MD

Abstract e15117: Immune checkpoint inhibitors combined with chemotherapy/radiotherapy, for EGFR wild-type lung cancer: Efficacy in real-world study.
First Author: Jifeng Feng, Doctor's degree

Abstract e15118: Comparing overall mortality between female and male advanced melanoma patients treated with ipilimumab plus nivolumab or nivolumab alone: A population-based study of sex effect modification by immunotherapy.
First Author: Se Ryeong Jang

Abstract e15119: Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME).
First Author: Corey Carter

Abstract e15120: Results of a phase Ib study investigating durvalumab in combination with eribulin in patients with metastatic HER2-negative breast cancer and recurrent ovarian cancer.
First Author: Chrystal Ann Landry, MD

Abstract e15121: Preliminary safety and efficacy from a phase I clinical trial of cosibelimab (anti-PD-L1 antibody) in patients with previously untreated advanced NSCLC.
First Author: Dean Laurence Harris, MD

Abstract e15122: Radiotherapy with sequential anti-PD-1 mAb compared with concurrent anti-PD-1 mAb for enhancing the abscopal effect by promoting the inflammatory tumor microenvironment.
First Author: Xiaoxia Zhu, MD
Abstract e15123: Retrospective study of cardiotoxicity surveillance during treatment with immune checkpoint inhibitors.
First Author: Sarah Waliany, MD, MS

Abstract e15124: Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS* Registry.
First Author: Michel M. Sun, M.D., Ph.D.

Abstract e15125: A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
First Author: Mark Voskoboynik, FRACP, MBBS

Abstract e15126: Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.
First Author: Saad A. Khan, MD

Abstract e15127: Hepatitis B reactivation with pembrolizumab, atezolizumab, and nivolumab: A pharmacovigilance study and literature review.
First Author: Ibrahim Muhsen

Abstract e15128: Incidence and outcomes of immune checkpoint inhibitor-related myositis.
First Author: Jeffrey Aldrich, MD

Abstract e15129: Checkpoint inhibitor-associated immune-related adverse events as harbinger of favorable clinical outcome: Systematic review and meta-analysis.
First Author: Robin Park

Abstract e15130: Retrospective analysis of immune checkpoint inhibitor-associated myocarditis from 12 cancer centers in China.
First Author: Feng WANG

Abstract e15131: Cardiotoxicity associated with immune checkpoint inhibitors: A systemic review and meta-analysis.
First Author: Sheeba Habeeb Ba Aqeel

First Author: Alessio Cortellini, MD

Abstract e15133: Cumulative steroid doses and response rates to immune checkpoint inhibitors in metastatic cancer.
First Author: Karine Tawagi, MD
Abstract e15134: Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (CPI) and survival outcomes correlation: To rechallenge or not?
First Author: Heidar Albandar

First Author: Fahmin Basher, MD, PhD

First Author: Dmitrii Shek, MD

Abstract e15137: Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1).
First Author: Patricia Iranzo, MD

First Author: Shinkichi Takamori

Abstract e15139: Immunotherapy initiation during cannabis use to lead to a shorter time-to-tumor progression and lower overall survival in patients with advanced cancer.
First Author: Gil Bar-Sela, MD

Abstract e15140: Camrelizumab in advanced or metastatic solid tumor patients with microsatellite instability–high/mismatch repair-deficient: Results from an open-label exploratory study.
First Author: Jingde Chen

Abstract e15141: The safety and efficacy of immune-checkpoint inhibitor therapy in HIV infected cancer patients.
First Author: Phyo Thazin Myint, MD, MS

Abstract e15142: Risk factors for emergency room and hospital care for patients with advanced solid tumors on immune checkpoint inhibitor therapy.
First Author: Anish B Parikh, MD

Abstract e15143: Hyperprogression on immune checkpoint inhibitors: A single institution, real-world retrospective analysis.
First Author: Koosha Paydary, MD

Abstract e15144: Immunotherapy related hepatitis: A retrospective study of Chilean patients.
First Author: Carlos Salinas, MD
Abstract e15145: Checkpoint inhibitors related renal vasculitis and use of rituximab.
First Author: Omar Mamlouk

Abstract e15146: Tolerability of single agent nivolumab in cancer patients—a meta-analysis.
First Author: Judy Huang

Abstract e15147: Baseline blood parameters as predictive biomarkers of immunotherapy efficacy in solid tumors.
First Author: Antonio Marra, MD

Abstract e15148: Racial differences in development of immune-related adverse events.
First Author: Shruti Bhandari, MD

Abstract e15149: Tolerability of dual checkpoint blockade with nivolumab and ipilimumab: A meta-analysis.
First Author: Alejandro Ramon Carvajal, MD

Abstract e15150: Personalized multimodality therapy (ICT) with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT), in advanced/refractory cancer.
First Author: Philip A. Salem, MD

Abstract e15151: Comparative efficacy, safety, and tolerability of immune checkpoint inhibitors (ICIs) in cancer.
First Author: Laith Al-Showbaki, MD

Abstract e15152: Cancerbiome: Defining a healthy microbiome for therapeutic targeting.
First Author: Hari S Babu, MBBS

Abstract e15153: Hypocalcemia with immune checkpoint inhibitors: The disparity among various reports.
First Author: swarna sri nalluru

Abstract e15154: Awareness of immune-related adverse events among medical residents in a community hospital.
First Author: Ajinkya Kulkarni, MD

First Author: Jie Wu, PhD

Abstract e15156: Overall survival in high and very high PD-L1 expressing patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors in a real-world data setting.
First Author: Chenan Zhang, PhD
First Author: Justin Lin, None

Abstract e15158: Characterizing toxicities, body composition, and health-related quality of life (HRQoL) among long-term survivors treated with anti-PD-1.
First Author: James Randall Patrinely Jr., BA

Abstract e15159: Predictors of immune-related adverse events associated with checkpoint inhibitors.
First Author: Alhareth Alsayed

Abstract e15160: Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.
First Author: Qian Qin, MD

Abstract e15161: Predicting overall survival (OS) and overall response (OR) following durvalumab treatment in patients with multiple cancer types using a hybrid modeling strategy.
First Author: Ting Chen

Abstract e15162: Investigating the impact of medical comorbidities in patients taking beta blockers and treated with immunotherapy for metastatic melanoma.
First Author: Paul Pyunggang Hong, BA

Abstract e15163: Management of immune-related adverse events: A single-center retrospective analysis in a real-world scenario.
First Author: Donatella Iacono, MD

Abstract e15164: Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.
First Author: Bozena Cybulska-Stopa

Abstract e15165: Nivolumab versus the standard of care for cancer therapy: A meta-analysis of 6 CHECKMATE trials comparing overall survival.
First Author: Ammar Al-Obaidi, MD

Abstract e15166: Outcome of immune checkpoint inhibitor (ICI) related diarrhea/colitis (IMDC) in cancer patients with superimposed GI infections.
First Author: Weijie Ma, MD

Abstract e15167: Comparative quantitative safety profiles of PD-1 and PD-L1 checkpoint inhibitor monotherapies: A Bayesian model-based meta-analysis.
First Author: Boris Shulgin, PhD
Abstract e15168: Comparative study between image-guided percutaneous biopsies and matched surgical specimens for the evaluation of PD-L1 status in non-small cell lung cancer.
First Author: Liang Zhao

Abstract e15169: Correlation between TMB and MSI in patients with solid tumors.
First Author: ZHENG ZHAO

Abstract e15170: Comparison of tumor mutational burden across eight types of human cancer.
First Author: Peng Chen

Abstract e15171: Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers.
First Author: Kiyofumi Shimoji, MD

Abstract e15172: Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors.
First Author: Akhil Kapoor, MD, DM

Abstract e15173: PD-1 inhibitor combined with radiotherapy and GM-CSF as salvage therapy in patients with chemotherapy-refractory metastatic solid tumors.
First Author: Yuehong Kong

Abstract e15174: Analysis of microsatellite instability differences in eight types of tumors.
First Author: Zhen Zhang

Abstract e15175: The frequency of HPD gene mutation profile in solid tumors with PD-L1 expression positive.
First Author: Sanyuan Tang

Abstract e15176: Distribution of PD-L1 expression level across major tumor types.
First Author: Shun Xu

Abstract e15177: Lung cancer immunochemotherapy: Codelivery of EGFR tki and PTX via an immunostimulatory dual functional nanocarrier.
First Author: Dingwei Diao

Abstract e15178: Correlation of galectin-9 expression with immunological tumor features and outcome in multiple cancer types as both a novel therapeutic target and a biomarker.
First Author: Aleksandra Filipovic, MD, PhD (c)

First Author: Brittany Barber, M.D., MSc., F.R.C.S.C
Abstract e15180: The potential target of double negative T cells in cancer immunotherapy. 
First Author: Kazumi Okamura

Abstract e15181: Metabolism of tumor cell in tumor micro environment assist immune escape. 
First Author: Ning He, MSc

Abstract e15182: Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. 
First Author: Tom van den Ende, BSc, MSc

Abstract e15183: Integration of TMB and tumor heterogeneity identify an immunologic subtype of melanoma with favorable survival. 
First Author: Chunhe Yang, MSc

Abstract e15184: Utilizing quantitative multiplex immunofluorescence to characterize paracrine interactions within the tumor-immune landscape of metastatic melanoma. 
First Author: Rachel L. Maus, Ph.D.

Abstract e15185: Modulating tumor immune microenvironment by the \textit{STK11/LKB1 signaling} in breast cancer. 
First Author: Hui-Ping Hsu, MD PhD

Abstract e15186: Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma. 
First Author: Ngar-Woon Kam

Abstract e15187: The role of TGF-\(\beta\) pathway in immune regulation as a potential biomarker of immunotherapy across pan-cancer. 
First Author: Yongmei Yin, MD

Abstract e15188: A phase I open-label dose-escalation study evaluating ACTR707 T cells in combination with trastuzumab in HER2-overexpressing solid tumors. 
First Author: Robert Wesolowski, MD

Abstract e15189: Evidence for persistent radiation-related injury to the immune system in patients with local breast cancer. 
First Author: Janhavi Athale, MD

Abstract e15190: Investigation on the mechanism of Epstein-Barr virus encoded miR-BART13 to promote immune evasion in nasopharyngeal carcinoma. 
First Author: Yuanji Xu Sr., PhD
Abstract e15191: Tumour immune characterization in adenoid cystic carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
First Author: Shengjin Dou, BA

Abstract e15192: Robust prediction of immune checkpoint inhibition therapy for non-small cell lung cancer.
First Author: Yiqun Zhang, MSc

Abstract e15193: CD8A and HAPLN3 expression profiling to reveal an immunologic subtype of bladder cancer with favorable survival.
First Author: Jingjiao Ma, MSc

Abstract e15194: Immune subtype of mismatch repair deficient colorectal carcinoma.
First Author: Ning He, MSc

Abstract e15195: Pd-1 inhibitors plus nab-paclitaxel with S1 (AS) as first line in patients with advanced biliary tract cancer.
First Author: Miaomiao Gou

Abstract e15196: Immunological functional study by use of the chemotherapy drug plus immunologic hapten like penicillin on the fibrosis of local tumor inflammatory reaction and the immunity of tumor-bearing mice.
First Author: Bian Li, MD

Abstract e15197: RNA pathway enrichment in serum-based mass spectroscopy prognostic analyses.
First Author: Benjamin D German, MD

Abstract e15198: Bioinformatic profiling of tumor immunity from patient biopsies to predict survival and response to immunotherapy.
First Author: Yamil Damian Mahmoud

Abstract e15199: Monitoring of inflammatory response to cancer immunotherapies.
First Author: Qimin Quan, PhD

Abstract e15200: A Novel TGF-beta targeted peptide HTPEP-001 enhances antitumor efficacy of anti-PD1 in mice models.
First Author: Xiaomei Li

Abstract e15201: Potential use of IL-7 and IL-15 for ex vivo generation of LAK.
First Author: Svetlana Yu. Filippova

First Author: Sergey A. Kolpakov
Abstract e15203: Novel synthetic immune modulators for the activation of tumor antigen-specific T cells.
First Author: Di Zhang, PhD

Abstract e15204: targetSCAPE and ultraSCAPE: Simultaneous identification and deep profiling of human antigen-specific T cells and other immune cell subsets by mass cytometry.
First Author: Brian Abel, MBA, PhD

Abstract e15205: Proteome-wide biomarker quantification and target screening.
First Author: Qimin Quan, PhD

Abstract e15206: Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response.
First Author: Gerrit Dispersyn

Abstract e15207: Potential therapeutic targets in melanoma harboring mutations in homologous recombination DNA damage repair pathway.
First Author: Tamara A. Sussman, MD

First Author: Shuoyen Jack Lin

Abstract e15209: Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.
First Author: Peter A. Kaufman, MD

Abstract e15210: AVIDIO as a novel oncolytic immunotherapy platform for the treatment of colorectal cancer.
First Author: Bijan Almassian, PhD

Abstract e15211: R-DOTAP (Versamune): A novel enantiospecific cationic lipid nanoparticle that induces CD4 and CD8 cellular immune responses to whole protein and tumor-specific peptide antigens.
First Author: Lauren Virginia Wood, MD

Abstract e15212: Effect of TP-1454, a PKM2 activator, on the tumor-immune microenvironment in preclinical models as a development path in combination with IO agents.
First Author: Clifford Whatcott, PhD

Abstract e15213: US oncologists' perception of the efficacy, safety, and willingness to prescribe biosimilar cancer therapies.
First Author: Cesar Galan, MBA
Abstract e15214: ANV419 is a novel IL-2/anti-IL-2 fusion protein with potent immune effector cell promoting function in vitro and in vivo.
First Author: Christoph Huber

Abstract e15215: Impact of a combined immune checkpoint inhibitor and mechanical focused ultrasound treatment in a MC38 preclinical model.
First Author: Cécile Fant

First Author: Tsering G. Lama Tamang, MD

Abstract e15217: Characteristics of carrier cells associated with clinical response in children treated with adenoviral virotherapy administered in autologous marrow-derived mesenchymal cells.
First Author: Manuel Ramirez

Abstract e15218: Modulation of CT-genes transcriptional activity in HT-29 cells by irradiation with a linear accelerator.
First Author: Denis S. Kutilin, PhD

Abstract e15219: M2 macrophages-induced GRP78 upregulation confers 5-fluorouracil resistance of tumor cells.
First Author: Xiao-Qing Lu

First Author: Tatiana V. Shamova

Abstract e15221: Rescue chemotherapy (CT) after immune oncology (IO) drugs in patients (pts) with refractory solid tumors: A propensity score (PS) matched cohort study.
First Author: Vladimir Galvao, MD

Abstract e15222: The landscape of chromosome 11q13 amplification in Chinese solid tumor patients and hyperprogressive disease (HPD) clinical example.
First Author: Jieli Yu

Abstract e15223: Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center.
First Author: Ravi Murthy, MD

Abstract e15224: Do concomitant medications alter immune checkpoint inhibitor efficacy for advanced solid tumors? A single-institution analysis.
First Author: Bo Wang, MD
Abstract e15225: Predictive value of sonoelastography of secondary changed lymphous nodes in the assessment of effectiveness of immunotherapy.
First Author: Fedor Vladimirovich Moiseenko, MD, PhD

Abstract e15226: The potential biomarkers of checkpoint inhibitor immunotherapy in solid malignancies.
First Author: Nausheen Hakim, DO

Abstract e15227: Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting.
First Author: Thiago Pimentel Muniz, MD

Abstract e15228: Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
First Author: Shira Peleg Hasson, MD

Abstract e15229: Comparative assessment of different radiological criteria to identify paradoxical hyperprogression (HPD) to IO drugs.
First Author: Ana Luiza Gomes de Morais, MD

Abstract e15230: Effect of combination therapy of anti-sense oligonucleotide targeting TGF-β2 (trabedersen) and IL-2 (proleukin) on solid cancers.
First Author: Juneui Park, PhD, RPh

Abstract e15231: Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and anti-angiogenic targeting agent as second line or later therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
First Author: Ziyi Xu

Abstract e15232: Key issues in the development and approval of new anti-cancer immune therapies.
First Author: Al Blunt, MD

Abstract e15233: Trends in PD-(L)1 checkpoint inhibitor combinations and resistance patterns.
First Author: Jacob Orme

Abstract e15234: Impact of corticosteroids use on efficacy of immune checkpoint inhibitors in cancer patients: A meta-analysis.
First Author: Jiarui Li

Abstract e15235: \textbf{RAD51B} \textsubscript{me} as predictive biomarker for PD-1 blockade response in non-small cell lung cancer.
First Author: Inês Maria Guerreiro, MD
Abstract e15236: Crosstalk between the MSI status and tumor microenvironment in colorectal cancer.
First Author: Peng Luo

Abstract e15237: Immunohistochemical determination of PD-L1 expression with three different antibody clones and determination of SOX10 expression in triple negative breast cancer.
First Author: Margit Maria Guhl, Diplom Biologist

Abstract e15238: High correlation between TMB, expressed TMB, and neoantigen load using tumor: Normal whole exome DNA and matched whole transcriptome RNA sequencing.
First Author: Christopher Szeto, PhD

Abstract e15239: Tumor lymphocytic infiltration impacts recurrence in endometrioid-type endometrial carcinoma.
First Author: Monica Avila

Abstract e15240: Cross-site concordance evaluation for the CIMAC-CIDC network to establish QC metrics enabling reliable generation of WES and RNA-seq data.
First Author: Ignacio Ivan Wistuba, MD

Abstract e15241: Lack of association of immune checkpoint protein expression with T stage or stage grouping in colorectal cancer (CRC): A tissue microarray (TMA) based analysis of clinical data.
First Author: Rachel Levy, MD, MPH

Abstract e15242: CIMAC-CIDC CyTOF harmonization.
First Author: Adeeb Rahman, PhD

Abstract e15243: Analytical validation of iSort digital cytometry for leukocyte enumeration in clinical tumor specimens.
First Author: Aaron M. Newman, PhD

Abstract e15244: Learning relevant H&E slide morphologies for prediction of colorectal cancer tumor mutation burden using weakly supervised deep learning.
First Author: Rohan P. Joshi, MD, PhD

Abstract e15245: Single cell dissociation from mouse tumor samples and analysis on BD FACSLyric Flow Cytometer.
First Author: Wei Huang, Ph.D.

First Author: Helen Ma, MD
Abstract e15247: Multi-institutional TSA-amplified multiplexed immunofluorescence reproducibility evaluation (MITRE Study): Reproducibility of a second generation high-sensitivity assay and its application to samples from patients on therapy revealing effective response prediction.
First Author: Clifford Hoyt, MSc

Abstract e15248: Panel sequencing-based tumor mutational burden as a predictive biomarker for immunotherapy response in real-world clinical samples with low purity.
First Author: Tae Hee Hong, MD

Abstract e15249: Effect of CCND1 amplification on immunosuppression and the association with a poor prognosis to immune checkpoint inhibitors in solid tumors.
First Author: Yingying Huang

Abstract e15250: Prevalence of \textit{prkdc} mutations and association with response to immune checkpoint inhibitors in solid tumors.
First Author: Yi Li

Abstract e15251: Investigation of Wnt ligand signaling regulators as a predictor of Anti-PD-1 response in metastatic melanoma.
First Author: Nicholas C. DeVito, MD

Abstract e15252: Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary.
First Author: Linda R. Mileshkin, MBBS, MD, FRACP

Abstract e15253: Technical validation of PD-L1 SP142 assay for TNBC in a large academic center: unexpected challenges.
First Author: Sharon Nofech-Mozes, MD

Abstract e15254: Predicting tumor mutational burden in head and neck squamous cell carcinoma based on CT imaging features: A TCGA/TCIA study.
First Author: Yangkun Luo Sr.

Abstract e15255: Comprehensive next-generation sequencing to portray distinctive molecular characteristics of hypermutant lung cancer.
First Author: Hongbin Zhang

Abstract e15256: Association of high TLR3 expression with improved survival in patients with clear cell renal cell carcinoma.
First Author: Mingjia Li, MD

Abstract e15257: PIK3 mutation as a predictor of immune checkpoint inhibitor response.
First Author: Aasems Jacob, MD
Abstract e15258: Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).
First Author: Jayesh Desai, FRACP

First Author: Yee Chao, MD, PhD

Abstract e15260: Developing and validating an approach for diagnosing and prognosticating cancer from biochemical motifs in T-cell receptors.
First Author: Jared L Ostmeyer, PhD

Abstract e15261: Identification and validation of stromal immunotype predict survival and benefit from neoadjuvant chemotherapy in patients of breast cancer.
First Author: Fei Ji

First Author: Bin Li

Abstract e15263: PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: a pooled analysis of randomized trials.
First Author: Federica Biello, MD

Abstract e15264: T-cell inflamed gene expression to predict prognosis and response to immune checkpoint inhibitors.
First Author: Yao Yu, MSc

Abstract e15265: Clinical value of piR-36026 and piR-651 in esophageal squamous cell carcinoma.
First Author: Wei Peng, M.D.

Abstract e15266: Role of immune checkpoint inhibitors (ICPi) in KRAS-mutated non-small cell lung cancer (NSCLC).
First Author: Monica Peravali, MD

First Author: Haihua Yang
Abstract e15268: Multipeptide vaccine to prevent epithelial ovarian cancer relapse by microenvironment immunomodulation.
First Author: Juan Pablo Marquez-Manriquez, MD

Abstract e15269: Phase I trial of personalized mRNA vaccine encoding neoantigen in patients with advanced digestive system neoplasms.
First Author: Xianbao Zhan, Pro.

Abstract e15270: Phase I, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papilloma virus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer after curative treatment.
First Author: Sandro Porceddu

Abstract e15271: Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.
First Author: Boris Minev, MD

First Author: Sergey A. Kolpakov

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract e15500: Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint blockade or chemotherapy in preclinical tumor models.
First Author: Min Cheng

Abstract e15501: Initial clinical experience of lucitanib in combination with nivolumab in patients (Pts) with an advanced metastatic solid tumor: Data from a phase Ib/II study.
First Author: Manish R. Patel, MD

Abstract e15502: An open-label phase Ib study to determine safety and preliminary efficacy of oral Lucitanib (AL3810) in patients with locally advanced or metastatic gastric, hepatocellular, nasopharyngeal carcinoma, malignant biliary, and thymic tumors.
First Author: Hongming Pan, MD

Abstract e15503: Effect of general anesthetics on the tumor micro-environment in mouse models of breast cancers of spontaneous metastasis.
First Author: Jun Lin, M.D., Ph.D.

Abstract e15504: Efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
First Author: Wei Zhang
Abstract e15505: VEGF-A polymorphisms affect the pharmacologic effect of bevacizumab on VEGF-A levels in patients with metastatic colorectal cancer.
First Author: Apostolos Papachristos, PharmD, MSc, PhD

Abstract e15506: A rare case of metastatic testicular adult granulosa cell tumor.
First Author: Guido Natoli, MD

Abstract e15507: Preclinical study of oncolytic adenovirus-mediated cytotoxic gene therapy with gemcitabine for chemoresistance of desmoplastic tumor.
First Author: Bo-Kyeong Jung

Abstract e15508: Real-world observation of the efficacy and prognostic factors analysis of apatinib for patients with advanced gastric cancer.
First Author: Qiwen Shen

Abstract e15509: Retrospective observational study to assess the outcomes post anti-PD-(L)1 therapy in patients (pts) with advanced urothelial carcinoma (UC) harboring fibroblast growth factor receptor (FGFR) alterations.
First Author: Arash Rezazadeh, MD

Abstract e15510: Liver x receptor and cholesterol metabolism in triple negative breast cancer chemoresistance.
First Author: James L Thorne

First Author: Jose Alejandro Perez-Fidalgo, MD, PhD

Abstract e15512: A phase I dose-escalation study of low-dose metronomic treatment with oral paclitaxel, as ModraPac001 and ModraPac005, in combination with ritonavir.
First Author: Marit Vermunt, MD

Abstract e15513: Alterations of Raman profiles of nasopharyngeal carcinoma cells after treated with chemodrugs detected by laser tweezer Raman spectroscopy.
First Author: Miaomiao Li

Abstract e15514: The KRAS mutation status and resistance to cetuximab in patients with squamous cell carcinoma of oral cavity.
First Author: Aza A. Lyanova

Abstract e15515: A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia.
First Author: Emily Jane Bryer, DO
Abstract e15516: Stability and visual compatibility of daunorubicin and cytarabine during Y-site administration with selected drugs.
First Author: Guillaume Sicard

Abstract e15517: Effect of different dox concentration with hapten and dose selection intratumoral injection on the survival time of tumor bearing mice.
First Author: Qiang Fu, MS

Abstract e15518: Abscopal effect induced intratumoral injection of chemotherapy drugs with hapten and tumor microstructure changes with protein expression of distal untreated tumors in mice.
First Author: Baofa Yu, MD

Abstract e15519: Long-term survival rates in cancer patients achieved with metronomic chemotherapy (cyclophosphamide and methotrexate).
First Author: Viacheslav Chubenko, MD, PhD

Abstract e15520: Factors associated with low chemotherapy dosing in high risk breast cancer.
First Author: Leilani Hernandez

Abstract e15521: A phase I, first-in-human, dose escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients (pts) with advanced solid tumors.
First Author: Erkut Hasan Borazanci, MD, MS

Abstract e15522: Taxane induced pulmonary toxicity in breast cancer.
First Author: Hrishi Varayathu

Abstract e15523: A new desensitization protocol, overcoming hypersensitivity reactions to chemotherapy.
First Author: Andrei Dan Havasi

Abstract e15524: Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy.
First Author: Hua Cao

Abstract e15525: Effect of local activation via SQ3370 on the safety of chemotherapy with concomitant anti-tumor immune response.
First Author: Sangeetha Srinivasan, PhD

Abstract e15526: Can tumor cells be distinguished from blood cells by mechanical parameters? A label-free CTC detection approach.
First Author: Ivonne Nel
Abstract e15527: Successful mutational profiling of single circulating epithelial tumor cells (CETCs) from patients with solid cancers for guiding therapy.
First Author: Dorothea Schott

Abstract e15528: MicroRNAs involved in immune response as prognostic markers in early and metastatic breast cancer.
First Author: Chara Papadaki, PhD

Abstract e15529: Assessment of mutation burden after clinical intervention in pancreatic ductal adenocarcinomas (PDAC), and biliary tract cancers (BTC) via profiling circulating tumor DNA (ctDNA).
First Author: Fabio Pittella-Silva, PhD

Abstract e15530: Morphology classification of circulating tumor cells could be a predictor of recurrent disease in patients with non-small cell lung cancer after surgery.
First Author: Yun Wu

Abstract e15531: The application of dynamic monitoring of circulating tumor DNA for detecting minimal residual disease and predicting recurrence in colorectal cancer patients.
First Author: Hiu Ting Chan, PhD

Abstract e15532: Liquid biopsy of lung cancer by deep learning and spectroscopic analysis of circulating exosomes.
First Author: Hyunku Shin

Abstract e15533: Biomarkers for predicting cancer in women with a suspicious mammogram.
First Author: Virginia A. Espina, PhD

Abstract e15534: Cell-free KRAS in pancreatic cancer as a rapid prognostic marker.
First Author: Patricia Saiz-Lopez, PhD.

Abstract e15535: Potential utility of methylation levels detected from circulating tumor DNA (ctDNA) in predicting molecular residual disease (MRD) in patients with resected non-small cell lung cancer (NSCLC).
First Author: Hong HU, MD

Abstract e15536: Clinical utility of circulating genetically abnormal cells within low-dose computed tomography lung cancer screening: A correlative MCPND trial study.
First Author: Mingxiang Feng

Abstract e15537: The systemic inflammation response index (SIRI) predicts oncological outcome and correlates with tumor burden in metastatic pancreatic cancer.
First Author: Vilma Pacheco Barcia, MD
Abstract e15538: Concordance of variant detection between NCLN ctDNA assay and matched tissue biopsy in solid tumors.
First Author: Peng Wang, M.D. Ph.D.

Abstract e15539: A novel method for enrichment and detection of the six major subtypes of EGFR exon 19 deletions simultaneously by capturing mutant-alleles.
First Author: Yue Pu, Ph.D.

Abstract e15540: Potentially targetable alterations identified in circulating tumor DNA (ctDNA) from patients (pts) with advanced rare cancers.
First Author: Hitomi Sumiyoshi Okuma, MD, PhD

Abstract e15541: Correlation of CTCs with disease progression in Indian oral cancer patients.
First Author: Jayant Khandare, PhD

First Author: Anne Louise Louise Sibille, M.D.

Abstract e15543: Combined use of albumin and neutrophil-to-lymphocyte ratio as new prognostic and predictive factor in patients with poorly differentiated neuroendocrine carcinomas.
First Author: Elena Colombo, MD

Abstract e15544: Monitoring of therapeutic efficacy to CDK4/6 inhibitors and early detection of metastatic relapse in breast cancer by ultra-deep sequencing of plasma cell-free DNA.
First Author: Yoon Ming Chin, PhD

Abstract e15545: Urinary cell-free DNA analysis for tumor mutation detection in patients with oligometastatic colorectal cancer.
First Author: Bruna Pellini, MD

Abstract e15546: Detection of pancreatic cancer using a novel blood-based DNA methylation signature.
First Author: Nishant Munugala, MD, MPH

Abstract e15547: Analytical performance testing of the NCLN circulating tumor DNA assay.
First Author: Robin Harrington

Abstract e15548: Association between central and peripheral circulating tumor cell (CTC) clusters in oral squamous cell carcinoma (OSCC): A prospective, observational study.
First Author: Ritvi K Bagadia, MDS, FIBCSOMS
Abstract e15549: Analytical validation of a tissue agnostic ctDNA MRD assay using tumor specific methylation and somatic variant profiles in early-stage CRC.
First Author: Carlo Artieri

Abstract e15550: Lung cancer exosome specific protein 1(LESP-1) as a potential factor for diagnosis and treatment of non-small cell lung cancer.
First Author: Hyun Koo Kim, MD, PhD

Abstract e15551: The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer.
First Author: Paolo D'amico, MD

First Author: Lorenzo Gerratana, MD

Abstract e15553: Biomarker screening for the early detection of prostate cancer using an exosomal-enrichment RNA liquid biopsy test.
First Author: Douglas Roberts, PhD

Abstract e15554: Plasma ctDNA sequencing supplementary to tissue-based molecular profiling as a source of additional actionable information in advanced cancers.
First Author: Bradley Allen Hancock, BS

Abstract e15555: Identification of germline cancer predisposition variants during clinical ctDNA testing.
First Author: Leigh Anne Anne Stout

Abstract e15556: Changes in biomarkers according to breast cancer status: Study on the efficacy of blood-based breast cancer diagnosis biomarker developed by proteomics technology in follow-up after treatment.
First Author: Yumi Kim, MD

Abstract e15557: Prediction and prognostic validation of colorectal cancer therapeutic effect of WM-S1-030 using pre-clinical CTC animal model.
First Author: Hae Ung Lee

Abstract e15558: Correlation of levels of extracellular vesicles in peripheral and pulmonary blood plasma with pathological stages of lung cancer patients.
First Author: Hyun Koo Kim, MD, PhD

First Author: Paul Y. Song, MD
First Author: Katrin Heider, PhD

Abstract e15561: An exploration of ARID1A alterations in circulating cell-free DNA (cfDNA) from 68,000 advanced cancer patients: Implications for tumor biology and therapeutic response.
First Author: Caroline Weipert, MS, CGC

Abstract e15562: A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors.
First Author: Andre Marcio Murad, MD, PhD

Abstract e15563: Greater than two coexisting mutations in KRAS and NRAS identified in the circulating tumor DNA fraction of liquid biopsies by NGS and confirmed with ddPCR.
First Author: Hala Boulos

Abstract e15564: Targeted next-generation sequencing (NGS) of 105 cancer-related genes in circulating tumor DNA (ctDNA) from patients with advanced cancers treated with immune checkpoint inhibitors (iCPI).
First Author: S. Greg Call, PhD

Abstract e15565: Detection of pan-tumor characterization of KRAS mutations (KRASm) in circulating tumor DNA (ctDNA) and concordance with paired tissue.
First Author: Jessica Kim Lee, MS

Abstract e15566: Mutational landscape of AKT1/2/3 in Chinese patients with solid tumors.
First Author: Hui Kong

Abstract e15567: A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results.
First Author: Zev A. Wainberg, MD

Abstract e15568: ROS new function for ECT imaging observation of sustained $^{99m}$Tc-labeled cytarabine in liver cancer patient with hydrogen peroxide.
First Author: Guoqin Zheng, MS

Abstract e15569: Effect of hydrogen peroxide on the sustained release of $^{99m}$Tc-labeled cytarabine in melanoma of C57 mice by ECT imaging pharmacology.
First Author: Yan Han, Jinan Jiazou Pharma

Abstract e15570: IL-6 influences PD-L1 expression in monocytes and macrophages by effecting protein tyrosine phosphatase receptor type O expression in-human breast cancer.
First Author: Lin Chen, Master Degree
Abstract e15571: Utilizing single-cell-subtype analysis via advanced microdissection methods and the impact on precision medicine.
First Author: Donald Joseph Johann Jr., MD

Abstract e15572: Application of automated segmentation and classification of PD-L1 immunohistochemistry images in cancer treatment prediction.
First Author: Xinrui Zhou

Abstract e15573: Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions.
First Author: Veronica Diermayr, PhD

Abstract e15574: Use of real-world clinical lab data to reveal Asian NTRK fusion test availability patterns.
First Author: Markus Eckstein

Abstract e15575: Whole genome SNP arrays for best practice for detection of diagnostic, prognostic and therapy related copy number changes and copy neutral-loss of heterozygosity across solid tumors and hematologic malignancies.
First Author: Patrick Alan Lennon, PhD

Abstract e15576: Targeted PCR vs NGS for molecular diagnostic in solid tumors and liquid biopsies. How to choose in real-life.
First Author: Jean-Louis Merlin, PhD, PharmD

Abstract e15577: NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP).
First Author: Hidetoshi Hayashi, MD, PhD

Abstract e15578: Machine learning algorithm analysis using genomic and transcriptomic data from commercially available 592-gene and whole transcriptome assays to accurately predict tumor type for carcinoma of unknown primary (CUP).
First Author: Jim Abraham

Abstract e15579: A new model to prognosticate man breast cancer in China.
First Author: Yunjiang Liu

Abstract e15580: Novel validation and testing strategies using tumor fraction in cfDNA sample for patient treatment selection.
First Author: Meijuan Li, PhD

Abstract e15581: Validation of a transcriptome-based tumor of unknown origin predictor.
First Author: Jack Michuda
First Author: Laura M. Kenny, MD

Abstract e15583: Validation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy.
First Author: Juan-Sebastion Saldivar, MD, FACMG

Abstract e15584: Enabling variant calling in challenging FFPE samples by coupling a novel library preparation chemistry with exome sequencing.
First Author: Bosun Min

Abstract e15585: Assessment of 5-methylcytosine and 5-hydroxymethylcytosine technologies in contrived ctDNA-like samples.
First Author: Eun-Ang Raiber-Moreau

Abstract e15586: Next-generation sequencing for genetic analysis of endobronchial ultrasound transbronchial needle aspiration samples in advanced lung cancer.
First Author: Xianjun Min

Abstract e15587: Distinct molecular profiles of interval and screen-detected tumors in a real-world breast cancer registry.
First Author: Sharon Wilks, MD

Abstract e15588: A functional precision medicine 3D microtumor platform to identify and personalize novel indications.
First Author: Christian Apfel, MD, PhD

Abstract e15589: Baseline radiomics features (RF) in metastatic colorectal cancer (mCRC): Correlation with m site and clinical-pathological characteristics.
First Author: Raffaella Vivolo, MD

Abstract e15590: The genes CNV and expression as a factors of HT-29 cells radioresistance.
First Author: Natalia G Kosheleva

Abstract e15591: The dark age of single organ screening is over: CD24 is a novel universal simple blood test for early detection of cancer.
First Author: Shiran Shapira, PhD

Abstract e15592: Effect and mechanism of ikkβ on proliferation, apoptosis, and metastasis of breast cancer cells with different expression levels of leptin and its receptors.
First Author: Yan Kong
Abstract e15593: Data-independent acquisition-based quantitative proteomic analysis reveals PARP1 as a potential therapeutic target in mucosal melanoma.
First Author: Zhiyuan Cheng

Abstract e15594: CSNK2 in cancer: Pathophysiology and translational applications.
First Author: Scott Strum, BSc, MD, MSc

Abstract e15595: First-in-class aPKCi (atypical protein kinase C iota) inhibitors: VAR 101/102.
First Author: Amar Mirza, MS

Abstract e15596: Chick chorioallantoic membrane (CAM) assays as a model of xenografts derived from circulating cancer stem cells from breast cancer patients.
First Author: Monika Pizon

Abstract e15597: Cytotoxic effect of unclassified group K rotaviruses on T98G and U87MG glioblastoma cells in vitro.
First Author: Anastasia O. Sitkovskaya

Abstract e15598: Effect of UV-curable and injectable dendrimer matrix on tumor pharmacokinetics and survival in a hepatocellular carcinoma mouse model using interstitial photodynamic therapy.
First Author: Sauli Vuoti

Abstract e15599: Treatment of breast, ovarian and lung cancer cells by inducing apoptosis with a deep eutectic solvent prepared from 2-deoxy-D-glucose and metformin: Cancer cell metabolism as a drug target.
First Author: Sauli Vuoti

Abstract e15600: Focused ultrasound ablation of solid tumors: Feasibility of planning tissue-selective treatments.
First Author: Lauren Mancia

Abstract e15601: Real-world utility of next generation sequencing in routine clinical practice.
First Author: Daniel Boon Yeow Chan, MBBS, MRCP, FRCP

Abstract e15602: Efficacy of telotristat ethyl: A peripheral tryptophan hydroxylase inhibitor that blocks serotonin biosynthesis against cultured liposarcoma, colon cancer, and cholangiocarcinoma cell lines.
First Author: Harvey J. Kliman, MD, PhD

Abstract e15603: Targeting MTOR and ERBB3 in afatinib-resistant NRG1 fusion-positive NSCLC.
First Author: Igor Odintsov, MD
Abstract e15604: Characterization of NRG2 gene fusions in solid tumors.
First Author: Sai-Hong Ignatius Ou, MD, PhD

Abstract e15605: NRG1 fusion-driven cancers: A systematic literature review and meta-analysis.
First Author: Viktoriya Stalbovskaya, PhD

Abstract e15606: EIT PACMAN Study preliminary results: OncoSignal pathway analysis identifies actionable cancer targets.
First Author: Patricia Martin, MD PhD

Abstract e15607: The AVI-PDX™: An innovative in vivo platform of miniaturized patient-derived xenografts for preclinical developments and personalized medicine.
First Author: Frédéric Berget

Abstract e15608: LCN2 and colon cancer – have we hit the jackpot.
First Author: Vijay Kumar Srinivasalu

First Author: Vijay Kumar Srinivasalu

First Author: Adam P. Dicker, MD, PhD, FASCO

Abstract e15611: Clinical and genomic analysis of patients with allosteric ERBB (AlloErb) mutations in screening for a phase I/II clinical trial of BDTX-189, an irreversible inhibitor of oncogenic AlloErb mutations including EGFR and HER2 exon 20 insertions.
First Author: Andrew McKenzie, PhD

Abstract e15612: Role of tafamidis in reducing the effect and progression of transthyretin amyloid cardiomyopathy.
First Author: Raghunandan Konda, MD

First Author: Fiona Dempsey, BSc PhD

First Author: Sunil Kumar KB

Abstract e15615: Landscape of RAS variations in 17993 solid tumors: a pan-cancer analysis.
First Author: Hao Wu, Ph.D
Abstract e15616: The multidirectional effects of some comorbid disorders on the malignant process and tumor-bearing organism in the experiment.  
First Author: Galina V. Zhukova

First Author: Elisabeth Luporsi, MD

Abstract e15618: Improvement of subcutaneous CDX model of lung cancer using A549 cell line.  
First Author: Tatiana P. Protasova

Abstract e15619: Comparison of the tumor cells proliferative activity in donor tissue and samples of xenograft generations.  
First Author: Ekaterina A. Lukbanova

Abstract e15620: Bstrongximab-MMAE, a novel antibody-drug-conjugate for metastatic gastric and pancreatic cancers.  
First Author: William Michael Schopperle, PhD

Abstract e15621: Bstronximab, a novel therapeutic antibody to treat metastatic testis cancer.  
First Author: William Michael Schopperle, PhD

Abstract e15622: Efficiency: Minimizing dose escalation steps by calculating human dosing preclinically.  
First Author: Steve Gyorffy, PhD

Abstract e15623: Multi-analyte liquid biopsies based treatment in advanced refractory cancers.  
First Author: Sewanti Limaye, MD, MS

Abstract e15624: Multi-analyte interrogation based treatment of advanced refractory cancers.  
First Author: Dadasaheb B Akolkar, PhD

Abstract e15625: Management of adverse events in early clinical trials by advanced practice providers in the outpatient setting.  
First Author: Diane D Barber

Abstract e15626: Biosimilar trastuzumab active post-marketing surveillance real-world data update: Results from a patient support program for patients under treatment with the first biosimilar trastuzumab approved in Brazil.  
First Author: Allisson Monteiro da Silva, MD

First Author: Juul M. Cox, PharmD
Abstract e15628: Molecular mechanism(s) of resistance to vandetanib in medullary thyroid carcinoma.
First Author: Brittany Glassberg

Abstract e15629: Tolerability of enzalutamide in prostate cancer: A meta-analysis.
First Author: Tejas Karawadia, MD

Abstract e15630: OSU-03012 induces apoptosis of gastric cancer cells through endoplasmic reticulum stress triggered inhibition of Akt and STAT3 signaling pathways.
First Author: Wei Peng, M.D.

Abstract e15631: Bevacizumab induced proteinuria and hypertension: A comparative analysis of anti-hypertensives utilized within a single institution.
First Author: Marwah Wafa Farooqui, DO, BS

Abstract e15632: A precision medicine tool “Knowledge Frames” to explain poor results of STING agonist trials.
First Author: Al Blunt, MD

Abstract e15633: Growth differentiation factor 15 (GDF-15) inhibition to increase muscle mass and function in cancer cachexia.
First Author: Matthew Peloquin

First Author: Inger Darling, Ph.D.

Abstract e15635: Injection mixed drug intratumoral to produce ROS and creating a coagulum as cancer therapeutics drug depot.
First Author: Jian Zhang, MS

Abstract e15636: Repurposing antimuscarinics to treat lethal chemoresistant prostate and lung cancers.
First Author: Tyler B Bland

Abstract e15637: Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase.
First Author: Chundao Yang

Abstract e15638: Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.
First Author: Antoine Italiano, MD
First Author: Shaoshuang Fan

Abstract e15640: Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.
First Author: Ruby Yun-Ju Huang, MD, PhD

First Author: Zhengxia Chen, PhD

Abstract e15642: Preclinical evaluation of SC0245, a small molecule inhibitor of ATR kinase.
First Author: Jian Wang

Abstract e15643: A preclinical model for skin sensitization prediction of antineoplastic drugs.
First Author: Jose Alejandro Perez-Fidalgo, MD, PhD

Abstract e15644: Delivery of all-trans-retinoic-acid (ATRA) in liposomes modulated MDSCs and T-cell activities in the tumor microenvironment.
First Author: Yuhong Xu

First Author: Xiao-Li Wei, PhD

Abstract e15646: Targeted therapy drugs approved in the United States, Japan and China from 2001 to 2019: An analysis of pharmacokinetic characteristics, dosing regimens and potential ethnic significance.
First Author: Diansong Zhou

Abstract e15647: X-ray crystal structure analysis of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), bound to estrogen receptor alpha ligand binding domain.
First Author: Sean W. Fanning, PhD

Abstract e15648: Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: Learnings from a survey of approved drugs.
First Author: Rajendar K Mittapalli, PhD

Abstract e15649: A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR-mutant NSCLC.
First Author: Makoto Nishio, MD, PhD
First Author: Elena Yu. Zlatnik

Abstract e15651: Role of mutant KRAS as a biomarker in FL118-induced apoptosis, reactive oxygen species (ROS) production and inhibition of survivin, Mcl-1 and XIAP in human bladder cancer.
First Author: Sreevidya Santha

Abstract e15652: Anlotinib, a multitarget tyrosine kinase inhibitor, for advanced lung cancer patients: Efficacy in real-world study.
First Author: Jifeng Feng, Doctor's degree

Abstract e15653: Searching for novel therapeutic targets to effectively treat cancers arising from NRG1 chromosomal rearrangements.
First Author: Eric Gladstone

First Author: Jefferson Parker

Abstract e15655: An IND-stage potent and selective NTRK/ROS1 inhibitor of WT and clinical resistant mutants with superiority to approved and next generation tyrosine kinase inhibitors (TKIs) LOXO101, entrectinib, and LOXO195.
First Author: zhiqiang yang

Abstract e15656: FIH phase I dose escalation study of FN1501, an investigational FLT-3 inhibitor with multiple targets in patients with relapsed or refractory solid tumors and acute myeloid leukemia.
First Author: Gary Edward Richardson, MD

Abstract e15657: Updated results of a phase I study of felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in adult patients with relapsed/refractory solid tumors.
First Author: Judy Sing-Zan Wang, MD

Abstract e15658: Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated HNSCC.
First Author: Francis Burrows

Abstract e15659: FGFR2 inhibition could suppress spermatogenesis.
First Author: Ilya Tsimafeyeu, MD

Abstract e15660: BDTX-189: A potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations.
First Author: Matthew O'connor
Abstract e15661: Novel CTC test followed by iodine therapy for the terminal stage of cancer patients.  
First Author: Taro Shirakawa

Abstract e15662: Preclinical evaluation of LX-086, a small molecule as a selective inhibitor of PI3K.  
First Author: Jiaqiang Dong

Abstract e15663: Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity.  
First Author: Philip Tatman

Abstract e15664: An integrative molecular framework to predict homologous recombination deficiency.  
First Author: Joshua SK Bell, PhD

Abstract e15665: Incidence and inpatient cost of severe adverse events (SAE) in unresectable or metastatic SOLID tumor patients (pts) exposed to larotrectinib or entrectinib.  
First Author: Todd E. Williamson, PhD

Abstract e15666: Whole exome and transcriptome sequencing of colorectal and pancreatic cancer.  
First Author: Gargi D. Basu, PhD

Abstract e15667: Drugging the undruggable: A market readiness analysis for KRAS-G12C.  
First Author: Fotios Loupakis, MD, PhD

Abstract e15668: Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.  
First Author: Monica Motwani, PhD

Abstract e15669: Clinical utility of homologous recombination deficiency in advanced thoracic and gastrointestinal cancers.  
First Author: Erica S Tsang, FRCPC, MD

Abstract e15670: The landscape of muti-PIK3CA variations of 10,000 Chinese solid-tumor patients.  
First Author: Weiguang Gu

Abstract e15671: Clinical impact of hemizygous deletion detection and panel-size in comprehensive genomic profiling.  
First Author: Kenta Takahashi
First Author: Claudia Escher, PhD

Abstract e15673: Immunohistochemical biomarker expression in gastro-entero-pancreatic neuroendocrine tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland.
First Author: Silvia Duschek

Abstract e15674: Variety of clinical trial enrollment by actionable tumor suppressor genotype.
First Author: Monica Avila

Abstract e15675: Expression profile and potential regulatory pathways of SFTPA1 in human tumors.
First Author: Lu Yuan

Abstract e15676: A whole transcriptome sequencing (WTS)-based cMet dysregulation biomarker assay with correlates to cMet DNA mutations and cMet protein expression.
First Author: Xiaoling Zhang, PhD

Abstract e15677: Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).
First Author: Megan Greally, MBBCh

**Gastrointestinal Cancer—Colorectal and Anal**

First Author: Nina Niu Sanford, MD

Abstract e16001: Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial.
First Author: Yuxian Bai

Abstract e16002: Neutrophil extracellular traps blockade in combination with PD-1 inhibition in treatment of colorectal cancer metastasis.
First Author: Amblessed Onuma

Abstract e16003: 20q amplification defined by genomic and clinical characteristics as a subgroup with increased prevalence and better survival in metastatic colorectal cancer.
First Author: Satish Maharaj, MBBS
Abstract e16004: Correlation of existence and number of mutations in DDR signaling pathway genes with poor survival after resection of colorectal liver metastases.
First Author: Kun Wang, PhD

Abstract e16005: Relationship of KIAA1199 on neutrophil recruitment and promotion of colorectal cancer liver metastasis via TGF-β signaling.
First Author: Haihong Wang

Abstract e16006: Regorafenib associated acute kidney injury.
First Author: Omar Mamlouk

Abstract e16007: Hepatic arterial infusion (HAI) chemotherapy via the medtronic pump-assessing dose delivery, response rates and toxicity.
First Author: Louise Catherine Connell, MD

Abstract e16008: Real-world evidence: Adjuvant chemotherapy in colorectal cancer with liver metastases.
First Author: Feng-Che Kuan, M.D.

Abstract e16009: Prognostic significance of Musashi 2 (MSI2) RNA-binding protein expression in precancerous polyps and during colorectal cancer (CRC) progression.
First Author: Leonid Kharin, MD

Abstract e16010: Safety and efficacy of pembrolizumab monotherapy in patients with advanced colorectal MSI-h/dMMR cancers.
First Author: Vasiliki Michalaki, MD, PhD

First Author: Janet Shirley Graham, MBChB, MRCP, PhD

Abstract e16012: 18F-FDG PET scan and liquid biopsy as tools to assess the pace of tumor progression and to predict overall survival (OS) in refractory colorectal cancer (rCRC): The CORIOLAN trial.
First Author: Silvia Camera, MD

Abstract e16013: Association between gut microbiome and T lymphocytes among different primary tumor sites of patients with metastatic colorectal cancer.
First Author: Lingyun Sun, MD

Abstract e16014: Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.
First Author: Zhihao Lu
First Author: Melanie Lindenberg, MSc

First Author: Qijing Wu

Abstract e16017: The results of a study of the concordance of RAS status in liquid and invasive biopsies in patients with metastatic colorectal cancer in the Republic of Kazakhstan.
First Author: Kaldigul Smagulova

Abstract e16018: Comparaison of the chemosensitivity of the metastatic sites of colorectal cancer by Oncogramme.
First Author: Muriel Mathonnet

Abstract e16019: Positioning of self-expandable metal stent insertion in colonic obstruction by extracolonic malignancy.
First Author: Chung Sook Hee

Abstract e16020: Mutational profiles and clinical outcomes in metastatic colorectal carcinoma patients with different metastases sites.
First Author: Xi Zhang, MD, PhD

Abstract e16021: Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer.
First Author: Koen Degeling

Abstract e16022: Survival impact of metastasis surgical resections and sidedness of primary (1º) tumor location in metastatic colorectal cancer (mCRC) without monoclonal antibodies: Retrospective review from 2003 through 2019.
First Author: Marcos André Marques Portella, MD

Abstract e16023: Phase I study of regorafenib and nivolumab in mismatch repair (MMR) proficient advanced refractory colorectal cancer.
First Author: Richard D. Kim, MD

Abstract e16024: Bevacizumab plus S-1 and raltitrexed for refractory metastatic colorectal cancer.
First Author: Ye Chen

Abstract e16025: A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer
Abstract e16026: The role of combined treatment of metastatic colorectal cancer inpatients with liver metastases.
First Author: Mikhail Trandofilov

Abstract e16027: An open-label, single-arm, phase I study to assess the safety, efficacy, and biomarker effects of OMT-110 in patients with refractory colorectal cancer.
First Author: Soobong Park

Abstract e16028: Efficacy and safety of fruquintinib in the treatment of poor patients with metastatic gastrointestinal cancer.
First Author: Yanzhi Cui, M.D.

Abstract e16029: Evaluation of prognosis of rectal cancer patients with neoadjuvant chemoradiotherapy by clinical TNM stage: Is it suitable?
First Author: Yue Chen

Abstract e16030: Cohort study on patients with metastatic colorectal cancer with integrated Chinese and western medicine.
First Author: Tong Zhang

Abstract e16031: Phase I study (PAYLOAD) of RRx-001 + irinotecan in patients with advanced solid malignancies.
First Author: Edward Jae-Hoon Kim, MD, PhD

Abstract e16032: Toxicity and tolerance profile of ANTI-EGFRS in metastatic colorectal cancer RAS wild type from the east of Algeria.
First Author: Ammari Abdelaziz, MD

First Author: Ma Dong, M.D.

Abstract e16034: Diffusion kurtosis imaging in predicting the chemotherapeutic response of colorectal liver metastases: The result of the FDZL-MRinCLM study.
First Author: Wenhua Li

Abstract e16035: Efficacy of single-agent epidermal growth factor receptor inhibition in the second-line setting for metastatic colorectal cancer with a goal towards retreatment strategies.
First Author: Jeremy D. Kratz, MD
Abstract e16036: Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
First Author: Bo Zhang, MD

Abstract e16037: Dehydration as a possible tool to slow down peritoneal metastases by changing the intraperitoneal environment.
First Author: Tanja Khosrawipour, MD, PhD

Abstract e16038: Prognostic significance of adipose tissue distribution and metabolic activity in PET-CT images of patients with metastatic colorectal cancer.
First Author: Tuba Karacelik, Assistant

Abstract e16039: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.
First Author: Takeshi Kato, MD, PhD

Abstract e16040: Anti-VEGF versus Anti-EGFR in the real world in metastatic colorectal cancer.
First Author: Fernando Namuche, MD

Abstract e16041: The role of continuity of systematic treatment and rehabilitation in patients with metastatic colorectal cancer in elderly and senile age.
First Author: Iuliia Vladimirovna Alekseeva

Abstract e16042: Impact of cetuximab sequence on progress-free survival (PFS) and overall survival (OS) in patients with RAS wild-type metastatic colorectal cancer (mCRC): A real-world study.
First Author: Qirong Geng

Abstract e16043: Role of palliative radiotherapy in patients with metastatic colorectal cancer: A propensity score matching analysis.
First Author: Zhenyu Lin, MD

Abstract e16044: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701).
First Author: Toshiki Masuishi, MD, PhD

Abstract e16045: Preparing the peritoneal surface for intraperitoneal chemotherapy using high-intensity ultrasound (HIUS): Investigation of technical feasibility, safety and possible limitations.
First Author: Veria Khosrawipour, MD PhD

Abstract e16046: LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases.
First Author: Gudrun Piringer, Dr
Abstract e16047: Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective trial.
First Author: Jasur Madyarov, Ph.D

Abstract e16048: Health economic analysis of doublet chemotherapy with and without bevacizumab for first-line treatment of RAS mutant metastatic colorectal cancer based on real-world data.
First Author: Koen Degeling

Abstract e16049: Differential genetic variations and prognostic predicting factors in colorectal cancer patients with or without liver metastasis.
First Author: Honghua Peng

Abstract e16050: Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.
First Author: Sunil Sharma, MD, FACP, MBA

Abstract e16051: The role of Systemic Inflammation Score (SIS) in BRAF(V600) mutant metastatic colorectal cancer (mCRC).
First Author: Nieves Martinez Lago, MD, PhD

Abstract e16052: Microsatellite instability and KRAS mutation in stage 4 CRC: prevalence, geographic discrepancies and outcomes from the National Cancer Database.
First Author: Johannes Uhlig, MD MPH

Abstract e16053: Meta-analysis and systematic review of the cardiotoxicity of TAS-102.
First Author: Carlos Alberto Lopez, MD, MPH

Abstract e16054: Correlation between DIDO1 variation and MSI-status in colorectal cancer.
First Author: Xingwei Zhang

Abstract e16055: Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
First Author: Annika Kurreck

First Author: Roham Salman Roghani, MD
Abstract e16057: Utility of circulating tumor DNA in genomic profiling of colorectal cancer with peritoneal metastasis.
First Author: Tenghui Ma

Abstract e16058: Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab.
First Author: Neel Ingemann Nissen, MS.c

First Author: Firas Baidoun, MD

Abstract e16060: The mutational landscape of the adjacent paracancerous tissues confirmed the safe margin of 2-5cm in colorectal cancer resection.
First Author: Jin Gu, M.D., Ph.D.

Abstract e16061: FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA.
First Author: Ivan De Dios

Abstract e16062: Immune tolerance to colon cancer is mediated by colon dysbiosis: Human results and experimental In Vivo validation.
First Author: Emma Bergsten, PhD

Abstract e16063: Clinically relevant multi-omic analysis of colorectal cancer.
First Author: Silvia von der Heyde

Abstract e16064: A new CRISPR mediated intestinal tumor mouse model targeting four canonical tumor suppressor genes.
First Author: Hajime Kashima, M.D., Ph.D.

First Author: Prasanth Ariyannur, MBBS, MD

Abstract e16066: Hsa-miR-196a2 Rs 11614913 C>T polymorphism and CRC susceptibility: A case-control study.
First Author: Li-zhu Chen

Abstract e16067: Mutation profile of colon cancer in hispanic population of central California.
First Author: Sanjay Hinduja
Abstract e16068: Stage II high-risk colon cancer: A retrospective analysis of the benefit of chemotherapy in patient subgroups based on the risk factor.
First Author: Linu Abraham Jacob, MD

Abstract e16069: Mismatch repair deficiency testing in colorectal cancer and factors associated with nonadherence to guidelines.
First Author: Phuong Ngo, MD

Abstract e16070: Do differences in the microbiome explain early onset in colon cancer?
First Author: Ajaratu Keshinro, MD

First Author: Debora Basile, MD

Abstract e16072: Assessing real-world outcomes in metastatic colorectal cancer with KRAS^{G12C} mutation.
First Author: Hui-Li Wong, FRACP, MBBS

Abstract e16073: Presence of circulating tumor cells is more significant than tumor stage in characterizing cellular local immunity in colorectal cancer.
First Author: Anastasia O. Sitkovskaya

First Author: Zunaira H Choudhary, MD

Abstract e16075: Tracking only pathogenic variants decreases sensitivity to track plasma ctDNA for detecting minimal residual disease in localized colon cancer.
First Author: Noelia Tarazona, MD, PhD

Abstract e16076: Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively.
First Author: Midhun Malla, MD, MS

Abstract e16077: Non-cancer clinical benefits of a strong local immune response, eg. a high immunoscore, in patients with colorectal cancer.
First Author: Franck Pages, MD, PhD

Abstract e16078: Associations between oncogenic risk markers and clinical outcomes among black and white colorectal cancer patients.
First Author: Victoria Starks
Abstract e16079: A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status.
First Author: Irvin Mark Modlin, MD, PhD

First Author: Jianming Ying

Abstract e16081: Patient characteristics and outcomes of colorectal cancer (CRC) at Butaro Cancer Center of Excellence (BCCOE): Results from a retrospective cohort.
First Author: Temidayo Fadelu, MD, MPH

Abstract e16082: Shorter time to treatment and comprehensive care at Commission on Cancer-accredited practices improves outcomes in rural patients with colorectal cancer.
First Author: Suneel Deepak Kamath, MD, BS

Abstract e16083: Correlation of LINE-1 hypomethylation with size and dysplasia in colorectal tubular adenomas, and risk for synchronous and metachronous CRC.
First Author: Alice Jiang

Abstract e16084: Trends in colorectal cancer incidence in India.
First Author: Vinay Mathew Thomas

Abstract e16085: Age-dependent prognostic value of KRAS mutation in metastatic colon cancer.
First Author: Muhammet Ozer, MD

Abstract e16086: Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis to enable detection of early-stage colorectal cancer.
First Author: Oscar Westesson

Abstract e16087: Prognostic value of piR-39980 in patients with colorectal cancer.
First Author: Wei Peng, M.D.

Abstract e16088: Outcomes of rectal cancer patients treated using Polish II neoadjuvant short course radiation therapy and chemotherapy approach in comprehensive cancer center.
First Author: Stephen Haff

Abstract e16089: Clinical utility of germline genetic testing after tumor genomic testing in colorectal cancer patients.
First Author: Nhu Ngo, MD

Abstract e16090: Incidence of and risk factors for hospitalizations from chemotherapy among patients with stage III and stage IV colorectal cancer.
First Author: April Falconi, MPH, PhD
Abstract e16091: The effectiveness of colorectal cancer screening for cancer survivors.
First Author: Chia-Jen Liu, MD

Abstract e16092: Predictive and prognostic factors of apatinib in metastatic colorectal cancer.
First Author: Fen Wang, MD

Abstract e16093: Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC).
First Author: Antonio Galvano

Abstract e16094: Genomic and transcriptomic correlates of response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
First Author: Sinead Toomey, PhD

Abstract e16095: Contrast-enhanced CT radiomics for predicting calcification in metastatic colorectal cancer: Based on machine learning.
First Author: Yuwen Zhou, Master

Abstract e16096: Exosomal marker CD63 expression pattern using immunohistochemistry (IHC) in patients with rectal adenocarcinoma in comparison with left-sided colon cancer.
First Author: Pranitha Prodduturvar, MBBS, MD

Abstract e16097: H&E image-based consensus molecular subtype classification of colorectal cancer using weak labeling.
First Author: Andrew J. Kruger, PhD

Abstract e16098: Deviation from the precisely timed phenomic ageotypes can assist in early CRC screening and reveal underlying pathophysiology.
First Author: Sheeno P. Thyparambil, PhD

Abstract e16099: Treatment of colorectal cancer in Armenia: A retrospective hospital-based study from a developing world.
First Author: Samvel Bardakhchyan, MD

First Author: Jing Lin

Abstract e16101: Exploring fingerprint ctDNA as a stratifying factor in colorectal cancer.
First Author: Wending Sun, PhD

Abstract e16102: Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.
First Author: Xiang Ling
Abstract e16103: Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
First Author: Anqi Lin

Abstract e16104: Copy number variation and expression of CT-genes in patients with colorectal cancer.
First Author: Yuriy A. Gevorkyan

Abstract e16105: Treatment modalities and outcomes in patients with rectal cancer (RC) in a referral center in Mexico.
First Author: Vanessa Rosas Camargo, MD

Abstract e16106: A novel xenonucleic acid mediated molecular clamping technology for early colorectal cancer diagnostics.
First Author: Qing Sun, Ph.D.

Abstract e16107: Overlooking MMR deficiency in carriers of certain pathogenic variants by routine MSI and/or IHC testing in Lynch syndrome: Implications for a wider MMR deficiency testing.
First Author: Marija Staninova Stojovska, PhD

Abstract e16108: Bevacizumab associated calcifications might be a prognostic marker in patients with metastatic colorectal cancer.
First Author: Yuwen Zhou, Master

Abstract e16109: Expression profile of micro-RNA of lymphovascular invasive colon cancer.
First Author: Zhongning Chen, MD

Abstract e16110: Utility of neutrophil to lymphocyte ratio in predicting colorectal cancer prognosis at a VA hospital: Do stage and sidedness matter?
First Author: Kee-Hwan Michael Kim

Abstract e16111: PD-L1 expression on tumor cells and tumor infiltrating immune cells in Chinese colorectal cancer patients.
First Author: Jianjun Yang

Abstract e16112: Circulating tumor DNA to monitor treatment response and investigate resistance mechanism in BRAF inhibitor treated colorectal cancer patients.
First Author: De-Shen Wang, MD, PhD

Abstract e16113: Multigene mutation signatures in colorectal cancer patients: Predict for the diagnosis, pathological classification, staging and prognosis.
First Author: Yan Zhuang
Abstract e16114: Prognostic value of De Ritis ratio (aspartate transaminase/alanine transaminase) in patients with non-metastatic colorectal carcinoma [izmir oncology group (IZOG) study].
First Author: Utku Oflazoglu Sr., MD, Dr

Abstract e16115: Identifying education, knowledge and communication gaps in biomarker testing between YO-CRC patients, caregivers, and their medical team.
First Author: Kim Lynn Newcomer, None

Abstract e16116: Do irinotecan (IRI) dose reductions driven by UGT1A1*28 genotyping prevent IRI-related severe neutropenia? A real-world study.
First Author: Nicola Personeni, MD

Abstract e16117: Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer.
First Author: Iosune Baraibar, MD

First Author: Debora Basile, MD

Abstract e16119: Genomic biomarkers to determine survival in Multicenter Study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.
First Author: Meaghan Dendy Case, MD

Abstract e16120: The clinical impact of MicroRNA-21 in low rectal cancers treated with curative radiotherapy in the organ preserving setting.
First Author: Torben Hansen, MD, PhD

Abstract e16121: Alterations of DNA damage repair genes in Chinese colorectal cancer patients.
First Author: Wenliang Li

Abstract e16122: Racial and socioeconomic disparities in overall survival in colorectal cancer (CRC) at West Cancer Center & Research Institute (WCCRI), Memphis, TN.
First Author: Vanessa Wookey, MD

Abstract e16123: Significance of lymph node (LN) retrieval as a high-risk factor in stage II and III colon cancer.
First Author: Yitak Kim

First Author: Matthew Loft, BPharm, MBBS
Abstract e16125: Six-year updated results of Japan Clinical Oncology Group study (JCOG0910): Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colorectal cancer.
First Author: Tetsuya Hamaguchi, MD, PhD

First Author: Jin Li, MD

Abstract e16127: A randomized, open-label, parallel-design phase III study to compare adjuvant 5-FU plus oxaliplatin (mFLOX) versus observation in locally advanced rectal cancer after neoadjuvant chemoradiation.
First Author: Maria Ignez Freitas Melro Braghiroli, MD

Abstract e16128: Metastatic lymph node ratio as better prognostic tool than TNM system in colorectal cancer.
First Author: Filipa Macedo

Abstract e16129: The prognosis valve of tumor regression grade in the same ypStage patients after neoadjuvant treatment in locally advanced rectal cancer: Post-hoc analysis of a prospective trial.
First Author: Jianwei Zhang, MD

Abstract e16130: The effect of hapten on the clinical efficacy and survival of patients with liver cancer treated by UMIPIC.
First Author: Feng Gao, MD

Abstract e16131: Phase II trial of induction chemotherapy plus chemoradiotherapy with aspirin or placebo in high-risk rectal cancer (ICAR).
First Author: Juliana Souza, MD, MD

Abstract e16132: Circulating mitochondrial DNA (mtDNA) variants to predict metastatic progression of rectal cancer.
First Author: Anne Hansen Ree, MD, PhD

First Author: Xiangbing Deng

Abstract e16134: Organ index of immunological and anti-tumor effect of intratumor injection of penicillin sodium combined with chemotherapy drug for tumor-bearing mice.
First Author: Qiang Fu, MS
Abstract e16135: Clinical study on the tunnel approach in laparoscopic radical right hemicolectomy.  
First Author: Xijie Zhang

Abstract e16136: Induction chemotherapy with mFOLFOXIRI in cT4N+ locally advanced rectal cancer: Subgroup analysis from a prospective trial.  
First Author: Jianwei Zhang, MD

Abstract e16137: Upfront chemotherapy vs. surgery for “very low” lying locally advanced rectal cancer without preoperative chemoradiation: The NAIR phase II/III trial.  
First Author: Yuichiro Tsukada, MD, PhD

Abstract e16138: A prospective pilot study of pharmacogenetic-based dosing of 5-fluouracil (5-FU) and irinotecan (IRI) in patients (pts) with gastrointestinal (GI) malignancies.  
First Author: Jeffrey Chi, MD

Abstract e16139: Safety and feasibility of systemic anticancer therapy in gastrointestinal (GI) cancer patients on hemodialysis (HD): The largest retrospective study.  
First Author: Jennifer Park

Abstract e16140: Patient-initiated approach to prevent oxaliplatin induced peripheral neuropathy: A social media experiment.  
First Author: Dana Cardinas, DPM, FACFAS

Abstract e16141: Prospective evaluation of current RAS mutation testing practices in newly diagnosed metastatic colorectal cancer: Middle East and North Africa Registry (MORE-RAS) Study.  
First Author: Mohammed Oukkal

Abstract e16142: A novel XNA-based NGS panel for cancer diagnostics.  
First Author: Qiang Gan, PhD

Abstract e16143: Acceptance of preventive colonoscopy in rural areas in Germany.  
First Author: Joerg Fahlke

Abstract e16144: Phase II expansion cohort in colorectal cancer to evaluate the safety and tolerability of RRx-001 blood mix.  
First Author: George A. Fisher Jr., MD, PhD

Abstract e16145: Serum-based multiplex protein assay for early detection of colorectal cancer and precancerous lesions in a FIT positive population.  
First Author: Herbert A. Fritsche, PhD
Abstract e16146: Survival among colorectal cancer patients with a history of previous cancer.
First Author: Sandi Pruitt, PhD

Abstract e16147: Clinicopathologic features and survival outcomes of signet cell carcinoma of the appendix: Analysis of the SEER database.
First Author: Kamelah Abushalha, MD

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Abstract e16500: Eosinophilic colitis in cancer patients.
First Author: Shruti Khurana, MD

Abstract e16501: Genetic landscape of 43 patients with dMMR gastric cancer and its clinical implications.
First Author: Dongliang Wang, MD, PhD

Abstract e16502: Mast cells positive to c-kit receptor and to tryptase in normal to cancer pancreatic tissue and the correlation with angiogenesis.
First Author: Carmelo Laface Sr., MD

Abstract e16503: In-hospital outcomes of splanchnic vein thrombosis including Budd Chiari syndrome associated with GI malignancies.
First Author: Shivani Handa, MD

Abstract e16504: Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers.
First Author: Jenny Peng, MD

Abstract e16505: Safety and preliminary antitumor activity of the transforming growth factor beta (TGF-β) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.
First Author: Minkyu Jung, MD, PhD

Abstract e16506: Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials.
First Author: Koji Oba, PhD

Abstract e16507: Outcome of locally advanced carcinoma of oesophagus: A single institution experience.
First Author: Thianeshwaran S
Abstract e16508: Hepatic arterial infusion oxaliplatin plus oral S-1 chemotherapy to improve prognosis for gastric cancer with multiple liver metastases. 
First Author: Kangxin Wang

Abstract e16509: Blockade of TRIM59 to enhance chemosensitivity of esophageal cancer cell to cisplatin by upregulating p53 expression. 
First Author: Rong feng Liu, PhD

Abstract e16510: Effects of removing heat and phlegm prescription on the proliferation and autoantigens expression of esophageal carcinoma cell. 
First Author: Fuchun Si Sr., PhD

Abstract e16511: Radiotherapy in localized gastric cancer management: To be or not to be? 
First Author: Amany Hussein, MD

Abstract e16512: Precise early detection of gastric cancer and blood cell circuit. 
First Author: Oleg Kshivets, MD, PhD

Abstract e16513: Can early changes in circulating tumor DNA (ctDNA) predict durable tumor responses in patients with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)? 
First Author: Constanza Linossi, MD

Abstract e16514: Cancer genomics-based screening of new therapeutic targets and biomarkers for esophageal cancer. 
First Author: Yataro Daigo, MD, PhD

Abstract e16515: Esophageal cancer, five years of experience in a regional oncologic reference center in Mexico. 
First Author: Adelina Alcorta-Garza, MD, PhD

Abstract e16516: Limonoid compounds from Xylocarpus granatum and their anti-cancer activity against esophageal cancer cells. 
First Author: Li Jing

Abstract e16517: Observation on the clinical effect and survival period of patients with esophageal cancer treated with UMIPIC combined with low dose radiotherapy. 
First Author: Jian Liu, MD

Abstract e16518: Genomic and immune intratumor heterogeneity in gastric linitis plastica. 
First Author: Jin Huang, MD, PhD
Abstract e16519: Management and prognosis of interval distant metastasis in patients with esophageal or gastroesophageal junction cancer: A population-based cohort study.
First Author: Tiuri E Kroese, MD

Abstract e16520: Identification and expression distribution of esophageal carcinoma autoantigens.
First Author: Fuchun Si Sr., PhD

Abstract e16521: ACTL6A to drive gastric cancer progression through induction of glutathione synthesis.
First Author: Lekun Fang

Abstract e16522: High intra-tumor heterogeneity observed in esophageal squamous cell carcinoma.
First Author: Jun Xue, PhD

Abstract e16523: Resting memory CD4+ T cells and plasma cells in gastric cancer may be potential immune biomarkers.
First Author: Jingde Chen

Abstract e16524: Camrelizumab (Camre) plus taxane-based chemotherapy (CT): Clinical outcomes and dynamic monitoring of CEA as a predictive biomarker of response in patients with recurrent or advanced esophageal squamous cell carcinoma (ESCC).
First Author: Cheng Kong

Abstract e16525: Brain metastasis from esophageal squamous cell carcinoma: Clinical characteristics and prognosis.
First Author: Linlin Xiao

Abstract e16526: Study of efficacy and tolerability of paclitaxel and carboplatin as a concurrent chemotherapeutic radiation sensitizer regimen in patients of esophageal cancer: Prospective observational study from tertiary center in northern India.
First Author: Pankaj. Goyal

Abstract e16527: Does radical surgery for gastric cancer after 70 years prolong survival?
First Author: Brice Chanez, MD, Ph.D

Abstract e16528: Prognostic value of baseline complete blood count components in advanced gastric cancer patients: A multicenter retrospective study.
First Author: Shereef Ahmed Elsamany, MD

Abstract e16529: Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy.
First Author: Rashida Orlova, PhD
Abstract e16530: The effects of combined modality therapy on stage II-III primary gastric signet ring cell carcinoma.
First Author: Yang Li

Abstract e16531: The IL-6/STAT3 signaling pathway mediated by radiotherapy regulates the expression of PD-L1 and affects the biological functions of esophageal cancer cells.
First Author: Yichen Zhou, M.M.

Abstract e16532: The effect of chronic diseases on the clinical effect and survival period of patients with solid tumor treated with UMIPIC.
First Author: Shanshan Cui, MD

Abstract e16533: Is the peritoneal lavage cytology coincided with peritoneal metastasis for gastric cancer?
First Author: Wei Wang, MD

Abstract e16534: Glutathione system in the blood of gastric cancer patients with various tumor histotypes and prevalence of the disease.
First Author: Irina A. Goroshinskaya

Abstract e16535: Clinicopathological features and outcomes of patients with esophageal cancer undergoing neoadjuvant chemoradiation (chemoRT) in Southern Brazil: A comparison to the Worldwide Esophageal Cancer Collaboration.
First Author: Gustavo Cartaxo de Lima Góssling, MD

First Author: Song Li, MD, PhD

Abstract e16537: Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.
First Author: Ian Chau, MD

Abstract e16538: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated to systemic chemotherapy for gastric cancer with diffuse peritoneal metastases in a palliative setting.
First Author: Pierre Emmanuel Bonnot, MD

Abstract e16539: Outcomes relative to paclitaxel dose-intensity when administered with ramucirumab in gastric and gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Michael J Allen, BSc, MBBS, MPH, FRACP
Abstract e16540: Concurrent docetaxel and S-1 compared with oxaliplatin and s-1 as first-line therapy for advanced gastric adenocarcinoma: A retrospective study.
First Author: Siyi Tan

Abstract e16541: Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.
First Author: Jeeyun Lee, MD

Abstract e16542: Preliminary results of a phase II study of neoadjuvant immune checkpoint inhibitor IMC-001 (anti-PD-L1 monoclonal antibody) in patients with resectable gastrointestinal cancers (NeoChance Study).
First Author: Hyeon-Su Im, MD

Abstract e16543: The genomic profile and potential predictive circulating cytokines of gastric cancer combine disseminated intravascular coagulation.
First Author: Jian Xiao

Abstract e16544: Effects of alkaline water intake on gastritis and miRNA expression (miR-7, miR-155, miR-135b and miR-29c) in the Amazon population.
First Author: Juliana Ramos Chaves, MD

Abstract e16545: Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas.
First Author: Sonal Brindley Hapuarachi, MBBS, BSC, MRCP

Abstract e16546: The microbial characteristics of esophageal squamous cell carcinoma (ESCC) and healthy subjects.
First Author: Wenjing Lv

Abstract e16547: The association between hyperfibrinogenemia and clinicopathological factors, and the survival analysis of gastric cancer.
First Author: Yu Su

Abstract e16548: Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy.
First Author: Koichi Kitagawa, MD

Abstract e16549: Efficacy and safety of camrelizumab combined with FOLFOX as neoadjuvant therapy for patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.
First Author: Yuzhou Zhao

Abstract e16550: Clinical and molecular features of responders to PD-1 blockade for patients with microsatellite instability high or mismatch repair deficient advanced gastrointestinal
tumors.
First Author: Keigo Chida, MD

Abstract e16551: Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy.
First Author: Zhihao Lu

First Author: Robert George Wadleigh, MD

Abstract e16553: The dynamic change of cancer genome and T-cell receptor repertoire of an early gastric cancer cohort.
First Author: Zhuoran Li

Abstract e16554: Exploration of the expression and significance of IL-6, STAT3 and PD-L1 in esophageal squamous cell carcinoma.
First Author: Yicheng Zhou, M.M.

Abstract e16555: Knockdown of KREMEN2 inhibits tumor proliferation and metastasis in gastric cancer.
First Author: Beibei Chen

Abstract e16556: Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel) versus EOX/EOF (epirubicin, oxaliplatin and capecitabine or fluorouracil) for locally advanced, resectable gastric or gastro-oesophageal junction (GOJ) adenocarcinoma: A regional center experience.
First Author: Emily Wong, MBChB

Abstract e16557: Cytokine status in the omentum and peritoneum in metastatic gastric cancer.
First Author: Elena Yu. Zlatnik

Abstract e16558: An analysis of clinicopathological characteristics and prognosis on hepatoid adenocarcinoma of stomach.
First Author: Juan Shi, Master's degree

Abstract e16559: Prognostic similarities between gastric adenosquamous carcinoma and typical gastric adenocarcinoma: A large population-based and propensity score-matched study.
First Author: Feng Zhao, Dr.

Abstract e16560: Clinical impact of oral intake on second-line treatment of advanced gastric cancer.
First Author: Takatsugu Ogata, MD
Abstract e16561: Factors related to the incidence of esophageal stenosis after treatment of advanced esophagus cancer.
First Author: Carla Simone Moreira de Freitas, MD, Msc

Abstract e16562: Tepotinib inhibits the epithelial-mesenchymal transition and tumor growth of gastric cancers via increasing GSK3β, ECAD, MUC5AC, and MUC6.
First Author: Dae Young Zang, MD, PhD

Abstract e16563: Safety of double and a half-layered esophagojejunal anastomosis in total gastrectomy with gastric cancer.
First Author: Pengfei Ma

Abstract e16564: The impact of neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer (rGC).
First Author: Camille Ng

Abstract e16565: Weight loss after minimally-invasive esophagectomy for esophageal cancer.
First Author: Malcolm Hart Squires III, MD

Abstract e16566: Survival benefit of oophorectomy in stage IV gastric cancer patients with Krukenberg tumors.
First Author: Ahmed Abdelhakeem, MD

Abstract e16567: FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally-advanced esophageal carcinoma—The results of cohort A.
First Author: Shun Yamamoto

Abstract e16568: Totally laparoscopic plus one transthoracic port esophagogastrectomy for Siewert-type Ⅱ adenocarcinoma of esophagogastric junction.
First Author: Wei Wang, MD

Abstract e16569: Clinical outcomes of patients with gastric cancer according to pre and post-neoadjuvant chemotherapy PD-L1 immunohistochemistry (IHC) expression.
First Author: Heber Salvador de Castro Ribeiro, PhD

Abstract e16570: Sex differences in patient characteristics, treatment, and survival of palliative esophagogastric cancer patients: A population-based cohort study.
First Author: Willemieleke P.M. Dijksterhuis, MD

Abstract e16571: TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with anti-angiogenic or standard chemotherapy regimens.
First Author: Nicholas William Fischer
Abstract e16572: Clinical characteristics and outcomes of signet ring cell carcinoma of the stomach: A retrospective analysis of SEER database.
First Author: Moataz Ellithi

Abstract e16573: Tumor response score with neoadjuvant FLOT versus FOLFOX in gastric cancer patients: Results from a United States-based cohort.
First Author: James Pereira De Andrade

Abstract e16574: Gastric juice piR-1245: A promising prognostic biomarker for gastric cancer.
First Author: Wei Peng, M.D.

Abstract e16575: Impact of FLOT vs. ECX on post-chemotherapy tumor regression grade and pathological stage: Results from a national cohort study.
First Author: Clare Hannon

Abstract e16576: Cardiotoxicity after chemoradiation for locally advanced esophageal cancer: Contributions of substructure and whole heart dose-volume parameters to risk prediction.
First Author: Guoxin Cai

Abstract e16577: Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers.
First Author: Lauren Amanda Beck, BSc

Abstract e16578: Immunogenomic classification of gastric cancer based on the tumor microenvironments expression of PD-L1 and CD8+ T-cell infiltration.
First Author: Yu Chen

Abstract e16579: The mutational pattern of homologous recombination (HR) related genes and its relevance to response to immunotherapy in gastric cancer.
First Author: Yue Fan

Abstract e16580: Deep learning-based unsupervised morphological subtyping in histopathology images of gastric cancer.
First Author: Kyu-Hwan Jung, PhD

Abstract e16581: The impact of surgery induced immune-nutritional change on the outgrowth of micrometastasis after potentially curative resection for gastric cancer.
First Author: Masaki Aizawa, MD. PhD

Abstract e16582: Cachexia and nutritional interventions in esophagogastric cancer patients: A multicenter cohort study.
First Author: Willemieke P.M. Dijksterhuis, MD
Abstract e16583: Effect of sites of metastatic dissemination on survival in metastatic gastroesophageal adenocarcinoma.
First Author: Xin Wang, MD, PhD

Abstract e16584: A propensity score matched analysis of the anti-PD-L1 phase II PERFECT trial compared to conventional neoadjuvant chemoradiotherapy for resectable esophageal adenocarcinoma.
First Author: Tom van den Ende, BSc, MSc

Abstract e16585: Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.
First Author: Xianli Yin, MBBS

Abstract e16586: Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1–positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.
First Author: Hyun Cheol Chung, MD, PhD

Abstract e16587: Efficacy of immune check point inhibitors (ICIs) in metastatic gastric or gastroesophageal junction (GEJ) cancer by patient subgroups: A systemic review and meta-analysis.
First Author: Hadar Goldvaser, MD

Abstract e16588: Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients.
First Author: Tuyen Hoang, PhD

First Author: Meena Sadaps, MD

Abstract e16590: Chemoradiation versus chemotherapy after D2 gastrectomy: A meta-analysis including randomized and real-world trials.
First Author: Chai Hong Rim, MD, PhD

Abstract e16591: Effect of significant incidence of Braf p.V600E mutations in esophageal cancer on potential use of tyrosine kinase inhibitors.
First Author: Thurai Moorthy, PhD

First Author: André Jefremow, Dr. med.
Abstract e16593: Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).
First Author: Li Xu, M.D. Ph.D

Abstract e16594: Does an association exist between liver fibrosis and non-HCC cancers.
First Author: Shristi Upadhyay Banskota

Abstract e16595: Clinical observations on the optimal supportive treatment plus the radiotherapy with a single high-dose of 7.5-8Gy to the liver area for diffuse hepatocellular carcinoma.
First Author: Juhui Chen

Abstract e16596: Real-world experience with Lenvatinib in the management of Hepatocellular Carcinoma: A single-center Indian experience.
First Author: Amit Rauthan, MD

Abstract e16597: Impact of immunotherapy use in patients with stage IV biliary carcinoma.
First Author: Mariajose Rojas

Abstract e16598: Survival of older patients with advanced biliary tract cancers by disease site.
First Author: Sarah Bobiak, PhD

Abstract e16599: A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma.
First Author: Renuka V. Iyer, MD

Abstract e16600: Does time to treatment initiation affect survival in patients with gallbladder cancer?
First Author: KM Islam

Abstract e16601: Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC).
First Author: Daniel Wilhelm Mueller, PhD

Abstract e16602: Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: Real-world data from a single center.
First Author: Yang-Kui Gu, M.D, Ph.D

Abstract e16603: Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma.
First Author: Qicong Mai
Abstract e16604: Expression of the type 3 inositol 1, 4, 5-trisphosphate receptor according to the chronic liver disease etiology in hepatocellular carcinoma.
First Author: Paulo Henrique Costa Diniz, MD

Abstract e16605: Outcome of FOLFOX based chemotherapy in advanced pancreatobiliary cancers presenting with hyperbilirubinemia.
First Author: Sandeep Batra, MD, DNB

Abstract e16606: To biopsy or to not biopsy, that is the question: A single-center retrospective analysis of outcomes of liver biopsy with hepatocellular carcinoma and other liver diseases.
First Author: Sophia Seo-hyeon Lee, MD

Abstract e16607: Significance of Inter aorto-caval lymph nodes in Gall bladder cancer management.
First Author: Kishore Singh, MD

Abstract e16608: Correlation of serum PIVKA-II and AFP level with portal vein tumor thrombus and BCLC stage in newly diagnosed hepatocellular carcinoma patients.
First Author: Goutham Gandham, MD

Abstract e16609: Compliance to the American Association for the Study of Liver Diseases (AASLD) guidelines and its impact on overall survival in patients with hepatocellular carcinoma.
First Author: Ashish Manne, MD, MBBS

Abstract e16610: Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.
First Author: Hui-Chuan Sun, MD, PhD

Abstract e16611: Efficacy and safety of anlotinib combined with transarterial chemoembolization versus transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma: A retrospective study.
First Author: Wenbo Guo Sr.

Abstract e16612: Impact of tumor histology and socioeconomic factors on survival of patients suffering from malignant vascular tumors of liver and hepatocellular carcinomas: A SEER database analysis.
First Author: Aditya Varnam Shreenivas, MD, MS

First Author: Jung Hoon Kim, M.D.
Abstract e16614: Comparison of mutational landscape of non-alcoholic fatty liver disease, viral hepatitis, and alcohol consumption related hepatocellular carcinoma.
First Author: Jinrong Qiu

Abstract e16615: Effect of an IncRNA-associated ceRNA regulatory network in MVI-positive hepatocellular carcinoma on their sensitivity to sorafenib.
First Author: Zhiwen Luo

Abstract e16616: Comparison of efficacy and recurrence patterns between computed tomography guidance and ultrasound guidance for percutaneous radiofrequency ablation treatment for small hepatocellular carcinoma: A retrospective study of long-term outcomes.
First Author: Wenchang Yu

Abstract e16617: Characterization of advanced hepatocellular carcinoma patients via a multi-omic cancer registry.
First Author: Joseph S Ryan

Abstract e16618: Implications of sarcopenia and the cachectic state on immune dynamics and survival in unresectable cholangiocarcinoma.
First Author: Katherine M. Jackson, MD

First Author: Masayuki Ueno

Abstract e16620: Distinct clinical and genetic characteristics of AFP-negative hepatocellular carcinoma patients infected by HBV or HCV.
First Author: Bixiang Zhang, PhD

Abstract e16621: Mutational profile of hepatocellular carcinoma by liquid biopsy of Hispanics in central California.
First Author: Mir Ali, MBBS

Abstract e16622: TP53 R249G/S mutation as an independent prognosis indicator in hepatocellular carcinoma.
First Author: Ledu Zhou

Abstract e16623: The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center.
First Author: Rachel Su Jen Wong

Abstract e16624: Epidemiology and patterns of care of intrahepatic cholangiocarcinoma (iCCA) in France: Real-life data from the French National Hospital-Discharge Summaries Database
Abstract e16625: Phase II study of avelumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
First Author: Dae-Won Lee, MD

Abstract e16626: Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy.
First Author: Yehia I. Mohamed, MD

Abstract e16627: Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.
First Author: Chi-Jung Wu

Abstract e16628: Genomic architecture of gallbladder cancer: Results of a first prospective study.
First Author: Amol Patel, MD, DM

Abstract e16629: The mutation profiles of HBV or HCV infected hepatocellular carcinoma patients underlie the varied responses to second-line immunotherapy.
First Author: Jingxian Duan, PhD

Abstract e16630: Association of immune related adverse events with superior outcomes in patients with hepatocellular carcinoma (HCC) treated with nivolumab.
First Author: Lorena Ostios-Garcia, MD

Abstract e16631: Efficacy and safety of immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC): A systematic review and meta-analysis of randomized clinical trials (RCTs).
First Author: Alexandre A. Jácome, MD, PhD

First Author: Dmitrii Shek, MD

First Author: Laura Alder, MD

Abstract e16634: Safety and clinical activity of combination treatment with regorafenib and milciclib in liver transplant patients with hepatocellular carcinoma recurrence.
First Author: Alessandra Pivetti
Abstract e16635: A risk scoring system to predict overall survival for patients with liver cancer.  
First Author: Haibei Xin

Abstract e16636: Targeted next-generation sequencing to reveal potential biomarkers for immunotherapy in patients with biliary tract cancer.  
First Author: Qing Wei

Abstract e16637: AST-to-APOA ratio to predict overall survival in hepatocellular carcinoma receiving TACE.  
First Author: Yongjian Chen

Abstract e16638: Association between alpha-fetoprotein (AFP), hepatocellular carcinoma (HCC) risk factors, and overall survival (OS) in real-world (rw) U.S. patients (pts) with advanced HCC (aHCC).  
First Author: Anala Gossai, PhD, MPH

Abstract e16639: Efficacy and safety of lenvatinib in the real-world treatment of hepatocellular carcinoma: Results from a Canadian multicenter database (HCC CHORD).  
First Author: Carla Pires Amaro, MD

Abstract e16640: Real-life efficacy and safety of regorafenib in Korean patients with unresectable hepatocellular carcinoma (uHCC): Impact of prior immune checkpoint inhibitors.  
First Author: Changhoon Yoo, MD, PhD

Abstract e16641: A novel pretreatment model identifying high-risk of refractoriness after transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.  
First Author: Xin Yin, ABFT

Abstract e16642: Predictors of immunotherapy (IO) response and subsequent tyrosine kinase inhibitor (TKI) response in hepatocellular carcinoma (HCC).  
First Author: Samantha Ann Armstrong, BS, MD

Abstract e16643: A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.  
First Author: Robin Lewis Jones, MD, MBBS, MRCP, BSc

Abstract e16644: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with immunotherapy: A “real world” retrospective study.  
First Author: Adel Chergui, DO

Abstract e16645: Reliability of mRECIST criteria for HCC in the relationship between response and progression.  
First Author: Manish Sharma, MD, DMRT, MBBS
Abstract e16646: PD-L1, tumor mutation burden, and overall survival among Hepatocellular carcinoma patients treated with standard of care.  
First Author: Mark Marsico

Abstract e16647: PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States.  
First Author: Johannes Uhlig, MD MPH

First Author: Bolanle Adepoju, MD, MPH

Abstract e16649: C5aR correlated with the dissemination capacity of circulating tumor cells in hepatocellular carcinoma by targeting INHBA-p-smad2/3-EMT/MMPs axis.  
First Author: Qian Dai

Abstract e16650: Co-mutations of KRAS/BRAF and TP53 or the high tumor mutation burden to predict survival in patients with biliary tract carcinoma.  
First Author: Lingling Guo

Abstract e16651: Hepatobiliary tumors in adolescents and young adults: Site, age and gender distribution.  
First Author: Evelyn Wong, MBBS, MRCP

Abstract e16652: The landscape of MET mutations in Chinese biliary tract cancers.  
First Author: Shifeng Xu, M.D.

Abstract e16653: Novel systemic therapies in hard to treat fibrolamellar hepatocellular carcinoma.  
First Author: Ariel Gliksberg, MD

Abstract e16654: Clinical effect of sequential therapy of LEN combination with anti-PD1 antibody in uHCC patients who progressed on LEN treatment: A real-world data in China.  
First Author: Yi Chen

Abstract e16655: A multiplexed immunohistochemical consecutive staining on single slide (MICSSS) analysis of the immune microenvironment of bile duct cancers (BDC) pre- and post-neoadjuvant chemotherapy (NACT).  
First Author: Sirish Dharmapuri, MD

Abstract e16656: Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis.  
First Author: Pablo Emilio Serrano Aybar, MD, MPH
Abstract e16657: Impact of race and socioeconomic factors on outcome in hepatocellular carcinoma.
First Author: Mahvish Muzaffar, MD

Abstract e16658: Risk score and prognostication modeling based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma.
First Author: Sunyoung S. Lee, MD, PhD

Abstract e16659: The role of ALBI and IGF-CTP score in refining prognostication of HCC.
First Author: Sunyoung S. Lee, MD, PhD

Abstract e16660: IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.
First Author: Yehia I. Mohamed, MD

First Author: Antonia Digklia

Abstract e16662: Controversial risk factors for cholangiocarcinoma.
First Author: Muhammad Talal Sarmini

Abstract e16663: Comprehensive molecular profiling of intrahepatic cholangiocarcinomas in Chinese population and therapeutic experience.
First Author: Longrong Wang

Abstract e16664: NTRK gene fusions in bilio-pancreatic cancers.
First Author: Anne Demols, MD, PhD

First Author: Taicheng Zhou

Abstract e16666: Prognostic significance of baseline neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients (pts) with biliary tract cancer (BTC).
First Author: Noor-ul-Ain Tariq, MBBS, MRCP, MRCP3, MPhil

Abstract e16667: Hepatocellular carcinoma with ARID1A mutation is associated with higher TMB and poor survival.
First Author: Yaorong Peng, M.D.
Abstract e16668: Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.
First Author: Fabian Finkelmeier, MD

Abstract e16669: CFL1 to promote proliferation and invasiveness and to regulate NF-κB-mediated inflammatory factors in hepatocellular carcinoma.
First Author: Chunyan Zhang

Abstract e16670: Mutational landscape and tumor mutation burden (TMB) feature of biliary cancer.
First Author: Bin Yi

Abstract e16671: Clinical utility of comprehensive genomic profiling and targeted therapy in biliary tract cancers: A real-world experience.
First Author: Mahum Shahid, MD

Abstract e16672: High serum sPD-1 and sPD-L1 levels predict outcome in hepatocellular carcinoma patients treated with radiotherapy.
First Author: Shisuo Du, M.D.PhD.

Abstract e16673: Classifying inpatient deaths among liver and intrahepatic bile duct cancer and the effect of palliative care utilization on overall health care burden.
First Author: Saqib Abbasi, MD

Abstract e16674: The characterization of IDH1 mutations in Chinese biliary tract cancers.
First Author: Kui Wang

Abstract e16675: Comparing clinicopathologic feature and treatment outcome of patients who underwent surgical resection or liver transplant for nonalcoholic fatty liver disease (NAFLD)-related and non-NAFLD related hepatocellular carcinoma (HCC).
First Author: Surendra Pal Chaudhary, MBBS

Abstract e16676: Real-world use of second-line treatments in patients with advanced hepatocellular carcinoma (HCC) of varying liver dysfunction: Analysis at a Hispanic-majority cancer center.
First Author: Jeffrey Xia

First Author: Petros Fessas, MB BChir

Abstract e16678: BRAF mutation in Chinese biliary tract cancer patients.
First Author: Wendong Li, M.D.
Abstract e16679: PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer.
First Author: Hyera Kim, MD

Abstract e16680: Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.
First Author: Philippe Merle, MD, PhD

Abstract e16681: Treatment of HCC and liver metastases with NBTXR3 radiation enhancing hafnium oxide nanoparticles activated by SBRT: A phase I/II trial.
First Author: Thierry De Baere, MD

Abstract e16682: Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India.
First Author: Chandan Krushna Das, MD, DM

Abstract e16683: Construction of immune-related risk model for prognosis of hepatocellular carcinoma.
First Author: Yue Li

Abstract e16684: A phase II study of apatinib treatment for advanced biliary tract carcinoma after failure of the standard chemotherapy.
First Author: Chenchen Wang

Abstract e16685: Sorafenib as an adjuvant therapy for hepatocellular carcinoma with microvascular invasion after radical resection: A prospective multicenter nonrandomized controlled study.
First Author: Li Xu, M.D. Ph.D

Abstract e16686: The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).
First Author: Lipika Goyal, MD

Abstract e16687: Genome-wide CRISPR/Cas9 library screening to identify PAK1 as a critical driver for lenvatinib resistance in HCC.
First Author: Shanzhou Huang

Abstract e16688: Characterization of patients with PALB2 mutant advanced solid tumors.
First Author: Jinesh S. Gheeya, MD, PhD

Abstract e16689: Long-term survival of combined ablation therapy and tremelimumab with or without durvalumab in advanced hepatocellular carcinoma.
First Author: M. Cecilia Monge B., FACP, MD, MPH
Abstract e16690: Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection.
First Author: Hui-Chuan Sun, MD, PhD

Abstract e16691: Treatment outcomes of well-differentiated high-grade (G3) neuroendocrine tumors.
First Author: Alex John Liu, MD

Abstract e16692: Blood levels of steroid hormone precursors allow differentiation between pancreatic adenocarcinoma and neuroendocrine tumors.
First Author: Viacheslav A. Aleynov

Abstract e16693: Characteristics of growth factors in the blood allowing determination of neuroendocrine component in pancreatic diseases.
First Author: Elena M. Frantsiyants

Abstract e16694: Cohort 1 results of a phase I study of autolytic immunotherapy of metastatic neuroendocrine neoplasms using intralesional rose bengal disodium.
First Author: Mark McGregor, BPharm, FRACP, MBBS

Abstract e16695: Effect of neuroendocrine component in pancreatic adenocarcinoma on blood levels of steroid hormones.
First Author: Viacheslav A. Aleynov

Abstract e16696: Diagnostic criteria of pancreatic pathology.
First Author: Irina V. Neskubina

Abstract e16697: Parameters of oxidative metabolism in the blood of patients with pancreatic tumors of different histotypes.
First Author: Irina A. Goroshinskaya

Abstract e16698: Prooxidant effect of α-tocopherol in pancreatic tumors.
First Author: Ekaterina I. Surikova

Abstract e16699: Comprehensive study of genetic features of pancreatic neuroendocrine tumors.
First Author: Vladimir S. Trifanov, MD, PhD

Abstract e16700: Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor.
First Author: Noritoshi Kobayashi, MD, PhD
Abstract e16701: Real-world analysis of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors.
First Author: Justin Chau, MD

Abstract e16702: Anorectal neuroendocrine carcinoma (NEC): Patient characteristics and treatment outcomes.
First Author: Benjamin Edward Ueberroth, MD

Abstract e16703: Phase II study of ONC201 in pheochromocytoma-paragangliomas (PC-PG), medullary thyroid carcinoma (MTC), and other neuroendocrine tumors.
First Author: Peter Meade Anderson, MD, PhD

Abstract e16704: Concurrent everolimus with hepatic transarterial bland embolotherapy (Evero-Embo) in patients with metastatic well-differentiated neuroendocrine tumor.
First Author: Lowell Brian Anthony, MD, MS, FACP

Abstract e16705: Molecular detection of pancreatic neuroendocrine tumors using methylated DNA markers: Discovery and tissue validation.
First Author: Shounak Majumder, MD

Abstract e16706: Molecular correlation of the activity of evofosfamide (EVO) in combination with sunitinib (SUN) in pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial.
First Author: Carlos López-López, MD, PhD

Abstract e16707: GETNE-SILVELUL study: A new immunohistochemical score (SPI) in patients (pts) with pancreatic neuroendocrine tumors (PanNET) treated with everolimus or captem.
First Author: Antonio Viudez

Abstract e16708: Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN): Awareness of specialized techniques and latest interventions.
First Author: Mark McDonnell

Abstract e16709: First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade III well-differentiated neuroendocrine tumors (NET G3).
First Author: Giuseppe Lamberti, MD

Abstract e16710: Distinct clinical characteristics in young-onset pancreatic neuroendocrine tumor: A propensity-adjusted analysis.
First Author: Suleyman Yasin Goksu, MD

Abstract e16711: Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.
First Author: Erica Villa, M.D.
Abstract e16712: A phase II study of anlotinib with cediranib as a second-line treatment for patients with advanced biliary tract cancers (aBTCs).
First Author: Ruihua Zhao, PhD

Abstract e16713: The oncogenic role of ARG2 in hepatocellular carcinoma.
First Author: Pin-Jen Lin

Abstract e16714: Changes on functional capacity after impact of oncological digestive surgery: Reality in Chilean patients at Clinical Oncology Institute Arturo López Pérez Foundation.
First Author: Veronica Hurtado

Abstract e16715: HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: A phase I clinical trial.
First Author: Tong Yang

Abstract e16716: Association of neoadjuvant chemotherapy on survival in locally advanced gallbladder cancer.
First Author: Syed Mohammad Ali Kazmi, MD

Abstract e16717: Patient-derived organoids as a potential tool for clinical decision in advanced gallbladder cancer.
First Author: Javiera Obreque

Abstract e16718: A new prognostic model for high-grade appendiceal mucinous neoplasms with peritoneal carcinomatosis.
First Author: Jason A Mouabbi, MD

Abstract e16719: Identification of malignant ascites using MR-based T1 mapping.
First Author: Fabian Kuetting, MD

Abstract e16720: Real-world hypothesis-generating cohort of pancreatic cancer patients with brain metastases.
First Author: Derek Cridebring, PhD

Abstract e16721: Analysis of statistics of pancreatic cancer in Ukraine for a period of 10 years.
First Author: Liliia Zrielykh

First Author: Mewa Singh, PhD

Abstract e16723: Prolongation of the average survival time in pancreatic cancer (a new measure of effect): Pooled analysis of adjuvant chemotherapy trials.
First Author: Eduardo Ceballos Barbancho
Abstract e16724: Differentiation of liposomal irinotecan from dose-dense non-liposomal irinotecan in patient-derived pancreatic cancer xenograft tumor models.
First Author: Sandrine Barbier, PhD

Abstract e16725: Utilization of imaging in pancreatic adenocarcinoma patients status post whipple procedure.
First Author: Neal Shah, MD

Abstract e16726: Muscle impairment during follow-up as an independent prognostic factor for poor overall survival in pancreatic cancer.
First Author: Aurélien Lambert, MD

Abstract e16727: Morphological and biochemical heterogeneity in the tissue of pancreatic ductal adenocarcinoma (PDAC) according to structural and spectrometric MRI data.
First Author: Dmitry Ya. Iozefi

Abstract e16728: A real-world comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine to nab-paclitaxel in treatment of advanced stage pancreatic cancer.
First Author: Shaik Abdul Samad Shaik Abdul Rashid, MBBS, MD

Abstract e16729: Association of fatty pancreas with increased risk of pancreatic adenocarcinoma.
First Author: Bara El Kurdi, MD

Abstract e16730: Clinical trials in pancreatic cancer: A comprehensive analysis.
First Author: Erryk Stephan Katayama

Abstract e16731: Intraoperative electrochemotherapy in locally advanced pancreatic cancer: Results and impact on quality of life. a single center experience.
First Author: Mariacristina Di Marco

Abstract e16732: Germline and somatic DNA damage repair gene mutations potentially predict the efficacy of relevant treatment in Chinese patients with pancreatic ductal adenocarcinoma.
First Author: Lin Shui

Abstract e16733: A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.
First Author: Kenneth H. Yu, MD

Abstract e16734: Endoscopic retrograde cholangiopancreatography (ERCP) findings to predict survival in patients with metastatic pancreatic adenocarcinoma.
First Author: Vishwajith Sridharan, MD, MBA
Abstract e16735: Use of a real-world data approach to rapidly generate outcomes data following a case study of a novel treatment combination in pancreatic adenocarcinoma. First Author: Lola Rahib, PhD

Abstract e16736: Employing patient-driven biology and Bayesian AI to validate treatment response and survival biomarkers in a phase II trial of BPM 31510-IV in advanced refractory pancreatic ductal adenocarcinoma (PDAC). First Author: Maria-Dorothea Nastke, PhD

Abstract e16737: A single institution experience of brain metastases and pancreatic adenocarcinoma: Patients' treatments and outcomes. First Author: Etienne Gouton

Abstract e16738: Association of losartan use with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. First Author: Jessica Allen

Abstract e16739: National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: an analysis of inpatient (IP) and emergency room (ER) admissions. First Author: Paul Cockrum, PharmD

Abstract e16740: Real-world use of liposomal irinotecan-based regimens among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) in the United States (U.S.). First Author: George P. Kim, MD


Abstract e16742: Establishment of patient-derived pancreatic ductal adenocarcinoma organoids and drug screening platform using EUS-guided FNA/B. First Author: Joo Kyung Park

Abstract e16743: Error-free, automated data integration of exosome cargo protein data with extensive clinical data in an ongoing, multi-omic translational research study. First Author: Ana Oromendia

Abstract e16744: Oncogenic roles of CEACAM6 in pancreatic ductal adenocarcinoma. First Author: Daruka Mahadevan, MD, PhD

Abstract e16745: Performance of neoadjuvant therapy in locally advanced adenocarcinoma of the pancreas: A single large volume center experience. First Author: Teresa Lee, MD, PhD
Abstract e16746: Germline ATM mutations on survival in metastatic pancreatic cancer patients.
First Author: Arjan Gower, MD, MS

First Author: Margaret Lashof-Sullivan, PhD

First Author: Arthur James Moser, MD, FACS

Abstract e16749: Germline mutations in Brazilian pancreatic carcinoma patients.
First Author: Livia Munhoz Rodrigues, PhD student

First Author: Chris Braumann

Abstract e16751: Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US).
First Author: Jim M. Koeller, PharmD

Abstract e16752: Osteoclast-like giant cell tumors of the pancreas: Clinical characteristics, genetic testing, and treatment modalities.
First Author: Benjamin Edward Ueberroth, MD

Abstract e16753: Cytokines as a prognostic biomarker of overall survival in pancreatic cancer.
First Author: Harold Nathan Choa Tan, MD, MBA

Abstract e16754: Myosteatosis to predict postoperative morbidity in pancreatic ductal adenocarcinoma patients receiving neoadjuvant chemotherapy.
First Author: Raphael Louie, MD, MPH

Abstract e16755: Real-world survival outcomes of using neoadjuvant chemotherapy in pancreatic cancer patients: Findings from the PURPLE clinical registry.
First Author: Belinda Lee, MBBS, MRCP, FRACP

Abstract e16756: The pattern of mucin 5AC (MUC5AC) expression using immunohistochemistry and its prognostic significance in patients with pancreatic ductal adenocarcinoma.
First Author: Ashish Manne, MD, MBBS
Abstract e16757: Exceptional sustained responses to ipilimumab/nivolumab (ipi/nivo) in patients (pts) with advanced pancreaticobiliary cancers and germline DNA damage repair (DDR) mutations.
First Author: Gretel Terrero, MD

Abstract e16758: The role of response as predictor of improved outcome in advanced pancreatic cancer (APC) patients (pts) treated with first-line Gemcitabine plus Nab-paclitaxel (GemNab).
First Author: Maria Bensi, MD

Abstract e16759: The impact of 2nd-line treatment (tx) after 1st-line Gemcitabine plus Nab-paclitaxel (GemNab) in advanced pancreatic cancer (APC) patients (pts).
First Author: Brunella Di Stefano, MD

First Author: Moataz Ellithi, MD

Abstract e16761: Nanomaterials augmented LDI-TOF-MS for pancreatic ductal adenocarcinoma diagnosis and classification.
First Author: Yaolin Xu

Abstract e16762: A prognostic and predictive nomogram for patients with resected pancreatic cancer and the effect of adjuvant chemotherapy in different risk groups: Data from two large cohorts in Taiwan.
First Author: Hsu Wu, MD

Abstract e16763: Survival and prognostic tests in a real-world phase II experience with a safe, moderate-dose, sequential chemotherapy (CT) algorithm (ALGO) for metastatic pancreatic adenocarcinoma (PANC).
First Author: Robert L. De Jager, MD, FACP

Abstract e16764: A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma (PDAC).
First Author: Anita Ahmed Turk, MD, BA

First Author: Sung Hwan Lee, MD, PhD

Abstract e16766: Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: MyCare-009-05.
First Author: Gordon Taylor Moffat
Abstract e16767: GRP78 expression and clinical outcomes in pancreatic cancer: A single institution review.
First Author: Brian Ernest Johnson, BS, MD

Abstract e16768: Liver-directed therapy (LDT) and systemic chemotherapy for pancreatic adenocarcinoma with liver metastases (PCLM): Experience of 12 years.
First Author: Shreya Prasad Goyal, MD

Abstract e16769: Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.
First Author: Ilaria Trestini

Abstract e16770: Phase I/IIa Study evaluating the safety, efficacy of K-001 in advanced pancreatic ductal adenocarcinoma.
First Author: Jiujie Cui

Abstract e16771: Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers.
First Author: Andrew H. Ko, MD, FASCO

Abstract e16772: FOLFIRINOX dose intensity (DI) and disease control in advanced pancreatic cancer patients (APC).
First Author: Antonin Vary

Abstract e16773: Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in the treatment of unresectable pancreatic cancer.
First Author: Juan Du

Abstract e16774: A PK/PD mathematical model to forecast severe toxicities in pancreatic cancer patients treated with FOLFIRINOX regimen.
First Author: Laure Deyme, Pharm.D.

Abstract e16775: Targeting the polymerase-theta mediated alternative NHEJ pathway for the treatment of homologous recombination deficient pancreatic ductal adenocarcinoma.
First Author: Mohammad Ahsan Sohail, MD

Abstract e16776: Radiomic texture analysis correlates with PDAC patient outcomes on SM-88.
First Author: Allyson J. Ocean, MD

Abstract e16777: Survival outcomes of neoadjuvant versus adjuvant chemotherapy in early-stage pancreatic adenocarcinoma: A subgroup analysis of the National Cancer Database.
First Author: Rohit Kumar, MD
First Author: Anas Albawaliz, MD

Abstract e16779: Cachexia, dietetic referral, and impact on survival in patients with pancreatic and periampullary cancer: A multicenter cohort study.
First Author: Anouk EJ Latenstein, MD

Abstract e16780: Real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan.
First Author: Laith I. Abushahin, MD

Abstract e16781: Predictors of recurrence and implications for overall survival in borderline resectable pancreatic cancer patients treated with total neoadjuvant therapy: A retrospective cohort study.
First Author: Jori Lee Kaplan, MD

Abstract e16782: BMK_PANC: Search for new predictive/prognosis biomarkers (BKs) in potentially resectable pancreatic adenocarcinoma (PDAC).
First Author: Antonio Viudez

Abstract e16783: Effect of access to germline genetic testing on pancreatic cancer precision treatment across disease stage and ethnicity.
First Author: Edward D. Esplin, FACMG, FACP, MD, PhD

Abstract e16784: Racial disparities in pancreatic resection and survival among elderly patients: A SEER database analysis.
First Author: Seojin Park, PharmD

Abstract e16785: Results of venous resections in cancer of the pancreatic head.
First Author: Oleg I. Kit

Abstract e16786: Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.
First Author: Michael Haas, MD

Abstract e16787: Novel nanobiosensor based protease biomarkers for early detection and prognosis of pancreatic cancers.
First Author: Anup Kasi, MD, MPH

Abstract e16788: Expectations of overall survival for patients with metastatic pancreatic cancer (mPC).
First Author: Joanne P. Willey, RN, OCN
Abstract e16789: Pembrolizumab in combination with the oncolytic virus pelareorep in patients progressing on systemic chemotherapy for advanced pancreatic adenocarcinoma: A phase II study.
First Author: Devalingam Mahalingam, MD

Abstract e16790: Value-based estimate of market size and opportunity for economic benefit through innovative pancreatic cancer (PC) therapies.
First Author: Vincent J. Picozzi, MD, MMM

Abstract e16791: FOLFIRINOX versus sequential 5-FU, oxaliplatin, and irinotecan-based regimens in patients with recurrent pancreatic cancer (rPDAC).
First Author: Hasan Rehman, MD

Abstract e16792: Combined recombinant humanized anti-PD-1 monoclonal antibody (JS001) and nab-paclitaxel/gemcitabine (AG) as the first-line therapy for patients with advanced pancreatic adenocarcinoma: Preliminary results of an open-label, phase Ib/II clinical study.
First Author: Ke Cheng

Abstract e16793: Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.
First Author: Myles Ingram, BA

Abstract e16794: Genomic-directed personalized matched targeted therapy approach may improve clinical outcomes among patients with advanced pancreatic cancer.
First Author: Justin Shaya, MD

Abstract e16795: Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.
First Author: Selina Wong, MD

Abstract e16796: Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP).
First Author: Amitesh Chandra Roy, FRACP, MD, MSc

Abstract e16797: A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
First Author: Benjamin Leon Musher, MD

Abstract e16798: Early detection for pancreatic cancer in individuals at elevated-risk, using endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) of the abdomen: Feasibility and preliminary outcomes.
First Author: Joshua P. Raff, MD
Abstract e16799: Circulating tumor DNA analysis to detect minimal residual disease and predict recurrence in patients with resectable pancreatic cancer.
First Author: Liu Yang

Abstract e16800: POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).
First Author: Lawrence Howard Schwartz, MD, MD

Abstract e16801: A novel prediction model to identify patients with early-stage pancreatic cancer.
First Author: Daniel R Cherry, BA

Abstract e16802: Similar response rates and survival with PARPi treatments for patients harboring somatic versus germline BRCA mutations: A meta-analysis and systematic review.
First Author: Ghulam Rehman Mohyuddin

First Author: Anup Kasi, MD, MPH

Abstract e16804: Prognostic biomarker potential of quantifying endotrophin in serum from pancreas cancer patients.
First Author: Nicholas Willumsen, PhD

Abstract e16805: DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts).
First Author: Helena Verdaguer, MD

Abstract e16806: Adjuvant chemotherapy impact on the overall survival of completely resected small bowel adenocarcinoma: An updated meta-analysis.
First Author: Philip A. Haddad, MD, FACP, FCCP

**Genitourinary Cancer—Kidney and Bladder**

Abstract e17000: Genome-wide association study on genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer.
First Author: Masaki Shiota, MD

Abstract e17001: Efficacy of carboplatin-based chemotherapy regimens in patients with bladder cancer in the neoadjuvant setting.
First Author: Hafiz Aslam
Abstract e17002: Comparison of oncologic outcomes for robotic-assisted radical cystectomy (RARC) versus open radical cystectomy (ORC) among locally advanced and node-positive patients: An analysis of the National Cancer Database (NCDB).
First Author: Akshay G Reddy, B.S.

Abstract e17003: Studying the interrelation between the HPV infection status and the morphological features of bladder cancer.
First Author: Tatiana A. Zykova

Abstract e17004: Combined OX40 agonist and PD-1 inhibitor immunotherapy improves the efficacy of vascular targeted photodynamic therapy in a urothelial tumor model.
First Author: Ricardo Alvim, MD

Abstract e17005: Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.
First Author: Olivia A Do

Abstract e17006: Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle invasive bladder cancer: Results from JCOG0209, a randomized phase III study.
First Author: Naotaka Nishiyama

Abstract e17007: Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.
First Author: Ariel Ann Nelson, MD

First Author: Chelsea K. Osterman, MD

Abstract e17009: Comprehensive genomic landscape in Chinese patients with urothelial carcinoma.
First Author: Haige Chen, MD

Abstract e17010: Functional outcomes of older adults treated with radical cystectomy for muscle-invasive bladder cancer.
First Author: Chelsea K. Osterman, MD

Abstract e17011: Clinical efficacy and metabolite biomarker analysis of patients with MTAP-deficient urothelial carcinoma treated with anti-folates.
First Author: Omar Alhalabi, MD
Abstract e17012: Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.
First Author: Leonidas Nikolaos Diamantopoulos, MD

Abstract e17013: Evaluation of mood disorders in bladder cancer patients and their primary caregivers.
First Author: Daniel Au, MD

Abstract e17014: Small Cell Bladder Cancer: Treatment Patterns and Clinical Outcomes.
First Author: Rishi Robert Sekar, BA, MD

Abstract e17015: Associations between baseline body composition and cancer-specific mortality following neoadjuvant chemotherapy and radical cystectomy for bladder cancer.
First Author: Leonidas Nikolaos Diamantopoulos, MD

Abstract e17016: Skeletal muscle index and adverse events during a bladder cancer treatment episode.
First Author: Steven Ngo

Abstract e17017: Immune-related adverse events (irAEs) among urothelial carcinoma (UC) patients treated with PD-1 VS PD-L1 inhibitors: A real-world observational study.
First Author: Saby George, MD, FACP

Abstract e17018: Predicting residual tumor for T1 high-grade bladder urothelial carcinoma before second transurethral resection specimens.
First Author: Ario Takeuchi

Abstract e17019: Systemic immune-inflammation index to predict survival in patients with metastatic urothelial carcinoma treated with second-line vinflunine.
First Author: Patrik Palacka, MD, PhD, MPH, MBA, BA

Abstract e17020: Pembrolizumab and concurrent radiation is an effective regimen for muscle invasive bladder cancer.
First Author: Niraj K. Gupta, MBBS

Abstract e17021: Single-institution experience of small cell bladder cancer at a community center.
First Author: Mina Makary

Abstract e17022: Systemic immune-inflammation index to predict survival in muscle-infiltrating urothelial carcinoma.
First Author: Jana Obertova, MD, PhD.
Abstract e17023: Marker of lipid peroxidation tbars predicts survival in patients with metastaticurothelial carcinoma (MUC).
First Author: Jan Slopovsky, MD

Abstract e17024: Comprehensive profiling of genomic in 80 Chinese patients with bladder cancer.
First Author: Zengjin Yuan, PhD

Abstract e17025: Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer.
First Author: Divya Natesan, BS

Abstract e17026: Intravesical therapy and risk of cystectomy and bladder cancer death after BCG fails.
First Author: Risa Liang Wong, BS, MD

Abstract e17027: Effect of epigenetic imprinting biomarkers in urine exfoliated cells (UEC) on the diagnostic accuracy of low-grade bladder cancer.
First Author: Ning Zhou

Abstract e17028: The role of HIF-1α in regulating NLRP3 inflammasome activation in bladder cancer.
First Author: Yuan-Ru Chen

Abstract e17029: Oncologic outcomes of complete transurethral resection prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
First Author: Jamie Sungmin Pak

Abstract e17030: Establishment of a primary cell culture of bone metastasis from urothelial carcinoma.
First Author: Chiara Spadazzi

Abstract e17031: Long-term outcomes among BCG-treated high-risk non-muscle invasive bladder cancer patients in an equal access setting.
First Author: Stephen B. Williams, MD, MS

Abstract e17032: Racial and gender disparities in stage at diagnosis for bladder cancer: Results from the surveillance, epidemiology, and end results (SEER) program, 2007 to 2016.
First Author: Sachin Gupta, MD

Abstract e17033: Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.
First Author: Rishi Robert Sekar, BA, MD
Abstract e17034: MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy.
First Author: Michal Sarfaty, MD

Abstract e17035: Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer.
First Author: Bernhard Kiss, MD

Abstract e17036: Neoadjuvant chemotherapy in muscle invasive bladder cancer: Real world data on safety and outcome.
First Author: Sree Vamsee Chetana Panthula

Abstract e17037: The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication.
First Author: Paolo Andrea Zucali, MD

Abstract e17038: Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma.
First Author: Piergiuseppe Colombo, MD

Abstract e17039: Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).
First Author: John Sfakianos, MD

Abstract e17040: PD-L1 and neutrophil to lymphocyte ratio (NLR) as predictive panel of prognosis in bladder cancer.
First Author: Tao Qin

Abstract e17041: Heterogeneity of PD-L1 expression between primary and metastatic bladder cancer tumors and therapeutic implications between the immune cell score and combined positivity score.
First Author: Gerald Bastian Schulz, M.D.

Abstract e17042: Clinical outcome in terms of survival and treatment response of patients with metastatic urothelial carcinoma harboring FGFR alterations compared to wild-type tumors.
First Author: Elena Sevillano, MD

Abstract e17043: Retrospective study to assess the efficacy and safety of checkpoint inhibitors in advanced urothelial carcinoma in real-world setting.
First Author: Elena Sevillano Fernandez
Abstract e17044: Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).
First Author: Catherine Curran, BA

Abstract e17045: Lack of association of robotic radical cystectomy with increased incidence of local pelvic recurrence.
First Author: Rabii Madi, MD

Abstract e17046: Neoadjuvant cisplatin based therapy in bladder cancer: Is less enough?
First Author: Saqib Abbasi, MD

Abstract e17047: Panel-derived TMB and immune-related GEP are associated with the response to immune checkpoint inhibitors (ICIs) in urothelial cancers.
First Author: Kien Thiam Tan, PhD

Abstract e17048: Oncotherad immunotherapy elicits promising responses in Bacillus Calmette-Guérin-unresponsive non–muscle invasive bladder cancer: Results from phase I/II study.
First Author: João Carlos Cardoso Alonso, PhD

Abstract e17049: Is it necessary to obtain a second review on outside pathology for patients referred with non-muscle invasive (NMI) bladder cancer?
First Author: Jared Brown, MD

Abstract e17050: Impact of preoperative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) on overall survival or recurrence free survival in muscle-invasive bladder cancer at cystectomy.
First Author: Scott Dawsey, MD

First Author: Jessica Mary Clement, MD

Abstract e17052: Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).
First Author: Hiren V. Patel, MD, PhD

Abstract e17053: Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).
First Author: Reem Akel, MD

Abstract e17054: High-dose chemotherapy (HDCT) and peripheral-blood stem cell transplant (PBSCT) in patients age 40 or older with relapsed metastatic germ-cell tumors (mGCT).
First Author: Vaibhav Agrawal, MD
Abstract e17055: Clinical outcome of patients diagnosed with testicular sex cord stromal tumors.
First Author: Syed Abdullah Javaid Bukhari, MBBS. MRCP UK . MRCP Medical Oncology

First Author: Nikola Hapakova, MD

Abstract e17057: Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).
First Author: Simon J. Crabb, PhD, MBBS

Abstract e17058: Accuracy of clinical staging in stage I and Ila/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
First Author: Arnav Srivastava, MD, MPH

Abstract e17059: Testicular cancer in Hispanics: Are we approaching ethnic parity?
First Author: Michelle Janania Martinez, MD

Abstract e17060: Localized testicular germ cell tumor surveillance: A Delphi consensus study.
First Author: Angélique DA Silva, MD

Abstract e17061: Standard-dose salvage chemotherapy in patients with refractory metastatic germ-cell tumors (mGCT) progressing after high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
First Author: Vaibhav Agrawal, MD

Abstract e17062: Effect of long-term peripheral neuropathy induced on cisplatin-based chemotherapy or radiation to the retroperitoneum in testicular germ cell tumor survivors.
First Author: Michal Chovanec, MD, PhD

Abstract e17063: Chemotherapy-induced peripheral neuropathy (CIPN) as a predictor of decreased quality of life and cognitive impairment in testicular germ cell tumor survivors.
First Author: Michal Chovanec, MD, PhD

Abstract e17064: CT abdomen only for active surveillance in patient with stage I germ cell tumor.
First Author: Hamed Ahmadi, MD

Abstract e17065: Clinical outcomes of checkpoint inhibitors in metastatic non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with variant features.
First Author: Guy vin Chang, MD
First Author: Xiao Wu

Abstract e17067: Risk of hypocalcemia in cancer patients treated with cabozantinib: A meta-analysis.
First Author: Adam Khorasanchi, MD

Abstract e17068: The serum level of the components of the renin-angiotensin system correlates with its tumor tissue expression in kidney cancer patients.
First Author: Roman Osokin

Abstract e17069: Intrarenal renin-angiotensin system in hypertensive patients with localized kidney cancer.
First Author: Roman Osokin

Abstract e17070: Survival outcomes of nonmetastatic, Non-clear cell renal cell carcinoma (non-ccRCC) after surgery.
First Author: Josiah An, MD, MS

Abstract e17071: Pharmacogenetics-based area-under-curve model to determine the initial axitinib dose for treatment of individuals with advanced renal cell carcinoma.
First Author: Yoshiaki Yamamoto, MD, PhD

First Author: Justin Shaya, MD

First Author: Maria Volkova

First Author: Fionna Sun, BA

Abstract e17075: Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL.
First Author: Jens Bedke, MD

Abstract e17076: Data to decisions: The impact of online education on immunotherapy in advanced renal cell carcinoma.
First Author: Kinjal Parikh, PharmD, BCOP
First Author: Ana Elena Martin Aguilar, MD

First Author: Saif Alimohamed

Abstract e17079: Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study.
First Author: Thomas E. Hutson, DO, FACP, PharmD

Abstract e17080: The role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
First Author: Yanal Mufeed Alnimer, MD

Abstract e17081: Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.
First Author: Sara Elena Rebuzzi

Abstract e17082: Real-world analysis of cabozantinib for metastatic renal cell carcinoma (mRCC) patients in Israel: Outcomes and associated factors.
First Author: Keren Rouvinov, MD

Abstract e17083: Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place.
First Author: Aafke Meerveld-Eggink

Abstract e17084: Decision tree model with tumor immune function genes for predicting response to anti-PD1 therapy in renal cell carcinoma.
First Author: Xingang Bi, MD, PhD

Abstract e17085: The change of serum C-reactive protein levels during molecular-targeted treatments could predict the response to anti-PD-1 treatment in metastatic renal cell carcinoma patients.
First Author: Kimiharu Takamatsu, M.D.

Abstract e17086: Predictors of first line systemic therapy for metastatic renal cell carcinoma in IMDC favorable risk patients.
First Author: Ryuichi Mizuno, MD
Abstract e17087: Exploration of Chinese early-onset renal cancer predisposed genetic features. First Author: Yu Gong, Ph.D., M.D.

Abstract e17088: Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O): A real-world study on behalf of Meet-URO group (MeetUro-7b). First Author: Marco Stellato, MD

Abstract e17089: A non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) in the United Kingdom. First Author: Manon Pillai

Abstract e17090: Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. First Author: Benjamin Garmezy, MD

Abstract e17091: The impact of the metastasis region on patients with metastatic renal cell cancer in the intermediate-risk group. First Author: Cengiz Karacin

Abstract e17092: Impact of treatment line on outcomes with salvage ipilimumab + nivolumab in metastatic renal cell carcinoma (mRCC). First Author: Ritesh Kotecha, MD

Abstract e17093: Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14). First Author: Marco Maruzzo, MD, PhD

Abstract e17094: Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N). First Author: Kunal Desai, MD, MBA, MS

Abstract e17095: Response to checkpoint inhibitors (CPI) in sarcomatoid renal cell carcinoma (sRCC). First Author: Iris Yeong-Fung Sheng, MD

Abstract e17096: Preliminary results of expanded phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients: Bench to bedside. First Author: Yousef Zakharia, MD

Abstract e17097: Understanding the treatment effect modification of mono- or combination PD-1/PD-L1 inhibitor therapies on survival outcomes in patients with metastatic renal cell
carcinoma: What does the literature say?
First Author: Neha Sati

Abstract e17098: NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma.
First Author: Arnab Basu, MBBS, MPH

Abstract e17099: Gender impact on renal cell carcinoma survival: A population-based analysis.
First Author: Firas Baidoun, MD

Abstract e17100: Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).
First Author: Zeynep Busra Zengin, MD

Abstract e17101: Survival outcomes of sarcomatoid renal cell cancer (sRCC) compared to clear cell renal cell cancer (ccRCC): An analysis of SEER data.
First Author: Ruby Gupta, MD

First Author: Seoyoung Lee

Abstract e17103: Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?
First Author: Hendik Eggers, MD

Abstract e17104: Percutaneous microwave ablation of stage T1b renal cell carcinoma: Assessment of technical feasibility, clinical outcomes, and safety.
First Author: Ronald Arellano

First Author: Justin Lin, None

First Author: James J Hsieh, MD, PhD

Abstract e17107: Skeletal muscle density as a positive predictive factor for nivolumab therapy in patients with metastatic renal cell carcinoma.
First Author: Meltem Ekenel
Abstract e17108: Safety of inactivated vaccines in patients with genitourinary (GU) malignancies receiving immune checkpoint inhibitors (ICI).
First Author: Elizabeth Marie Wulff-Burchfield, MD

First Author: Whitley Hatton

Abstract e17110: Dynamic changes in full blood count (FBC) occurring in patients treated with immune checkpoint inhibitors (ICIs) to predict responses in patients with metastatic renal cell carcinoma (mRCC).
First Author: Yasmin Abu Ghanem

First Author: Zev Leopold

Abstract e17112: Examining the real-world utility of immune checkpoint inhibitors in genitourinary oncology: A single-institution retrospective.
First Author: Lydia Glick, BS, BA

Abstract e17113: A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.
First Author: Huayan Xu

Abstract e17114: Effect of local therapies on survival in patients with metastatic adrenocortical carcinoma.
First Author: Impana Shetty

Abstract e17115: Underrepresentation of genitourinary cancers in studies of venous thromboembolism (VTE) prophylaxis.
First Author: Max S Perlmutt, BA

First Author: Mohammad Khan, DO, MSBS

**Genitourinary Cancer—Prostate, Testicular, and Penile**

Abstract e17500: Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters.
First Author: Anuradha Jayaram, MBBS, MRCP
Abstract e17501: Plasma circulating tumor DNA (ctDNA) based prognosis and pharmacodynamic changes during chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Manish Kohli, MD

Abstract e17502: Changes in ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC).
First Author: Daniel Vargas Pivato de Almeida, MD

Abstract e17503: Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer.
First Author: Matthew Dallos, MD

Abstract e17504: Alternative inflammatory cytokines pathways in prostate cancer: In search of new therapeutic options.
First Author: Marlena Janiczek, MD, PhD

Abstract e17505: Germline mutation in multiple primary malignancies associated with prostate cancer.
First Author: Yiming Gong

Abstract e17506: Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome.
First Author: Eric Kim, MD

Abstract e17507: A novel artificial intelligence biomarker: Validation of the automated bone scan index (aBSI) in veterans with metastatic prostate cancer.
First Author: Vipal P. Durkal, MD

First Author: George Dominguez, PhD

First Author: Pai-Chi Teng, MD

Abstract e17510: Comorbidity burden in prostate cancer patients by ESRD status.
First Author: Nagaraju Sarabu, M.D.

Abstract e17511: A genomic blood test (NETest) identifies neuroendocrine transformation of prostate cancer.
First Author: Kambiz Rahbar, MD
Abstract e17512: Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.
First Author: Jasmine Jiemei Wang, MD

Abstract e17513: Prostate cancer outcomes by ESRD status.
First Author: Nagaraju Sarabu, M.D.

Abstract e17514: Effect of PSA on equal treatment of high-risk patients.
First Author: Basil Ferenczi

Abstract e17515: Insights into Chinese prostate cancer germline gene mutation profile: HOXB13 G84E mutation is unsuitable for genetic testing.
First Author: Baijun Dong, MD

Abstract e17516: Landscape of somatic DNA damage repair (DDR) gene mutations in genitourinary cancer in China.
First Author: Kaiwei Yang, MD

Abstract e17517: Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).
First Author: Ahmad Zarzour, MD

Abstract e17518: Long-term prospective health related quality of life (HRQoL) outcomes: Impact of active surveillance before treatment of low risk prostate cancer (PCa).
First Author: Nathan Jung, MD

Abstract e17519: The impact of circulating free tumor DNA (cfDNA) in testicular germ cell tumors (TGCT) management.
First Author: Eugen Kubala, MD

Abstract e17520: Clinicopathological predictors of bone metastases in prostate cancer patients.
First Author: Ingrid Portilla

First Author: Adithya Chennamadhavuni, MBBS

Abstract e17522: Colina 111 PET results in a nonmetastatic castration-resistant cancer (nmCRPC) in population that is negative by conventional imaging: True incidence from real-world evidence data.
First Author: Martin Pitzzu
Abstract e17523: Germline mutations in DNA repair genes in a large series of unselected Chinese prostate cancer patients.
First Author: Yu Wei, M.D

First Author: Jinan Guo

Abstract e17525: Genomic analysis of castration sensitive and resistant prostate cancer patients by multiple-gene targeted sequencing.
First Author: Liancheng Fan, MMed

First Author: Sagar Patel

Abstract e17527: Determination of biologic and prognostic feature scores from whole slide histology images using deep learning.
First Author: Okyaz Eminaga, MD, PhD

Abstract e17528: Tumor subtypes associated with prostate cancer (PCa) both as first and second primary tumors: A registry-based analysis.
First Author: Andrew Wellen

Abstract e17529: Prevalence and genetic features of TMPRSS2-ERG fusion in Chinese patients with prostate cancer.
First Author: Wei He

Abstract e17530: Epidemiological profile of patients diagnosed with prostate cancer at Muriaé Cancer Hospital, Minas Gerais, Brazil.
First Author: Carla Simone Moreira de Freitas, MD, Msc

Abstract e17531: Genomic profiling and mutation burden of Chinese prostate patients with microsatellite instability.
First Author: Ning Zhang, MD

Abstract e17532: Defining diagnostic criteria for ductal prostate cancer on prostatic MRI.
First Author: Weranja Kalana Bodhisiri Ranasinghe, MBChB, MRCS, PhD

Abstract e17533: Combined 18F-naf and fluciclovine administration for PET imaging of prostate cancer.
First Author: Franklin W. Huang, MD, PhD
Abstract e17534: Inhibition of PIM kinase with fractionated radiation and docetaxel in preclinical prostate cancer models.
First Author: Anne Rajkumar-Calkins, MD

Abstract e17535: An artificial intelligence-enabled analysis of ECG changes after androgen deprivation therapy (ADT) for prostate cancer.
First Author: William Breen, MD

Abstract e17536: A prospective study of 68Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.
First Author: Lucia Baratto

Abstract e17537: Role of nitric oxide-based immunotherapy in augmenting prostate cancer progression by targeting androgen receptor heterogeneity.
First Author: Himanshu Arora, PhD

First Author: Maysa Tamara Silveira Vilbert

Abstract e17539: Treatment of metastatic castration sensitive prostate cancer (mCSPC) by disease volume: A systematic review and a meta-analysis.
First Author: Qurat Ul Ain Riaz Sipra, MD

Abstract e17540: Addition of carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in post-second generation hormone therapy setting: Does it improve treatment response and survival outcomes?
First Author: Jamal Alamiri, M.B., B.Ch., B.A.O

Abstract e17541: Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer.
First Author: Mallika Marar

Abstract e17542: Early PSA decline as a predictor of progression in patients with metastatic castration-naive prostate cancer (mCNPC) treated with abiraterone acetate and prednisone (AA/P).
First Author: Pedro C. Barata, MD, MSc

Abstract e17543: Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study.
First Author: Andrei Gafita, MD
Abstract e17544: Prostate cancer associated natural killer cells show a pro-angiogenic and pro-inflammatory phenotype.
First Author: Adriana Albini, PhD

Abstract e17545: Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients.
First Author: Maysa Tamara Silveira Vilbert

Abstract e17546: Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: Racial considerations for 250 consecutive cases.
First Author: Rabii Madi, MD

Abstract e17547: Combinatorial expression of androgen receptor splice variants: No predictive value in castration-resistant prostate cancer patients treated with enzalutamide (enza) or abiraterone (abi).
First Author: Katrin Schlack, MD

Abstract e17548: Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing.
First Author: Jessica Hawley, MD

Abstract e17549: Preclinical profile of clinical candidate, EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer.
First Author: Ronan Le Moigne, PhD

First Author: Salil Vengalil, MBBS, FRCR

First Author: Julio Araujo, MD

Abstract e17552: Treatment decision making in metastatic prostate cancer (mPC).
First Author: Frank Schumacher, BS

Abstract e17553: Completion time in prostate cancer treated with proton beam therapy: Do interruptions matter?
First Author: Shaakir Hasan, DO

Abstract e17554: Using longitudinal PSA values and machine learning for predicting progression of early stage prostate cancer in veterans.
First Author: Ioana Danciu
Abstract e17555: A prospective observational study of combinatorial abiraterone (AA) and radical radiotherapy (RT) in node-positive (N+) prostate cancer (PCa).
First Author: Mark Ting Le Tan, MD

Abstract e17556: Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.
First Author: Baijun Dong, MD

Abstract e17557: The role of programmed death-ligand 1 and non-epithelial circulating tumor cells in locally advanced prostate cancer.
First Author: Ke Li, professor

Abstract e17558: Genomic profiles and clinical outcomes to distinguish primary from secondary metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Emily Nizialek

Abstract e17559: INTH-454: A modulator of the p300/CBP interactome to exploit the vulnerability of Rb-deficient cancers and overcome therapy resistance associated with lineage plasticity in castration resistant prostate cancer.
First Author: Valentino Cattori, PhD

First Author: Ganesh Bakshi, MBBS MS MCH DNB [Urology]

Abstract e17561: Inflammatory and insulinemic dietary patterns: Influence on circulating biomarkers and prostate cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) cohort.
First Author: Desmond Aroke

Abstract e17562: Multi-institutional analysis of treatment outcomes in metastatic prostate cancer (mPCa) patients with DNA damage repair mutations (DDM).
First Author: Daniel Kwon, MD

Abstract e17563: Real-world outcome with abiraterone low-dose plus prednisone in patients with mCRPC in a Brazilian Public Cancer Center.
First Author: Luis Eduardo Rosa Zucca, MD, MSc

Abstract e17564: Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT) in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
First Author: Charles Joel Rosser, MD, MBA
Abstract e17565: Plasma IL-8 and PD-L1 and overall survival in metastatic castration-resistant prostate cancer patients (mCRPC).
First Author: Hyma Vani Polimera, MD

Abstract e17566: Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal high frequency of potential therapeutic targets.
First Author: Di Maria Jiang, MD, FRCPC, MSc

Abstract e17567: Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients.
First Author: Samira Masoudi

Abstract e17568: Real-world patterns of genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neal D. Shore, FACS, MD

Abstract e17569: Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.
First Author: Shruti U. Gandhy, MD, PhD

Abstract e17570: PectaSol-C modified citrus pectin (P-MCP) treatment (tx) in non-metastatic biochemically relapsed prostate cancer (M0, BRPC): Final results of a prospective phase II study.
First Author: Daniel Keizman, MD

Abstract e17571: The study of the treatment efficacy in metastatic castration-resistant prostate cancer of low dose abiraterone with food.
First Author: Kanta Makphancharoenkit, MD

Abstract e17572: Barriers to access of contemporary treatment for lethal prostate cancer: An Ontario population-based study.
First Author: Jennifer Leigh, MD, MSc

Abstract e17573: Sequence decision making for cabazitaxel versus abiraterone or enzalutamide post-docetaxel in a publicly funded health care system.
First Author: Alexander Watson, D.Phil, MD

Abstract e17574: Obesity, metabolic syndrome, and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew W Hahn, MD

Abstract e17575: PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy.
First Author: Bobby Chi-Hung Liaw, MD
Abstract e17576: The prognostic biomarkers of the patients treated with platinum-based chemotherapy in treatment emergent or related neuroendocrine prostate cancer.
First Author: Takeo Kosaka, MD, PhD

Abstract e17577: Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin-releasing hormone agonist versus antagonist.
First Author: Yaara Ber, PhD

Abstract e17578: Randomized multicenter open-label trial of GT0918 (proxalutamide) in patients with mCRPC that progressed on abiraterone or enzalutamide.
First Author: Nicholas J. Vogelzang, MD, FASCO, FACP

Abstract e17579: A prospective trial of $^{68}$Ga-PSMA and $^{18}$F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.
First Author: Beihe Wang

Abstract e17580: Phase II study of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with previously-untreated, metastatic, prostatic adenocarcinoma.
First Author: Seonggyu Byeon, MD

Abstract e17581: Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Rahul Raj Aggarwal, MD

Abstract e17582: Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Herrero Rivera

Abstract e17583: Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release.
First Author: Ben Buelow, MD, PhD

Abstract e17584: Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.
First Author: Jeffrey C. Goh, FRACP, MBBS

Abstract e17585: Cabazitaxel activity in men with metastatic castration-resistant prostate cancer (mCRPC) with and without DNA damage repair defects (DDR). 
First Author: Mihaela Aldea, MD, PhD
Abstract e17586: Pre-therapy visceral metastases in castrate resistant metastatic prostate cancer: Role in tumor progression.
First Author: Kathleen Ruchalski

Abstract e17587: The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
First Author: Alex John Liu, MD

Abstract e17588: Real-world experience with sipuleucel-T (Sip-T) in Asian men with castrate-resistant prostate cancer (CRPC).
First Author: Jingsong Zhang, MD, PhD

Abstract e17589: Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population.
First Author: Hala Borno, MD, BS

Abstract e17590: Effects of age on outcomes in men receiving treatment for metastatic castration-resistant prostate cancer (mCRPC): Analysis of Medicare fee for service (FFS) claims data.
First Author: Tanya B. Dorff, MD

Abstract e17591: Impact of flu vaccine on survival after immunotherapy for metastatic castration resistant prostate cancer (mCRPC): Analysis of Medicare claims data.
First Author: Russell Kent Pachynski, MD

Abstract e17592: Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).
First Author: A. Oliver Sartor, MD

Abstract e17593: Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).
First Author: Orazio Caffo, MD

Abstract e17594: Prognostic implications of gene amplifications identified by circulating tumor DNA (ctDNA) analysis in metastatic prostate cancer (mPC).
First Author: Toros Dincman, MD, PhD

Abstract e17595: Outcomes of patients with metastatic castration resistant prostate cancer according to somatic sequencing of damage DNA repair genes.
First Author: Zoé Neviere, MD, MSc
Abstract e17596: Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile.
First Author: Edwin Lin, MA, PhD

Abstract e17597: Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.
First Author: Giordano Fabricio Cittolin Santos, MD PhD

Abstract e17598: ARCHES: The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC)—Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels.
First Author: Russell Zelig Szmulewitz, MD

Abstract e17599: Clinically relevant genomic alterations identified by targeted exome sequencing in U.S. veterans with prostate cancer.
First Author: Eman Dadashian

Abstract e17600: MR guided high intensity focused ultrasound (MRgFUS) for the treatment of oligometastatic prostate cancer bone metastasis.
First Author: Alessandro Napoli, Associate Professor

Abstract e17601: Tumor response to a mastermind inhibitor protein.
First Author: Agamemnon A. Epenetos, PhD, FRCP

Abstract e17602: Prostate specific antigen testing as disease surveillance and monitoring five years after definitive therapy for localized prostate cancer.
First Author: Ibrahim M. Asiri, PhD Candidate

Abstract e17603: High-risk non-metastatic prostate cancer in the elderly: Does adjuvant chemotherapy affect survival?
First Author: Komal Akhtar, MD

Abstract e17604: Accuracy of prostate imaging reporting and data system (PI-RADS v2) in the detection of prostate cancer (PCa).
First Author: David Michael Gill, MD

Abstract e17605: Relative risk of HTN and major cardiovascular events associated with use of androgen receptor antagonists for nonmetastatic, castration-resistant prostate cancer.
First Author: Nusrat Jahan

Abstract e17606: Efficacy of androgen receptor antagonists in combination with androgen deprivation therapy in nonmetastatic, castration-resistant prostate cancer: A systematic review
and meta-analysis of published phase III randomized controlled trials.
First Author: Nusrat Jahan

Abstract e17607: Safety and tolerance of androgen receptor antagonists in nonmetastatic, castration-resistant prostate cancer.
First Author: Sariya Wongsaengsak, MD

Abstract e17608: Is prostate brachytherapy a dying art? Evidence of increasing utilization in Ontario, Canada.
First Author: Mark Thomas Corkum, MD, MSc

Abstract e17609: Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
First Author: Tate Janet, ScD

Abstract e17610: Sequential or concomitant radiotherapy treatment for patients with localized prostate cancer.
First Author: Ramachandran Venkitaraman, MD

First Author: David Margel, MD, PhD

First Author: Brian Warnecke, DO

Abstract e17613: Preliminary immune responses from ProVent: A randomized phase III study of sipuleucel-T (sip-T) in active surveillance (AS) for prostate cancer (PC).
First Author: James L. Gulley, MD, PhD, FACP

Abstract e17614: Dissection of primary prostate cancer to determine the clonal origin of synchronous lymph node metastasis.
First Author: Srinivas Nallandhighal, M.S.

Abstract e17615: Expansion of germline genetic testing criteria for prostate cancer yields findings across all stages of disease.
First Author: Sarah M. Nielsen, MS

Abstract e17616: The impact of complications after diagnostic biopsy on repeat biopsy in men: Results from the Prostate Cancer Research International: Active surveillance (PRIAS-JAPAN) study.
First Author: Yoichiro Tohi, MD
Abstract e17617: Possibilities for improving the diagnosis of clinically significant prostate cancer based on 3D modeling.
First Author: Sergey N Dimitriadi

Abstract e17618: Redefining the role of adjuvant versus salvage radiation therapy for prostate cancer after radical prostatectomy for T3 disease and/or positive margins.
First Author: Barry W. Goy, MD

Gynecologic Cancer

First Author: Oren Gilad, PhD

Abstract e18001: Retrospective analysis of clinical characteristics and prognostic factors of neuroendocrine carcinoma of the gynecologic tract: A preliminary report of ten years follow-up.
First Author: Y Zhang

Abstract e18002: Association of LINC00858 with clinical outcome of patients with cervical cancer who received standard concurrent chemo-radiotherapy.
First Author: Shun Lu

Abstract e18003: Molecular profiles and immune checkpoint inhibitor-related biomarkers analysis in advanced cervical cancer.
First Author: Qin Xu

Abstract e18004: Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with stage IIA-III A cervical carcinoma.
First Author: Mingyang Yuan

Abstract e18005: Identification of risk factors associated with pelvic lymph node metastasis in patients with stage IB1 cervical cancer.
First Author: Ping Jiang, M.D

Abstract e18006: Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab.
First Author: Kathryn Miller

Abstract e18007: The efficacy and safety of pembrolizumab in advanced cervical cancer—a real world treatment study in an irish healthcare setting.
First Author: Iseult Browne, MD
Abstract e18008: Genetic and clinical characteristics to predict the efficacy of neoadjuvant chemoradiotherapy in Chinese patients with cervical cancer.
First Author: Yuchun Wei, MD

Abstract e18009: Treatment patterns in cervical cancer patients initiating systemic therapy.
First Author: Anuj Shah

Abstract e18010: Effect of the oral CXCR4 inhibitor X4-136 on tumor control and side effects in cervical cancer treated with radiotherapy and concurrent chemotherapy.
First Author: Naz Chaudary, PhD

Abstract e18011: A new perspective of different schemes of neoadjuvant chemotherapy followed by concurrent chemotherapy and radiotherapy for locally advanced cervical cancer.
First Author: Xue Tian

Abstract e18012: Clinicopathological correlation of serum vascular endothelial growth factor and tissue carbonic anhydrase factor IX in stage IA to IIA carcinoma cervix.
First Author: Shalini Rajaram, MD

Abstract e18013: GOTIC-018: Phase I, open-label, multicenter, multicohort study to assess the safety and feasibility of ONO-4538 (nivolumab) with concurrent chemoradiation (CCRT) in patients (pts) with locally advanced cervical carcinoma (LACvCa).
First Author: Kosei Hasegawa, MD, PhD

Abstract e18014: Impact of leucocyte modifications in patients with locally advanced cervical treated by chemoradiotherapy.
First Author: Christine Gennigens, MD

Abstract e18015: Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix in the surveillance, epidemiology, and end results database.
First Author: Jinluan Li

First Author: Adrien Joseph, MD

Abstract e18017: Evaluation of the constructed device along with the software for digital archiving, sending the data, and supporting the diagnosis of cervical cancer.
First Author: Jacek Gronwald, prof

Abstract e18018: Efficacy and safety of PEGylated recombinant human granulocyte stimulating factor in the prevention of neutropenia during concurrent chemoradiotherapy.
First Author: Dongling Zou
Abstract e18019: Treatment patterns among newly diagnosed women with cervical cancer in the United States.
First Author: Anuj Shah

Abstract e18020: Opportunities and challenges in cervical cancer screening program in Kazakhstan: results after imPACT review.
First Author: Dilyara Kaidarova, MD, PhD, DSc

Abstract e18021: A retrospective study of carboplatin and liposomal doxorubicin in patients with locally advanced or recurrent squamous cell carcinoma of the cervix.
First Author: LEI Chang, PhD

Abstract e18022: Dendritic cell vaccine as an alternative to opioid analgesia in patients with advanced cervical cancer.
First Author: Anna P. Menshenina

First Author: Nidal Salim, MD

Abstract e18024: Quality of life of cervical cancer patients after specialized treatment in Kazakhstan.
First Author: Dilyara Kaidarova, MD, PhD, DSc

Abstract e18025: Hormonal rehabilitation in patients with endothelial and cervical cancers.
First Author: Natalia V. Chernikova

Abstract e18026: Patterns of treatment failure after radiotherapy in patients with locally advanced cervical cancer.
First Author: Yifei Wang

Abstract e18027: Novel HPV-E7 immune modulators to activate HPV-specific T cells to eliminate cervical cancer.
First Author: Lihua Shi, PhD

Abstract e18028: Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer: Preliminary results.
First Author: Peter Van Dam, MD, PHD, Professor

Abstract e18029: Relative gene copy numbers in various patterns of cervical cancer growth.
First Author: Natalya N. Timoshkina

Abstract e18030: Ozone therapy as accompanying treatment for chemoradiotherapy in patients with locally advanced cervical cancer.
First Author: Olga G. Rodionova
Abstract e18031: Correlation of PR and ER expression in tumors in various growth patterns of cervical cancer as a prognostic factor.
First Author: Elena P. Ulianova

Abstract e18032: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.
First Author: Rebecca Sophie Kristeleit, MD, PhD

First Author: Trish Dinh, MD

Abstract e18034: Outcomes among women with brain metastases from gynecologic (gyn) malignancies.
First Author: Kristen Cagino, MD

Abstract e18035: Present-day management of uterine leiomyosarcoma: Evaluation of treatment sequencing and other prognostic factors.
First Author: Emily Hinchcliff, MD, MPH

Abstract e18036: Treatment patterns of advanced or recurrent endometrial cancer following platinum-based therapy in the US real-world setting.
First Author: Andrew J. Klink, PhD, MPH, BS

Abstract e18037: Is there a high risk of renal dysfunction and the need for its prevention in patients with gynecological cancers after surgery?
First Author: Sergey V. Tumanyan

Abstract e18038: Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy.
First Author: Lance G. Laing, PhD

Abstract e18039: Combination treatment with AZD6738 and teriflunomide: A novel precision medicine strategy for ARID1A-mutated cancers.
First Author: Zhigui Li, PhD

Abstract e18040: Open label phase I trial using SPL-108 in combination with weekly paclitaxel final report with molecular correlates.
First Author: Eugenia Girda, MD

Abstract e18041: Utilizing porcupine (PORCN) and DKK1 inhibition to improve anti-tumor immunity in a murine model of ovarian cancer.
First Author: Jaclyn Wall
Abstract e18042: Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?
First Author: Haley Moss, MD, MBA

Abstract e18043: Association of time interval from neoadjuvant chemotherapy to interval cytoreduction and interval cytoreduction to adjuvant chemotherapy with survival outcomes and risk of platinum resistance.
First Author: Viviane Alencar

Abstract e18044: Results of a deep-dive survey on practice patterns of oncologists and advanced practice providers utilizing PARP inhibitors as maintenance therapy for patients with ovarian cancer.
First Author: Wendy Turell, DrPH

Abstract e18045: Endocrine biomarkers in low-grade serous ovarian cancers (LGSC) and serous ovarian tumors of low malignant potential (LMP).
First Author: Sarah E. Taylor

Abstract e18046: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
First Author: Sally Anne Mullany, MD

Abstract e18047: Mutational and immunoprofiling analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy.
First Author: Elizabeth Santos

Abstract e18048: Characterization of mutations in HRR genes, TMB, and PD-L1 expression in Chinese patients with ovarian cancer.
First Author: Hong Zheng

Abstract e18049: Uptake of targeted therapy in clinical practice among US patients with ovarian cancer.
First Author: John K. Chan, MD

Abstract e18050: A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release.
First Author: Ben Buelow, MD, PhD

Abstract e18051: The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
First Author: Laura J Havrilesky, MD, MHSc
Abstract e18052: Hrd in ovarian cancer: Defined today, evolving for the future.
First Author: Markus Eckstein

Abstract e18053: A post-hoc study of relative dose intensity in elderly patients with advanced ovarian cancer (JGOG3016-A3).
First Author: Yoshio Itani, MD, PhD

Abstract e18054: CRS + HIPEC in stage IIIc epithelial ovarian cancer and comparison of oncological outcome only with CRS and IV chemotherapy and CRS + IP chemotherapy.
First Author: S.P. Somashekar, FRCS, MCh

Abstract e18055: Factors affecting recurrence rates in women with borderline ovarian tumors.
First Author: Lauren Scanlon

Abstract e18056: Sex cord stromal and germ cell ovarian cancer: Is there a racial disparity?
First Author: Fatima Reyes, MD

Abstract e18057: Surface-modified nanoparticle transport evaluated in a multistage model of ovarian cancer.
First Author: Stephen Winter, M.E.

Abstract e18058: Identification of new lesion with disease progression in Ovarian cancer per RECIST 1.1.
First Author: Manish Sharma, MD, DMRT, MBBS

Abstract e18059: Dose-dense carboplatin and paclitaxel versus three weekly regimen in the first-line treatment of ovarian carcinoma.
First Author: Rafaela Pirolli

Abstract e18060: Impact of the timing and extent of debulking surgery on progression-free survival (PFS) and overall survival (OS) in advanced epithelial ovarian cancer (EOC): Single-center experience.
First Author: Muhieddine A-F Seoud, MD

Abstract e18061: FSCN1 as prognostic marker in borderline tumors of the ovary.
First Author: Ahmed El-Balat

Abstract e18062: Evaluation of adaptive NK cells in ovarian cancer patients with cytomegalovirus (CMV) reactivation and systemic inflammation.
First Author: Erin Wesley, PhD

Abstract e18063: Capturing the pathway logic of cell signaling for epithelial-mesenchymal transition in ovarian cancer cell lines.
First Author: Matthew Morris
Abstract e18064: Participant demographics and disparities in ovarian cancer clinical trials.
First Author: Elizabeth Howell, BS

Abstract e18065: Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1-amplification to paclitaxel by targeting APC/C and the pro-survival protein MCL-1.
First Author: Sven Becker, MD, PhD

Abstract e18066: Efficacy of dose-dense chemotherapy as first-line treatment of advanced ovarian cancer patients after non-optimal debulking.
First Author: Alexey Rumyantsev, MD

Abstract e18067: The impact of obesity on treatment and outcomes in ovarian cancer by race/ethnicity.
First Author: Alexandra Martin

Abstract e18068: Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer.
First Author: Mark C. Valentine, MD, PhD

Abstract e18069: Use of clinical classification software to differentiate good versus poor prognostic patients with ovarian cancer: A SEER-Medicare database analysis from the viera study.
First Author: Gboyega Adeboyeje

Abstract e18070: Comparison of poly(ADP-ribose) polymerase inhibitors (PARPi's) as maintenance therapy for platinum-sensitive ovarian cancer: Systematic review and network meta-analysis.
First Author: Amos Stemmer

Abstract e18071: The role of imaging in early detection of patients at risk for neuropathy during primary chemotherapy for ovarian carcinoma.
First Author: Sarah Bell

Abstract e18072: Defining the tumor cell: CA-MSC interactions which mediate ovarian cancer metastasis.
First Author: Ester Goldfeld, MS

Abstract e18073: Evaluation of the occurrence and management of PARP inhibitor toxicities.
First Author: Rachel Hatch, PharmD

Abstract e18074: Biomarker lead time for predicting progression in women with ovarian cancer compared to imaging.
First Author: Alexandra Samborski, MD
Abstract e18075: OvarianTag biomarker panel in order guide treatment decisions cisplatin-based for women with epithelial ovarian cancer.
First Author: Leticia da Conceição Braga, PhD

Abstract e18076: Efficacy of platinum-based chemotherapy in platinum-resistant ovarian cancer: A systematic review with pooled analysis of outcomes.
First Author: Alexey Rumyantsev, MD

Abstract e18077: Tissue factor pathway inhibitor II as a specific biomarker for pre-operative prediction of clear-cell carcinoma of the ovary.
First Author: Etsuko Miyagi, MD, PhD

Abstract e18078: Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.
First Author: Yanna Zhang, M.D.

Abstract e18079: Immunomodulator in combination treatment of patients with ovarian cancer and its influence on DNA cytometric and immunological parameters.
First Author: Anna Yu. Ardzha

Abstract e18080: Multiomics-based energy metabolism heterogeneity and its regulation by antiparasite drug ivermectin.
First Author: Na Li

Abstract e18081: Markers of a metastatic niche in the omentum in ovarian cancer.
First Author: Tatiana I. Moiseenko

Abstract e18082: The regulation of RNA Polymerase II mediated transcription by Caspase-8 in ovarian cancer.
First Author: Sven Becker, MD, PhD

Abstract e18083: Adult ovarian granulosa cell tumor: Role of systemic chemotherapy and surgical treatment.
First Author: Anna Beliaeva

Abstract e18084: Correlation of longtime efficacy maintenance PARP inhibitor therapy with pretreatment in a single-institution experience.
First Author: Maria Ornella Nicoletto, MD

Abstract e18085: The development of a homologous recombination deficiency (HRD) score to identify HR-deficient tumors.
First Author: Xiaohua Wu
Abstract e18086: Effect of bevacizumab in first-line chemotherapy on progression-free survival in advanced ovarian clear cell carcinoma.
First Author: Shinichi Tate

Abstract e18087: Real-world conditional survival analysis of women with newly diagnosed ovarian cancer.
First Author: Elizabeth A. Szamreta, Ph.D., M.P.H.

Abstract e18088: Germline and somatic mutations in 25 hereditary breast and ovarian cancer related genes and platinum-based chemotherapy response among Chinese patients with epithelial ovarian cancer.
First Author: Lei Li

Abstract e18089: Paraneoplastic ataxic syndrome with anti-Yo antibodies in breast and ovarian cancer: A retrospective analysis.
First Author: Akshjot Puri, MD

Abstract e18090: Development of a personalized ex vivo drug screening test for patients with ovarian cancer.
First Author: Luzi Brückner

Abstract e18091: Pressurized intra peritoneal aerosol chemotherapy (PIPAC) vs. intravenous chemotherapy to assess quality of life & response rates in unresectable peritoneal metastases secondary to platinum resistant ovarian cancer: A comparative study.
First Author: S.P. Somashekhar, FRCS, MCh

Abstract e18092: Efficacy and toxicity of immunotherapy with immune checkpoint inhibitors in gynecologic cancers.
First Author: Michelle Kuznicki

Abstract e18093: National patterns and factors predicting employment disruption in women diagnosed with endometrial cancer.
First Author: Roni Nitecki

Abstract e18094: Impact of neoadjuvant chemotherapy on survival in women with endometrial cancer: A national cancer database analysis.
First Author: Laura Chambers

Abstract e18095: Chemotherapy response score as a prognostic tool in advanced-stage endometrial cancer patients treated with neoadjuvant chemotherapy.
First Author: Ina Jani, MD

Abstract e18096: Seven-year survival analysis in women with unsuspected uterine malignancy after laparotomic versus laparoscopic hysterectomy: A national claim data retrospective cohort
Abstract e18097: A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707).
First Author: Eleftheria Kalogera, MD

Abstract e18098: A Novel predictive probability algorithm to determine risk for malignancy between uterine fibroids versus uterine sarcoma.
First Author: Alexandra Michelle Blackman

Abstract e18099: Prognostic significance of hormone receptor (ER/PR) status in endometrial carcinoma in black women: Implications with lymph node metastasis.
First Author: Manan Shah, MD

First Author: Aifen Wang

Abstract e18101: A single-center analysis of adjuvant sequential versus ‘sandwich’ chemoradiotherapy for patients with stage III endometrial cancer.
First Author: Janice Shen, MD

Abstract e18102: Treatment and outcome of patients with uterine carcinosarcoma: Data from developing world.
First Author: Seema Gulia, MD, DM

Abstract e18103: CXCL13+ CD8 T-cell axis links neoantigen load to de novo lymph node formation in high-responder populations for immunotherapy.
First Author: Hans Nijman, PhD, MD

Abstract e18104: Age-related clinicopathologic features and survival in papillary serous uterine cancer patients older and younger than 70: An exploratory analysis of a series of consecutive patients.
First Author: Jaren Lerner, MD

Abstract e18105: Effect of MUC5B mutation on prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer.
First Author: Hong Zheng

Abstract e18106: Malignant MIXED mullerian tumors and serous endometrial cancer: Molecular targets the need of the hour.
First Author: Manan Shah, MD
Abstract e18107: Selecting patients with recurrent endometrial carcinoma for secondary cytoreduction.
First Author: Lea Anne Moukarzel, MD

Abstract e18108: Effect of inducing HR deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor, on response to olaparib in uterine serous cancer.
First Author: Michael Driscoll Toboni, MD, MPH

Abstract e18109: Impact of inpatient hospitalization on opiate usage for minimally invasive hysterectomy amongst gynecologic oncology patients.
First Author: Shannon Michelle Grabosch, MD

Abstract e18110: Clinicopathologic and protein markers distinguishing POLE and copy-number low group in endometrial cancer.
First Author: Kidong Kim Sr., MD, BA

Abstract e18111: Diagnosis and treatment of uterine carcinosarcoma.
First Author: Anna Beliaeva

**Head and Neck Cancer**

Abstract e18500: Exploratory phase Ib/Ila study of intratumorally administered tigelanol tiglate (TT) to assess safety, tolerability, and tumor response in patients with head and neck squamous cell carcinoma (HNSCC).
First Author: Richard H. Gallagher, MBBS FRACS

Abstract e18501: Survey of the experience of head and neck cancer patients with a percutaneous endoscopic gastrostomy tube.
First Author: Kamal Kant Sahu, MD, DM Clinical Hematology

Abstract e18502: Novel immunotherapy combinations for betel-nuts related HNSCC: One institutional experience in Taiwan.
First Author: Jo-Pai Chen

Abstract e18503: Effectiveness of PD-L1 inhibitors in metastatic or recurrent squamous cell carcinoma of head and neck: An observational, indirect comparison.
First Author: Michel Bila, MD, DDS

Abstract e18504: A review of head and neck squamous cell carcinoma response to taxane chemotherapy treatment in the pre versus post nivolumab era.
First Author: carolyn moloney
Abstract e18505: Indication of adjuvant chemoradiation post neoadjuvant chemotherapy in very locally advanced borderline resectable head and neck cancer.
First Author: Sudeep Das, MD, DM

First Author: Andrea Botticelli, assistant professor

Abstract e18507: Long-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy.
First Author: Amit Kumar

Abstract e18508: The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial.
First Author: Andrea Botticelli, assistant professor

Abstract e18509: Initial safety and tumor control results from a phase I prospective trial evaluating a novel alpha-emitting radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and head and neck.
First Author: Aron Popovtzer, MD

Abstract e18510: Safety/efficacy of a phase I/II study of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN).
First Author: William Smith, MD

Abstract e18511: Prognostic and predictive value of skeletal muscle mass (SMM) in squamous cell carcinoma of the head and the neck (SCCHN) patients treated with immune checkpoint inhibitors (ICI).
First Author: Lorena Arribas

Abstract e18512: Efficacy and tolerability of weekly 40mg/m² cisplatin radiosensitizing modified regimen for locally-advanced head and neck squamous cell carcinoma radical treatment with chemoradiotherapy: A university hospital experience.
First Author: Bruna Bighetti

First Author: Rujul H Parikh, MD

Abstract e18514: The humanistic burden reported by first-line (1L) head and neck cancer patients diagnosed with recurrent/metastatic squamous cell carcinoma (R/M SCCHN) in europe:
A real-world study.
First Author: Prianka Singh

Abstract e18515: Capecitabine therapy in recurrent/metastatic nasopharyngeal cancers.
First Author: Bader I Alshamsan, MBBS

Abstract e18516: End-of-life health care utilization (EOLHCU) in patients with recurrent, metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with immune checkpoint inhibitors (IO).
First Author: Cameron Chalker, MD

Abstract e18517: Clinicopathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single-institutional experience.
First Author: Abdulla K P, MBBS, MS, DNB, MCh Surgical oncology trainee

Abstract e18518: Exploration of associations between adverse drug reactions and clinical outcomes in anlotinib treatment against medullary thyroid carcinoma (MTC): A subgroup analysis based on the ALTER01031 trial.
First Author: Yihebali Chi, MD, PhD

Abstract e18519: Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma.
First Author: Dora Lai Wan Kwong, MD

Abstract e18520: Validation of secreted protein OASEP1 as a prognostic biomarker and therapeutic target for oral cancer.
First Author: Atsushi Takano, MD, PhD

Abstract e18521: Comparison of circulating tumor cells and cell-free DNA in the molecular characterization of patients with head and neck cancer.
First Author: Santiago Cabezas-Camarero, MD

First Author: Melissa Taylor

Abstract e18523: Is there a role of functional endoscopic evaluation of swallowing (FEES) in aiding tracheotomy decannulation post oral cancer surgery?
First Author: Vibhu Ranjan Sahni, None

Abstract e18524: Comparison of treatment costs for pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma based on KEYNOTE-040 clinical trial.
First Author: Justin Yeh
Abstract e18525: Second malignancy post-chemoradiation in head and neck cancer patients.
First Author: Gunjesh Kumar Singh

Abstract e18526: Performance of machine learning-augmented analysis of radiomics for the
head and neck cancer histopathological diagnosis: A systematic review and meta-analysis.
First Author: Sotirios Bisdas, MD, PhD, MSc (Advanced Oncology)

Abstract e18527: DNA methylation profiling in patients with head and neck squamous cell
carcinoma treated with immune checkpoint inhibitors.
First Author: Angelika Martina Starzer, MD

Abstract e18528: Neoantigen-based vaccination as a practical measure for head and neck
cancer treatment.
First Author: Xiao-bin Zheng

Abstract e18529: Multigene profiling to identify clinically relevant actionable mutations in head
and neck cancers: An Indian study.
First Author: Sateesh S. Kunigal, PhD

Abstract e18530: Genomic landscape of head and neck cancers.
First Author: Anand Subash, MBBS, MS, DNB, FHNO

Abstract e18531: Impact of failure to thrive on inpatient mortality and resource utilization in
patients with head and neck cancer: A nationwide analysis.
First Author: Binav Baral

Abstract e18532: The incidence of NTRK fusion in Chinese head and neck cancer and response
to crizotinib treatment.
First Author: Lianke Liu

Abstract e18533: Association of driver genes with high-tumor mutation burden and outcome in
patients with head and neck cancer: Implications for immunotherapy.
First Author: Yu Chen

Abstract e18534: Prognostic value of HER2, PD-L1 and RET mRNA expression in salivary gland
tumor.
First Author: Svetlana Kutukova

Abstract e18535: Transcriptomic correlates of immunologic activation in head and neck cancer
and lung adenocarcinomas.
First Author: Mariona Baliu Piqué, PhD
Abstract e18536: Predictive scoring systems for distant metastases in oral cavity squamous cell carcinoma.
First Author: Hsueh Ju LU

Abstract e18537: Are the demographics of recurrent oropharyngeal and oral cavity squamous cell carcinoma changing?
First Author: Jeffrey Means, DO

Abstract e18538: Prediction of local recurrence in oral squamous cell carcinoma using immune markers.
First Author: Damiana Pierssens

Abstract e18539: Prevalence of herpes simplex virus I, II, cytomegalovirus, Epstein–Barr virus and human papillomavirus (6, 11, 16 and 18) in normal oral mucosa and OSCC patients in Saint-Petersburg (Russia).
First Author: Svetlana Kutukova

Abstract e18540: An in silico comparative planning study investigating the predicted benefit of dysphagia-optimised volumetric arc therapy (Do-VMAT), relative to standard VMAT (S-VMAT), to reduce radiotherapy-associated dysphagia (RAD) in oropharyngeal cancers (OPC).
First Author: Imran Petkar, FRCR, MBBS, MD

Abstract e18541: Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).
First Author: Ritu Chaudhary

Abstract e18542: Mechanism of sensitivity to TPF chemoagents and its potential alternative of erbB2 in oral cancer with GDF15 overexpression.
First Author: Lai-Ping Zhong, MD, PhD

Abstract e18543: Comprehensive analysis of key genes associated with ceRNA networks in nasopharyngeal carcinoma.
First Author: Xinyi Huang

Abstract e18544: Survival for oropharyngeal and oral cavity cancer patients based on time to recurrence and HPV status.
First Author: Jeffrey Means, DO

Abstract e18545: PD-L1 in combination with CD8*TIL and HIF-1α are promising prognosis predictors of head and neck squamous cell carcinoma.
First Author: Jinming Yu
Abstract e18546: Ameloblastoma of the head and neck (HNAMB): A comprehensive profiling (CGP) study.
First Author: Jeffrey S. Ross, MD

Abstract e18547: Identifying the distant metastasis genes by next-generation sequencing panel in nasopharyngeal carcinoma.
First Author: Man Hu

Abstract e18548: Comparison of intraoperative imprint cytology with frozen section for lymph node metastasis in patients with head and neck cancer.
First Author: Saheer Neduvanchery

Abstract e18549: Phase II study: Induction chemotherapy & transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): An update and retrospective review of non-study patients.
First Author: Robert S. Siegel, MD

Abstract e18550: Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).
First Author: Lakhan Kashyap, MD

Abstract e18551: Incidence of hypothyroidism in head and neck squamous cell carcinoma patients receiving radiotherapy with and without immune checkpoint inhibitors.
First Author: Jennifer Leddon, MD, PhD

First Author: ZiBin Liang, PHD

Abstract e18553: Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer.
First Author: Atanu Bhattacharjee, Ph.D

First Author: Atul Sharma, MD, FRCPC

Abstract e18555: Carboplatin versus cetuximab chemoradiation in cisplatin ineligible locally advanced head and neck squamous cell carcinoma.
First Author: Kannan Thanikachalam, MBBS
Abstract e18556: Factors impacting use of adjuvant therapy in lip and oral cavity squamous cell carcinoma: A NCDB analysis.
First Author: Poornima Ramadas

Abstract e18557: Correlation of pathologic tumor grade with survival in oral cavity squamous cell carcinoma.
First Author: Eric Anderson, MD

Abstract e18558: Delayed PET/CT scanning in locally advanced squamous cell carcinoma of the head and neck (SCCHN) receiving definitive chemoradiation: Outcomes and management of “incidental” findings.
First Author: Sunitha Alluri, MD

Abstract e18559: Lymphnode metastasis patterns in primary sites of hypopharyngeal cancer: A retrospective analysis from multicenter data.
First Author: Xiwei Zhang

Abstract e18560: Prevention of cisplatin nephrotoxicity (CN) in head and neck cancer patients receiving concurrent chemoradiation (CCRT) by adding oral rehydration solution (ORS) to short hydration regimen: A randomized open-label controlled trial.
First Author: Aungsumal Maisrikrod

Abstract e18561: The role of routine surveillance imaging in detecting oral cavity cancer recurrence in asymptomatic patients.
First Author: Jeffrey Chi, MD

Abstract e18562: Low-dose cisplatin administration through the superficial temporal artery combined with definitive radiotherapy for maxillary sinus squamous cell carcinoma.
First Author: Tatsuo Masubuchi, MD, PhD

Abstract e18563: VEGF-A and TGF-β in bioptates of oral squamous cell carcinoma reflect tumor response to chemotherapy and monoclonal antibodies (cetuximab).
First Author: Liubov Yu Vladimirova, MD, PhD

Abstract e18564: Insulin-like growth factors in the blood of patients with oral squamous cell carcinoma receiving therapy with monoclonal antibodies (cetuximab).
First Author: Aza A. Lyanova

Abstract e18565: Treatment failure pattern of oropharyngeal cancer, especially for the aspect of retropharyngeal lymph node.
First Author: Byung-Hee Kang
Abstract e18566: Comparative efficacy of primary treatment approaches in anaplastic thyroid carcinoma (ATC): An updated network meta-analysis.
First Author: Kevin M. Gallagher, MD

Abstract e18567: Patterns of thyroid dysfunctions during treatment with immune checkpoint inhibitors (ICI) in 59 solid cancer patients.
First Author: Yong Jiang, MD

Abstract e18568: A phase II randomized clinical trial and mechanistic studies using improved probiotics to prevent oral mucositis induced by concurrent radiotherapy and chemotherapy in nasopharyngeal carcinoma.
First Author: Chunling Jiang, MD

Abstract e18569: Papillary thyroid microcarcinoma: Analysis of outcomes and features predicting risk of recurrence.
First Author: Chandra Shekhar Dravid

First Author: Juan Cintron-Garcia, MD

Abstract e18571: DNA methylation signature for prediction of metastasis and response to multikinase inhibitors of differentiated thyroid carcinoma.
First Author: Jorge Hernando, MD, PhD

Abstract e18572: Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer (RR-DTC): A retrospective study.
First Author: Chihiro Matsuyama

First Author: Prashanth Ashok Kumar, MBBS

Abstract e18574: Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis.
First Author: Aju Mathew, MD, MPhil, FACP

Abstract e18575: Clinical implications of genomic profiles in recurrent or metastatic thyroid cancer with a focus on the most frequently mutated genes.
First Author: Hyun Ae Jung, MD

Abstract e18576: T-Cell receptor repertoire and genomic analysis of tracheal adenoid cystic carcinoma.
First Author: Fei Wang
Abstract e18577: BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) and treatment with BRAF-inhibitors: Real-world data from a single-institution, still far from the cure.
First Author: Francesca Platini, MD, PhD

Abstract e18578: CTNNB1, PIK3CA, EIF1AX, and PTEN polymorphisms found in aggressive types of differentiated thyroid cancer.
First Author: Dauren Adilbay, MD, PhD

Abstract e18579: Differential immune pathways in classic and mixed variants of anaplastic thyroid cancer.
First Author: Hannah J Young, BS

Health Services Research and Quality Improvement

Abstract e19000: Cancer in Belize: Characteristics of patients presenting to a public oncology clinic.
First Author: Yannis Valtis

Abstract e19001: Mental distress and mental health services receipt in foreign-born survivors of cancer: A national health interview survey analysis.
First Author: Melaku A Arega

Abstract e19002: Pediatric cancer care in Armenia: The results of a qualitative analysis.
First Author: Saten Hovhannisyan, MD, MPH

Abstract e19003: Has Medicaid expansion improved access to care among socioeconomically disadvantaged breast cancer patients? An NCDB analysis.
First Author: Leah Elson, MS

First Author: Karla Diaz Ramirez

Abstract e19005: Investigation of triple negative breast cancer rates in women diagnosed with breast cancer in Trinidad and Tobago.
First Author: Gerneiva Parkinson, MD, MHS

Abstract e19006: The influence of health disparities on risk factors in patients with colorectal cancer.
First Author: Neha Hippalgaonkar

Abstract e19007: Pancreatic cancer: Do disparities in mortality rates exist with respect to socioeconomic status?
First Author: Richard Stephen Sheppard
Abstract e19008: Disparities in clinical characteristics and treatment of multiple myeloma in African American patients.
First Author: Shivam Mathura

Abstract e19009: ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC.
First Author: Manoj Menon, MD

Abstract e19010: Differences in real-world liver cancer treatment patterns among people living with HIV/AIDS (PLWHA) compared to those without HIV/AIDS (PWoHA).
First Author: Angelica Falkenstein, PhD

Abstract e19011: Outcomes of a lung cancer screening program in a Hispanic urban population: The University of Miami experience.
First Author: Kunal Gawri, MD

Abstract e19012: Profiling and prognostic implications of variants of unknown significance (VUS) in solid tumors.
First Author: Meena Sadaps, MD

Abstract e19013: Material, psychological, and behavioral financial hardship and prostate cancer treatment type.
First Author: Reginald Tucker-Seeley, ScD

Abstract e19014: Feasibility of an electronic risk score questionnaire in rural practice.
First Author: Ajaz Bulbul

First Author: Jennifer Dent, MBA

Abstract e19016: "Does better understanding of cancer care needs impact outcomes...?" The experiences of the Kigali City Cancer Challenge innovation.
First Author: Christian Ruchaho Ntizimira

Abstract e19017: Neighborhood disparities in timeliness of treatment for early stage lung cancer patients.
First Author: Chelsea A Obrochta, MPH

Abstract e19018: Barriers identified in a patient navigation program for starting and completing definitive radiotherapy treatment in a limited resource setting.
First Author: Carolina Martins Vieira
Abstract e19019: Role of patient navigation in improving access to radiotherapy treatment in a limited resource setting.
First Author: Carolina Martins Vieira

Abstract e19020: Change in body mass index in breast cancer patients in the first two years from diagnosis.
First Author: Maysa M. Abu-Khalaf, MD

First Author: Jesus Garcia-Foncillas, MD, PhD

Abstract e19022: The use of surgical & interventional procedures for the diagnosis and treatment of pediatric tumors: An example from an upper middle income country.
First Author: M. Tezer Kutluk, MD

Abstract e19023: Association of socioeconomic status and molecular testing in stage IV colorectal cancer.
First Author: Salman Rafi Punekar, MD

Abstract e19024: Implementation science of district cancer care delivery model (Pendharkar model).
First Author: Dinesh Pendharkar, MD, PhD

Abstract e19025: Characteristics and factors affecting mortality of patients admitted for chemotherapy in the United States during the year 2017.
First Author: Arya Mariam Roy, MD

Abstract e19026: Racial and socioeconomic disparities in the treatment of resectable hepatocellular carcinoma.
First Author: Young soo Rho, MDCM

First Author: Prasanth Lingamaneni, MD

Abstract e19028: Incidence of colon cancer in younger population and lower incidence in Asians and females in central valley of California: Health disparity and epigenetic study model.
First Author: Soujanya Sodavarapu

First Author: Soujanya Sodavarapu
Abstract e19030: The effect on financial toxicity and well-being of cancer trial patients through the reimbursement of ancillary costs by the Lazarex Care Program (LCP).
First Author: Dana Dornsife, BS

Abstract e19031: Latino/non-Latino differences in understanding the intents of, and the value in, chemotherapy treatments in end-of-life cancer care.
First Author: Paul K. Maciejewski, PhD

First Author: Rao Rashid Mushtaq, MD, FACP

Abstract e19033: Medicare compared with private insurance for the treatment of cancer.
First Author: Phillip Martinez-Knouse, MD

Abstract e19034: Screening for health literacy at an urban academic cancer center.
First Author: Amy Leader, DrPH, MPH

Abstract e19035: Exclusion rates of patients living with HIV from cancer immunotherapy clinical trials.
First Author: Kruti Bhagirath Vora, BA

Abstract e19036: Prognostication based on TNM staging for socioeconomically disadvantaged colorectal cancer patients.
First Author: Yan Lu, MPH, MD

First Author: Ravi Bharat Parikh, MD

Abstract e19038: Differences in self-reported health-related quality of life in heterosexual and sexual minority women surviving cancer: 2013 to 2018 national health interview survey.
First Author: Megan Leigh Gleason Hutchcraft, MD

Abstract e19039: Under-reporting of race at national hematology conference.
First Author: Ansh Mehta, MD

Abstract e19040: Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN).
First Author: Bei Hu, MD

Abstract e19041: Patient-reported physical and mental health of socioeconomically disadvantaged cancer patients.
First Author: Aaron Gehr, MPH
Abstract e19042: Real-world biomarker testing practices in cancer treatment in a lower-middle income country in Southeast Asia.
First Author: Lance Isidore Garcenila Catedral

Abstract e19043: The effect of locality of residence (LOR) and socioeconomic status (SES) on mortality in patients with squamous cell carcinoma of the head and neck (HNSCC): 20-year experience at the UPMC Hillman Cancer Center.
First Author: Janielle Taylor, MD(c), MSPH

Abstract e19044: Impact of US population demographic changes on projected incident cancer cases from 2019 to 2045 in three major cancer types.
First Author: Jimmy Nguyen

First Author: Michael Del Rosario, MD

First Author: Ash Alpert

Abstract e19047: Geographic and demographic disparities in colorectal cancer: A population-based study.
First Author: Navpreet Kaur Rana, DO

Abstract e19048: Psychological distress, social function and financial burden of cancer patients receiving treatment in an African setting.
First Author: Musliu Adetola Tolani, MBBS, FWACS

Abstract e19049: Esophageal cancer: How far is close enough?
First Author: Leighton Andrew Elliott, MD

Abstract e19050: A qualitative study of barriers and facilitators to enrollment of adolescents and young adults onto cancer clinical trials at NCI community oncology research program (NCORP) sites.
First Author: Elizabeth Siembida, MPH, PhD

Abstract e19051: A comparative study on costs of cancer and access to medicines in Europe.
First Author: Nils Erik Wilking, MD, PhD

Abstract e19052: Relationship of area-level socioeconomic status and nutritional anemias: Analysis of folate, vitamin B12, and iron deficiencies.
First Author: Miguel Gonzalez Velez, MD
Abstract e19053: Differences in clinical characteristics and outcomes between white (W) and non-white (NW) patients with metastatic germ cell tumor (mGCT) treated at Indiana University (IU).
First Author: Manuel Ricardo Espinoza Gutarra, MD

Abstract e19054: The complex comorbidities of uninsured cancer patients.
First Author: Shreni Shah, BS

Abstract e19055: Disparities in advanced stage breast cancer: The socioeconomic and geographic contributions.
First Author: Kelli Clemons

Abstract e19056: Gynecologic oncology, gender and relevant leadership in academic medicine.
First Author: Sarah Madhu Temkin, MD

Abstract e19057: Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.
First Author: Amy J. Davidoff, PhD

Abstract e19058: Impact of age on racial disparity in early stage breast cancer in the United States.
First Author: Shruti Bhandari, MD

Abstract e19059: The comparative effectiveness of biologic agents among non-hispanic black (NHB) patients with metastatic colorectal cancer (mCRC): Preliminary results of a SEER-medicare analysis.
First Author: Sanjay Goel, MD

Abstract e19060: Socioeconomic status, race, and mortality disparities in insured patients in southern California.
First Author: Robert Michael Cooper, MD

Abstract e19061: Racial disparities in obesity and comorbidities among women with early breast cancer.
First Author: Kirsten A. Nyrop, PhD

Abstract e19062: Medical oncologists’ perceptions of clinical trials for underrepresented populations.
First Author: Giselle Katiria Perez, PhD

Abstract e19063: Getting rurality right: Investigating cancer across the rural-urban interface.
First Author: Amy K. Taylor, MD
Abstract e19064: Implementation of a triage system in the *Alerta Rosa* breast cancer navigation program.
First Author: Cynthia Villarreal-Garza, MD, DSc

Abstract e19065: “When offered to participate:” A systematic review and meta-analysis of patient agreement to participate in clinical trials.
First Author: Joseph M. Unger, PhD

Abstract e19066: Access to new therapies: FDA accelerated approvals and the corresponding Canadian regulatory and funding decisions.
First Author: Howard John Lim, MD, PhD

Abstract e19067: Development of a stop light tool using the bellarmine norton assessment tool (BNAT) for physical therapy referral.
First Author: Catherine Elizabeth Crandell, PT, DPT, MDiv,

Abstract e19068: Beyond patient-level barriers: Evaluation of rural residency and area-level deprivation and clinical trial (CT) participation.
First Author: Joseph M. Unger, PhD

Abstract e19069: A single institution study on the demographics and response rates of Hispanic women with HER2+ disease.
First Author: Michelle Cholankeril, MD

Abstract e19070: Explorative analysis of expanded access for intermediate-size and larger patient populations.
First Author: Andriy Krendyukov, MD, MBA

Abstract e19071: Using implementation science to examine impact of a social responsibility agenda on addressing cancer health disparities in ceará, Brazil.
First Author: Hermano Alexandre Lima Rocha, MD, MPH, PhD

First Author: Rebecca N. W. Tsai, MS

Abstract e19073: A knowledge, attitudes and practices survey for medical trainees about cancer in the LGBTQ community.
First Author: Alankrita Taneja, MBBS

Abstract e19074: Breast cancer receptor subtypes in East Africa: A systematic review and meta-analysis.
First Author: Pallvi Popli, MD
Abstract e19075: Cancer clinical trial consent forms: A readability analysis.
First Author: Mohana Roy, MD

Abstract e19076: Investigating potential disparities in clinical trial eligibility, offers and enrollment at an NCI-designated comprehensive cancer center.
First Author: Monica Arun Patel, MD

Abstract e19077: Prostate cancer screening patterns among LGBT populations.
First Author: Sung Jun Ma, MD, MD

Abstract e19078: Forecasting global essential childhood cancer drug need and cost: An innovative model-based approach.
First Author: Avram Denburg, FRCPC, MD, MSc, PhD

Abstract e19079: Social disparities in access to innovation and treatment delivery in early breast cancer (BC) patients (pts) with universal health care coverage.
First Author: Gwenn Menvielle, PhD

Abstract e19080: Effect of rurality and neighborhood disadvantage on clinical trial interest and decision-making style in patients with cancer living in the Deep South.
First Author: Nicole Caston, BS

Abstract e19081: Comparison of advanced care discussions between Chinese-American and Caucasian stage IV cancer patients at a single American cancer center.
First Author: Avery Glover

Abstract e19082: The impact of affordable care act on the treatment disparities for stage-IV colorectal cancer: A contemporary analysis.
First Author: Thejus Thayyil Jayakrishnan, MD

First Author: Kyle S.Y. Miyazaki, MD

Abstract e19084: Distance from a comprehensive cancer center: A poor proxy for serous endometrial cancer outcomes?
First Author: Patrick Blackburn, MD

First Author: Soniya Dulal, MD
Abstract e19086: Effect of race and insurance status on stage at diagnosis and overall survival of triple-negative breast cancer (TNBC): Analysis of the National Cancer Data Base (NCDB).
First Author: Rafiullah Khan, MD

Abstract e19087: Disparities in use of immunotherapy for stage III and IV melanoma patients.
First Author: Richard L. White Jr., MD

Abstract e19088: Factors affecting time to treatment in hepatocellular cancer.
First Author: Karan Seegobin, MBBS

Abstract e19089: Changes in black-white disparity in receipt of guideline concordant treatment for women with early-stage breast tumors.
First Author: Hasan Nadeem, B.S.

Abstract e19090: Addressing rural disparities in cancer care via telehealth.
First Author: Laurence J. Heifetz, MD

Abstract e19091: Dynamic of time estimation and its relation with levels of distress.
First Author: Nikolay Vladimirov Conev

Abstract e19092: Clinicopathologic and molecular genetic comparison of primary uterine serous adenocarcinomas from African American and Caucasian women.
First Author: Aifen Wang

Abstract e19093: Nationwide analysis of healthcare burden and risk of mortality in cancer patients with deep venous thrombosis.
First Author: Sheeba Habeeb Ba Aqeel

Abstract e19094: Application of neo-bioscore to a real-world cohort: Potential implications for patient selection, for escalation, and de-escalation of therapy.
First Author: Christine E. Simmons, MD

Abstract e19095: Rising incidence of clostridium difficile infection and associated clinical outcomes in hospitalized cancer patients: A national perspective.
First Author: Shivani Dalal

Abstract e19096: The impact of therapeutic mediastinal radiation on stent healing in cancer patients: An optical coherence tomography study.
First Author: Jordan Graham, MD

Abstract e19097: Cardiotoxicity and heart failure in patients receiving chemotherapy: A nationwide analysis.
First Author: Arya Mariam Roy, MD
Abstract e19098: Prognostic impact of hepatic involvement on spontaneous tumor lysis syndrome in solid tumors.
First Author: Dhiran Verghese

First Author: Jun Lin, M.D., Ph.D.

Abstract e19100: Retrospective study of the evaluation and management of febrile neutropenia in cancer patients in a tertiary center.
First Author: Megan Emmich, DO

Abstract e19101: Timing of assessments for PRO measures in advanced RCC clinical trials.
First Author: Sundeep Agrawal, MD

Abstract e19102: Temporal trends in inpatient outcomes and resource utilization in patients with tumor lysis syndrome (TLS) with solid and hematologic cancers: A nationwide analysis.
First Author: Krishna Rekha Moturi

Abstract e19103: National estimates of mental health needs among non-elderly adult cancer survivors.
First Author: Xu Ji, PhD, MSPH

Abstract e19104: Outcomes of Pneumocystis jiroveci pneumonia complicating treatment of solid tumors.
First Author: Andrew Peter Dean, MD

Abstract e19105: Patient-reported diarrhea impact on physical functioning and quality of life in clinical trial data submitted to the U.S. Food and Drug Administration.
First Author: Ting-Yu Chen, PhD

Abstract e19106: Partner engagement and patients’ receipt of colorectal cancer surveillance.
First Author: Christine M Veenstra, MD, MS

Abstract e19107: Chronic opioid therapy among a high-risk cancer survivor population.
First Author: Talya Salz, PhD

Abstract e19108: Hundreds of ongoing immunotherapy trials: An assessment for bias.
First Author: Peter Bach, FACS, MD

Abstract e19109: Impact of oligometastatic disease on survival in ER positive breast cancer: A population-based analysis.
First Author: Nathalie LeVasseur, MD, FRCPC
Abstract e19110: Variations in objective knowledge among decision-support persons of patients with early stage breast cancer.
First Author: Victoria A Wytiaz, MD, MA

First Author: Pramit Nadpara, PhD, MS, BPharm

Abstract e19112: Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).
First Author: Surbhi Sidana, MD

Abstract e19113: Marital status and suicide as a competing cause of mortality among cancer survivors.
First Author: Nosayaba Osazuwa-Peters, MPH, PhD

Abstract e19114: Missing data in breast cancer: Relationship with survival in national databases.
First Author: Jennifer Kay Plichta, MD, MS

Abstract e19115: Feasibility of randomized controlled trials (RCTs) for drugs approved by the United States Food and Drug Administration (FDA) based on single arm studies.
First Author: Rebekah Rittberg

Abstract e19116: Mental distress among adolescent and young adult (AYA) and adult cancer survivors.
First Author: Eric Adjei Boakye, PhD

Abstract e19117: Distribution and frequency of patient-reported symptomatic adverse events at a comprehensive cancer center.
First Author: Jessica Cleveland, MS

Abstract e19118: Unplanned hospital admissions are a marker of decreased overall survival in patients with solid tumor malignancies.
First Author: Zachary L. Quinn, MD

Abstract e19119: The use of a chatbot based on artificial intelligence to collect patients reported outcomes in oncology practice. A pilot study with real-world data.
First Author: Munir Murad Junior, MD

First Author: Rohit Gosain, MD
Abstract e19121: Prognostic value of programmed death-ligand 1 in solid tumors: A meta-analysis.
First Author: Jordan L Scott, MD

Abstract e19122: Factors associated with end-of-life (EOL) care for patients with acute myeloid leukemia (AML).
First Author: Dagny Vaughn, BA

Abstract e19123: Impact of bolus versus continuous infusion of doxorubicin (DOX) on cardiotoxicity in patients with breast cancer (BC) and sarcomas: Analysis of real-world data.
First Author: Lee D. Cranmer, MD, PhD

Abstract e19124: Annual lung cancer screening by chest X ray to avoid further examinations.
First Author: Tatsuo Kimura, MD, PhD

Abstract e19125: Tumour burden, inherent organ specific lymphatico-venous communications and intra-organ rhythmic pressure changes influence incidence of metastasis at presentation in solid tumours.
First Author: Rajendra A. Badwe, MD

First Author: Wee-Kheng Soo, MBBS, FRACP

Abstract e19127: Adoption patterns of an electronic patient-reported outcomes tool in oncology.
First Author: Fernanda CG Polubriaginof, MD, PhD

Abstract e19128: Brazilian medical waste program as an intent to reduce costs and air release of carcinogens.
First Author: Fabiane Kellem Oliveira Cesario, MD

Abstract e19129: Usefulness of Charlson comorbidity index (CCI) to predict early mortality and overall survival (OS) in acute myeloid leukemia (AML).
First Author: Prajwal Dhakal, MBBS

Abstract e19130: Blood pressure variability in lung cancer patients receiving chemotherapy.
First Author: Yosef Landman, MD

Abstract e19131: Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).
First Author: Xuehua Ke, PhD
Abstract e19132: Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.
First Author: Fengmin Zhao, PhD

Abstract e19133: Association of gynecologic versus medical oncology specialty with survival, utilization, and spending in women with gynecologic cancers.
First Author: Emily Meichun Ko, MD

Abstract e19134: Quantifying treatment preferences and their association with financial toxicity in women with breast cancer.
First Author: Courtney Williams, MPH

Abstract e19135: Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group.
First Author: Mark S. Walker, PhD

Abstract e19136: Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.
First Author: John Peipert, PhD

Abstract e19137: Factors associated with oral chemotherapy adherence in specialty pharmacies.
First Author: Shanada Monestime, PharmD

Abstract e19138: Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US).
First Author: Xuehua Ke, PhD

Abstract e19139: Would patients benefit from a decision aid for surgical decision making for rectal cancer? A qualitative analysis.
First Author: Jenaya Goldwag, MD

Abstract e19140: Relative dose intensity and pathologic response rates in HIV-infected and HIV-uninfected breast cancer patients who received neoadjuvant chemotherapy.
First Author: Yehoda M. Martei, MD, MSCE

Abstract e19141: EUROQoL-5D as a valid patient-reported outcome measurement (PROM) tool to predict health-related quality of life (HRQoL) and survival in patients with hematological malignancies.
First Author: Raul Cordoba, MD, PhD, MS
Abstract e19142: Emerging trends and utilization of patient-reported outcomes (PROs) in clinical trials of chimeric antigen receptor (CAR) T-cell therapies.
First Author: Anthony John Messina, CCRP, MHSc

Abstract e19143: Real-world outcomes of early breast cancer patients undergoing neoadjuvant chemotherapy in a multidisciplinary setting.
First Author: Teresa Smit, MPharm

Abstract e19144: Use of a dynamic disease progression model to estimate prevalence and prognosis for patients with urothelial carcinoma (UC) in the United States (US).
First Author: Sarah Fleming, MPH

Abstract e19145: NGS testing use and results: A survey of U.S. oncologists.
First Author: Mary Lou Smith, JD, MBA, FASCO

Abstract e19146: Improved outcomes among breast cancer patients with more frequent mammography screening.
First Author: Ying Liu, PhD

Abstract e19147: Evaluation of patient-reported outcomes (PROs) in phase I oncology clinical trials (CTs).
First Author: Ira A Jacobs

Abstract e19148: Utilizing a novel four-drug regimen to reduce the incidence of infusion-related reactions for first-dose rituximab infusions: An institutional review of rituximab infusion-related reactions in lymphoma patients.
First Author: Trace Bartels

Abstract e19149: Transitioning adriamycin ifosfamide mesna (AIM) chemotherapy in sarcoma patients to the outpatient setting: Evaluation of outpatient chemotherapy in an oncology care model setting.
First Author: Cindy Banh

Abstract e19150: Utilization of liquid biopsy in a large community oncology practice.
First Author: Dipen Patel

Abstract e19151: Do Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved systemic oncology therapies demonstrate clinically meaningful improvements in quality of life (QOL)?
First Author: Vanessa Sarah Arciero

Abstract e19152: Implementation of 11 system-wide, disease-specific, multidisciplinary tumor boards connecting 24 hospitals in an integrated health care system.
First Author: Brook Clayton, CTR
Abstract e19153: End-of-life health care utilization (EOLHCU) in patients with thoracic, head and neck cancers with or without phase I study participation at a single institution.
First Author: Dominic Min-Tran, BSc

Abstract e19154: Patient characteristics and outcomes at the University of Kansas Cancer Urgent Care (CUC).
First Author: Rahul Atul Parikh, PhD, MBBS

Abstract e19155: Overcoming difficult conversations: Training medical professionals to discuss mental health with cancer survivors.
First Author: Shelby Roberts, MPH

Abstract e19156: An ethnographic study illuminating the effect of endogenous and exogenous uncertainty on tumor board decision making.
First Author: Barbara Oureilidis-DeVivo

Abstract e19157: Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study.
First Author: John L. Gore, MD, MS

Abstract e19158: Improving timeliness of care for breast, GYN and lung cancer patients with nurse navigators in a safety net hospital.
First Author: Teralyn Carter, MD

Abstract e19159: Impact of travel distance on timeliness of adjuvant chemotherapy in veterans with colorectal cancer.
First Author: Richard Lewis Martin, MD, MPH

Abstract e19160: Assessing oncology patients’ perceptions of treatment goals.
First Author: Phuong Ngo, MD

Abstract e19161: Enhancing the effectiveness of chemotherapy prescribing: A validation study of ChemoPalRx.
First Author: Serene Tareen, MD

Abstract e19162: Identifying appropriate questionnaires for cancer caregivers for a lung cancer longitudinal study: Applicability to the heterogeneous journey of a caregiver.
First Author: Upal K. Basu Roy, PhD, MPH

Abstract e19163: Clinical benefits of a nutrition-focused quality improvement intervention at a safety-net hospital gastrointestinal oncology clinic.
First Author: Nicholas Levonyak, MD
Abstract e19164: Factors associated with inpatient admissions of lung cancer patients: Does type and line of therapy matter?
First Author: Amanda Cass, PharmD

Abstract e19165: Clinical decision support tools (CDST) provide education at the point-of-care to assist provider treatment choices.
First Author: Aimee Ginsburg, PharmD, BCPS

Abstract e19166: Design and implementation of a core tool for quality evaluation of cancer care in 10 oncology institutions in Colombia.
First Author: Luis Eduardo Pino, MD MSc MBA

First Author: Eric Michael Lander, MD

Abstract e19168: Impact of cardiologist monitoring on inpatient hospitalizations in breast cancer patients receiving doxorubicin.
First Author: Karna Sheth

Abstract e19169: Opioid safety among high-risk cancer survivors.
First Author: Talya Salz, PhD

Abstract e19170: A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-reported quality-of-life (HRQoL) results.
First Author: Dina Randazzo, DO, MS

Abstract e19171: Temporal trends in receipt of adjuvant chemotherapy for veterans with colorectal cancer.
First Author: Richard Lewis Martin, MD, MPH

Abstract e19172: Real-world practice patterns and barriers to quality care in acute myeloid leukemia (AML).
First Author: Maen A. Hussein, MD

Abstract e19173: PROMIS-10 scores at six months post-baseline among breast and gynecologic oncology patients participating in a text-based symptom monitoring program with patient navigation.
First Author: Michelle Joy Naughton, PhD

Abstract e19174: Real-world data and patient perspectives on quality care and maintenance therapy (MT) decision-making for recurrent ovarian cancer (ROC).
First Author: Robert L. Coleman, FACOG, FACS, FASCO, MD
Abstract e19175: Development and evaluation of patient reported outcomes-based performance measures during chemotherapy.
First Author: Benjamin Urick, PharmD, PhD

Abstract e19176: Oncology team perception and patient experience discordances in triple-negative breast cancer (TNBC) care.
First Author: Sara A. Hurvitz, MD

Abstract e19177: Extent of implementation of low-dose CT in lung cancer screening.
First Author: Merin Jose, MD

Abstract e19178: Trend in incidence, first course of treatment, and survival in patients with glioblastoma.
First Author: Eunyoung Yang

Abstract e19179: The impact of a precision medicine program on molecular testing rates for advanced non-small cell lung cancer (aNSCLC): Based on community-based provider survey assessment.
First Author: Natasha Clinton, MSN, AOCNP, APRN

First Author: Vicente Guillem, PhD

First Author: Mark A. Socinski, MD

Abstract e19182: Mortality within 30 days of receiving checkpoint inhibitor immunotherapy: an Australian multicenter review.
First Author: James Fletcher, MBBS, BSc

Abstract e19183: Quality of care: Clinical value and cost effectiveness of vitamin B12 deficiency testing using B12 and methylmalonic acid levels.
First Author: Yael Kusne, MD PhD

Abstract e19184: Real-world adoption of PD-L1 testing in metastatic urothelial carcinoma.
First Author: Shilpa Gupta, MD

Abstract e19185: Implementing a genomic oncology program in an integrated health care network with large scale genomic Next Generation Sequencing (NGS) testing of advanced cancers in a community setting.
First Author: Jennifer Marie Suga, MD
Abstract e19186: Bone pain associated with rhG-CSF or PEG-rhG-CSF in oncology patients.
First Author: Zhisong Fan

Abstract e19187: Review of annual compliance of low-dose CT for lung cancer screening among internal medicine resident physicians in a university teaching program.
First Author: Nerea Lopetegui-Lia, M.D.

Abstract e19188: Measuring team effectiveness in healthcare: A comprehensive and practical tool.
First Author: Stephanie Zajac, Industrial/Organizational Psychologist, PhD

Abstract e19189: Oncology nursing training: A blended teaching approach in resource-limited countries.
First Author: Mehrunnissa Taj, MS, AOCNP, APRN

Abstract e19190: Pattern of prescribing after disease progression following upfront docetaxel in metastatic hormone-naïve prostate cancer within the UK: Results from a national study.
First Author: Prantik Das, MBBS, MRCP, FRCR

Abstract e19191: Using an ePRO tool to help meet quality metric reporting standards: Screening for tobacco usage and falls risk.
First Author: Joanne S. Buzaglo, PhD (c)

First Author: Peter Doukas, BS

Abstract e19193: A retrospective evaluation of treatment decision making for thyroid cancer using clinical decision support in Brazil.
First Author: Sergio Juacaba

Abstract e19194: Barriers to caring for survivors of childhood cancer: Primary care providers’ and oncologists’ perspectives.
First Author: Aminat Adewumi

Abstract e19195: Improving care for patients with stage III/IV NSCLC: Learnings for multidisciplinary teams from the ACCC national quality survey.
First Author: Ravi Salgia, MD, PhD

Abstract e19196: The impact of a multidisciplinary approach (MA) in the management of pancreatic disease (PD).
First Author: Brunella Di Stefano, MD
Abstract e19197: Inappropriate colorectal and breast cancer screening in patients with advanced cancer.
First Author: Jonathan Pirruccello

Abstract e19198: Pharmacist assistance for patients on oral oncologic therapy: Impact on adherence and costs.
First Author: Munir Murad Junior, MD

First Author: Sandhya Maradana

Abstract e19200: Developing a performance matrix for multidisciplinary teams.
First Author: Lynleigh Evans, MBA, MBBS, PhD

Abstract e19201: Automated identification of lymphoma involving the bone from PET/CT reports using natural language processing and adaptive learning.
First Author: Anastasia Navitski, BA

Abstract e19202: Retrospective chart review to characterize admission to the ICU in the last 30 days of life and use of systemic anticancer therapy in the last two weeks of life at the Lifespan Cancer Institute.
First Author: Han You, MD

Abstract e19203: What is most important in predicting survival? Quantifying the relative effect of patient factors, stage, hospital, quality metrics, and treatment on survival following GI cancer resection.
First Author: Christopher Thomas Aquina, MD, MPH

Abstract e19204: Evaluation of high-dose methotrexate serum concentration requirement for discharge.
First Author: Amulya Yellala

Abstract e19205: Quantifying quality of informed consent (IC) in patients enrolled in phase I (Ph 1) oncology clinical trials with a validated instrument (QuIC Parts A, B) in a large United Kingdom phase I trials unit.
First Author: Abhijit Pal, MBBS, FRACP

Abstract e19206: Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors.
First Author: Ramy Saleh, MD, MSc
Abstract e19207: Treatment patterns in pancreatic cancer: Differences between expert and community practitioners.
First Author: Ryan P. Topping, PhD

Abstract e19208: Deaths within 30 days of anticancer treatment: Comparison of immunotherapy and chemotherapy at an Australian tertiary cancer center.
First Author: Kay Xu

First Author: Mengyang Di, MD, PhD

First Author: Marisa C. Weiss, MD

Abstract e19211: 4R Program results: what is the impact of 4R care delivery model on patient self-management and which patients benefited?
First Author: Julia Rachel Trosman, PhD, MBA

Abstract e19212: Oral oncolytic education and adherence monitoring in poor, rural and minority patients.
First Author: Tiffany Menhorn

Abstract e19213: Choosing Wisely Africa: 10 low-value or harmful practices that should be avoided in cancer care.
First Author: Fidel Rubagumya, MD

Abstract e19214: Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321.
First Author: Lisa M. Kopp, DO, MPH

Abstract e19215: Colorectal cancer: Improving screening in rural clinic.
First Author: Thuy Thanh Thi Le, DO

Abstract e19216: Improving the referral rate of universal genetic counseling for pancreatic ductal adenocarcinoma (PDAC) at the Cleveland Clinic Taussig Cancer Center: A quality improvement project.
First Author: Kanika G. Nair, MD

Abstract e19217: Clinical trial awareness in oncology patients of diverse ethnic background: A single-institution analysis.
First Author: Gautam Valecha, MBBS
Abstract e19218: Perceptions of process barriers to lung cancer screening at community oncology programs.
First Author: Linda Sutton, MD

Abstract e19219: Evaluation of the inclusion rate in clinical trials of bladder cancer patients evaluated for first time in the oncology department.
First Author: Natalia Vidal, Medical Degree

Abstract e19220: Sociodemographic factors associated with cancer treatment completion among women with breast cancer at Butaro Cancer Center of Excellence (BCCOE) in Rwanda.
First Author: Abirami Natarajan, MD

Abstract e19221: Selection of a set of quality indicators (QIs) for oncological clinical pathway with patient associations and healthcare professionals.
First Author: Mario Di Palma, MD

Abstract e19222: Characteristics of end-of-life (EOL) chemotherapy (CTx) received by patients with advanced cancers and association with EOL emergency department (ED) and intensive care unit (ICU) care.
First Author: Cathy Zhang, MD

Abstract e19223: Implementing a tumor program strengthening initiative in western Sydney.
First Author: Lynleigh Evans, MBA, MBBS, PhD

Abstract e19224: Plant-based diet trends in oncology patients.
First Author: Bradley R Webster

Abstract e19225: Changes in intravenous immunoglobulin (IVIG) usage for hypogammaglobulinemia (HG) after implementation of a stewardship program.
First Author: Benjamin Avi Derman, MD

Abstract e19226: Pegfilgrastim on-body injector: Post-market performance analysis.
First Author: Lucas Maahs, MD

Abstract e19227: Facilitators of inappropriate ovarian cancer screening.
First Author: Courtney Macdonald

Abstract e19228: Will oncologists and patients make trade-offs between efficacy and toxicities in first-line treatment of advanced HER2 negative breast cancer?
First Author: Suvina Amin, BSc, MPH

Abstract e19229: Characterizing patients with breast cancer who seek second opinions at an academic cancer center.
First Author: Sarah Fracci
First Author: Anaeze Offodile II, MD, MPH

Abstract e19231: Contrasting fake news in oncology: The first declaration of good communication.
First Author: Rossana Berardi, MD

First Author: Ran Feng, MD

Abstract e19233: Implementation of the Institute of Medicine treatment plan in oncology practice.
First Author: Shanthi Sivendran, MD

Abstract e19234: Physician perceptions about goals of care of hospitalized patients with malignancies.
First Author: Nino Balanchivadze, MD

Abstract e19235: Elevating the standard of care: Impact of a regimen-level prior authorization tool on provider adherence to clinical guidelines.
First Author: Rogelio Alberto Brito, DO

Abstract e19236: Real-world clinical and economic burden associated with hospitalization in metastatic triple-negative (ER-/PR-/HER2-) breast cancer.
First Author: Amie Tan

Abstract e19237: Real-world treatment patterns and clinical outcomes in U.S. community oncology patients with early triple-negative (ER-/PR-/HER2-) breast cancer.
First Author: Amie Tan

Abstract e19238: The use of antihypertensive medications in cancer patients on chemo immunotherapy: Protection or not?
First Author: Bohdan Baralo, MD

Abstract e19239: Navigating herbal dietary supplements: Oral chemotherapy drug interactions in a community cancer center.
First Author: Heather F. McCarthy, BS, PharmD

Abstract e19240: Number of sentinel lymph nodes (SLN) removed in breast cancer (BC) patients undergoing sentinel lymph node biopsy (SLNB) in the province of Saskatchewan, Canada. Real-world experience.
First Author: Tyrell Wess, MD student
Abstract e19241: Assessing patient satisfaction after comprehensive medication review including oral chemotherapy adherence with an oncology pharmacist at the Southcoast Centers for Cancer Care (SCCC).
First Author: Patrick John Skeffington, PharmD, MHA

Abstract e19242: Similar negative emotional impact on hair loss in neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy in young women with breast cancer from patient reported outcomes.
First Author: Sung-chan Gwark, M.D., Ph.D.

Abstract e19243: Engaging patients on tumor boards: A multi-stakeholder perspective study.
First Author: Kelly M Smith, PhD

First Author: Maen Farha, MD

Abstract e19245: Physician practice variability in the utilization of extended-fraction radiation therapy for bone metastases: Are we choosing wisely?
First Author: Arjun Gupta, MD

Abstract e19246: Physician burnout: An innovative way to find “sanity out of madness” in the infusion center of a cancer institute.
First Author: Sarah Sewardalhahab, MD

Abstract e19247: Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for chemotherapy induced nausea-vomiting (CINV) prevention in patients receiving high-emetogenic chemotherapy (HEC).
First Author: Suthinee Ithimakin, MD

First Author: Carlos Eduardo Salazar-Mejía, MD

First Author: JoAnne Meng, MD

Abstract e19250: The utility of routine endocrinopathy testing in patients treated with ipilimumab for solid malignancies.
First Author: Grant Jester, MD
Abstract e19251: Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data.
First Author: Shivam Mathura

First Author: Hui Zhao, PhD

Abstract e19253: Rare triple-negative breast cancers (TNBC): An NCDB analysis.
First Author: Elizabeth Blessing Elimimian, MD

Abstract e19254: Assess how non-oncology care settings influence the longitudinal journey of cancer patients.
First Author: Daniel Carnegie, MD, MPH, MBA

Abstract e19255: The role of non-oncology specialties in the real world longitudinal journey of prostate cancer patients.
First Author: Daniel Carnegie, MD, MPH, MBA

Abstract e19256: Clinicopathological features and prognosis of rare carcinomas of the breast: A comparative analysis from the NCDB.
First Author: Elizabeth Blessing Elimimian, MD

Abstract e19257: Hepatic failure in malignancy: A nationwide analysis.
First Author: Binav Baral

Abstract e19258: Safety of immunotherapy in Peruvian patients with diverse type of malignancies: Experience at a private center.
First Author: Alfredo Aguilar, MD

Abstract e19259: Real-world data of a cohort of patients with soft tissue sarcoma in a single institution of Colombia.
First Author: Luis Eduardo Pino, MD MSc MBA

First Author: Daniel Lane, PharmD, PhD, MBA

First Author: Marcos Costa
Abstract e19262: Stratification of patients by tumor type using molecular profiling in real-world data.
First Author: Alyssa Antonopoulos

Abstract e19263: Longitudinal health utilities, symptoms and toxicities in anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients: A real world assessment.
First Author: Brandon C Tse

Abstract e19264: Relapse rate and health care resource utilization associated with relapse in Stage IIA-IIIB adjuvant NSCLC patients treated in a U.S. oncology community network.
First Author: Beilei Cai

Abstract e19265: Immune related adverse effects (IRAEs) in patients with cancer who received immune checkpoint inhibitors (ICIs): A single center experience from rural Maine.
First Author: Anannya Patwari, MD

Abstract e19266: Implementation and impact of the first two years of a systemwide molecular tumor board at Henry Ford Health System (HFHS).
First Author: Igor I. Rybkin, MD, PhD

Abstract e19267: The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium.
First Author: Abdulaziz AlJassim AlShareef

Abstract e19268: Clinical outcomes of pancreas cancer patients with peritoneal spread: Results from the chord consortium.
First Author: Mehrnoosh Pauls, MD

Abstract e19269: Assessment of glomerular filtration rate in a cohort of 1,200 cancer patients using serum creatinine-based equations and serum cystatin C.
First Author: Verônica Torres Costa E Silva, MD, PhD

Abstract e19270: Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.
First Author: Donna R Rivera, PharmD., MSc

Abstract e19271: Comprehensive clinicogenomic insights into a uniquely large collection of cholangiocarcinoma patients treated in the real world.
First Author: Victoria M. Raymond, MS

Abstract e19272: Cancer types applicable to efficacy assessment using real-world data analyzed from PMDA-approved data.
First Author: Yuka Kato, MD, PhD
Abstract e19273: Udenyca has equivalent efficacy to the pegfilgrastim originator in breast cancer patients receiving highly myelosuppressive chemotherapy.  
First Author: Jennifer Webster, MS

Abstract e19274: Rates of primary prophylaxis for venous thromboembolism in high-risk patients with pancreatic and gastric cancer: A single tertiary care academic center experience.  
First Author: Karlyn Martin, MD

Abstract e19275: Genomic heterogeneity and associated clinical outcomes of breast cancers treated with CDK4/6 inhibitors: Insights from real-world clinical genomic data.  
First Author: Thereasa A. Rich, CGC, MS

Abstract e19276: Real-world incidence of grade III/IV side effects, emergency room visits, and hospital admissions after treatment with adjuvant durvalumab in locally advanced non-small cell lung cancer.  
First Author: Syed Imran Mustafa Jafri, MBBS

Abstract e19277: Trends in lung cancer mortality between 2001 and 2017: An observational study in USA and EU.  
First Author: Chinmay Jani, MBBS

Abstract e19278: Comorbidities and patient-reported outcomes among individuals with cancer enrolled in a digital health coaching program.  
First Author: Kelly Jean Brassil, MSN, PhD, RN

Abstract e19279: Landscape of targetable alterations discovered by next generation sequencing demonstrates the role a community hospital can play in precision-guided oncology: Experience from Lenox Hill Hospital.  
First Author: Morana Vojnic, MD, MBA

Abstract e19280: Real-world sustained minimal residual disease (MRD) negativity using NGS in multiple myeloma.  
First Author: Audrey Demaree, PharmD

Abstract e19281: Patient-centric real-world clinico-genomic insights from a novel siteless clinical research methodology.  
First Author: Naveen S Kumar

First Author: Nikita Nikita, MBBS, MPH
Abstract e19283: Establishing the common oncology data model for the national biobank consortium of Taiwan.
First Author: Yang Yi-Hsin, PhD

Abstract e19284: Real-world (RW) systemic treatment patterns and clinical outcomes in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) patients (pts).
First Author: Thao Vo, PhD

Abstract e19285: What are the challenges for building real world comparative cohorts in oncology?
First Author: Nikita Jeswani

Abstract e19286: Adherence to intensive nutrition care in head and neck cancer patients undergoing radiotherapy.
First Author: Sheilla de Oliveira Faria, MS

Abstract e19287: Real-world data of a cohort of patients with EGFR mutated metastatic non-small cell lung cancer (NSCLC), follow up of 52 months in Fundación Santa Fe de Bogota.
First Author: Aylen Vanessa Ospina Serrano

Abstract e19288: An analysis of trends in prostate cancer treatment from a CMS database.
First Author: Andre A. Konski, MD, MBA, MA, FACR

Abstract e19289: Do assumptions in health economic evaluations hamper drug uptake?
First Author: Fanny Franchini, BSc, MSc, PhD

Abstract e19290: Clinical management of patients (PTS) with metastatic uveal melanoma (mUM) in a community setting since immune checkpoint inhibitor (ICI) approval: The Kaiser Permanente Northern California (KPNC) experience with a rare cancer.
First Author: Juraj Kavecansky, MD

Abstract e19291: Molecular profiles and treatment recommendations for invasive lobular carcinoma in a real-world prospective breast cancer registry.
First Author: Beth-Ann Lesnikoski, MD

Abstract e19292: Factors contributing to delayed lung cancer diagnosis in an advocacy organization maintained patient registry.
First Author: Andrew Ciupek, PhD

Abstract e19293: Venous thromboembolism (VTE) incidence and risk factors in patients (pts) with non-small cell lung cancer (NSCLC) receiving front-line therapy.
First Author: Jai Narendra Patel, BCOP, PharmD
Abstract e19294: Examination of PD-1/PD-L1 inhibitor use and adverse events in a real-world setting.
First Author: Debra E. Irwin, PhD, MPH

Abstract e19295: Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.
First Author: Christina D Williams, PhD

Abstract e19296: Access to molecular testing and targeted molecular therapy among Mexican patients with lung adenocarcinoma.
First Author: Adriana González-Gutiérrez, MD

Abstract e19297: Development and validation of a novel EHR-based tumor progression outcome to support biomarker discovery.
First Author: Kenneth L. Kehl, MD, MPH

Abstract e19298: Timing of pre-treatment antibiotic exposure and the risk of hospitalization after immune checkpoint inhibitor use among patients with cancer: A population-based study.
First Author: Grace L. Lu-Yao, MPH, PhD

Abstract e19299: Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer.
First Author: Robert S. Epstein, MD, MS

First Author: Robert S. Epstein, MD, MS

Abstract e19301: Real-world treatment attrition rates in advanced esophagogastric cancer.
First Author: Erica S Tsang, FRCPC, MD

Abstract e19302: An analysis of inpatient and ED admissions within 30 days of chemotherapy: An OP-35 review.
First Author: Jay Carlson

Abstract e19303: An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.
First Author: Ramy Saleh, MD, MSc

Abstract e19304: The impact of home hospice care on patients with hematologic disorder in Taiwan population-based cohort study.
First Author: Yuehshih Chang, MD
Abstract e19305: Analysis of bleeding risk with concurrent treatment of VEGFR tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors.
First Author: Tiffany L. George, MD

First Author: Nathan Kuehne

Abstract e19307: Profile of cancer patients admitted in a emergency room of a charity hospital in Southeast Brazil.
First Author: Sabina B. Aleixo, MD

Abstract e19308: Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
First Author: Daniel X. Yang, MD

Abstract e19309: Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.
First Author: Daniel X. Yang, MD

First Author: Philippa Gail Corrie, FRCP, PhD

First Author: Lawrence H. Kushi, DSc

Abstract e19312: Factors associated with emergency department visits and admissions among a diverse population of gynecologic cancer patients receiving chemotherapy.
First Author: Julia Fehniger, MD

Abstract e19313: The master observational trial—a novel method to unify precision oncology data collection.
First Author: Dane J. Dickson, MD

Abstract e19314: Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).
First Author: Yasmin Karimi, MD

Abstract e19315: Real-world evidence: A retrospective-cohort study of castration-resistant advanced prostate cancer (CRAPC) patients treated with abiraterone 1000 mg or 250 mg.
First Author: Leonel Smolje, MD
Abstract e19316: Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.
First Author: Ravi Bharat Parikh, MD

Abstract e19317: Preferences for research participation among individuals with Lynch syndrome: Findings from the HEROIC Registry.
First Author: Robin Beth Dubin, MBA

First Author: Smita Agrawal

Abstract e19319: Real-world evidence of treatment patterns and pharmacy costs among patients with metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States.
First Author: Kelvin A. Moses, MD, PhD

Abstract e19320: Impact of assessment frequency on the prevalence of real-world toxicity data in metastatic breast cancer (mBC).
First Author: Qixing Liang, PhD

First Author: Laurence Albiges, MD, PhD

Abstract e19322: Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): Analysis of real-world data in the United States (US).
First Author: Neeraj Agarwal, MD

Abstract e19323: Study on deep vein thrombosis (DVT) risk factors at the time of cancer diagnosis in patients from the multicenter, prospective Cancer-Venous Thromboembolism (VTE) Registry.
First Author: Yasuo Ohashi, PhD

Abstract e19324: Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.
First Author: Wanyuan Cui, MBBS, FRACP

Abstract e19325: Outpatient cancer rehabilitation to improve patient reported and objective measures of function.
First Author: Mackenzi Pergolotti, PhD
Abstract e19326: Prospective review of SPEP orders confirms need for testing algorithm.
First Author: Sandra Ann Mazzoni, DO, BS

Abstract e19327: MSI/MMR test usage and checkpoint inhibitor practices in Europe.
First Author: Bradley Smith, PhD

Abstract e19328: Treatment workload by stage and subtype in patients with breast cancer: A SEER-Medicare analysis.
First Author: Alex Cheng

Abstract e19329: Real-world frequency of hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia (CLL).
First Author: Ian J. Hooley

Abstract e19330: Real-world data highlights diagnostic and treatment delays in NSCLC and potential racial disparities in access to tyrosine kinase inhibitors (TKI) therapy.
First Author: Zaw Phyo, MS

Abstract e19331: Financial toxicity (FT) real-world data evidence (RWDE) in American patients (pts) receiving cancer immunotherapy drugs (IOT).
First Author: Daniel A. Vorobiof, MD

Abstract e19332: Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): updated real-world (RW) data from US MM-6.
First Author: Saulius Kazmiems Girnius, MD

Abstract e19333: Overall survival (OS) in metastatic melanoma since the introduction of immunotherapy: A National Cancer Database analysis.
First Author: Sunny R K Singh, MBBS

Abstract e19334: Is scalp cooling system effective in chemotherapy induced alopecia? A real-world experience in Asian patients.
First Author: Shruti Kate Sr.

Abstract e19335: Outcomes of patients with left ventricular assist device receiving cancer directed therapies.
First Author: Ilana Schlam, MD

Abstract e19336: Real-world examination of remission patterns in patients (pts) with acute myeloid leukemia (AML).
First Author: Ashley Tabah
Abstract e19337: A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma.
First Author: Robert M. Rifkin, MD, FACP

Abstract e19338: Patterns of care and barriers to utilization of definitive concurrent chemoradiation therapy for stage III non-small cell lung cancer in Russia.
First Author: Natalia Dengina, MD

First Author: Zohra Nooruddin, MBBS

Abstract e19340: Analyzing the outcome of clostridium difficile infection in cancer patients.
First Author: Kamal Kant Sahu, MD, DM Clinical Hematology

Abstract e19341: Real-life implementation of the SCOT trial findings: An interrupted time series analysis.
First Author: Catherine Hanna

Abstract e19342: Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The pancreatic cancer action network (PanCAN) online patient registry experience.
First Author: Arjun Gupta, MD

Abstract e19343: Pembrolizumab (P) as a monotherapy or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 TPS ≥50%: a real-world data.
First Author: Elizabeth Dudnik, MD

Abstract e19344: Regorafinib outcomes from the population-based South Australian mCRC registry (SAmCRCR).
First Author: Timothy Jay Price, MBBS, FRACP, D.H.Sc

Abstract e19345: Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.
First Author: Daniel Simmons, PharmD

Abstract e19346: Time from diagnosis to 1st line immunotherapy (IOT) and its challenges, in a retrospective, multicenter study of Israeli patients (pts) with advanced non-small cell lung cancer (NSCLC).
First Author: Udi Shimony, MA, MBA
Abstract e19347: Characterization of first-line use of cyclin dependent kinase 4/6 (CDK4/6) inhibitors in metastatic breast cancer among Florida health care systems.
First Author: Reshma L. Mahtani, DO

Abstract e19348: Hematologic neoplasms incidence categorised by WHO classification and centralization of treatment facilities in Japan: Analysing a nationwide Hospital-Based Cancer Registry data.
First Author: Ayako Okuyama, PhD

Abstract e19349: Patterns of hedgehog inhibitor (HHI) treatment interruptions and re-initiations among patients with basal cell carcinoma (BCC) in real-world clinical practice.
First Author: Jessica J. Jalbert, PhD

Abstract e19350: Naloxegol for patients with cancer pain diagnosed with opioid induced constipation (OIC): NACASY observational study.
First Author: Andrew Davies

Abstract e19351: Real-world treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR T).
First Author: Jessica J. Jalbert, PhD

Abstract e19352: Bevacizumab for the treatment of brain radionecrosis in cancer patients.
First Author: Luis E. Raez, MD, FACP, FCCP

Abstract e19353: Incidence and prognosis of patients with pulmonary metastases at diagnosis of primary extrapulmonary malignancy: A population-based study.
First Author: Hao Li, MD

Abstract e19354: Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.
First Author: Kerry Anne Rogers, MD

Abstract e19355: Safety and outcomes of immunotherapy re-challenge in lung cancer.
First Author: Xinyu Nan, MD

Abstract e19356: Phyllodes tumor of breast, real-world data from a referral center in Mexico.
First Author: María Inés Contreras-Salcido, M.D.

Abstract e19357: Real-World data (RWD) of physician’s advice on BRCA genetic testing for ovary (OC) and breast cancer (BC) patients (pts).
First Author: Daniel A. Vorobiof, MD
Abstract e19358: Blockchain-authenticated sharing of cancer patient genomic and clinical outcomes data.
First Author: Shohei Burns, BS

Abstract e19359: Preventable patient acute mortality after EMR-generated QTc alerts.
First Author: Benjamin Aaron Bleiberg, BS

Abstract e19360: Examining the relationship between the clinical benefit of oncology drug indications and the time from pan-Canadian Oncology Drug Review (pCODR) recommendation to public reimbursement.
First Author: Sasha Thomson

Abstract e19361: Does targeted therapy dominate in terms of a higher level of effectiveness for a given cost compared to wild-type treatment? An analysis of cost and outcome of metastatic lung cancer patients in Saudi Arabia.
First Author: Omar B. Da'ar, PhD

Abstract e19362: Cost savings of biosimilar pegfilgrastim in a Medicare OCM population.
First Author: Jennifer Webster, MS

Abstract e19363: Pathways impact on OCM drug cost.
First Author: Valerie Pracilio Csik, MPH

First Author: Monali K. Vasekar, MD

Abstract e19365: Incidence and economic burden of infections in cancer patients receiving immune checkpoint inhibitors.
First Author: swarna sri nalluru

Abstract e19366: Estimated treatment-related economic burden of HPV-related oropharyngeal cancers in the United States attributable to the seven high-risk human papillomavirus (HPV) types targeted by the nonavalent HPV vaccine.
First Author: Vimalanand Prabhu, BE, MMGMT, PhD

Abstract e19367: The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
First Author: Kerin B. Adelson, MD

Abstract e19368: Comparison of treatment costs of pembrolizumab versus nivolumab in head and neck squamous cell carcinoma.
First Author: Justin Yeh
Abstract e19369: A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Ambika Parmar, MD

First Author: Bellinda King-Kallimanis, PhD

Abstract e19371: Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer.
First Author: Ali McBride, PharmD, MS

Abstract e19372: Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis.
First Author: Ali McBride, PharmD, MS

First Author: Syed Hussaini, MD, MS

First Author: Jesus Rodriguez-Pascual, MD, PhD

Abstract e19375: Successful transition from bortezomib subcutaneous to generic intravenous bortezomib: Cost savings initiative with global economic impact.
First Author: Bhavesh Shah, RPh

Abstract e19376: Association of hospital type with prices, spending, and acute care utilization among privately insured patients undergoing cancer surgery.
First Author: Samuel U Takvorian, MD, MS

Abstract e19377: Value of systemic therapies in locally advanced nasopharyngeal cancer treated with curative intent in randomized phase III trials.
First Author: Teng Hwee Tan, MBBS

Abstract e19378: The forgotten cost of acute myeloid leukaemia: The productivity impact over ten years.
First Author: Catriona Parker
Abstract e19379: A community oncology practice financial experience in oncology care model pilot (OCM).
First Author: Adil Jamal Akhtar, MD

Abstract e19380: Economic evaluation of the oncotype DX test for hormone receptor positive (HR+) early-stage breast cancer (BC) from the Brazilian societal perspective.
First Author: Andre Mattar, MD, PhD

Abstract e19381: Estimating productivity losses for cancer patients and caregivers of cancer patients.
First Author: Kevin Chiu, PhD

Abstract e19382: Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma.
First Author: Kishan Patel

Abstract e19383: Cost-effectiveness of triplet and doublet therapy in metastatic BRAF-mutated colorectal cancer.
First Author: Kishan Patel

Abstract e19384: The cost-effectiveness of childhood cancer treatment units in Sub-Saharan Africa: A multi-center study across four countries.
First Author: Sumit Gupta, MD, PhD

First Author: Jia Li Low

First Author: Tsuguo Iwatani

First Author: Patrick T Courtney, BA

First Author: Mia A Salans, BA

Abstract e19389: Examining perceptions of financial toxicity among cancer patients: The Financial Toxicity 16 Questionnaire.
First Author: Roberto Bordonaro, MD
Abstract e19390: Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).
First Author: Kamaneh Montazeri, MD

Abstract e19391: Do we consider to apply the value framework of cancer drugs to clinical practice and health insurance coverage in Korea?
First Author: Do Yeun Kim, MD, PhD, MPH

First Author: Divya Ahuja Parikh, MD

Abstract e19393: Early physician spillover responses to the oncology care model.
First Author: Brigham Walker

Abstract e19394: Comparing total cost of care for Medicare FFS patients with pancreatic cancer by chemotherapy regimen.
First Author: Jared Hirsch, BS

Abstract e19395: Healthcare expenditure trajectories among older patients with breast cancer.
First Author: Kelly Kenzik, PhD

Abstract e19396: Establishing the six-month resource utilization and cost-of-care for the treatment of first-line metastatic BRAF (V600) melanoma with combination BRAF and MEK inhibitors.
First Author: Shiraz Halloush

First Author: Eleanor Paul

Abstract e19398: Cost effectiveness analysis of additional NK-1 receptor antagonist to olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin.
First Author: Wasamol Mahaparn, MD

Abstract e19399: Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States.
First Author: Courtney Penn

Abstract e19400: Experience of financial burden and distress among people with ovarian cancer.
First Author: Branlyn W. DeRosa, PhD
Abstract e19401: Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk.
First Author: Edward C. Li, PharmD, MPH

First Author: Jingfeng Jing, MD

Abstract e19403: Predictors of increased episode expenditure and exceeding target price under the oncology care model.
First Author: Seojin Park, PharmD

First Author: Carolina Gabay, MD

Abstract e19405: Factors related to drug pipeline success for oncology companies using stock performance as a surrogate.
First Author: Matthew J. Ferris, MD

First Author: Cole Friedes

Abstract e19407: Reducing time to treatment and patient costs with breast cancer: The impact of patient visits.
First Author: Sarah Sittenfeld, MD

Abstract e19408: Real-world healthcare resource utilization and costs among relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients receiving ibrutinib or chemoimmunotherapy (CIT).
First Author: Nilanjan Ghosh, MD, PhD

Abstract e19409: Pharmaco-economic assessment of subcutaneous compared to intravenous trastuzumab in HER2-positive breast cancer patients: A single institution experience.
First Author: Shereef Ahmed Elsamany, MD

First Author: Ellen Cusano, MD
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Abstract e19500: Role of epigenetic regulators in single-base substitution patterns in AML.
First Author: Madhuri Paul, PhD

Abstract e19501: Bleeding and thrombosis outcomes in patients with acute leukemia.
First Author: Amar Harry Kelkar, MD

Abstract e19502: Superior therapy response predictions for patients with acute myeloid leukemia (AML) using Cellworks Singula: MyCare-009-01.
First Author: Guido Marcucci, MD

Abstract e19503: Hypoalbuminemia as a prognostic biomarker for overall survival in acute myeloid leukemia (AML).
First Author: Kimberley Doucette

Abstract e19504: Fluconazole vs. voriconazole prophylaxis for prevention of invasive fungal infections post haploidentical stem cell transplant.
First Author: Issam Hamadeh, PharmD

Abstract e19505: Measurements of Mcl-1 protein dependencies using dimerization-specific antibodies as predictive biomarkers for BH-3 mimetic class therapies in AML.
First Author: Michael H. Cardone, PhD

Abstract e19506: The incidence of invasive fungal infections in acute myeloid leukemia (AML) patients treated with a hypomethylating agent (HMA).
First Author: Michael Ozga, MD

Abstract e19507: Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN).
First Author: Joanna Q. Huang, PharmD

Abstract e19508: Dermatologic adverse events (dAEs) associated with liposomal daunorubicin and cytarabine in patients with acute myeloid leukemia (AML).
First Author: Joseph R. Stoll, BTL

First Author: Sumeet Panjabi, PhD

Abstract e19510: Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
First Author: Thomas Curley, MD
Abstract e19511: An ultrasensitive amplicon-based sequencing panel for noninvasive molecular testing of hematological malignancies using blood.
First Author: Chae Yin Cher, PhD

Abstract e19512: The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
First Author: Sophie van Beekhuizen, MSc MPhil

Abstract e19513: Treatment outcomes and healthcare resource utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting.
First Author: Roger M. Lyons, MD

Abstract e19514: Clearance of leukemic blasts by flow cytometry versus minimal residual disease as predictors of clinical outcome in elderly patients with acute myeloid leukemia.
First Author: Giovanni Rossi, PhD

Abstract e19515: Genomic profile at diagnosis by targeted high throughput sequencing, and real-world clinical outcomes in patients diagnosed with acute myeloid leukemia at a tertiary care cancer center.
First Author: Vivek Sulekha Radhakrishnan, MD, DM

Abstract e19516: Evaluation of the differences between extramedullary and bone marrow relapse in adult acute lymphoblastic leukemia patients in terms of clinical features and survival outcomes.
First Author: Nilgun Sayinalp, Prof

Abstract e19517: Pharmacokinetics/pharmacodynamics of liposomal cytarabine (VYXEOS) in AML patients: Influence of cytidine deaminase genetic polymorphisms.
First Author: Mélanie Donnette

Abstract e19518: Intestinal microbiota in patients with acute leukemia (AL) and allogeneic hematopoietics stem cell transplantation (allo-HSCT).
First Author: Brenda Lizeth Acosta-Maldonado

First Author: Zafer Gulbas, Prof Dr

Abstract e19520: Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors.
First Author: Jacinth Joseph, MD
Abstract e19521: Outcomes of reduced intensity regimen with fludarabine, melphalan and TBI in allogeneic stem cell transplant recipients.
First Author: Dipenkumar Modi, MD

First Author: Taner Demirer

First Author: Alaa Nabil Elshamy, MBBCh

First Author: Benjamin Puliafito

Abstract e19525: Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center.
First Author: Mahmoud Gaballa, MD

First Author: Aditi Jain

Abstract e19527: Factors other than sheer numbers of blood cells in circulation may be responsible for clinical presentations in chronic myeloid leukaemia.
First Author: Nicolas Anthony Othieno-Abinya, MD

Abstract e19528: Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02.
First Author: Anthony Selwyn Stein, MD

Abstract e19529: Under-use of hypomethylating agents (HMAs) in patients with higher-risk myelodysplastic syndrome (HR-MDS).
First Author: Namita Joshi, PhD, MS

Abstract e19530: Intensive chemotherapy in patients with high grade myelodysplastic syndromes (MDS): A systematic review and meta-analysis.
First Author: Raed Benkhadra

First Author: Yongzhi Feng, master degree candidate
Abstract e19532: Quantifying unmeasured confounding in three epidemiological studies associating myelodysplastic syndromes (MDS) with cardiovascular disease (CVD).
First Author: Abhay Singh, MD, MPH

Abstract e19533: Genomic analysis of myeloproliferative neoplasm (MPN) patients from a single institution in South Korea to reveal novel pathogenic mutations and perturbed pathways.
First Author: Dilhan Weeraratne, PhD

First Author: Gustavo Rivero, MD

Abstract e19535: Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.
First Author: Naveen Pemmaraju, MD

Abstract e19536: A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm.
First Author: Muhit Ozcan, MD

Abstract e19537: Phlebotomy requirements are lower in polycythemia vera patients with low ferritin stores.
First Author: Lindsay Hammons, BS

First Author: Gordon Ruan, MD

Abstract e19539: Real-world disease burden for patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX).
First Author: Aaron Thomas Gerds, MD, MS

Abstract e19540: Correlative study of disease activity in Langerhans cell histiocytosis.
First Author: Jeffrey Garnet Edwards, BA

Abstract e19541: Defining parameters that can guide public cord blood units (CBUs) in Korea.
First Author: Jung Lim Lee, MD

First Author: Amany Keruakous, MD
Abstract e19543: Langerhans cell sarcoma: The Mayo Clinic experience with an extremely rare disease.
First Author: Muhamad Alhaj Moustafa, MD

**Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia**

First Author: Douglas W. Blayney, MD, FASCO

Abstract e20001: Clonal lineage analysis of CLL research samples by IGH chain sequencing to reveal novel CLL subgroups defined by ongoing class-switch recombination and somatic hypermutation.
First Author: Timothy Looney, PhD

Abstract e20002: Leveraging real world data and AIML to inform smart patient care in oncology.
First Author: Li Zhou

Abstract e20003: Retrospective cohort study of real-world treatment patterns and overall survival in patients with chronic lymphocytic leukemia (CLL) diagnosed between 2010 to 2017 in Ontario, Canada.
First Author: Shazia Hassan

Abstract e20004: Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.
First Author: Amy S. Ruppert, PhD

Abstract e20005: Phase IIIb study to evaluate debulking regimens prior to initiating venetoclax therapy in untreated patients with chronic lymphocytic leukemia.
First Author: Jeff P. Sharman, MD

Abstract e20006: Anti-membrane IgM monoclonal antibody, mAb4, as a novel, next generation BTK inhibitor mediating B-cell leukemia and lymphoma cell death.
First Author: Rachel Welt, PhD

Abstract e20007: Safety and activity of the once daily selective Bruton tyrosine kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukemia (CLL) and lymphoma.
First Author: Chan Cheah, MD

Abstract e20008: Biomarker testing and treatment in patients (pts) with chronic lymphocytic leukemia (CLL) before and after the approval of novel agents.
First Author: Danielle M. Brander, MD
Abstract e20009: Voruciclib plus venetoclax show high efficacy for CLL b cells on human stromal cells.
First Author: Connie Lesnick

Abstract e20010: Patient and physician decision-making on the use of novel agents in chronic lymphocytic leukemia (CLL): What drives preferences?
First Author: Hannah Le, PharmD

Abstract e20011: Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.
First Author: Mary Ann Anderson

Abstract e20012: Survival trend of chronic lymphocytic leukemia and prognostic factors in the United States: An analysis of the National Cancer Database.
First Author: Ning Dong, MD, MS

Abstract e20013: M.D. Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma.
First Author: Ranjit Nair, MBBS, MD

Abstract e20014: Long-term toxicity analysis of immune-related adverse events to illustrate treatment tolerability in Hodgkin lymphoma.
First Author: Alexandra Higgins, MD

Abstract e20015: The association between tonsillectomy and Hodgkin’s lymphoma: A systematic review and meta-analysis.
First Author: Anas Albawaliz, MD

First Author: Anas M Saad

Abstract e20017: Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice.
First Author: Serena Zheng

Abstract e20018: Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).
First Author: David J. Sermer, MD

Abstract e20019: The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).
First Author: Susan K. Parsons, MD
Abstract e20020: Brentuximab vedotin with chemotherapy for advanced stage untreated classic Hodgkin’s lymphoma in a real-world setting.
First Author: Raphael Steiner, MD

Abstract e20021: Clinical anti-lymphoma effect of T cells expressing an anti-CD19 chimeric antigen receptor in synthetic biology optimizing system.
First Author: Hong-jiu Dai

First Author: David A. Veron, MD

Abstract e20023: Prognostic value of chromosomal abnormalities in follicular lymphoma (FL).
First Author: Radowan Elnair, MD

Abstract e20024: Survival analysis of CLL/SLL patients with Richter’s transformation to DLBCL: An analysis of the SEER database.
First Author: Radowan Elnair, MD

Abstract e20025: Incidence patterns and survival outcomes in primary small intestine B-cell lymphoma (PSIBCL) and the effect of Rituximab.
First Author: Apoorva Jayarangaiah, MD

Abstract e20026: Post-transplant lymphoproliferative disorder (PTLD) after solid organ transplant (SOT): A multicenter real world analysis (RWA) of 877 patients (pts) treated in the modern era.
First Author: Deepa Jagadeesh, MD, MPH

Abstract e20027: Primary extranodal non-Hodgkin lymphoma: Clinical characteristics and outcome.
First Author: Tara Rajendran

Abstract e20028: Symptomatic delayed seromas vs incidental findings on MR, and likelihood of BIA-ALCL in women with textured implants.
First Author: Paola Ghione, MD

Abstract e20029: Examination of necrosis in tumors treated with AVM0703 compared to chemotherapy.
First Author: Theresa Deisher, PhD

Abstract e20030: Toxicity and tolerability of DA-EPOCH-R for aggressive lymphomas in the elderly: A retrospective cohort study.
First Author: Shanley Banaag, DO
Abstract e20031: Prognostic value of baseline elevated red cell distribution width in DLBCL.
First Author: Akiva Diamond, MD

First Author: Carla Casulo, MD

Abstract e20033: Factors affecting 48-hour methotrexate levels following high-dose methotrexate (HDMTX) in lymphoma.
First Author: Darragh O'Donoghue, MB BCh BAO

Abstract e20034: Clinicopathological characteristics and outcome of plasmablastic lymphoma patients: A single-center retrospective analysis.
First Author: Anna P Dabrowska-Iwanicka, MD, PhD

Abstract e20035: Complications of high-dose methotrexate (HDMTX) in lymphoma patients.
First Author: Darragh O'Donoghue, MB BCh BAO

First Author: Leyla Bojanini Molina, MD

Abstract e20037: Phase Ib study of brentuximab vedotin (BV) with low-dose total skin electron beam (LD-TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS).
First Author: Shiyu Song, MD, PhD

First Author: Selami Kocak Toprak, MD

Abstract e20039: Economic assessment of diagnostic revision in peripheral T-cell lymphoma.
First Author: Julie M. Lisano, PharmD

First Author: Florent Amatore

First Author: Weiping Liu, MD

Abstract e20042: Prognostic value of event-free survival at 24 months for adolescent and adult T-cell lymphoblastic lymphoma.
First Author: Haizhu Chen, MD.
First Author: Nibash Budhathoki, MBBS

Abstract e20044: Primary cutaneous diffuse large B-cell lymphoma, leg-type: The Mayo Clinic experience.
First Author: Muhamad Alhaj Moustafa, MD

Abstract e20045: Use of brentuximab-ICE and romidepsin-ICE in relapsed/refractory peripheral T-cell lymphoma.
First Author: Cesar Giancarlo Gentille Sanchez

Abstract e20046: Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
First Author: Jeremy S. Abramson, MD

Abstract e20047: A closer look at Hispanics with follicular lymphoma in a majority-minority community.
First Author: Michelle Janania Martinez, MD

Abstract e20048: Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma.
First Author: Jennifer Gile, M.D.

Abstract e20049: Factors influencing infusion-related reactions following dosing of reference rituximab (RTX) and PF-05280586, a RTX biosimilar.
First Author: Jocelyn Courville, PhD

Abstract e20050: Effect of tafasitamab (MOR208) and rituximab combination on B-cell lymphoma cell death in vitro.
First Author: Maria Patra

Abstract e20051: Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study.
First Author: Haiyan Yang, MD, PhD

Abstract e20052: Effect of tafasitamab (MOR208) and lenalidomide combination on B-cell lymphoma cell death in vitro.
First Author: Maria Patra

First Author: Matthew Roger LeBlanc, BSN
Abstract e20054: Survival from time of transformation in patients with transformed lymphoma at time of diagnosis.
First Author: Alaina Kelly

Abstract e20055: The value of bendamustine dose and cycles, sIL-2R, and LDH in follicular lymphoma patients treated with bendamustine plus rituximab.
First Author: Tatsuro Jo, PhD

Abstract e20056: Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88\textsuperscript{WT}) Waldenström macroglobulinemia (WM).
First Author: Ramón Garcia-Sanz, MD, PhD

First Author: Natalia Castillo Almeida, MD

Abstract e20058: Presenting international prognostic scoring system affects time to treatment: A retrospective single center review.
First Author: Sierra Sutcliffe

Abstract e20059: Impact of p53 and recurrent somatic mutations detected by next generation sequencing in the outcomes of diffuse large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
First Author: Vania Phuoc, MD

Abstract e20060: Adult lymphoma-associated hemophagocytic lymphohistiocytosis: A clinical case series in a predominantly Hispanic cohort from the University of Miami/Jackson Memorial Hospital.
First Author: Eduardo Edelman Saul

Abstract e20061: Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor in the primary and secondary prevention of chemotherapy-induced neutropenia in patients with lymphoma.
First Author: Meifeng Tu, MD

Abstract e20062: Clinicopathological features and outcome of diffuse large B-cell lymphoma patients treated in a resource-limited setting.
First Author: Sukesh C Nair, MD

First Author: Ajay Gogia, MD, MBBS
Abstract e20064: Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.
First Author: Reem Karmali, MD

Abstract e20065: Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma.
First Author: Krystle Nomie, PhD

Abstract e20066: A retrospective observational study on the efficacy and safety of pegylated recombinant human granulocyte-colony stimulating factor and recombinant human granulocyte-colony stimulating factor in patients with lymphoma.
First Author: Lihong Liu, professor

First Author: Hendrik-Tobias Arkenau, MD, PhD

Abstract e20068: Association between bone involvement on PET/CT and event free survival (EFS) in follicular lymphoma (FL) grade 3b.
First Author: Frederique St-Pierre, MD, CM

Abstract e20069: Bendamustine (B) + methylprednisolone (MP) and peg-filgastrim in indolent lymphoma.
First Author: Walter Quan, MD

Abstract e20070: Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin's lymphoma (RR-NHL).
First Author: Vincent Lin

Abstract e20071: Age-related lymphoma patient experience: Results from the Lymphoma Coalition 2018 Global Patient Survey.
First Author: Raul Cordoba, MD, PhD, MS

Abstract e20072: Serum soluble CD25 and ferritin in distinguishing patients with uncomplicated hematologic malignancies from patients with hematologic malignancies complicated by hemophagocytic lymphohistiocytosis.
First Author: Adi Zoref Lorenz

Abstract e20073: “Miro” Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma.
First Author: Alessandro Pulsoni, MD
Abstract e20074: Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma.
First Author: Aung Tun, MBBS

Abstract e20075: Population pharmacokinetic and exposure-efficacy assessment of tafasitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies.
First Author: Frank Striebel

Abstract e20076: Outcome of germinal center B-cell type compared to non-germinal center/activated B-cell type diffuse large b-cell lymphoma as determined by immunohistochemistry using the Hans algorithm.
First Author: Neha Patil, MD

Abstract e20077: Post-approval outcomes of polatuzumab vedotin in relapsed/refractory aggressive b-cell lymphoma.
First Author: Stephen Douglas Smith, MD

Abstract e20078: Circulating nucleosomes in hematological malignancy.
First Author: Jason Terrell, MD

Abstract e20079: Clinicopathologic features and outcome of extra-nodal diffuse large B-cell lymphoma: An institutional experience from North India.
First Author: Sukesh C Nair, MD

Abstract e20080: Real-world treatment patterns of patients with breast implant-associated anaplastic large cell lymphoma.
First Author: Emily Westheimer, MSc

Abstract e20081: REPOCH compared with RCHOP for the treatment of diffuse large B-cell lymphoma of activated B-cell type.
First Author: Phillip Martinez-Knouse, MD

Abstract e20082: Molecular predictors of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL).
First Author: Jozal Waroich, MD

Abstract e20083: Is ethnicity related to the distribution of lymphomas by subtype in a majority minority Hispanic community?
First Author: Juan Garza, MD

Abstract e20084: Prognosis and outcomes of patients with post-transplant lymphoproliferative disorder: A single center retrospective review.
First Author: William Pearse, MD, MS, BA
Abstract e20085: Epidemiology of HHV-8-negative/idiopathic multicentric Castleman disease in the era of interleukin-6 directed therapy using a large administrative claims dataset. 
First Author: Sudipto Mukherjee, MD, PhD

Abstract e20086: Changes in erythron peripheral component during chemotherapy in patients with malignant lymphomas and parvovirus B19 infection. 
First Author: Nailya K. Guskova

Abstract e20087: T-cell receptor gene rearrangement clonality, flow cytometry status, and associated outcomes in early-stage CTCL. 
First Author: Jennifer Aline Marks, MD

Abstract e20088: Health care utilization and end-of-life (EOL) outcomes in patients receiving CAR T-cell therapy. 
First Author: Patrick Johnson, MD

First Author: Seren Durer

Hematologic Malignancies—Plasma Cell Dyscrasia

Abstract e20500: Poor mobilizers in multiple myeloma patients undergoing autologous stem cell transplantation: Use of a Risk-adapted strategy. 
First Author: Surya Prakash Vadlamani

Abstract e20501: Decline in cause-specific late mortality among multiple myeloma (MM) patients treated with autologous peripheral blood stem cell transplantation (aPBSCT): A BMTSS report. 
First Author: Smith Giri, MBBS, MHS

Abstract e20502: A pro-oxidant combination of resveratrol and copper to reduce post-transplant toxicity in patients with multiple myeloma receiving high-dose melphalan: Results of an exploratory study (RESCU 001). 
First Author: Anshul Agarwal, MBBS, MD, DM

Abstract e20503: Updates on safety and efficacy of maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma: A systematic review. 
First Author: Ahsan Wahab, MBBS

Abstract e20504: Disparities in utilization of autologous stem cell transplantation as consolidative therapy for multiple myeloma: A single-institution retrospective review. 
First Author: Oleksandra Lupak, MD
Abstract e20505: Impact of immunoparesis on clinical outcomes following bone marrow transplantation.
First Author: Nicholas Torgerson, DO

Abstract e20506: Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.
First Author: Abdullah S. Al Saleh, FRCPC, MD

Abstract e20507: Predictors of response to upfront bortezomib, lenalidomide and dexamethasone (VRd) in multiple myeloma.
First Author: Amany Keruakous, MD

Abstract e20508: Outcomes of daratumumab, pomalidomide, and dexamethasone (DPd) followed by high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) in patients with relapsed/refractory myeloma RRMM.
First Author: Al-Ola A. Abdallah, MD

Abstract e20509: Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
First Author: Christopher Lemieux, MD

Abstract e20510: Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.
First Author: Bharat Nayar Nandakumar, MBBS

Abstract e20511: ISS stage and network risk score to predict benefits of multiple myeloma treatment options.
First Author: Yu Liu, Ph. D

First Author: Nisha Joseph, MD

Abstract e20513: Outcomes of sepsis in patients with multiple myeloma.
First Author: Krishna Rekha Moturi

Abstract e20514: Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone.
First Author: Claudio Cerchione, MD, PhD

Abstract e20515: Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.
First Author: Alissa Visram, MD
Abstract e20516: First-line CyborD treatment for graft ineligible multiple myeloma patients: Real-life efficacy and tolerability.
First Author: Dominic Duquette, B. Pharm., M. Sc.

Abstract e20517: Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era.
First Author: Claudio Cerchione, MD, PhD

Abstract e20518: The effect that β-lactam antibiotics have on progression free and overall survival in multiple myeloma patients undergoing autologous stem cell transplantation.
First Author: Marshall McKenna, MD

Abstract e20519: Triplet versus doublet therapy in multiple myeloma patients over 75 years.
First Author: Zuhair Alam, MD

Abstract e20520: Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.
First Author: Nadine Abdallah, MD

Abstract e20521: Exploring the validity of a synthetic control arm (SCA) for augmentation or replacement of a randomized control in difficult-to-study indications: A case study in relapsed or refractory multiple myeloma (R/R MM).
First Author: Ruthie Davi, PhD

Abstract e20522: Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.
First Author: Sundar Jagannath, MD, FASCO

Abstract e20523: Error propagation in simulated treatment comparisons for multiple myeloma: Results from a simulation.
First Author: Eric Mackay, MA, MSc

Abstract e20524: Real-world outcomes of venetoclax refractory multiple myeloma patients.
First Author: Kathryn T. Maples, PharmD

Abstract e20525: Assessing the relationship in relapsed-refractory multiple myeloma between response, progression, and survival between pooled clinical trial subjects and a real-world electronic medical record data source.
First Author: Mark Layton Watson, MD, PhD

Abstract e20526: Lebanese experience in treating multiple myeloma: A multicenter retrospective study.
First Author: Fadi Nasr, MD
First Author: Rakesh Popat, MD

Abstract e20528: Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM).
First Author: Brandon R. Shank, Pharm.D.

Abstract e20529: Daratumumab (DARA) + lenalidomide/bortezomib/dexamethasone (RVd) in African American/black patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Subgroup analysis of Griffin.
First Author: Ajay K. Nooka, MBBS

First Author: Jessica M. Stempel, MD

First Author: Laurie Eliason, MPH

Abstract e20532: The impact of first-line therapy with novel agents in multiple myeloma patients age 80 and above: A systematic review.
First Author: Sadaf Rahman, MD, BHSc

Abstract e20533: Maintenance dosing of denosumab in multiple myeloma: A real-world experience at a large academic cancer center.
First Author: E. Bridget Kim, PharmD

Abstract e20534: Daratumumab-induced lymphopenia predicts adverse events and outcomes in patients with Myeloma.
First Author: Francesca Cottini, MD

Abstract e20535: Advances in precision therapy with venetoclax in multiple myeloma with t(11;14) and high BCL2 expression: A systematic review.
First Author: Zahoor Ahmed, MD

Abstract e20536: Real-world stem cell mobilization (PBSC) patterns in MM pts receiving autologous transplant (ASCT).
First Author: Parameswaran Hari, MD
Abstract e20537: Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma.
First Author: Dharminder Chauhan, PhD

Abstract e20538: BrUOG 299: Ixazomib (Ixa), oral metronomic cyclophosphamide (Cy), and dexamethasone (Dex) for newly diagnosed multiple myeloma (NDMM): A phase II Brown University Oncology Group study.
First Author: Peter Barth, MD

Abstract e20539: Medical resource utilization among multiple myeloma (MM) patients who were triple-exposed to a proteasome inhibitor, an immunomodulatory agent, and daratumumab.
First Author: Maneesha Mehra, MPH

Abstract e20540: Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.
First Author: Maneesha Mehra, MPH

Abstract e20541: The pharmacokinetics and pharmacodynamics of the CD38 antibody TAK-079 after subcutaneous administration to relapsed/refractory myeloma patients.
First Author: Eric Fedyk, B.S. M.S. Ph.D.

Abstract e20542: Intestinal microbiome diversity and clinical outcomes with multiple myeloma: A systematic review.
First Author: Aqsa Ashraf, MD

Abstract e20543: Treatment patterns in multiple myeloma: Real-world experience of the triple-class exposed (TCE) patient.
First Author: Nina Shah, MD

Abstract e20544: Adverse event and outcome patterns in patients with advanced multiple myeloma in the United States.
First Author: Joshua Ryan Richter, MD

Abstract e20545: Health-related quality of life improvement in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone (D-Vd): Results from the phase III CASTOR trial.
First Author: Vania Hungria, MD, PhD

Abstract e20546: Preclinical evaluation of TQB3602, a small molecule proteasome inhibitor clinical candidate.
First Author: Xiquan Zhang
Abstract e20547: Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients.
First Author: Swetha Kambhampati, MD

First Author: Umar Zahid, MD, MPH

Abstract e20549: Daratumumab-based three drug regimens for high-risk multiple myeloma: A meta-analysis.
First Author: Arafat Ali Farooqui, MD

Abstract e20550: Efficacy and tolerability of elotuzumab-based three-drug regimens for high-risk multiple myeloma: A meta-analysis.
First Author: Arafat Ali Farooqui, MD

Abstract e20551: Clinicopathologic profile of extramedullary plasmacytoma in Central Valley.
First Author: Salimah Valliani

Abstract e20552: Retrospective review of chronic pain causes and management in multiple myeloma patients.
First Author: Ami Atulkumar Dave, MD

Abstract e20553: Mortality of multiple myeloma diagnosed peri-hospitalization.
First Author: Sam Rubinstein, MD

Abstract e20554: Heparanase in myeloma related renal dysfunction: Role in promoting nephrotoxicity and potential as a novel biomarker for early detection.
First Author: Sunil Rangarajan, MD

Abstract e20555: Health-related quality of life in patients with relapsed or refractory multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) in the phase III POLLUX trial.
First Author: Torben Plesner, MD

First Author: Tamer Othman, MD

Abstract e20557: Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
First Author: Eric Leon Tam, MD
Abstract e20558: Exploring multiple myeloma survivor interest in lifestyle interventions.
First Author: Allen Hodge

Abstract e20559: The novel CELMoD agent CC-92480: Translation of preclinical data to a phase I clinical trial design.
First Author: Lilly Wong

Abstract e20560: Incidence of adverse events in patients with multiple myeloma (MM) who continued with denosumab after receiving denosumab or zoledronic acid: An open-label extension study.
First Author: Noopur S. Raje, MD

Abstract e20561: Effect of daratumumab based four drug combinations on surrogate endpoints and high-risk features in newly diagnosed multiple myeloma: A systematic review.
First Author: Mohammad Ammad Ud Din, MD

Abstract e20562: Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.
First Author: Fredrik Schjesvold, MD

Abstract e20563: Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.
First Author: David Samuel DiCapua Siegel, MD, PhD

Abstract e20564: Carfilzomib, dexamethasone, and daratumumab (KdD) versus Kd in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase III CANDOR study by number of prior lines of therapy (pLOTs) and prior therapies (Tx).
First Author: Hang Quach, MD

Abstract e20565: HealthTree Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing.
First Author: Nathan W. Sweeney, PhD

Abstract e20566: Comparative efficacy and tolerability of continuous lenalidomide (LLD), which emulates transdermal delivery, compared to once-daily LLD in a xenograft model of multiple myeloma (MM).
First Author: Jamie C. Oliver, PharmD

Abstract e20567: HealthTree Patient Portal mediated myeloma patient-reported vaccination and antibiotic use.
First Author: Michael A. Thompson, MD, PhD, FASCO
Abstract e20568: Impact of doxycycline on outcomes in AL amyloidosis.
First Author: Brandon Jamaal Blue, MD

Abstract e20569: Front-line daratumumab in newly diagnosed AL amyloidosis patients.
First Author: Vanessa Elaine Kennedy

Abstract e20570: HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).
First Author: Maria-Victoria Mateos, MD

**Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

Abstract e21000: Use of treatment pathways reduce cost and increase entry into clinical trials in patients (pts) with non-small cell lung cancer (NSCLC).
First Author: James L. Weese, MD, MD

Abstract e21001: Comprehensive immune cell analysis from lung cancer patients with PD-1 inhibitor neoadjuvant immunotherapy using single cell sequencing.
First Author: Zhenzhen Hui

Abstract e21002: Contribution of DNA damage repair gene mutations and concomitant TP53 variations to the efficacy of platinum-based chemotherapy as initial therapeutic option in Chinese NSCLC patients.
First Author: Ke Ma, M.D

Abstract e21003: The association of CD8+ T-cell infiltration and PD-L1 expression with prognosis of Chinese pulmonary large cell neuroendocrine carcinoma.
First Author: Ye Li

First Author: Shuai Zhu

Abstract e21005: Post-PACIFIC trial era: Patterns of outcomes and toxicities from a single private institution in a developing country.
First Author: Daniel Przybysz, MD

Abstract e21006: The mutation frequency of HPD related genes in different lung cancer stages.
First Author: Yanhui Wan

Abstract e21007: Management of bronchopulmonary carcinoid: NCDB database analysis.
First Author: Mojun Zhu, MD
First Author: Yuan Zeng

Abstract e21009: The role of adjuvant chemotherapy in the management of surgically resected primary pulmonary salivary gland-type carcinomas. 
First Author: Moustafa Younis, MD

Abstract e21010: Stereotactic body radiation therapy (SBRT) in a developing country: Patterns of failure and response rates. 
First Author: Daniel Przybysz, MD

Abstract e21011: Dynamic changes of lymphocyte subsets during multimodal treatment of patients with inoperable stage III NSCLC. 
First Author: Thomas Philipp Hofer

Abstract e21012: Comprehensive analysis of T-cell receptor sequencing in resectable squamous cell lung cancer patients with neoadjuvant therapy of PD-1 inhibitor and chemotherapy. 
First Author: Yuan Feng, M.D., Ph.D

Abstract e21013: Cancer-IgG upregulation of radioresistance in non-small cell lung cancer patients and cell lines. 
First Author: Guangying Zhu, PhD MD

Abstract e21014: The mutation profile of genes related to primary resistance to EGFR-TKI in early NSCLC. 
First Author: Jiangang Ye

Abstract e21015: Interferon gamma resistance in setting of LKB1 loss: Phenotypic characterization and investigation of mechanism. 
First Author: Jacob Kaufman, MD, PhD

First Author: Nimisha Schneider, BS

Abstract e21017: Low TWEAK expression indicates poor survival and is correlated with sparse TILCs in lung adenocarcinoma (LUAD). 
First Author: Jinchun Wu

Abstract e21018: Efficient and scalable profiling of an average of 1,779 plasma proteins in 268 subjects with multi-nanoparticle (NP) proteograph platform enables robust detection of early-stage non-small cell lung cancer (NSCLC) and classification versus healthy and comorbid
Abstract e21019: Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders.
First Author: Katy Beckermann, MD, PhD

Abstract e21020: Peripheral blood leukocytes-related early diagnosis for lung cancer.
First Author: Qi Mei

Abstract e21021: Correlation of gene expression profile to identify tumors with extreme sensitivity to the alkylating agent LP184.
First Author: Umesh Kathad

Abstract e21022: Expression level of ACE2 in lung adenocarcinoma.
First Author: Danni Liu

First Author: Yuan Qiu

Abstract e21024: Clinical and patho-genomic characteristics of concomitant mutated status of TP53, EGFR, KRAS genes in Chinese patients with resected lung adenocarcinoma.
First Author: Qiu Yuan

Abstract e21025: Characterization of the tumor microenvironment landscape and deep learning-guided prediction of prognosis in lung adenocarcinoma with bulk RNA sequencing data.
First Author: Philippe Gui, Ph.D.

First Author: Susan Raju Paul, PhD

Abstract e21027: The validity of 5-aminorevrinic acid as a biomarker for risk screening and supportive diagnostic parameters in lung cancer patients.
First Author: Yoshikane Yamauchi, MD, PhD

Abstract e21028: A rare family case study of multiple siblings with multiple synchronous primary lung cancers.
First Author: Rui Lin, Ph.D.
Abstract e21029: PD-1 or PD-L1 co-localizes with immune cells for prediction of prognosis in non-small cell lung cancer.  
First Author: Chengzhi Zhou

First Author: Meiying Guo

Abstract e21031: Genetic profiling and TCR repertoire feature of synchronous multiple primary lung carcinomas.  
First Author: Huaxia Yang

Abstract e21032: The effect of different dose and sites of irradiation on lymphocyte subsets in peripheral blood of patients with lung cancer.  
First Author: Xiaotong Duan

Abstract e21033: MCM4 as a prognostic biomarker of early-stage lung cancer.  
First Author: Virote Sriuranpong, MD, PhD

Abstract e21034: Breathomics eNose technology as a noninvasive, inexpensive, point-of-care predictive test to detect early-stage lung cancer in never or former light smokers.  
First Author: Sabine Schmid

Abstract e21035: The impact of estrogen receptor status on EGFR/TP53/CTNNB1 axis in the evolution of non-small cell lung cancer.  
First Author: Yoko Tani, MD

Abstract e21036: Characterizing the molecular and immunological features of lung micropapillary adenocarcinoma.  
First Author: Shirong Zhang

Abstract e21037: Analysis of exhaled breath of lung cancer patients using infrared spectroscopy.  
First Author: Tony J. Reiman, MD

Abstract e21038: Prognostic value of the TGFβ1 rs4803455 single nucleotide polymorphism and its association with prophylactic cranial irradiation in small cell lung cancer.  
First Author: Pablo Ayala de Miguel

Abstract e21039: Association of higher EGFR mutation in the primary lesions with lymph node metastasis in early lung adenocarcinoma.  
First Author: Yi Zhang, MD
Abstract e21040: Liquid chromatography coupled to multiple reaction monitoring (LC-MRM) for quantification of PD-L1 and PD1-signaling proteins in non-small cell lung carcinoma (NSCLC).
First Author: Vincent Lacasse, MSc

First Author: JUN WANG

Abstract e21042: Changes of plasma GARP-LTGFβ1 complex during chemoradiotherapy may predict survival in non-small cell lung cancer (NSCLC).
First Author: Yishan Yu

Abstract e21043: Association between homologous recombination deficiency and tumor mutational burden in lung cancer.
First Author: Yong Jiang, MD

Abstract e21044: Development and validation of a CT-based radiomic model combined with margin-related radiomic features to distinguish precancerous lesions from early-stage lung adenocarcinoma.
First Author: Luyu Huang, MD

Abstract e21045: 18F-ALF-NOTA-PRGD2 Ⅱ PET/CT may predict survival in patients with stage Ib to IV non-small cell lung cancer.
First Author: Yuchun Wei, MD

Abstract e21046: Immune-related adverse events with durvalumab consolidation in a real-world cohort of patients with non–small cell lung cancer (NSCLC).
First Author: Gabriela Liliana Bravo Montenegro, MD

Abstract e21047: Phase II prospective trial of primary lung tumor stereotactic body radiation therapy (SBRT) followed by concurrent mediastinal chemoradiation and adjuvant immunotherapy for locally-advanced non-small cell lung cancer (NSCLC): Planned toxicity analysis.
First Author: John H Heinzerling

Abstract e21048: Epidemiology, treatment, and outcomes in locally advanced spindle cell lung cancer.
First Author: Michelle Sterpi, MD

First Author: Weiwei Li
First Author: Min Hu, MD

Abstract e21051: Deciphering molecular characters of multiple lung lesion using comprehensive genomic profiling and its association of histology.
First Author: Changbin Zhu, M.D Ph.D

Abstract e21052: Salvage radiotherapy after chemotherapy for unresectable locally advanced non-small cell lung cancer in real world.
First Author: Qinghua Xu, MD

Abstract e21053: Early-stage KRAS G12C-mutated non-small cell lung cancer (NSCLC) in Australia.
First Author: Paul Mitchell, MD, FRACP, MBBS

Abstract e21054: The association between IDO activity and clinical prognosis in patients with early stage non-small cell lung cancer after stereotactic body radiotherapy.
First Author: Yaoyao Zhu

Abstract e21055: Epigenetic imprinted gene biomarkers significantly improve the accuracy of presurgical bronchoscopy diagnosis of lung cancer.
First Author: Jian Zhou

Abstract e21056: The genomic landscape of immune-related genes and its correlations with TMB and PD-L1 expression in Chinese NSCLC.
First Author: Linxin Zheng

Abstract e21057: Variant allele frequency of circulating tumor DNA mutations detected in preoperative blood is indicator for lymph node metastasis in early stage lung cancer.
First Author: Rusi Zhang, M.D.

Abstract e21058: Locoregional control, failure patterns and clinical outcomes in patients with stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
First Author: Michael Offin, MD

Abstract e21059: Multidimensional development and translational validation of models to predict probability of cancer in multiple pulmonary nodules: A multi-centric cohort study (3M-Study).
First Author: Kezhong Chen, MD

Abstract e21060: The variance of lymphatic vascular invasion (LVI) diagnosis and its impact on overall survival(OS) independent of node stage in patients undergoing surgical resection on
NSCLC.
First Author: Christine Hebert

First Author: Xiao Wu

Abstract e21062: Sublobar resection versus lobectomy for early-stage pulmonary carcinoid tumors with three centimeters or less in size: A population-based study.
First Author: Xiongfei Li, MD

First Author: Takahiro Mimae, MD, PhD

Abstract e21064: A nomogram for predicting overall survival in resected non-small cell lung cancer with chemotherapy.
First Author: Yuan Zeng

Abstract e21065: Radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC): A prospective, observational study.
First Author: Janna Berg, MD

Abstract e21066: Multiple immune features based signature for predicting recurrence and survival of inoperable la-NSCLC patients.
First Author: Meiying Guo

Abstract e21067: Targeted sequencing analysis of predominant histological subtypes in resected stage I invasive lung adenocarcinoma.
First Author: Chong Li

Abstract e21068: An exploratory study of PD-1 inhibitor for high-risk multiple ground-glass nodules (mGGNs) in synchronous stage I non-small cell lung cancer patients.
First Author: Lin Xu, MD and PhD

Abstract e21069: Recurrence patterns following curative therapy for stage I NSCLC.
First Author: Emily Butts, MD

Abstract e21070: PD-L1 expression and progression risk of stage III NSCLC patients on durvalumab consolidation.
First Author: Khalid Jazieh, MD
Abstract e21071: Impact of clinical and pathological variables on stage I non-small cell lung cancer outcomes.
First Author: Matthew C Lee, MD

Abstract e21072: Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC.
First Author: Shelley Kuang, MD

Abstract e21073: Trends in management of locally advanced large cell neuroendocrine carcinoma of the lung.
First Author: Vladimir Limonnik, DO

Abstract e21074: Comparison between T1 with lymph node metastases and T3-4 without lymph node metastases in patients with non-small cell lung cancer.
First Author: Naixin Liang

Abstract e21075: The role of surgery for clinical and pathological N2 lung cancer with interstitial pneumonia.
First Author: Kazunori Hata, MD, PhD

Abstract e21076: Predictive value of the Lung Immune Prognostic Index (LIPI) in locally advanced non-small-cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) in the multicenter retrospective study.
First Author: Yuko Oya, MD

Abstract e21077: Phase I study of weekly carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small-cell lung cancer.
First Author: Shota Omori, MD

Abstract e21078: Phase II trial of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non-small cell lung cancer.
First Author: Hisashi Tanaka, PhD

First Author: David Qian

Abstract e21080: Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.
First Author: Andrea S. Fung, PhD, MD
Abstract e21081: Stereotactic body radiotherapy and systemic dose chemotherapy for locally advanced lung cancer, single-arm phase II study.
First Author: Greg Kubicek

Abstract e21082: Management of medical inoperable and tyrosine kinase inhibitor-naive early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: A retrospective multi-institutional analysis.
First Author: Yue Mei Sun, MD

Abstract e21083: Study of immune regulatory receptor expression upon combination of chemotherapy and immune checkpoint blockade in a murine lung cancer model.
First Author: James C. M. Ho

Abstract e21084: Prediction of lymph node metastasis using 5-point visual scale criteria of [18F]-fluoro-2-deoxy-D-glucose on positron emission tomography / computed tomography for early stage lung adenocarcinoma.
First Author: Atsushi Kagimoto, MD

Abstract e21085: Developing post-treatment PET/CT volumetric prognostic index for non-small cell lung cancer.
First Author: Liu Liu, MD and Ph.D.

First Author: Liping Wang

Abstract e21087: Propensity score matching analysis of patients with inoperable stage III NSCLC treated with chemoradio- vs. chemoradioimmunotherapy.
First Author: Farkhad Manapov, MD

Abstract e21088: Clinical characteristics and outcomes of simultaneous multiple primary lung cancer.
First Author: Ying Liu

Abstract e21089: Mutational distinction between adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma in lung cancer patients with multiple tumors.
First Author: Jixian Liu, MD

Abstract e21090: Comprehensive investigation of mutational features of various lung adenocarcinoma histological subtypes among Chinese patients.
First Author: Yuchen Han
First Author: Hiroki Izumi, MD, PhD

Abstract e21092: Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).
First Author: Marie-Pier Gauthier

Abstract e21093: A single-center retrospective cohort study evaluating the role of neoadjuvant chemotherapy in malignant peritoneal mesothelioma.
First Author: Xiao Wang, MD

Abstract e21094: Real-world outcomes of pembrolizumab in peritoneal mesothelioma.
First Author: Melina Elpi Marmarelis, MD

Abstract e21095: Phase II study of amrubicin for previously treated patients with malignant pleural mesothelioma.
First Author: Kazumasa Akagi

Abstract e21096: Real-world data in limited-disease small-cell lung cancer: Results from a retrospective nationwide population-based cohort study in Korean HIRA database.
First Author: Seoree KIM

Abstract e21097: Marvelous objective response of low dose radiotherapy plus ICIs for extended stage small cell lung cancer.
First Author: Lin Zhou, PhD

Abstract e21098: Identifying genomic alterations in small cell lung cancer using the liquid biopsy of bronchial washing fluid.
First Author: Jinfang Zhai

Abstract e21099: Genetic landscape and PD-L1 expression of Chinese patients with small cell lung cancer.
First Author: Meifang Chen

Abstract e21100: Clinical utility of ctDNA and CTCs to portary genomic profiles and monitor chemotherapy response in patients with small cell lung cancer.
First Author: Yu Feng

First Author: David J. Stewart, MD
Abstract e21102: Weekly chemotherapy instead of best supportive care alone must be considered for patients of small cell lung cancer with poor performance status.
First Author: Gunjan Shrivastav, MD

Abstract e21103: Intratumoral heterogeneity and tumor evolution of small cell lung cancer through multi-regional sequencing.
First Author: Yaxiong Zhang, MD

Abstract e21104: First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
First Author: Jian Shi

Abstract e21105: Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202).
First Author: Ying Liu, PhD

Abstract e21106: Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202).
First Author: Ying Cheng, MD

Abstract e21107: Is there a role for hypofractionated thoracic radiotherapy in limited-stage small cell lung cancer? a propensity score matched analysis.
First Author: Sondos Zayed, MDCM

Abstract e21108: Prognostic value of SOX2 and CD8+TIL in limited stage small cell lung cancer.
First Author: Jinsoo Lee

Abstract e21109: The role of surgery in stage I small-cell lung cancer: A national VA database analysis.
First Author: Ibrahim Azar, MD

Abstract e21110: Atezolizumab and platinum-based chemotherapy in extensive-stage small cell lung cancer: A single center experience.
First Author: MARKO JAKOPOVIC

Abstract e21111: Genomic characterization of circulating tumor DNA from Chinese advanced small-cell lung cancer to reveal potential therapeutic opportunities.
First Author: Jing Yang, Ph.D

Abstract e21112: Immunomodulatory role of multi-agent therapy in thymic epithelial tumors and severe immunological dysregulation.
First Author: Giovannella Palmieri, MD
Abstract e21113: Clinical implications of distinct immunoprofiles in patients with thymic epithelial tumors and autoimmunity.
First Author: Margaret Ottaviano, MD

Abstract e21114: Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.
First Author: Fabio Conforti, MD

Abstract e21115: Nivolumab for thymic epithelial tumors: Case series.
First Author: Adnan Aydiner, MD

Abstract e21116: Reconstruction of the superior vena cava in patients with thymic malignancies.
First Author: Lei Yu

Abstract e21117: Investigation of immune repertoires in thymoma.
First Author: Priyadarshini Pathak, MD

Lung Cancer—Non-Small Cell Metastatic

First Author: Chebli Mrad, MD

Abstract e21501: Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.
First Author: Xinghao Ai

Abstract e21502: Real-world data on liquid biopsies utilization in lung cancer patients in the community setting: The Mount Sinai experience.
First Author: Kathrin Dvir, MD, MSc

Abstract e21503: Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer.
First Author: Jeremy Fricke, BS

Abstract e21504: Effect of personalized approach to therapy in non-small cell lung cancer (NSCLC) with liver metastasis with immunotherapy on outcomes.
First Author: Kristine Badin, MD

Abstract e21505: Monitoring immunotherapy response in non-small cell lung cancer patients using 5-hydroxymethylcytosine signatures in circulating cell free DNA.
First Author: Gulfem Guler, PhD
First Author: Saleha Rizwan, MD

First Author: Foteinos-Ioannis D. Dimitrakopoulos, MD, PhD

Abstract e21508: Could soluble levels of CD40L and galectin-9 be possible prognostic biomarkers and therapeutic targets in NSCLC?
First Author: Guilherme Jorge Costa Sr., Doctorate

Abstract e21509: Survival differences between smokers and nonsmokers with EGFR mutated non-small cell lung cancer.
First Author: David Macari, MD

Abstract e21510: Prospective study for usefulness of circulating-free DNA on prediction of third generation EGFR tyrosine kinase inhibitors.
First Author: Hironori Yoshida, MD

Abstract e21511: Molecular characterization of patients with advanced lung adenocarcinoma at diagnosis with next generation sequencing by liquid biopsy in the Mexican population.
First Author: José Fabián Martínez-Herrera, MD

Abstract e21512: Neoantigen screening identifies EGFR L858R mutation immunogenicity in 1862 Chinese NSCLC patients.
First Author: Jin Lin

Abstract e21513: Analysis of canonical and noncanonical splicing site mutation of MET that causes exon 14 skipping.
First Author: Yongfeng Yu

Abstract e21514: Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers.
First Author: Kristin Ayers, PhD

Abstract e21515: Clinical and molecular characteristics of the patients in the liquid biopsy study in mEGFR-NSCLC in a Spanish population (OPH-1).
First Author: Fernando Franco, MD

Abstract e21516: Clinical utility of a liquid biopsy diagnostic approach in lung cancer using amplicon-based next-generation sequencing in parallel with allele-specific PCR.
First Author: Yukti Choudhury, PhD
Abstract e21517: Mutational profiles of lung adenocarcinoma subtypes.
First Author: Shuai Chang

Abstract e21518: Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.
First Author: Atocha Romero

Abstract e21519: Association of HLA class 1 homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer (NSCLC) treated with PD-1 inhibitor as first-line therapy.
First Author: Young Kwang Chae, MD, MPH, MBA

Abstract e21520: Clinico-genomic analyses of ROS1-positive non-small cell lung cancer in the international genomic screening system (LC-SCRUM-Asia).
First Author: Takaya Ikeda, MD, PhD

Abstract e21521: Clinical management of lung adenocarcinoma patients with HER2 V659E mutation.
First Author: Ziqi Jia

Abstract e21522: Evaluation of TKI toxicity according to inflammatory markers and body mass index in patients with non-small cell lung cancer (NSCLC) harboring an EGFR mutation: A retrospective observational study.
First Author: Thanya Runciman

Abstract e21523: MMR deficiency of lung cancer patients.
First Author: Zongjuan Ming

Abstract e21524: Genomic alterations profiling by liquid biopsy and their association to immune checkpoints inhibitors (ICI) response in a cohort of non-small cell lung cancer (NSCLC) patients.
First Author: Ana Callejo, MD, PhD

First Author: Baihua Zhang

Abstract e21526: Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
First Author: JUN WANG

Abstract e21527: Specific organ metastases and survival of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation.
First Author: Tiantian Shi
Abstract e21528: Major pathologic response of EGFR mutated non-small cell lung cancer (NSCLC) on 1-3 G TKI.
First Author: Fedor Vladimirovich Moiseenko, MD, PhD

Abstract e21529: Deep-learning analysis of CT imaging biomarker for PD-L1 expression to predict heterogeneous response to immune checkpoint inhibitors in non-small cell lung carcinoma.
First Author: Jaehong Aum, PhD

Abstract e21530: Characterization of heterogeneity in three lung cancer patients with multiple nodules by whole exome sequencing.
First Author: Dongcheng Liu

Abstract e21531: Evaluation of blood-based proteomic biomarkers associated with response to anti-PD-1 treatment in NSCLC.
First Author: Nicholas Dupuis, PhD

Abstract e21532: Molecular epidemiology of KRAS G12C mutations in Chinese lung cancer patients.
First Author: Herbert H. F. Loong, MBBS

Abstract e21533: Differences in molecular profiles between elderly versus younger patients with non-small cell lung cancer.
First Author: Ruqin Chen, MD, MS

Abstract e21534: Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal cancers.
First Author: Wanlong Ma

Abstract e21535: Bimodal ntrk expression and correlation with activation of PI3K/AKT pathway in lung cancer.
First Author: Wanlong Ma

First Author: Yu Wakabayashi

Abstract e21537: Identification of clinical features to predict the consistency of mutational profiles obtained from plasma and tissue of advanced non-small cell lung cancer (NSCLC) patients.
First Author: Xiaodong Jiao
First Author: Meagan Elizabeth Miller, MD

Abstract e21539: Digital pathology to evaluate PD-L1 IHC scoring as a predictor of outcome with second-line avelumab treatment in patients with non-small cell lung cancer (NSCLC).
First Author: Thomas Mrowiec

Abstract e21540: Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertions.
First Author: Kaiyan Chen

Abstract e21541: Sarcopenia as a negative predictive marker for treatment with pembrolizumab as a second line in patients with metastatic non-small cell lung cancer.
First Author: Milla Petrova, MD, PhD

Abstract e21542: Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.
First Author: Susana Millan

Abstract e21543: Expression of immune response markers in Arab patients with lung cancer.
First Author: Abdul Rahman Jazieh, MD, MPH

Abstract e21544: Human skin biomarkers and his relation with the response to treatment to tyrosine kinase inhibitors in advanced EGFR mutated lung adenocarcinoma.
First Author: Jeronimo Rafael Rafael Rodriguez Cid, MD

Abstract e21545: Comparison of the analytical performance in the detection of uncommon EGFR mutation of non-small cell lung cancer.
First Author: Shinji Atagi, MD

Abstract e21546: High neutrophil to lymphocyte ratio as a predictor for hyperprogressive disease in patients with metastatic non-small cell lung cancer treated with pembrolizumab as a second line.
First Author: Milla Petrova, MD, PhD

Abstract e21547: Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer.
First Author: Fahmin Basher, MD, PhD

First Author: Hui Zhao, M.D.
Abstract e21549: Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903).
First Author: Ryan D. Gentzler, MD, MS

First Author: Yuval Shaked

Abstract e21551: KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
First Author: Hongyuan Zhu, MD

Abstract e21552: Gender disparities in hormone positive lung cancer.
First Author: Bing Xia, MD

First Author: Vijendra Singh

Abstract e21554: A large-scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (LC-SCRUM-Liquid).
First Author: Ryo Itotani, MD

First Author: Federico Rojo, MD

Abstract e21556: Assessment of quality and clinical similarity (pharmacokinetic and safety) of HD204, a biosimilar of bevacizumab.
First Author: Jocelyn Hii, PhD

First Author: Wen xian Wang

Abstract e21558: Does CNS metastases reduce systemic therapy lines for NSCLC patients with EGFR mutation?
First Author: Danilo Giffoni, MD

Abstract e21559: A retrospective analysis of pembrolizumab use in NSCLC from a real-world setting.
First Author: Saleha Rizwan, MD
Abstract e21560: Tumor growth rate (TGR) as an early predictor of outcomes in advanced non-small cell lung cancer treated with PD-1 axis inhibitor.
First Author: Li-na He

Abstract e21561: Characteristics of patients with EGFR mutant non-small cell lung cancer who benefited from immune checkpoint inhibitors.
First Author: Eiki Ichihara, MD, PhD

Abstract e21562: Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer.
First Author: Angel Ray Baroz, BS

Abstract e21563: Next-generation sequencing of tissue and liquid rebiopsy favors post-progression outcomes of EGFR T790M-positive NSCLC patients treated with osimertinib.
First Author: Jiangtao Cheng

Abstract e21564: Correlation between tissue PD-L1, TMB, and blood PD-L1, MSI biomarkers in patients with advanced-stage non-small cell lung cancer (NSCLC).
First Author: Sujitha Nandimandalam

Abstract e21565: Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC.
First Author: Gabriela Liliana Bravo Montenegro, MD

Abstract e21566: Histopathological prognostic markers in metastatic lung adenocarcinoma, validation of stromal fibrosis and immunoscore as easy to interpret findings and their correlation with survival.
First Author: Luis Leonardo Rojas Puentes, MD

Abstract e21567: Can polymetastatic disease be arrested using SABR? A dosimetric analysis to inform development of a phase I trial.
First Author: Mark Thomas Corkum, MD, MSc

Abstract e21568: Association between inflammatory markers and progression-free survival in patients with advanced EGFR-mutated non-small cell lung cancer under treatment with tirosin kinasa inhibitors: Real-world data from Peru.
First Author: Rodrigo Motta Guerrero

Abstract e21569: Human papillomavirus infection in metastatic lung adenocarcinoma is associated with better outcomes with immune checkpoint inhibitor treatment.
First Author: Luis Leonardo Rojas Puentes, MD
Abstract e21570: A meta-analysis comparing therapeutic outcomes for anti-EGFR monotherapy to targeted therapy combinations for non-small cell lung cancer.
First Author: Sonali Kurup, PhD

Abstract e21571: Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.
First Author: Saad A. Khan, MD

First Author: Gabriella Galffy

Abstract e21573: Management of lung cancer in elderly population: A mono-centric retrospective study at University Hospital of Caen, Normandy, France.
First Author: Youssef Oulkhouir, MD

Abstract e21574: Concordance of provider treatment patterns with NCCN oncology treatment guidelines (NCCN Guidelines) for metastatic non-small cell lung cancer (mNSCLC).
First Author: Brian S. Seal, PhD, RPh, MBA

First Author: Harry E Fuentes

Abstract e21576: Assessing the risk of serious adverse events (SAEs) and death in non-small cell lung cancer (NSCLC) trials.
First Author: Nirali Marvania, MD

First Author: Leila Khaddour, MD

First Author: Feng Liang

Abstract e21579: Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).
First Author: Kartik Sehgal, MD

Abstract e21580: EGFR tyrosine kinase inhibitor therapy continuation with high-dose hypofractionated radiotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients
with oligoprogressive disease.
First Author: Mariacarmela Santarpia, MD

Abstract e21581: A retrospective study evaluating clinical and molecular predictors of duration of response (DoR) to immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Yahya Ibrahim, MD

First Author: Krisztina Bogos, MD, PhD

Abstract e21583: Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC).
First Author: Alexander Deneka, MD

Abstract e21584: A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.
First Author: Renhua Guo

First Author: Abdoulaye Karaboué, MD

Abstract e21586: Prevalence of ALK mutations in advanced NSCLC patients in the United States: Analysis with a real world oncology database.
First Author: Timothy Allen

First Author: Jinliang Wang, BA, MA, MD

Abstract e21588: Efficacy of first-line pembrolizumab in advanced NSCLC PD-L1<50%: Preliminary results (PEOPLE NCT03447678).
First Author: Claudia Proto, MD

Abstract e21589: Use of pulse steroids to treat renal IRAE to maintain patients with metastatic non-small cell carcinoma cancer on pembrolizumab.
First Author: Ala Abudayyeh

First Author: Yanni Lou, MD
Abstract e21591: YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).
First Author: Hiroki Sato, MD, PhD

Abstract e21592: Real-world testing compliance to NCCN guideline and factors of underutilization in U.S. community clinics.
First Author: Eric Bernicker, MD

Abstract e21593: Neutrophil to lymphocyte ratio and lipi score prognostic value in patients with non-small cell lung cancer in a Mexican population.
First Author: Eduardo Reyes, Dr.

Abstract e21594: Final analysis of a phase II, open label, randomized study of osimertinib versus osimertinib plus carboplatin/pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with previous EGFR-TKI and whose tumours harbour a T790M mutation (LOGIK1604/NEJ032A).
First Author: Kentaro Tanaka, MD, PhD

Abstract e21595: Genomic Heterogeneity of Multifocal NSCLC.
First Author: Mingjiu Chen

Abstract e21596: Artificial intelligence model to predict slow progression for advanced non-small cell lung cancer (aNSCLC) patients receiving second-line therapies.
First Author: Francois Charest, PhD

First Author: Antonios Vassias

Abstract e21598: BRAF fusion in lung cancer.
First Author: Jun Zhao

Abstract e21599: Exploratory analysis of the efficacy and severe immune-related adverse events (irAEs) of pembrolizumab plus chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC).
First Author: Teng Li

Abstract e21600: PD-1 inhibitor plus chemotherapy as 2nd/subsequent line therapy had similar clinical outcome with PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC.
First Author: Xiaoyang Zhai
First Author: Riccardo Lobefaro, MD

Abstract e21602: Factors influencing disease control in metastatic lung cancer with intracranial metastasis post gamma-knife radiotherapy.
First Author: Laura Tam, MBBS, MPhil

Abstract e21603: Monitoring through flow cytometry as a biomarker of early response to checkpoint inhibitor.
First Author: Elisabeth Perez Ruiz, MD, PhD

First Author: Renping Wan

Abstract e21605: Observation of clinical efficacy and survival of lung cancer patients with UMIPIC combined with low-dose chemotherapy.
First Author: Jianbin Feng, MD

First Author: Alessandro De Toma, MD

Abstract e21607: Molecular subtyping reveals stage-specific mutational landscape and prognostic predicting factors of stage IV NSCLC.
First Author: Yuqing Huang

Abstract e21608: Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia.
First Author: Beung-Chul AHN, MD

Abstract e21609: Intergration of common clinical and laboratory parameters for predictive modeling of outcome with immune checkpoint inhibitors (ICIs) in patients (pts) with non-small cell lung cancer (NSCLC).
First Author: Konstantinos Rounis, MD

Abstract e21610: Phase Ib study of LXH254 + LTT462 in patients (pts) with KRAS- or BRAF-mutant NSCLC.
First Author: Juergen Wolf, MD
Abstract e21611: Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study. First Author: Tobias Nicolaas Dechow, MD

Abstract e21612: The predictive values of mutation patterns, concurrent mutations and efficacy of different generations of EGFR-TKIs in advanced non-small cell lung cancer harboring non-resistant uncommon EGFR mutations. First Author: Pengbo Deng

Abstract e21613: Efficacy of first or second generation EGFR TKIs as first-line chemotherapy and treatment patterns and outcomes of sequential treatment in uncommon EGFR mutation-positive NSCLC. First Author: Hyun Ae Jung, MD

Abstract e21614: Artificial intelligence-assisted CT characterizations and quantitative analysis for differentiating pre-invasive lesions from invasive adenocarcinomas in pulmonary subsolid nodules ≤ 2cm. First Author: Bingyu Zhang

Abstract e21615: CONCORDANCE study: An observational, multicenter, prospective study to evaluate concordance of detecting EGFR mutations by circulating tumor-free DNA versus tissues biopsy in NSCLC. First Author: Kumar Prabhash, MD, DM

Abstract e21616: Co-mutation features in treatment-naïve EGFR-mutant lung adenocarcinoma. First Author: Jun Zhao

Abstract e21617: Sputum supernatant as an alternative source for liquid biopsy in patients with advanced lung cancer. First Author: Ting Guo

Abstract e21618: A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis. First Author: Shengxiang Ren, PhD

Abstract e21619: Safety and tolerability of sintilimab in combination with radiotherapy in treatment naïve PD-L1 positive stage IV non-small cell lung cancer (NSCLC). First Author: Rui Li, MD

Abstract e21620: Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy. First Author: Melina Elpi Marmarelis, MD
First Author: Feng-Che Kuan, M.D.

Abstract e21622: Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors (ICI): Role of race, gender, and concurrent chemotherapy in a multiethnic urban cohort.
First Author: Angelica D'Aiello, MD

Abstract e21623: IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).
First Author: Jacek Jassem, MD, PhD

First Author: Konstantinos N. Syrigos, MD, PhD

First Author: Danielle Crawley, MBBS Bsc PhD

Abstract e21626: Patterns of post-progression treatment and impact of subsequent immunotherapy (IO) in stage III unresectable non-small cell lung cancer (uNSCLC) patients (pts).
First Author: Sarah Shin, MD

Abstract e21627: Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumor DNA.
First Author: Corinna Woestmann

Abstract e21628: Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.
First Author: Thomas Newsom-Davis, MD PhD

Abstract e21629: Real-world brigatinib dosing patterns in patients with ALK+ NSCLC.
First Author: Huamao Mark Lin, PhD

Abstract e21630: Utilization patterns of immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC) within the veterans health administration (VHA).
First Author: Drew Moghanaki, MD, MPH, BS
First Author: Yung-Hung Luo

Abstract e21632: Preliminary analyses of ALK-positive non-small-cell lung cancer (NSCLC) patients with first-used alectinib or crizotinib followed by alectinib: A multicenter cohort real-world study in China.
First Author: Zihua Zou, MD

First Author: Nikolaus Krall, PhD

Abstract e21634: Exploratory analysis of factors associated with hyperprogression in advanced non-small cell lung cancer (NSCLC) treated with PD1/PDL1 inhibitors.
First Author: Marios P. Decatris, MD

First Author: Zhiwei Xiao, MD

Abstract e21636: Efficacy of afatinib in the clinical practice: Final results of the GIDEON study in EGFR mutated non-small cell lung cancer (NSCLC) in Germany.
First Author: Wolfgang M. Brueckl, Prof. Dr. med.

Abstract e21637: IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.
First Author: Robert M. Jotte, MD, PhD

First Author: Yuankai Shi, MD, PhD

Abstract e21639: The impact of prior chemotherapy (PrC) on immunotherapy outcomes in non-small cell lung cancer (NSCLC) patients: Real data from a mono-institutional study.
First Author: Marianna Macerelli, MD

Abstract e21640: Concordance of actionable genomic alterations identified by next-generation sequencing (NGS) analyses of circulating tumor DNA (ctDNA) and tissue biopsy in advanced non-small cell lung cancer (NSCLC): KLLIP (Korean Lung Liquid versus Invasive Biopsy Program).
First Author: Myung-Ju Ahn, MD, PhD

Abstract e21641: Lungful: An observational prospective study to assess the molecular epidemiology of EGFR mutations upon progression on or after first line EGFR-TKI therapy,
real-life clinical settings in Greece.
First Author: Giannis Socrates Mountzios, MD

First Author: Deborah Zhou, MD

Abstract e21643: Tetracyclins increase survival of NSCLC patients treated with EGFR TKIs: A retrospective nation-wide study.
First Author: Jussi Koivunen, MD, PhD

Abstract e21644: Cancer cachexia syndrome in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a single-institution, prospective, observational study.
First Author: Dimitrios Mavroudis, MD, PhD

Abstract e21645: C-reactive protein (CRP) as a predictive biomarker in lung cancer patients receiving immune checkpoint inhibitors (ICI).
First Author: Aneesha Ananthula, MBBS, MD

First Author: Hongbin Zhang

Abstract e21647: Clinical and molecular characteristics of TSC1/2 mutant lung cancer.
First Author: Yanye Wang

First Author: Armelle Lavole

First Author: Dean A. Fennell

First Author: Rong Wang

Abstract e21651: Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.
First Author: Alfredo Addeo
First Author: Hui Zhang

Abstract e21653: The genomic characterization of different progression patterns in advanced lung cancer (LC) patients upon immune checkpoint inhibitor (ICI) treatment.
First Author: Hua Zhong, MD, PhD

Abstract e21654: Immune checkpoint inhibitors (ICPi) impact on overall survival (OS) of patients (pts) with advanced large cell neuroendocrine tumors of lung (aLCNEC): A real-world data.
First Author: Elizabeth Dudnik, MD

Abstract e21655: PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
First Author: James Feisal, MD

Abstract e21656: Clinical activity and safety profile of dacomitinib in advanced epidermal growth factor receptor-positive non-small cell lung cancer patients with brain metastases.
First Author: Jinyao Zhang

Abstract e21657: Are the herbal drinks augments the cytotoxic effect against different cancer cells? Are they potent stimulators of innate and acquired immunity?
First Author: Israa Adnan

Abstract e21658: Comparison of treatment outcomes in patients with metastatic lung cancer who did or did not develop EGFR T790M mutation.
First Author: Zhen Wang, MD

Abstract e21659: ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC).
First Author: Alexander I. Spira, MD, PhD, FACP

Abstract e21660: LP-300 as a potential first-in-class combination agent with tyrosine kinase inhibitors (TKIs) in non-smoker lung adenocarcinoma.
First Author: Aditya Kulkarni

Abstract e21661: Efficacy of immune checkpoint blockade alone or combined with chemotherapy and smoking status in NSCLC: A systematic review and meta-analysis.
First Author: Shanshan Wang, M.D.

Abstract e21662: Immune-related adverse events and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients.
First Author: Javier López Gallego
Abstract e21663: Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.
First Author: Jianfei Wang

First Author: Pablo Ayala de Miguel

First Author: Xiaohong Xie, MD

Abstract e21666: The efficacy and safety of EGFR-TKI combined with chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR co-mutation with other oncogenic alterations.
First Author: Qitao Yu

Abstract e21667: Different efficacy of osimertinib in pre-TKI treated NSCLC patients with brain metastases harboring EGFR exon 19del and L858R mutant.
First Author: Xuanzong Li

Abstract e21668: RB1 mutation had influenced on bone metastases in advanced treatment-naive lung cancer.
First Author: Chengzhi Zhou, MD

Abstract e21669: Radiogenomics for the prognosis in advanced non-small cell lung cancer patients receiving bevacizumab.
First Author: Butuo Li

First Author: Chongrui Xu, MD, PhD

Abstract e21671: The potential of a CLIA-certified prognostic/predictive molecular test to address the rising costs of non-small cell lung cancer.
First Author: Michael J Mann, MD

Abstract e21672: Efficacy of lorlatinib via early/expanded access programs for patients (pts) with TKI-refractory ALK+ or ROS1+ non-small cell lung cancer (NSCLC): An international, multicenter, retrospective analysis.
First Author: Viola Weijia Zhu, MD, PhD

Abstract e21673: Impact of programmed death-ligand 1 (PD-L1) expression on the efficacy of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in metastatic
EGFR-mutated non-small cell lung cancer (NSCLC).
First Author: Chia Ching Lee, MD

Abstract e21674: Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer.
First Author: Naomi Fei, BSc, MD

First Author: Nicole Yun, MD

Abstract e21676: Patient reported outcomes and survival in advanced non-small cell lung cancer (NSCLC) treated with atezolizumab.
First Author: Ashley Mark Hopkins, PhD

Abstract e21677: High incidence of brain metastasis in young patients with lung adenocarcinoma.
First Author: Ilene Ramirez, MD

First Author: Jacqueline V Aredo, BS

Abstract e21679: Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.
First Author: Samuel Cytryn, MD

Abstract e21680: Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.
First Author: Afshin Dowlati, MD

Abstract e21681: Updated network meta-analysis of first-line EGFR targeted tyrosine kinase inhibitor treatments for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations.
First Author: Jasmina Ivanova, MA

Abstract e21682: A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
First Author: Suresh S. Ramalingam, MD

First Author: Jeffrey Melson Clarke, MD
Abstract e21684: Efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with different metastatic sites: A systematic review and meta-analysis.
First Author: Kaili Yang

Abstract e21685: 3rd-line Anaplastic Lymphoma Kinase (ALK) inhibitors (ALKi) in advanced Non-Small Cell Lung Cancer (aNSCLC); real-world comparison to non-ALKi therapy.
First Author: Natalie Maimon, MD

Abstract e21686: A phase II trial of alectinib-refractory non-small cell lung cancer with EML4-ALK fusion genes: Okayama lung cancer study group 1405.
First Author: Toshihide Yokoyama, MD

First Author: Qing Zhou, MD

First Author: Caicun Zhou, MD, PhD

Abstract e21689: SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.
First Author: Jin-Ji Yang

Abstract e21690: Dynamic changes in circulating PD-1+CD8⁺ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small cell lung cancer.
First Author: Chang Gon Kim, MD

Abstract e21691: Anti-PD-1 antibody monotherapy or anti-PD-1 antibody combination with chemotherapy treated non-small cell lung cancer (NSCLC) patients with EGFR mutation: A retrospective analysis.
First Author: Shaorong Yu, PhD

Abstract e21692: Culture of circulating tumour cells derived from non-small cell lung cancer.
First Author: Kenneth John O'Byrne, MD, PhD

First Author: Anthony Sireci, MD
First Author: Saiama Naheed Waqar, MBBS, MS

Abstract e21695: Detection of ALK and ROS1 fusion transcripts in FFPE samples of non-small cell lung cancer patients using a novel RT-PCR based assay and targeted RNA sequencing.
First Author: Marc G. Denis, PhD, PharmD

Abstract e21696: Osimertinib in poor PS patients with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) after progression on first- or second-generation EGFR TKI treatments (NEJ032B).
First Author: Ryota Saito, MD, PhD

Abstract e21697: Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: James Chih-Hsin Yang, MD, PhD

First Author: Shangbiao Li

Abstract e21699: Real-world treatment patterns and survival outcome in advanced anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients.
First Author: Christian Britschgi, MD, PhD

First Author: Danrong Yang

Abstract e21701: Immunotherapy efficacy of strong positive PD-L1 expression non-small cell lung cancer (NSCLC) patients: A systematic review and meta-analysis.
First Author: Hongmin Lu

Abstract e21702: A phase I clinical trial to assess the safety, pharmacokinetics, and antitumor activity of glumetinib (SCC244) in patients with advanced non-small cell lung cancers (NSCLCs).
First Author: Hua-Jun Chen, MD

Abstract e21703: A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018.
First Author: Lin Wu
First Author: Yuichi Ozawa, MD, PhD

Abstract e21705: A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.  
First Author: Yong Fang

Abstract e21706: Responses to targeted therapy in Chinese non-small cell lung cancer (NSCLC) patients harboring uncommon epidermal growth factor receptor (EGFR) mutant who tested next generation sequencing (NGS)-positive and amplification refractory mutation (ARMS)-negative.  
First Author: Ziyi Xu

Abstract e21707: Effect of tumor size change (TSC) and duration of response (DOR) on OS with first-line (1L) pembrolizumab (pembro) + pemetrexed-platinum (chemo) for metastatic nonsquamous non-small cell lung cancer (NSCLC).  
First Author: Steven Francis Powell, MD

First Author: Jung Yueh Chen, MD

Abstract e21709: Molecular profiling of lung adenocarcinoma using pleural effusion specimens.  
First Author: Wei Zhang

Abstract e21710: First-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC: US real-world demographics and treatment patterns.  
First Author: Jorge J. Nieva, MD

Abstract e21711: The efficacy of EGFR-tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) patients (pts) with synchronous brain metastasis: A real-world study.  
First Author: Jin-Hyuk Choi, MD, PhD

First Author: Shaoxing Guan

Abstract e21713: Randomized phase II trial of pemetrexed plus bevacizumab versus pemetrexed alone after the treatment with cisplatin, pemetrexed and bevacizumab in advanced nonsquamous, non-small cell lung cancer (TORG1321).  
First Author: Tetsuro Kondo, MD
Abstract e21714: Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada. First Author: Martin Sebastian, MD

Abstract e21715: Using real world data to examine outcomes in immunotherapy-treated patients with metastatic non-small cell lung cancer. First Author: Sierra Luciano, BA

Abstract e21716: Evaluation of the fully automated Idylla EGFR Mutation Assay in Chinese patients with lung adenocarcinoma. First Author: Tian Qiu, Ph.D.

Abstract e21717: Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC). First Author: Ashley Tabah

Abstract e21718: Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the subtypes of EGFR mutation in advanced non-small cell lung cancer (NSCLC): A real-world study. First Author: Yong Won Choi

Abstract e21719: Impact of chemoradiotherapy (CRT) on immune-related tumor microenvironment and the efficacy of anti-PD-1 therapy after the recurrence of CRT in unresectable locally advanced NSCLC patients. First Author: Masayuki Shirasawa

Abstract e21720: Retrospective analysis of clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) exposed to immunotherapy: The experience of the Oncology Center of Hospital Moinhos de Vento. First Author: Fernando Castilho Venero, MD

Abstract e21721: Sequential serum let-7a to predict accelerated reproliferation of lung cancer cells during chemotherapy and long-term survival. First Author: Peng Xie, MD, PhD

Abstract e21722: A phase II and biomarker study of alectinib combined with bevacizumab in ALK-positive nonsquamous non-small cell lung cancer. First Author: Satoshi Watanabe

Abstract e21723: Immune checkpoint inhibitors’ (ICI) efficacy according to PD-L1 expression for advanced or metastatic NSCLC: Systematic review and meta-analysis. First Author: Glauber Maciel
Abstract e21724: The role of radiation dose-dependent enhancement of fatty acid oxidation in radiation surviving/resistant lung cancer cells.
First Author: Shangbiao Li

Abstract e21725: Population pharmacokinetic (PK) and exposure-response analyses from the pivotal ALTA-1L study: Model-based analyses supporting the brigatinib dose in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC).
First Author: Neeraj Gupta

Abstract e21726: Single institution experience looking at efficacy of PD-1 inhibitors after progression on PD-L1 inhibitors or vice-versa in metastatic non-small cell lung cancer (NSCLC).
First Author: Kerri McGovern, MD

First Author: Ani K John

First Author: Konstantinos N. Syrigos, MD, PhD

Abstract e21729: Prognostic role of filgrastim and derived neutrophil-to-lymphocyte ratio (dNLR) in the effectiveness of PD1/PDL1 inhibitors in previously treated non-small cell lung cancer.
First Author: Juan Francisco Marin Pozo, PhD, PharmD

First Author: Kazuhiko Nakagawa, MD, PhD

Abstract e21731: Comparative effectiveness of immune-checkpoint inhibitors as first-line treatment for advanced nonsquamous non-small cell lung cancer patients: A network meta-analysis and a systematic review.
First Author: Roberto Jorge Bitton, MD, MSc

Abstract e21732: Peripheral blood biomarkers associated with outcome in non-small cell lung cancer patients treated with nivolumab and durvalumab monotherapy.
First Author: Lin Wu
Abstract e21733: ROS1 immunohistochemistry as a screening tool for detection of ROS1 rearrangement in non-small cell lung cancer: Comparison between SP384 and D4D6 clones. First Author: Yi-wen Chang

Abstract e21734: The effect of under and uninsured status on survival in lung cancer while adjusting for other mortality risk factors. First Author: Mohamed K. Mohamed, MD, PhD

Abstract e21735: Apatinib combined with pemetrexed-platinum doublet chemotherapy for chemo-naïve Chinese non-squamous non-small cell lung cancer patients: A prospective phase II clinical study. First Author: Guangjian Yang, MD

Abstract e21736: EGFR gene mutation is not a significant prognostic factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone. First Author: Takeshi Masuda, PhD, MD

Abstract e21737: Activin as a biomarker for platinum resistance in non-small cell lung cancer. First Author: Jennifer Wen Ying Lim, MBBS, MPH, FRACP

Abstract e21738: Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of costs proposal. First Author: Helmy M. Guirgis, MD

Abstract e21739: Phase I trial of combination afatinib (Afat) and necitumumab (Neci) in EGFR mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to first or third generation EGFR tyrosine kinase inhibitors (TKIs). First Author: Sukhmani Kaur Padda, MD

Abstract e21740: Brain metastasis in lung cancer: Are there any predictive risk factors? First Author: Salma Ait Batahar

Abstract e21741: Efficacy and safety of apatinib plus docetaxel for non-squamous non-small cell lung cancer with bone metastases. First Author: Aimin Zang

Abstract e21742: TP53 fusions with next-generation sequencing (NGS) in Chinese non-small cell lung cancer (NSCLC): A multicenter study. First Author: Huafei Chen

Abstract e21743: Cause of mortality in patients with lung cancer and brain metastasis. First Author: Rajat Thawani
Abstract e21744: Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).
First Author: Robert M. Jotte, MD, PhD

Abstract e21745: Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer (NSCLC).
First Author: Yuxin Mu

Melanoma/Skin Cancers

Abstract e22000: Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
First Author: Hussein Abdul-Hassan Tawbi, MD, PhD

Abstract e22001: Single-institution outcomes with less than two-year anti-PD-1 antibody therapy in metastatic melanoma.
First Author: Tsering G. Lama Tamang, MD

Abstract e22002: Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869).
First Author: Mohammad Khurram Khan, MD, PhD

Abstract e22003: Real-world experience of talimogene laherparepvec in patients receiving immunotherapy in metastatic melanoma.
First Author: Tapas Ranjan Behera, MD

Abstract e22004: Intersection of ethnicity, biology and tumor mutation burden (TMB) in response to checkpoint inhibitors (CPI) in advanced acral melanoma (AM).
First Author: Kaysia Ludford, MD, MSc

Abstract e22005: Outcome of metastatic melanoma following immune checkpoint inhibitor treatment by tumor infiltrating lymphocyte of primary cutaneous site.
First Author: Upendra P. Hegde, MD

Abstract e22006: Metabolic activity of liver metastases to predict different survival in patients with metastatic uveal melanoma.
First Author: Luis P. Del carpio, MD

Abstract e22007: The efficacy of anti-PD-1 combined with temozolomide in unresectable, advanced melanoma from one center.
First Author: Tu Hu
Abstract e22008: Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.
First Author: Ester Simeone

Abstract e22009: Clinical experience with the targeted therapy in melanoma patients with brain metastases.
First Author: Natalia V. Zhukova

First Author: Soo Jung Lee, MD. Ph.D.

Abstract e22011: Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.
First Author: Seonggyu Byeon, MD

Abstract e22012: Comparison of baseline patient characteristics in immunotherapy versus targeted therapy trials for advanced melanoma.
First Author: Shivani Handa, MD

Abstract e22013: Adjuvant systemic therapies for melanoma in Alberta: An early descriptive analysis of population characteristics and treatment outcomes.
First Author: Rodrigo Rigo, MD, MSc

Abstract e22014: Safety and efficacy of checkpoint inhibitors in solid organ transplant recipients with cutaneous squamous cell carcinoma.
First Author: Irene Tsung, MD

Abstract e22015: Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.
First Author: Jinho Lee, Ph.D.

Abstract e22016: Influence of age and cancer history on prevalence of autoimmunity in patients with metastatic melanoma: A large retrospective study.
First Author: Aaron N. Holmes

Abstract e22017: Metastatic melanoma of the heart: A systematic review.
First Author: Alexander M. Balinski, B.S.

First Author: Abir Belaala
Abstract e22019: Salvage chemotherapy in the treatment of metastatic melanoma after progression on immunotherapy.
First Author: Payal Shah, BS

First Author: Matthew Stephen Block, MD, PhD

Abstract e22021: Role of AXL in metastatic melanoma and impact of TP-0903 as a novel therapeutic option for melanoma brain metastasis.
First Author: Eemon Tizpa, BA, MS

Abstract e22022: Patterns of disease presentation, treatment choices and survival in real world for patients diagnosed with advanced melanoma: A prospective observational study by Spanish Melanoma Group (GEM-1801).
First Author: Ivan Marquez-Rodas, MD, PhD

Abstract e22023: Vitiligo is correlated with clinical benefits in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors (ICI).
First Author: Gaston Martin Reinas, MD

Abstract e22024: Methylated DNA marker panel for metastatic melanoma: Discovery and tissue validation.
First Author: Alexander Meves, MD

Abstract e22025: Second primary melanoma in advanced melanoma patients treated with anti-PD-1 monoclonal antibodies.
First Author: Elisa Funck-Brentano, MD, PhD

Abstract e22026: Efficacy and safety of apatinib in patients with recurrent or refractory melanoma.
First Author: Zibing Wang

Abstract e22027: Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma.
First Author: Maya Dimitrova, MD

Abstract e22028: Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice.
First Author: Maria Carmen Álamo de la Gala

Abstract e22029: Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel –Study informing treatment Pathway dEcisions in Merkel cell
cARcinoma (MCC).
First Author: Charles Lance Cowey, MD

First Author: Claire Christen

Abstract e22031: Real-world patterns of molecular testing in advanced melanoma (advMel): adherence to guidelines.
First Author: Anthony J. Olszanski, MD, RPh

Abstract e22032: Retrospective analysis of retreatment with Ipilimumab in patients with metastatic melanoma.
First Author: André Alexandre Formozo, MD

Abstract e22033: Molecular profiling of melanoma brain metastases compared to primary melanomas.
First Author: Theresa Michelle Medina, MD

Abstract e22034: Cyclooxygenase inhibitor use during checkpoint immunotherapy and effect on time to progression and overall survival for metastatic melanoma and non-small cell lung cancer patients.
First Author: Shang-Jui Wang

Abstract e22035: Toxicity profile of immune checkpoint inhibitors after rechallenge when held previously for immune related toxicities.
First Author: Theresa Michelle Medina, MD

Abstract e22036: Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy.
First Author: Leonel Fernando Hernandez-Aya, MD

Abstract e22037: On-treatment circulating tumor DNA (ctDNA) levels and kinetics associate with response to immune checkpoint inhibition (ICI) in patients with unresectable or metastatic melanoma.
First Author: Mahrukh M Syeda, MS

Abstract e22038: Estimating long-term survivorship in patients with advanced melanoma treated with immune checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial.
First Author: Peter Mohr, MD

Abstract e22039: The use of PET/CT to detect early recurrence after resection of high-risk stage III melanoma, prior to the start of adjuvant therapy and during follow-up.
First Author: Bernies Van Der Hiel, MD
Abstract e22040: A process mining approach to real-world advanced melanoma treatments. 
First Author: Camille Lea Gerard, MD

Abstract e22041: Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy. 
First Author: Gil Awada, MD

Abstract e22042: Mortality prediction in real world advanced melanoma patients treated by anti-PD1 within MelBase, a French multicentric prospective cohort. 
First Author: Bastien Oriano

Abstract e22043: Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy. 
First Author: Li Zhou, MD

First Author: Veronica Guerra, MD

Abstract e22045: Bone metastasis as an independent prognostic factor for survival in patients with advanced melanoma treated with immune checkpoint blockade. 
First Author: Marcos Rezende Teixeira

Abstract e22046: Effect of administration of systemic steroids on survival benefit associated with immunotherapy-induced skin toxicity. 
First Author: Nicholas Gulati

Abstract e22047: Thromboembolism (TE) in patients (pts) with melanoma receiving immunotherapy (IO) adversely impacts survival. 
First Author: Tamara A. Sussman, MD

Abstract e22048: Factors predicting overall survival (OS) and progression-free survival (PFS) in real-life: Classification and regression tree analysis of a 5-year (5Y) cohort follow-up study of advanced melanoma patients (pts) that have initiated pembrolizumab. 
First Author: Philippe Saiag, MD, PhD

Abstract e22049: Association of K1505Ac IHC signal loss and response to immunotherapy in patients with metastatic cutaneous melanoma. 
First Author: Daniel S. Altman, MD, BS

Abstract e22050: An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts. 
First Author: Mark R. Middleton, PhD
Abstract e22051: Clinical models that predict site of first and subsequent melanoma metastases (MM) in 6,031 patients (pts).
First Author: Ines Pires Da Silva, MD PhD

Abstract e22052: Patterns of hepato-pulmonary metastasis and their impact on clinical outcomes in uveal melanoma.
First Author: Asad Javed, MBBS

Abstract e22053: Emerging use of comprehensive genomic profiling (CGP) in routine cancer care of metastatic melanoma (mMel) patients (pts) in a real-world setting.
First Author: Paolo Antonio Ascierto, MD

Abstract e22054: Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi).
First Author: John J. Park, MBBS, MPH, FRACP

Abstract e22055: Role of glutamine metabolism in CD8⁺PD-1⁺TIM-3⁺ T cells in ICI resistant melanoma.
First Author: Samjhana Thapaliya

First Author: Carola Berking

Abstract e22057: Incidence and time course of toxicities associated with cobimetinib (C) combined with atezolizumab (A) in the phase III IMspire170 study.
First Author: Ana Arance, MD, PhD

Abstract e22058: Evaluation of NRAS and BRAF mutations (mts) as predictive biomarkers for patients (pts) with advanced melanoma (MEL) receiving anti-PD1 +/- anti-CTLA4 immunotherapy.
First Author: April A. N. Rose, MD, PhD

Abstract e22059: A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.
First Author: Takami Sato, MD, PhD

Abstract e22060: Integrated analysis of comprehensive genomic profiling (CGP) and PD-L1 immunohistochemistry in melanoma.
First Author: Erik Abraham Williams, MD

Abstract e22061: Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347).
First Author: azka ali, MD
Abstract e22062: Open label, phase II study of axitinib, a selective inhibitor of vascular endothelial growth factor receptors, in patients with stage III malignant melanoma.  
First Author: Eric Zhuang, MD

Abstract e22063: Effectiveness of PD1-inhibitors in advanced Merkel cell carcinoma: Real life data in a Swedish cohort.  
First Author: Hannah Bjorn-Andtback, MD

Abstract e22064: Pathway-flux based biomarker for immunotherapy response in melanoma.  
First Author: Jian Li

Abstract e22065: Treatment of locally advanced or multiple basal cell carcinoma with vismodegib in real world setting.  
First Author: Janja Ocvirk, MD, PhD

Abstract e22066: Cutaneous melanoma mutation pathways and driver mutations as racially biased.  
First Author: Margaret I Sanchez, MD

Abstract e22067: Development of a translatable targeted therapy-resistant melanoma model.  
First Author: Alexander C. Chacon, MD

Abstract e22068: Identification of potential predictive biomarkers of rapid progression and rapid response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients.  
First Author: Domenico Mallardo

Abstract e22069: Plasma next generation sequencing (NGS) to analyse clonal evolution in metastatic melanoma (MM) patients (pts) with early acquired resistance to immune checkpoint inhibitors (ICI).  
First Author: Jenny HJ Lee, MD

Abstract e22070: Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.  
First Author: Nicolai Grønne Jørgensen, MD

First Author: Pedram Gerami, MD

Abstract e22072: Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma.  
First Author: Thiago Pimentel Muniz, MD
Abstract e22073: Exosomal microRNA in serum is a prognostic factor in cutaneous squamous cell carcinoma.
First Author: Jonggwon Choi Jr., MD, PhD

Abstract e22074: Exposure-response analyses of dabrafenib and trametinib in melanoma patients.
First Author: Stefanie L. Groenland, MD

Abstract e22075: CDC20 is a novel potential therapeutic target in NF1-mutant melanoma.
First Author: Douglas M. Donnelly III, BS

Abstract e22076: Cost-effectiveness of nodal observation versus completion lymphadenectomy in patients with melanoma and sentinel lymph node metastases.
First Author: Elena Parvez

Abstract e22077: Prospective observational trial of low-dose skin electron therapy in mycosis fungoides using rotational technique.
First Author: Neil Newman, MD

Abstract e22078: Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609.
First Author: Ahmad A. Tarhini, MD, PhD

Abstract e22079: The value of lymph node ultrasound and whole body PET/CT in stage IIB/C patients prior to SLNB.
First Author: Emma H.A. Stahlie, MD

Abstract e22080: Recurrence rates and relapse-free survival for patients with completely resected melanoma: Contemporary experience.
First Author: Asim Amin, MD, PhD

Abstract e22081: Neoadjuvant itraconazole (I) in patients (pts) with resectable basal cell carcinoma (BCC): A phase II multistage study.
First Author: Rodrigo Perez Pereira, MD

Abstract e22082: Chronic neurogenic pain activates growth factors in the blood of patients with cutaneous melanoma.
First Author: Valeria A. Bandovkina

Abstract e22083: Inhibitory effect of PAI-I in perifocal and resection line tissues on tumor growth in women with melanoma.
First Author: Ludmila Ya. Rozenko
Abstract e22084: Local hormonal status of tumor and adjacent tissues in patients with melanoma depending on their gender.
First Author: Valeria A. Bandovkina

Abstract e22085: Relationship of chronic neurogenic pain and fibrinolysis in the blood of patients with melanoma.
First Author: Ludmila Ya. Rozenko

Abstract e22086: Toxicities with combination BRAF and MEK inhibition in resected stage III melanoma.
First Author: Govind Warrier, MD, MPH

Abstract e22087: Molecular profiling and clinical characteristic of malignant melanoma in younger patients.
First Author: Jomjit Chanharasamee, MD, MD

Abstract e22088: Identification of stage IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
First Author: Renske Wever, BS

Abstract e22089: Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load.
First Author: Emma H.A. Stahlie, MD

Abstract e22090: Unknown primary tumor high-risk melanoma as a unique patient population with distinct prognosis in the adjuvant setting: An ECOG-ACRIN E1609 study analysis.
First Author: Ahmad A. Tarhini, MD, PhD

Abstract e22091: Implications of a prognostic 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (cSCC) on staging-based risk assessment and adjuvant therapy trial design.
First Author: Chrysalyne Schmults, MD

Abstract e22092: The utility of obtaining baseline PET-CT scans in patients with melanoma.
First Author: Surya Ravichandran

Abstract e22093: Predictors of extensive subclinical spread in squamous cell carcinoma.
First Author: Anna Eversman, BS

Abstract e22094: AMBLor: A prognostic and stratifying biomarker for adjuvant immunotherapy of AJCC stage II melanomas.
First Author: Marie Labus, PhD
Abstract e22095: Adjuvant therapy in non-metastatic melanoma result from a Brazilian cohort. First Author: Sinara Figueiredo Silva

Abstract e22096: Preoperative treatment for marginally resectable metastatic melanoma: A single center experience in China. First Author: Yu Xu

Abstract e22097: Effect of chronic neurogenic pain on blood levels of hormones in patients with melanoma depending on their gender. First Author: Viktoria V. Pozdnyakova

Abstract e22098: Three times of intratumor injection of the sustained released by ROS with penicillin-combined chemotherapy drugs for the long of survival period of the tumor-bearing mouse. First Author: Dong Chen, MD

Abstract e22099: Effect of urokinase gene knockout and chronic neurogenic pain on melanoma growth in the experiment. First Author: Irina V. Kaplieva

Abstract e22100: Association of prior interferon-alpha treatment with the efficacy of adjuvant pembrolizumab in resected melanoma. First Author: Gu Jin

Abstract e22101: Surgical wound dehiscence in dermatologic surgery. First Author: Tanner Harding

Abstract e22102: Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study. First Author: Ambika Satija, ScD

Abstract e22103: Influence of chronic neuropathic pain on VEGFA in tumors of mice with genetically determined inhibition of tumor growth. First Author: Elena M. Frantsiyants

Abstract e22104: MAP2K1/2 and MAP3K14 as a prognostic biomarker on immunotherapy and correlated with immune infiltrates in melanoma. First Author: Jing Chen

Abstract e22105: Quantifying the additional prognostic value of sentinel lymph node status over established clinicopathologic primary tumor features for predicting survival outcomes in melanoma patients. First Author: Serigne Lo, PhD
Abstract e22106: Clinicopathological demographics of malignant melanoma of the vulva and vagina in Japan: Japanese Gynecologic Oncology Group (JGOG)/Japanese Skin Cancer Society (JSCS)—Intergroup Study.
First Author: Shin Nishio, MD, PhD

Abstract e22107: Tanning bed exposure in association with multiple primary melanoma.
First Author: Lilit Karapetyan, MD

First Author: Nishitha Thumallapally, MBBS

Abstract e22109: Influence of urokinase gene knockout on tissue levels of biogenic amines in mice with melanoma.
First Author: Irina V. Kaplieva

**Pediatric Oncology**

Abstract e22500: Differences in care of adolescent and young adult (AYA) oncology patients treated at a pediatric versus an adult facility.
First Author: Amy Moskop, MD

Abstract e22501: A single-center, open-label clinical study to evaluate pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte stimulating factor in pediatric patients with acute lymphoblastic leukemia.
First Author: Wenyu Yang, Doctor

Abstract e22502: Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.
First Author: LaQuita Marie Jones, DO

Abstract e22503: Body composition and treatment-related toxicity in pediatric lymphoma.
First Author: Aman Wadhwa, MD, MSPH

Abstract e22504: Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
First Author: Veronique Minard

Abstract e22505: Thrombotic Complications of Pediatric, Adolescent and Young Adult Acute Lymphoblastic Leukemia.
First Author: O. Zulfikar, Prof
Abstract e22506: Language barriers and incidence of febrile neutropenia among pediatric and young-adult patients with acute lymphoblastic leukemia.
First Author: Bao Truong

First Author: Shakilu Jumanne Kayungo, MD

First Author: Irene Nzamu

Abstract e22509: Innovations in retinoblastoma treatment and reflection to enucleation rate of 362 eyes of 262 CASES: Twenty years retrospective assessment at Ankara University.
First Author: Emel Cabi Unal, MD

Abstract e22510: The long tail of diagnoses in a cohort of over 800 pediatric patients with solid tumors enrolled and sequenced in the profile cancer research study.
First Author: Suzanne J. Forrest

Abstract e22511: ZEB1 expression in tumor tissues in patients with localized and advanced Ewing's sarcoma.
First Author: Darya Yu. Yurchenko

Abstract e22512: FAM120A-PTPN3 variations in neuroblastoma: Implications for poor prognosis and relapse.
First Author: Lan Sun, Dr.

First Author: M. Tezer Kutluk, MD

Abstract e22514: Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.
First Author: Kevin M. Campbell, MD

Abstract e22515: The role of long non-coding RNA ANRIL in chemosensitivity in osteosarcoma and clinical outcomes.
First Author: Asmaa Ferdjallah

Abstract e22516: Percutaneous cryoablation in pediatric solid tumors: A case series.
First Author: Cristiana Hentea, MD
Abstract e22517: Levels of mRNA of iLBP family genes and retinoic acid receptors in embryonal tumors in children.
First Author: Olga P. Popovyan

Abstract e22518: Female genital tract rhabdomyosarcoma in childhood and adolescence: A single center experience.
First Author: Inci Yaman Bajin

Abstract e22519: Development and validation of targeted treatments for the rare tumor syndrome infantile myofibromatosis.
First Author: Ying Chen, MD

Abstract e22520: Cost-effective method to incorporate molecular classification of medulloblastoma into a Latin-American clinical trial.
First Author: Sidnei Epelman, MD

Abstract e22521: Image-guided core needle biopsy for relapsed and refractory neuroblastoma: A focus on sample adequacy for genetic sequencing.
First Author: Andrew Samoyedny

Abstract e22522: Perceived value of cancer survivorship care among Asians and Native Hawaiian/Pacific Islanders.
First Author: Jared David Acoba, MD

Abstract e22523: Primary care utilization and barriers among pediatric cancer and bone marrow transplant survivors.
First Author: Keagan Lipak, BA

Abstract e22524: Evaluation of the quality-of-life (QOL) and socio-demographic characteristics of patients with leukemia and lymphoma: Comparison with sibling and control group.
First Author: Nurdan Tacyildiz, MD

First Author: Daniel M. Green, MD

First Author: Diana Lone, DO

Abstract e22527: Screening practices for late effects in pediatric patients on tyrosine kinase inhibitors.
First Author: Stephanie M Smith, MD, MPH
Abstract e22528: The role of peer support in psychosocial outcomes among adolescent and young adult (AYA) cancer survivors.
First Author: Motohiro Matsui, MD

Abstract e22529: Immunogenicity and safety of the three-dose human papillomavirus (HPV) vaccine series in young cancer survivors.
First Author: Wendy Landier, PhD

Abstract e22530: Longitudinal symptoms predict future clinically assessed chronic health conditions (CHCs) in adult survivors of childhood cancer: A follow-up study over two decades.
First Author: I-Chan Huang, PhD

Abstract e22531: Mutational analysis of radiation-induced subsequent thyroid cancers in pediatric patients.
First Author: Jennifer Hess, DO, MS

Abstract e22532: “Being healthy and living life as if I never had cancer”: The meaning of “living well” from adolescents with cancer.
First Author: Katherine Schreiner

Abstract e22533: Effect of FAmily CEntered (FACE) advance care planning (ACP) on families’ appraisals of caregiving for their teens with cancer.
First Author: Justin N. Baker, MD

Abstract e22534: Implementation of psychosocial support project in a pediatric oncology camping program.
First Author: Simone Lehwess Mozzilli

Abstract e22535: Risk factors associated to infectious complications in children with febrile neutropenia induced by chemotherapy: A cohort study.
First Author: Karla Díaz Ramírez

Professional Development and Education Advances

Abstract e23000: HemeOncoPoeisis: A fellow’s perspective on training.
First Author: Marwah Wafa Farooqui, DO, BS

Sarcoma

Abstract e23500: Functional and oncologic outcomes after excision of proximal femur primary bone tumors using a cost-effective indigenous prosthesis.
First Author: Ashish Gulia, MD
Abstract e23501: The outcome of vincristine, dactinomycin D, ifosfamide and doxorubicin (VAIA) as first-line therapy for adult-patients with metastatic ewing sarcoma; a single-center experience.
First Author: Jean Paul Atallah, MD

Abstract e23502: Bioinformatic analysis of selinexor-induced gene expression in patient-derived-chordomas to reveal mechanisms of action leading to tumor growth inhibition.
First Author: Christopher James Walker, Ph.D.

First Author: Iwona Lugowska, MD, PhD

Abstract e23504: T cells armed ex vivo with GD2-CD3 and HER2-CD3 bispecific antibodies to treat osteosarcoma.
First Author: Jeong A Park

Abstract e23505: Updated 5-year local control (LC), metastasis-free survival (MFS), and overall survival (OS) data from a phase I study of nilotinib plus radiation (RT) in high-risk chordoma.
First Author: Gregory Michael Cote, MD, PhD

Abstract e23506: Evaluation of baseline neutrophil to lymphocyte (NLR), platelet to lymphocyte (PLR), and lymphocyte to monocyte ratios (LMR) as prognostic factors in osteosarcoma: The Toronto Sarcoma Program Experience.
First Author: Olubukola Ayodele, MBBS, MRCP

Abstract e23507: Locally advanced GCTB recurrence after neoadjuvant denosumab use.
First Author: Gabriela Monte Tenorio Taveira

Abstract e23508: Staging work up in chondrosarcoma: Is a bone scan warranted for the metastatic workup of chondrosarcoma?
First Author: Ashish Gulia, MD

Abstract e23509: Mesenchymal chondrosarcoma: An Australian multi-centre cohort study.
First Author: Madeleine Cornelia Strach, FRACP, MBBS

Abstract e23510: New antibody therapeutic targeting connexin hemichannels in treatment of osteosarcoma and breast cancer bone metastasis.
First Author: Jean X. X. Jiang, PhD

Abstract e23511: Conditional survival of patients with nonmetastatic bone osteosarcoma.
First Author: Ruoyu Miao, MD
First Author: Susan Tsang, B.S.

Abstract e23513: Bone turnover markers in primary and metastatic bone tumors.
First Author: Nailya K. Guskova

Abstract e23514: Clinical characteristics, treatment modalities, and oncological outcomes in patients with gastrointestinal stromal tumors in Mexico.
First Author: Luis Guillermo Anaya Sanchez

First Author: Shenglan Yang, Ph.D and MD

Abstract e23516: Neoadjuvant therapy for localized gastrointestinal stromal tumors (GISTs): A propensity score weighted analysis.
First Author: Kathryn E. Marqueen

Abstract e23517: Multimodal treatment response assessment incorporating volumetric imaging data analysis (VIDA) and sequenced circulating tumor (ct) DNA in gastrointestinal stromal tumors (GIST).
First Author: Ciara Marie Kelly, MBBCh, MD

First Author: Silvia Gasperoni, MD

Abstract e23519: Diagnostic algorithm for gastrointestinal stromal tumor (GIST) using patient registry data impacts pathology guidelines.
First Author: Sara Rothschild, MPH

Abstract e23520: Predictive factors of the efficacy of dose escalation in patients with advanced gastrointestinal stromal tumor (GIST) who progressed on imatinib 400 mg/day.
First Author: Jwa Hoon Kim, M.D.

Abstract e23521: Clinical and pathologic prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
First Author: Hyungwoo Cho, MD

Abstract e23522: A comprehensive characterization of anatomical and molecular risk factors in gastric gastrointestinal stromal tumor.
First Author: Kjetil Boye, MD, PhD
Abstract e23523: Dual-energy CT as a quantitative response parameter in patients with GIST undergoing targeted therapy: A prospective multicenter trial.
First Author: Mathias Meyer, MD

Abstract e23524: The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).
First Author: Piotr Rutkowski, MD, PhD

Abstract e23525: High frequency of c-KIT genetic variants in exons 9, 11, 13 and 17 and PDGFRA in exon 18 in gastric GIST tumors.
First Author: Ekaterina P. Omelchuk

Abstract e23526: Preliminary safety, pharmacokinetics, and efficacy results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
First Author: Jian Li, MD

Abstract e23527: Modulation of YAP/TAZ by statins to improve survival in epithelioid hemangioendothelioma (EHE).
First Author: Aparna Subramaniam, MBBS, MPH

Abstract e23528: The impact of next generation sequencing on sarcoma diagnosis.
First Author: Gang Zhao

Abstract e23529: Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning.
First Author: Ari Rosenberg, MD

Abstract e23530: Comprehensive genomic profiling in malignant myoepithelioma to suggest potential alternative diagnosis.
First Author: Brittany Siontis, MD, MS

Abstract e23531: The prognostic value of CINSARC in a randomised trial comparing histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001).
First Author: Sandro Pasquali

Abstract e23532: Radiomic features for patients with primary soft tissue sarcomas: A prognostic study.
First Author: Sandro Pasquali

Abstract e23533: Pembrolizumab monotherapy as a salvage treatment in sarcoma patients: A retrospective analysis.
First Author: Angelika Martina Starzer, MD
Abstract e23534: Development of urine metabolomic biomarkers for ifosfamide-induced encephalopathy (IIE) in soft tissue sarcoma patients.  
First Author: Garrett Kinnebrew, MD

Abstract e23535: Immune signature and molecular profiling of epithelioid hemangioendothelioma (EHE): A Toronto sarcoma program study.  
First Author: Olubukola Ayodele, MBBS, MRCP

Abstract e23536: Multiscale omic assessment of EWSR1-NFATc2 fusion positive sarcomas to identify conserved fusion breakpoint and activation of the mTOR pathway.  
First Author: Nathan David Seligson, PharmD

First Author: Se Jun Park, MD

Abstract e23538: Sarcoma Treatment Efficacy Portal (STEP): A novel informatics portal providing real-time, real-world outcomes to clinicians.  
First Author: Nicholas Grosenbacher

Abstract e23539: Potential use of homologous recombination deficiency score as an indicator of therapy selection in leiomyosarcoma patients.  
First Author: Yuhong Zhou, MD

Abstract e23540: Uterine sarcomas, insight into its risk factors: A systematic review.  
First Author: Caroline Hana

Abstract e23541: Analysis of beta-blocker and agonist use, beta-adrenergic receptor expression, and treatment outcomes in advanced angiosarcoma.  
First Author: Andrew Johns, MD

Abstract e23542: The potential role of extracellular matrix in the activity of trabectedin.  
First Author: Alessandro De Vita

Abstract e23543: The Epstein-Barr virus and osteosarcoma in Iranian children.  
First Author: Mahtab Rahbar V, Associated professor of clinical /surgical pathology

Abstract e23544: Multi-institutional collaboration in sarcoma and central nervous system tumors.  
First Author: Jacob Gillingham

Abstract e23545: Factors of angiogenesis (VEGF and CD34) in primary and recurrent soft tissue sarcomas.  
First Author: Evgeniya M. Nepomnyashchaya
Abstract e23546: Impact of upfront multidisciplinary tumor board (MTB) evaluation on breast sarcoma (BS) outcome.
First Author: Francesco Tolomeo

Abstract e23547: Patient-reported global health predicts adverse health outcomes in a cohort of patients with advanced sarcoma.
First Author: Marium Husain, MD

Abstract e23548: Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma.
First Author: Yihebali Chi, MD, PhD

First Author: Lakshmi Priyanka Pappoppula, MBBS

Abstract e23550: Multi-institutional analysis of treatment and outcomes of sarcoma patients who develop brain metastases.
First Author: Nam Bui, MD

Abstract e23551: Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.
First Author: Monica S. Thakar, MD

Abstract e23552: Epithelioid sarcoma: Molecular insights into proximal versus classic variant.
First Author: Anna Maria Frezza, MD

Abstract e23553: Patient and diagnostic intervals of sarcoma patients: results from a survivorship study in the Netherlands.
First Author: Vicky L.M.N. Soomers

Abstract e23554: Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.
First Author: Pawel Teterycz, MD

Abstract e23555: Clinical behavior and treatment outcomes in angiosarcoma: A 10-year retrospective review.
First Author: Andrea P. Espejo Freire, MD, BA

Abstract e23556: Prevalence of delay to seeking medical attention in patients with synovial sarcoma and association with inferior outcomes.
First Author: Tiffany Seto
Abstract e23557: The prognostic impact of unplanned excision in primary STS of the extremities and trunk wall: Is re-excision always mandatory?  
First Author: Maria Danieli

Abstract e23558: Analysis of signaling pathway activity in desmoid-type fibromatosis (DF) to identify druggable pathways.  
First Author: Anja Van De Stolpe, MD, PhD

Abstract e23559: Radiochemotherapy with gemcitabine as radiosensitizer in patients with soft tissue sarcoma.  
First Author: Marinela Augustin

Abstract e23560: HLA genotyping in synovial sarcoma: Identifying HLA-A*02 and its association with clinical outcome.  
First Author: Evan Rosenbaum

Abstract e23561: Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma.  
First Author: Carter Kent Fairchild Jr., M.S.

Abstract e23562: Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status.  
First Author: Zhiwei Fang

Abstract e23563: We couldn’t resist comparing central with local RECIST1.1 and with Choi assessment: Exploratory analysis of tumor imaging in EORTC STBSG Phase 2 trial 1317 “CaboGIST.  
First Author: Anastasios Kyriazoglou

Abstract e23564: Irinotecan and temozolomide upfront and in relapsed Ewing sarcoma: A translational study on MGMT (O6-methylguanine–DNA methyltransferase) and ABCG2 (MGMTLiberati).  
First Author: Emanuela Palmerini, MD, PhD

Abstract e23565: Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.  
First Author: Nicholas M. Bernthal, MD

Abstract e23566: Role of glyoxalase-1 in trabectedin-resistant myxoid liposarcoma.  
First Author: Sonia Simonetti, PhD

Abstract e23567: Impact of next-generation sequencing on the management of patients with soft-tissue sarcoma.  
First Author: Brian Schulte
Abstract e23568: Single-institution retrospective review of patients with unresectable metastatic soft tissue sarcoma treated with ipilimumab and nivolumab followed by nivolumab monotherapy.
First Author: Maggie Zhou

Abstract e23569: Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
First Author: Yoshihiro Nishida

Abstract e23570: Hyperthermia combined with nanoparticles to enhance cytotoxic effects of fresh human soft tissue sarcoma.
First Author: Shailaja KS Raj, MD

Abstract e23571: Effect of beta blocker use in soft tissue sarcomas.
First Author: Edward De Leo, MD

Abstract e23572: Integrated genomic and functional analysis of patient-derived sarcoma cell lines validates their use for candidate treatment discovery including knockdown of a novel BCOR fusion gene.
First Author: Sabina Swierczek, PhD

Abstract e23573: Growth factor and its role in the treatment of patients with soft tissue extremity sarcoma receiving chemotherapy managed at an academic center: A retrospective study.
First Author: Neha Pancholy, MD

Abstract e23574: Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDCS], histiocytic sarcoma [HS]).
First Author: Mee-young Lee, MSN, ANP-BC

Abstract e23575: Retrospective analysis of intraoperative radiation therapy with low-kilovoltage x-rays (IORT-LK) in soft tissue sarcomas (STS).
First Author: Waldec Jorge David, MD

Abstract e23576: Qualitative patient interviews on symptoms and impacts in metastatic synovial sarcoma (mSS).
First Author: Brandon Becker

Abstract e23577: Current treatment efficacy for metastatic soft tissue sarcoma: A targeted literature review.
First Author: Heide Stirnadel-Farrant, PhD
First Author: Charles G. Drake, MD, PhD

Abstract e23579: Combined surgeries for retroperitoneal tumors.
First Author: Oleg I. Kit

Abstract e23580: Evaluation of patient and healthcare provider (HCP) knowledge, attitudes, and behavior for safety and use of pexidartinib.
First Author: Maribel Salas

Abstract e23581: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy +/- intraoperative radiation therapy in the management of peritoneal sarcomatosis; Real world experience.
First Author: Ahmed ali Badran, MD

**Symptoms and Survivorship**

Abstract e24000: Searching for the “exit ramp”: Bereaved caregivers (BCGs) describe discontinuation of transfusions at the end of life (EOL) for loved-ones (LOs) dying from acute myeloid leukemia (AML).
First Author: Larry Dean Cripe, MD

Abstract e24001: Unused prescription opioids and benzodiazepines after death among Medicare part D beneficiaries.
First Author: Laura Van Metre Baum, MD

Abstract e24002: Relationship described by bereaved caregivers (BCGs) between blood transfusions and hospice utilization for loved-ones (LOs) who died from acute myeloid leukemia (AML).
First Author: Larry Dean Cripe, MD

Abstract e24003: End-of-life care in the immune checkpoint inhibitor era.
First Author: Alyssa Buckenheimer, MD

Abstract e24004: Intention versus Reality: Analysis of end-of-life treatment at a university hospital.
First Author: Deniz Gencer

Abstract e24005: End-of-life characteristics associated with short hospice length of service for patients with solid tumors enrolled on phase I clinical trials.
First Author: Ramy Sedhom, MD
Abstract e24006: Analysis of hospice duration and metrics in cancer patients in rural Appalachia.
First Author: Sukesh Manthri, MBBS, MD

Abstract e24007: Impact of advance care planning on the place of death for cancer patients: A retrospective cohort study.
First Author: Martina Orlovic, MSc, PhD

Abstract e24008: End-of-life (EOL) trajectories among older adults dying with lung cancer (LC).
First Author: Amy J. Davidoff, PhD

Abstract e24009: The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).
First Author: Carolyn J Presley, MD, MHS

Abstract e24010: Effectiveness of a medical student-led, advanced care planning intervention in an inpatient cancer population.
First Author: Linda Nguyen, MA

Abstract e24011: Systematic analysis of extracting data on advance directives from patient electronic health records in terminal oncology patients.
First Author: William Paul Skelton IV

Abstract e24012: Psychological and spiritual distress among elderly advanced cancer patients in a supportive/palliative care outpatient clinic at a comprehensive cancer center.
First Author: Marvin Omar Delgado-Guay, MD

Abstract e24013: Comparing the relationship of perceptions of immunotherapy with anxiety between older and younger patients with advanced genitourinary cancer.
First Author: Cristiane Decat Bergerot, PhD, MS, BS

Abstract e24014: Immune checkpoint inhibitor toxicity and associated outcomes in a geriatric population.
First Author: Peter James Polewski, MD, MA

Abstract e24015: Exploring the decision-making process in older women with early-stage breast cancer.
First Author: Meghan Sri Karuturi, MD

Abstract e24016: Treatment trends with immune checkpoint inhibitor (ICI) therapy in older adults with lung cancer.
First Author: Christine Marie Walko, PharmD, BCOP, FCCP
Abstract e24017: Gradual dose de-escalation of antiemetic dexamethasone for older patients receiving moderately emetogenic FOLFOX chemotherapy.
First Author: Koung Jin Suh, MMedSc

Abstract e24018: Sarcopenia and clinical evaluation in predicting treatment tolerability and outcomes in aggressive non-Hodgkin B cell lymphoma.
First Author: Samuel Bernard Drory, M.D.

Abstract e24019: Efficacy of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase III EF-14 trial.
First Author: Zvi Ram, MD, PhD

First Author: Fahad Almugbel

Abstract e24021: Rate of complete chemotherapy as planned with comprehensive geriatric assessment guided intervention among vulnerable elderly cancer patients: A randomized-open-label study.
First Author: Manupol Maikami

Abstract e24022: Patient factors associated with changes in functional status during systemic cancer therapy in older adults: A systematic review.
First Author: Vivian Lam, BA

Abstract e24023: Does age contribute to distress in new geriatric oncology patients?
First Author: Harish Saiganesh, MD

Abstract e24024: Post-operative delirium in older patients following cancer related and other high-risk surgeries.
First Author: Rawad Elias, MD

Abstract e24025: Optimal dose of eribulin as 1st line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
First Author: Ursula Hasler-Strub

Abstract e24026: Response and toxicity to immune checkpoint inhibitors (ICI) in geriatric patients >80 years old.
First Author: Caroline Nebhan, MD, PhD

Abstract e24027: Breast cancer, placing drug interactions in the spotlight: Is polypharmacy the cause of everything?
First Author: José Alberto Domínguez-Alonso
Abstract e24028: The impact of frailty on the occurrence of immune-related adverse events in older patients with advanced melanoma.
First Author: Cheryl P. Bruijnen, MD

Abstract e24029: Does age matter? Documentation of AE reporting using an electronic tool (eSource) at Princess Margaret Cancer Centre (PM).
First Author: Ainhoa Madariaga, MD

Abstract e24030: Integrating touchscreen-based geriatric assessment and frailty screening for adults with acute myelogenous leukemia to drive personalized treatment decisions.
First Author: Debra Wujcik, PhD, RN

Abstract e24031: Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan.
First Author: Takashi Osaki

Abstract e24032: Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.
First Author: Helen Perry Knight, MD

Abstract e24033: Preoperative frailty assessment with Robinson Frailty Score (RFS) and Edmonton Frail Scale (EFS) in older surgical patients with cancer.
First Author: Tomohiro F. Nishijima, MD

Abstract e24034: Outcomes for geriatric patients evaluated in a same-day multidisciplinary central nervous system clinic for radiation oncology and neurosurgery in a community hospital setting.
First Author: Wencesley A. Paez, MD

First Author: Alberto Alves

First Author: Josephine Louella Feliciano, MD

Abstract e24037: Perspectives on healthcare providers’ role in health promotion among cancer survivors.
First Author: Karina I. Halilova, MD, MPH

Abstract e24038: Unmet supportive care needs and health behaviors in Hispanic/Latino cancer survivors with cardiometabolic comorbidities.
First Author: Patricia Moreno, PhD
First Author: Anne Bellens, medical doctor, gynaecology

Abstract e24040: Gender disparity on cigarette smoking among cancer survivors: Results from the National Health Interview Survey.
First Author: Changchuan Jiang, MD, MPH

Abstract e24041: Body weight management in overweight and obese breast cancer survivors (BCs): A systematic review and meta-analysis.
First Author: Janette L. Vardy, MD, PhD

Abstract e24042: Enhancing safety of exercise for individuals with bone metastases: Screening recommendations developed through Delphi consensus process.
First Author: Kristin L. Campbell, PT, PhD

Abstract e24043: Dashboard directed decision support to increase cancer survivorship care plan adherence.
First Author: Yazan Rizeq, BS

Abstract e24044: Health behaviors (HBs) among head and neck cancer (HNC) survivors.
First Author: Linda A. Jacobs, PhD

Abstract e24045: Patterns and perceptions of cannabis use by cancer survivors.
First Author: Lawson Eng, MD

Abstract e24046: The prevalence and sociodemographic predictors of mobile health applications ownership among cancer survivors.
First Author: Gideon T Dosunmu, MD

Abstract e24047: Clinician perspectives of complementary and integrative medicine (CIM) at an academic cancer center.
First Author: Marium Husain, MD

Abstract e24048: Safety and efficacy of fecal microbiota transplantation (FMT) in the management of recurrent clostridioides difficile infection (rCDI) in cancer patients.
First Author: Hiba Ali, MD

Abstract e24049: Khorana score as a predictive tool of venous thromboembolism in cancer patients in rural practice.
First Author: Ahmed Khalil
Abstract e24050: Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL).
First Author: Danielle M. Brander, MD

Abstract e24051: Promoting patient health maintenance with cancer care planning at diagnosis and during treatment: baseline data of the Coleman Supportive Oncology Collaborative (CSOC).
First Author: Christine B. Weldon, MBA

Abstract e24052: Improve, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-hispanic white breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics.
First Author: Cynthia Owusu, MD

Abstract e24053: Impact of cancer related stress on illness beliefs and glycemic control in breast cancer survivors with comorbid diabetes.
First Author: Jenny J. Lin, MD, MPH

Abstract e24054: Physical activity platform to improve bone health in cancer survivors.
First Author: Cathy Skinner, MA

Abstract e24055: Patterns in progression from early stage melanoma to late stage melanoma: Implications for survivorship follow up.
First Author: Benjamin Switzer, DO, MHSA, MS

Abstract e24056: Objective and subjective vulvovaginal symptoms in breast cancer patients.
First Author: Shari Beth Goldfarb, MD

Abstract e24057: Family building preferences among young women with invasive breast cancer.
First Author: Angelena Crown

Abstract e24058: Acquired immunity modulates cardiac responses to radiation exposure.
First Author: Carmen Bergom, MD, PhD

Abstract e24059: Impact of breast cancer chemotherapy on ovarian damage and recovery.
First Author: Shari Beth Goldfarb, MD

Abstract e24060: Prospective investigation of immunotherapy-induced fatigue by rest and stress echocardiography.
First Author: Roman Zingarelli

Abstract e24061: Human sperm cryopreservation prior cancer treatment: Follow up of 480 males for 23 years.
First Author: Isadora B Teloken, Medical Student
Abstract e24062: Self-reported memory problems in adult-onset cancer survivors in the United States with or without: Type 2 diabetes mellitus, hypertension and hyperlipidemia.
First Author: Valerie Thimothee, MS

Abstract e24063: Association of germline WFS1 rs62283056 single nucleotide polymorphism (SNP) with cisplatin-associated ototoxicity and survival outcomes in chemoradiation-treated head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Mary Mahler, MBBCh

Abstract e24064: Cancer's role in chemotherapy-induced neuropathy.
First Author: Stephen Nick Housley, PT, DPT

Abstract e24065: The impact of socioeconomic factors and survivorship on radiation induced hypothyroidism in a single institution cohort study.
First Author: Zvonimir Milas, MD

Abstract e24066: Hypothyroidism and its impact on outcomes in head and neck cancer.
First Author: Sujay Srinivas

Abstract e24067: Cognitive impairment in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.
First Author: Andrea T. Meuleman, BS

Abstract e24068: Feasibility and acceptability of yoga to improve psychosocial and physical function among patients with lung cancer: A pilot study.
First Author: Mary E Medysky, PhD

Abstract e24069: Pectoralis muscle wasting during chemotherapy.
First Author: Jason Wiederin, MD

Abstract e24070: Genitourinary symptoms in women with early breast cancer: Attitudes of health professionals.
First Author: Antonia Pearson, MBBS

First Author: Allison B. Wang, PT, DPT

Abstract e24072: Association between tamoxifen and cataract risk in breast cancer patients: Analysis of a national health insurance database.
First Author: Cheng-wei Chou
Abstract e24073: Patterns of self-reported symptom distress among survivors of head and neck cancers.
First Author: Guadalupe R. Palos, DrPH, RN

Abstract e24074: Matrix metalloproteinases 9 and 14 polymorphisms and long-term complications in surgically treated breast cancer patients.
First Author: Nikola Besic

Abstract e24075: Clinical application value of prognostic nutritional index for predicting survival in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy (CRT) or radiotherapy.
First Author: Tao Li, MD

Abstract e24076: Effect of weight loss on survival in esophageal cancer patients undergoing neoadjuvant chemoradiotherapy and surgery.
First Author: Tao Li, MD

Abstract e24077: Determinants of social disparities in return to work (RTW) after early breast cancer (BC).
First Author: Gwenn Menvielle, PhD

Abstract e24078: Characterization of chemotherapy-induced peripheral neuropathy (CIPN) using patient-reported outcomes (PRO) and quantitative sensory testing (QST).
First Author: Ting Bao, MD

First Author: Michael W. Parsons

Abstract e24080: Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.
First Author: Eva Battaglini

Abstract e24081: Fertility counseling in young patients with colorectal cancer.
First Author: Chengwei Peng, BS

First Author: Scott Capozza, MS, PT

Abstract e24083: Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.
First Author: Terry L. Ng, MD
First Author: Mohammed Alaeddine Saidi, MD

First Author: Jami Aya Fukui, MD

Abstract e24086: Nasal vestibulitis: An MNCCTN natural history trial—Nasal vestibulitis symptoms associated with paclitaxel, docetaxel, and other chemotherapy agents.
First Author: Elizabeth Jane Cathcart-Rake, MD

Abstract e24087: Cancer-related fatigue (CRF) in breast cancer survivors after treatment: A focus on physical condition.
First Author: Ana Ruiz-Casado

Abstract e24088: Determining the unmet survivorship needs in patients with head and neck cancer: A prospective, longitudinal study.
First Author: Meredith Elana Giuliani, MBBS, FRCPC, MEd

Abstract e24089: Cancer survivors with multiple chronic conditions: A rising challenge—Trend analysis from National Health Interview Survey.
First Author: Changchuan Jiang, MD, MPH

Abstract e24090: Excessive mortality in 1,353 five-year survivors of nasopharyngeal cancer.
First Author: Chi Leung Chiang, MBChB, PDip in Epi & Biostat

Abstract e24091: First phase implementation of cardio-oncology program in the middle-income country of Costa Rica at Hospital Metropolitano healthcare system.
First Author: Andres Wiernik, MD, MBA

Abstract e24092: Trastuzumab-induced cardiotoxicity and hypertension among racially and ethnically diverse patients with HER2-positive early-stage breast cancer.
First Author: Monica F. Chen, MD

Abstract e24093: Peripheral neuropathy after breast cancer: An analysis of data from the Women’s Health Initiative Life and Longevity After Cancer cohort.
First Author: Mandana Kamgar, MD, MD, MPH

Abstract e24094: Association of pectoralis muscle area and survival outcomes after chemotherapy.
First Author: Christina Gu

Abstract e24095: The chemo-brain effect in colorectal cancer patients.
First Author: Matilda Lee, MBBS
Abstract e24096: Development and testing of an online fertility preservation decision aid for female cancer patients.
First Author: Michelle van den Berg, MD

Abstract e24097: Trajectories of sexual dysfunction and its risk factors in women with gynecologic cancer across radiation therapy and healthy controls.
First Author: Jinbing Bai, PhD

Abstract e24098: Factors associated with frequent insomnia among breast cancer survivors.
First Author: Agnes Kwak, BS

Abstract e24099: Quality of life after diagnosis in survivors of aggressive lymphomas.
First Author: Robert M. Kraft, MD

Abstract e24100: The inadequacy of cardiovascular safety reporting in breast cancer clinical trials.
First Author: Arsalan Hamid, MD

Abstract e24101: Diabetes mellitus in childhood and young adult cancer survivors: A meta-analysis.
First Author: Igal Kushnir, MD

First Author: Melissa McShane, MD

Abstract e24103: N-terminal pro-brain natriuretic peptide levels after receipt of anthracycline for breast cancer.
First Author: Shruti R Patel, MD

First Author: Bogda Koczwara, MD

Abstract e24105: PDGFC signaling is a potential therapeutic target for radiation proctopathy.
First Author: Lekun Fang

Abstract e24106: Assessment of scalp cooling to prevent chemotherapy-induced alopecia using standard infusion room documentation and patient surveys.
First Author: Dina Hagigheorges
Abstract e24107: Amino acid mixture (enterade) as a new approach to reducing cancer therapy-induced gastrointestinal toxicity: a retrospective study.
First Author: Aman Chauhan, MBBS

First Author: Marco Platania, MD

Abstract e24109: Validation and clinical correlates of a brief prognostic marker of patient-reported sleep disturbance in early-phase clinical trials clinic patients.
First Author: Goldy George, PhD

First Author: Audrey Ready, DO

Abstract e24111: Patterns of use of medical cannabis in a community oncology clinic.
First Author: Deepti Behl, MD

Abstract e24112: Real-world implementation of serious illness care program (SICP) in cancer care.
First Author: Safiya Karim, MD, MSc

Abstract e24113: Violence and chronic pain in cancer patients in northeastern Mexico.
First Author: Adelina Alcorta-Garza, MD, PhD

Abstract e24114: Integrating pharmacogenomics panel testing for supportive care medications in patients with solid tumors.
First Author: Adrijana Kekic, Pharm.D.

Abstract e24115: A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome.
First Author: Zoneddy R. Dayao, MD

First Author: Weijia Wang, MS

Abstract e24117: Patterns of inpatient palliative care consultation for patients with brain and spine metastases.
First Author: Elizabeth Howell, BS

Abstract e24118: Early referral to palliative care: Where are we in Brazil?
First Author: Andre Filipe Junqueira Santos, PhD, MD
Abstract e24119: Effect of rhEGF treatment on EGFR inhibitors-induced skin barrier and immune defects.
First Author: Sung Yong Oh, MD

Abstract e24120: Palliative chemotherapy for patients (pts) with malignant bowel obstruction (MBO).
First Author: Rafael Caparica Bitton, MD

Abstract e24121: Changes in physical activity from pre-diagnosis to first five years post-diagnosis: A prospective cohort study in Chinese breast cancer patient.
First Author: Yuanyuan Lei, MD, PHD

Abstract e24122: Aprepitant in weekly cisplatin with radiation in head and neck cancer: Is it required?
First Author: Hollis D'souza

First Author: Akhil Rajendra

Abstract e24124: A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation.
First Author: Sachin Babanrao Dhumal

Abstract e24125: Knowledge, attitude and practices regarding the use of medical cannabis: A national survey among Israeli oncologists.
First Author: Dan Mirelman, MD

Abstract e24126: Compatibility of topical agents with tumor treating fields (TTFields) for treatment of associated skin events in glioblastoma (GBM).
First Author: Moshe Giladi, PhD

Abstract e24127: Efficacy of WC03 in treating radiotherapy-induced oral mucositis (RIOM): A multicenter nonrandomized controlled clinical trial.
First Author: Dongmei Chen, MD

Abstract e24128: Patient-reported and clinician-rated performance status and general health among women with gynecologic cancers on palliative chemotherapy.
First Author: Hanneke Poort, MSc, PhD

Abstract e24129: Appropriateness of opioid prescribing in cancer patients.
First Author: Robert M. Matera, MD
Abstract e24130: Cannabidiol: Assessing preclinical safety in ovarian and endometrial carcinoma cell lines.
First Author: Shannon Rush, MD

Abstract e24131: Prevalence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy in platinum-based regimens.
First Author: Nilomi Shah

Abstract e24132: Developing survivorship services in Ghana and Tanzania.
First Author: Nazima Jaffer Dharsee, MD

Abstract e24133: Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
First Author: Lee S. Schwartzberg, MD, FACP

Abstract e24134: The long and winding road in drug development: Learnings from on-going development of IEPA for chemotherapy-induced myelosuppression.
First Author: Dirk Pleimes, MD

Abstract e24135: Advanced cancer patients' (CP) attitudes and perceptions regarding reasons for outpatient supportive care (SC) referral at a comprehensive cancer center: A randomized controlled study.
First Author: Angelique Wong, MD

Abstract e24136: Efficacy of topical capsaicin for treatment of chemotherapy-induce peripheral neuropathy: Prospective cohort study.
First Author: Chanchai Charonponsuntorn, MD

Abstract e24137: Feasibility and effects of home parenteral nutrition (HPN) in cancer patients with or without migrant background.
First Author: Lena Rebekka Schickhaus

Abstract e24138: Aggregated n-of-1 randomized controlled trial of nebulized fentanyl or nebulized furosemide in palliative care patients with refractory breathlessness.
First Author: Pongput Pimsa

Abstract e24139: Correlational study of different analgesic programs on patients' quality of life, mood, and dignity.
First Author: Long Wang

First Author: Rachel Jorge Dino Cossetti Leal, MD, MSc
Abstract e24141: Patterns and prognostic factors of malignant ascites in hospitalized patients with advanced stage cancer.
First Author: Shanila Ahmed

Abstract e24142: The clinical significance of gabapentin in combination with opioids in controlling outbreak of pain in cancer patients.
First Author: Xue Zhang

Abstract e24143: Cannabis use patterns and patient reported outcomes in oncology and hematology patients: An anonymous survey.
First Author: Shanmuga Subbiah, MD, MBBS

Abstract e24144: Evaluation of prescribing practices of denosumab and zoledronic acid in breast and prostate cancer patients at University of Chicago Medicine.
First Author: Heng Yang, PharmD

Abstract e24145: Pain medication use in patients with HR+, HER2-neg advanced breast cancer treated with endocrine therapy and a CDK 4/6 inhibitor: A U.S. FDA pooled analysis.
First Author: Jennifer J Gao, MD

Abstract e24146: M-palliative care link: Improving symptom control and information exchange among specialists and local health workers treating late-STAGE Tanzanian cancer patients.
First Author: Susan Miesfeldt, MD

First Author: Suzanne Cole, MD, FACP

First Author: Ling En Koh

First Author: Yong Liu

Abstract e24150: Breakthrough cancer pain clinical features and differential opioids response: A machine learning approach in 4,016 cancer patients of IOPS-MS study.
First Author: Francesco Pantano, MD, PhD

Abstract e24151: Moderate to vigorous physical activity effect on chemotherapy-induced peripheral neuropathy.
First Author: Grace Kanzawa-Lee, RN, BSN, PhD
First Author: Sam Brondfield, MD, MA

Abstract e24153: Effect of growth differentiation factor 15 (GDF-15) inhibition on energy balance in cancer cachexia and in lipopolysaccharide (LPS)-induced sepsis mouse models.
First Author: Danna Breen

Abstract e24154: Treatment in patients with cat receiving LMWH: Learnings from predicare, a non-interventional prospective cohort study.
First Author: Florian Scotte, MD

Abstract e24155: Analysis of the efficacy and safety of naloxegol administered to patients with cancer and opioid-induced constipation with laxative-inadequate response: A real-world 12 months of follow-up study.
First Author: Manuel Cobo Dols, MD, PhD

Abstract e24156: Radiofrequency ablation versus stereotactic body radiotherapy for painful osseous metastases: A comparative correlation meta-analysis of pain relief.
First Author: Tej Mehta, B.S.

Abstract e24157: Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia.
First Author: Raghav Sundar, MBBS

Abstract e24158: ICES (international carboplatin emesis survey for the evaluation) of the emetogenicity of carboplatin-based chemotherapy. A MASCC antiemetics study group prospective, observational, real-world study.
First Author: Teresa Smit, MPharm

Abstract e24159: Febrile neutropenia outside of clinical trials in intermediate-risk patients receiving chemotherapy: A MASCC neutropenia, infection and myelosupression study group prospective, real world study.
First Author: Bernardo Leon Rapoport, MD

Abstract e24160: Evaluation of emergency department visits in patients treated with immune checkpoint inhibitors.
First Author: Deniz Can Guven

First Author: Lu Li
Abstract e24162: Growth differentiation factor 15 (GDF-15) as a key regulator of cachexia induced by platinum-based chemotherapy.
First Author: Danna Breen

Abstract e24163: Health-related values of newly-diagnosed cancer patients: Qualitative analysis of oncology nurse-led discussions.
First Author: Paul Shin, MD, Ph.D.

Abstract e24164: Using consistent terms in precision medicine to eliminate patient confusion.
First Author: Nikki A. Martin, MA

Abstract e24165: Caregiver and patient distress in young adults with new cancer diagnoses.
First Author: Laura Van Metre Baum, MD

Abstract e24166: “Where did you read that?” External sources of information and patients perceptions of prognostic goals.
First Author: Rushad Patell, MBBS

Abstract e24167: Accuracy of oncology patients’ expectations of cure.
First Author: Paul Shin, MD, Ph.D.

First Author: Fay J. Hlubocky, PhD, MA

Abstract e24169: Effectiveness of brief-focused cognitive behavioral therapy in the reduction of cancer-related distress and emotive problems: A comparative study.
First Author: Alessandro Rossi, Psychologist, PhD

Abstract e24170: Neural mechanisms of impaired executive function in untreated colorectal cancer patients.
First Author: David Anderson, PhD

Abstract e24171: Pastoral care of cancer patients: Defining utilization of services at a comprehensive cancer center.
First Author: Elizabeth Palmer, PhD

Abstract e24172: Delay discounting as a predictor of adjuvant endocrine therapy adherence among breast cancer survivors.
First Author: Jennifer Vaughn, MD, MSPH

Abstract e24173: Understanding the daily needs and challenges of caregivers of patients with lung cancer.
First Author: Yanyan Zhu
Abstract e24174: Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC).
First Author: Daniel Vargas Pivato de Almeida, MD

Abstract e24175: Factors influencing patients’ decision to undergo scalp cooling in breast and gynecological cancer.
First Author: Elizabeth Elliott, DO

First Author: Jon Charles Tilburt, MD

Abstract e24177: Use of artificial intelligence for analyzing emotion vs patient global impression of change of melanoma treatments.
First Author: Ashley Su

Abstract e24178: Cannabis and cancer: Examining the use and perceived benefits in an Irish cancer cohort.
First Author: zac coyne

Abstract e24179: Can a brief multimedia intervention facilitate breast cancer patients’ communication about sexual health? Findings from a randomized controlled trial.
First Author: Jennifer B. Reese, PhD

Abstract e24180: Evaluating sexual function in adolescent and young adult childhood cancer survivors.
First Author: Jenna Sopfe, MD

Abstract e24181: Streamlining survivorship care plan (SCP) creation and delivery to primary care providers in poor, rural, and minority patients.
First Author: Bernard Tawfik, MD

Abstract e24182: Effect of adolescent and young adult cancer placements on advanced communication skills.
First Author: Helen Hatcher, MD, PhD

Abstract e24183: Individual and community respite as supportive care for adult cancer patients, their caregivers and their families.
First Author: Marcella Schankweiler
Abstract e24184: Quality assessment of online hepatocellular carcinoma patient education materials.
First Author: Jim (Zhang Hao) Li

Abstract e24185: Surviving metastatic non-small cell lung cancer (mNSCLC): The lived experience and supportive care needs of patients (pts) receiving immunotherapy (IT) or targeted therapy (TT).
First Author: Julia Elizabeth Lai-Kwon, MBBS

Abstract e24186: Understanding therapy preferences of cancer patients with the use of therapy preference scale.
First Author: Prajwal Dhakal, MBBS

Abstract e24187: Patient knowledge and expectations of anti-cancer treatments in the advanced disease setting.
First Author: Darren Cowzer

Abstract e24188: Communicating cancer and its treatment to Australian Aboriginal patients with cancer: A qualitative study.
First Author: Ian N. Olver, MD, PhD, FRACP

Abstract e24189: Lessons on humanity: The voice of cancer patients through a literary contest.
First Author: Darío Niewiadomski, MD

First Author: Eric James Miller, MD

Abstract e24191: Drivers and barriers to clinical trials (CTs) participation among oncological and non-oncological patients in Poland: A cross sectional survey.
First Author: Artur Kotowski, Medical doctor

First Author: Debra Wujcik, PhD, RN

Abstract e24193: Effect of informational charts on patient understanding of nontherapeutic research procedures in phase I trials.
First Author: Gavin Paul Campbell, BS

Abstract e24194: Depression in cancer: An evaluation of patient education resources.
First Author: Jim (Zhang Hao) Li
Abstract e24195: Gender and time estimation as novel potent indicators of emotional concerns in cancer patients.
First Author: Asen Yanchev

Abstract e24196: A trauma-informed sensitive practice tool to enhance quality of care for breast radiotherapy patients.
First Author: Deborah Catherine Marshall, MD

Abstract e24197: The DISCO app: A pilot test of an electronic patient intervention to reduce the financial burden of cancer through improved cost communication.
First Author: Lauren M. Hamel, PhD

Abstract e24198: Video conferencing long distance caregivers during oncology appointments: Implications for clinical practice.
First Author: Eric Blackstone, MA

Abstract e24199: Information sources and treatment information preferences of patients with blood cancer.
First Author: Kah Poh Loh, MBBCh

Abstract e24200: Longitudinal investigation of Distress Thermometer scores in patients with cancer.
First Author: Fauzia Ullah

Abstract e24201: Cancer patients’ perceptions of physicians who use an integrated electronic health record (EHR) approach during clinic visits: A double-blinded randomized clinical trial (RCT).
First Author: Ali Haider, MD